[
  {
    "title": "IP Patents Monetization Strategies",
    "create_time": 1749496831.900489,
    "update_time": 1749619307.488118,
    "mapping": {
      "client-created-root": {
        "id": "client-created-root",
        "message": null,
        "parent": null,
        "children": [
          "e2b81c45-1087-4fec-b2e5-2f6d97b7f460"
        ]
      },
      "e2b81c45-1087-4fec-b2e5-2f6d97b7f460": {
        "id": "e2b81c45-1087-4fec-b2e5-2f6d97b7f460",
        "message": {
          "id": "e2b81c45-1087-4fec-b2e5-2f6d97b7f460",
          "author": {
            "role": "user",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749496831.181,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "give me the most exhaustive and extensive review on IP and patents in the innovation economy. Cover these topics:\n- What are all existing IP-based monetization strategies, everything from common to super niche and clever ones.\n- Which organizations/institutions are profiting the most from IP, especially those for whom IP is the main source of income (if such places exist)\n- How universities profit from ip/patents. Name all fields and how the costs break down for each field."
            ]
          },
          "status": "finished_successfully",
          "end_turn": null,
          "weight": 1.0,
          "metadata": {
            "caterpillar_selected_sources": [
              "web"
            ],
            "selected_mcp_sources": [],
            "selected_sources": [
              "web"
            ],
            "selected_github_repos": [],
            "system_hints": [
              "research"
            ],
            "serialization_metadata": {
              "custom_symbol_offsets": []
            },
            "request_id": "94d2fc9dfa60b612-ORD",
            "message_source": null,
            "timestamp_": "absolute",
            "message_type": null
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "client-created-root",
        "children": [
          "f344b688-5689-4647-9171-0ae0189d7b4f"
        ]
      },
      "f344b688-5689-4647-9171-0ae0189d7b4f": {
        "id": "f344b688-5689-4647-9171-0ae0189d7b4f",
        "message": {
          "id": "f344b688-5689-4647-9171-0ae0189d7b4f",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749496837.094069,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "To make sure I cover your request thoroughly, could you clarify the following:\n\n1. Should the review focus globally or on a specific country or region (e.g., U.S., EU, Asia)?\n2. Is there a time range or specific era you'd like emphasized (e.g., current decade vs historical development)?\n3. When you ask for cost breakdowns by field in university patenting, would you like estimates for R&D, patent filing, maintenance, litigation, etc.?\n4. Should the output be formatted as a formal report with sections and tables?\n\nOnce I have this, I\u2019ll begin the deep research and compile the most comprehensive review possible."
            ]
          },
          "status": "finished_successfully",
          "end_turn": true,
          "weight": 1.0,
          "metadata": {
            "message_type": null,
            "model_slug": "research",
            "default_model_slug": "o3",
            "parent_id": "e2b81c45-1087-4fec-b2e5-2f6d97b7f460",
            "request_id": "94d2fc9dfa60b612-ORD",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "e2b81c45-1087-4fec-b2e5-2f6d97b7f460",
        "children": [
          "ad70df27-59aa-4047-beb4-c0611995fcdb"
        ]
      },
      "ad70df27-59aa-4047-beb4-c0611995fcdb": {
        "id": "ad70df27-59aa-4047-beb4-c0611995fcdb",
        "message": {
          "id": "ad70df27-59aa-4047-beb4-c0611995fcdb",
          "author": {
            "role": "user",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749497217.189,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "focus on US, but if you find interesting policies in other countries that are better, I would like to know. Find things like interesting experiments that people have tried that failed and succeeded.\nTime range should be fairly recent, e.g. last 50 years\nfor costs, I just want breakdown of fields (e.g. material science, biology, experimental physics) and how much each brings in in patents. I want to compare that to the total operating costs of these institutions / companies, but I don't really care about the breakdown of operating costs.\nNo formality required, but maximize for the most informative for me. I want clever insights and case studies where crazy ideas have been tried and succeeded/failed, but also the boring stuff that really runs the world of innovation"
            ]
          },
          "status": "finished_successfully",
          "end_turn": null,
          "weight": 1.0,
          "metadata": {
            "caterpillar_selected_sources": [
              "web"
            ],
            "selected_mcp_sources": [],
            "selected_sources": [
              "web"
            ],
            "selected_github_repos": [],
            "system_hints": [
              "research"
            ],
            "serialization_metadata": {
              "custom_symbol_offsets": []
            },
            "request_id": "94d3060ae86210fd-DFW",
            "message_source": null,
            "timestamp_": "absolute",
            "message_type": null
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "f344b688-5689-4647-9171-0ae0189d7b4f",
        "children": [
          "55c976f1-e37c-4bd2-9981-78a2d4950679"
        ]
      },
      "55c976f1-e37c-4bd2-9981-78a2d4950679": {
        "id": "55c976f1-e37c-4bd2-9981-78a2d4950679",
        "message": {
          "id": "55c976f1-e37c-4bd2-9981-78a2d4950679",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749497231.065329,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "Great. I\u2019ll begin a comprehensive review of intellectual property and patents in the U.S. innovation economy, covering the last 50 years. This will include all IP-based monetization strategies\u2014from common to niche\u2014along with the most IP-reliant organizations and how universities profit from patents by field, comparing revenues from IP to overall budgets. I\u2019ll also highlight innovative and unusual case studies, both successful and failed, and draw in global examples where other countries have implemented standout policies or experiments.\n\nI\u2019ll let you know as soon as it\u2019s ready."
            ]
          },
          "status": "finished_successfully",
          "end_turn": null,
          "weight": 1.0,
          "metadata": {
            "message_type": null,
            "model_slug": "research",
            "default_model_slug": "o3",
            "parent_id": "ad70df27-59aa-4047-beb4-c0611995fcdb",
            "request_id": "94d3060ae86210fd-DFW",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "ad70df27-59aa-4047-beb4-c0611995fcdb",
        "children": [
          "971838a9-1a08-4f0b-bd62-9ce330345184"
        ]
      },
      "971838a9-1a08-4f0b-bd62-9ce330345184": {
        "id": "971838a9-1a08-4f0b-bd62-9ce330345184",
        "message": {
          "id": "971838a9-1a08-4f0b-bd62-9ce330345184",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749497219.151545,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "{\n  \"task_violates_safety_guidelines\": false,\n  \"user_def_doesnt_want_research\": false,\n  \"response\": \"Great. I\u2019ll begin a comprehensive review of intellectual property and patents in the U.S. innovation economy, covering the last 50 years. This will include all IP-based monetization strategies\u2014from common to niche\u2014along with the most IP-reliant organizations and how universities profit from patents by field, comparing revenues from IP to overall budgets. I\u2019ll also highlight innovative and unusual case studies, both successful and failed, and draw in global examples where other countries have implemented standout policies or experiments.\\n\\nI\u2019ll let you know as soon as it\u2019s ready.\",\n  \"title\": \"IP and Patents in the U.S. Innovation Economy\",\n  \"prompt\": \"Conduct an exhaustive and extensive review of intellectual property (IP) and patents in the U.S. innovation economy over the last 50 years. Include the following:\\n\\n1. A comprehensive list of all IP-based monetization strategies, ranging from common (e.g., licensing, patent sales) to super niche or clever ones (e.g., patent-backed securitization, patent privateering, patent assertion entities, etc.).\\n2. Identify which organizations and institutions profit the most from IP, with a special focus on those for whom IP is the primary revenue source (e.g., patent assertion firms, IP holding companies, etc.).\\n3. Explore how U.S. universities generate revenue from patents and IP. Provide a breakdown by field (e.g., biology, materials science, experimental physics), indicating how much revenue each generates from patents relative to the university\u2019s total budget.\\n4. Include noteworthy case studies\u2014both successful and failed\u2014of innovative or unconventional IP monetization efforts, especially those that had an outsized impact on innovation or policy.\\n5. Draw on global comparisons where relevant: highlight international policies or experiments that outperformed or underperformed U.S. norms, and analyze why.\\n\\nMaximize insight and depth of information over formality. Include the boring industry-standard mechanisms as well as the lesser-known, experimental, or fringe practices that influence the world of IP and innovation.\"\n}"
            ]
          },
          "status": "finished_successfully",
          "end_turn": false,
          "weight": 1.0,
          "metadata": {
            "finish_details": {
              "type": "stop",
              "stop_tokens": [
                200007
              ]
            },
            "is_complete": true,
            "citations": [],
            "content_references": [],
            "message_type": null,
            "model_slug": "research",
            "default_model_slug": "o3",
            "parent_id": "55c976f1-e37c-4bd2-9981-78a2d4950679",
            "request_id": "94d3060ae86210fd-DFW",
            "timestamp_": "absolute",
            "is_loading_message": true
          },
          "recipient": "research_kickoff_tool.start_research_task",
          "channel": null
        },
        "parent": "55c976f1-e37c-4bd2-9981-78a2d4950679",
        "children": [
          "60a721d3-521c-478f-85ef-5cb9e5e41eb9"
        ]
      },
      "60a721d3-521c-478f-85ef-5cb9e5e41eb9": {
        "id": "60a721d3-521c-478f-85ef-5cb9e5e41eb9",
        "message": {
          "id": "60a721d3-521c-478f-85ef-5cb9e5e41eb9",
          "author": {
            "role": "tool",
            "name": "research_kickoff_tool.start_research_task",
            "metadata": {}
          },
          "create_time": 1749497233.424233,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": []
          },
          "status": "finished_successfully",
          "end_turn": false,
          "weight": 1.0,
          "metadata": {
            "async_task_title": "IP and Patents in the U.S. Innovation Economy",
            "async_task_prompt": "give me the most exhaustive and extensive review on IP and patents in the innovation economy. Cover these topics:\n- What are all existing IP-based monetization strategies, everything from common to super niche and clever ones.\n- Which organizations/institutions are profiting the most from IP, especially those for whom IP is the main source of income (if such places exist)\n- How universities profit from ip/patents. Name all fields and how the costs break down for each field.\n\nfocus on US, but if you find interesting policies in other countries that are better, I would like to know. Find things like interesting experiments that people have tried that failed and succeeded.\nTime range should be fairly recent, e.g. last 50 years\nfor costs, I just want breakdown of fields (e.g. material science, biology, experimental physics) and how much each brings in in patents. I want to compare that to the total operating costs of these institutions / companies, but I don't really care about the breakdown of operating costs.\nNo formality required, but maximize for the most informative for me. I want clever insights and case studies where crazy ideas have been tried and succeeded/failed, but also the boring stuff that really runs the world of innovation",
            "async_task_type": "research",
            "async_task_status_messages": {
              "initial": "IP and Patents in the U.S. Innovation Economy",
              "completed_with_time": "Research completed in 8m",
              "completed_no_time": "Completed research",
              "completed": "Researched for ",
              "error": "Research failed",
              "cancelled": "Research cancelled"
            },
            "b1de6e2_s": true,
            "command": "start_research_task",
            "message_type": null,
            "model_slug": "research",
            "default_model_slug": "o3",
            "parent_id": "971838a9-1a08-4f0b-bd62-9ce330345184",
            "request_id": "94d3060ae86210fd-DFW",
            "timestamp_": "absolute",
            "async_task_id": "deepresch_684735918524819198d58ef4b4e766ba",
            "async_task_conversation_id": "68473591-871c-8005-b395-94b2d0ca4d42",
            "async_task_created_at": "2025-06-09 19:27:14.136807+00:00",
            "deep_research_version": "full"
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "971838a9-1a08-4f0b-bd62-9ce330345184",
        "children": [
          "b20f8f3c-057e-43a9-bf41-fda21610da74"
        ]
      },
      "b20f8f3c-057e-43a9-bf41-fda21610da74": {
        "id": "b20f8f3c-057e-43a9-bf41-fda21610da74",
        "message": {
          "id": "b20f8f3c-057e-43a9-bf41-fda21610da74",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749497693.863764,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "# IP and Patents in the Innovation Economy: An Exhaustive Review\n\n## Introduction  \nIntellectual property (IP) \u2013 especially patents \u2013 plays a pivotal role in today\u2019s innovation economy. Over the past 50 years, patents have evolved from mere legal protections into strategic assets that drive revenue, influence corporate strategy, and shape research priorities. This review explores **how IP can be monetized**, identifies **who profits most from IP** (including companies, non-practicing entities, and universities), and examines **the role of patents in academia** (by field, with cost/revenue breakdowns). While focusing on the United States, we will also highlight notable international policies and experiments \u2013 both successes and failures \u2013 in IP monetization. The goal is to cover everything from the \u201cboring\u201d fundamentals that quietly run the innovation world to clever, niche strategies and case studies that illustrate the extremes of IP-based business models.  \n\n## IP-Based Monetization Strategies  \nThere are numerous strategies to extract economic value from IP. Some are very common (e.g. licensing a patent to others for royalties), while others are more niche or innovative (e.g. using patents as collateral for financing). Below is a comprehensive list of monetization methods, from mainstream approaches to creative tactics:\n\n- **Patent Licensing & Royalties:** Licensing is the most straightforward and prevalent way to monetize patents. The patent owner grants permission to another party to use the invention in exchange for royalties or fees. This can take forms such as *exclusive licenses* (one licensee gets sole rights), *non-exclusive licenses* (multiple licensees), or *field-of-use licenses* (rights limited to certain industries or applications). According to a survey by the Licensing Executives Society, licensing accounted for over **40% of patent monetization income** among surveyed firms\u30103\u2020L144-L152\u3011. A special form is **cross-licensing**, where companies swap rights to each other\u2019s patents (often to settle disputes or access each other\u2019s technology)\u30103\u2020L153-L161\u3011. Another collaborative approach is **patent pools**, where multiple patent holders bundle their patents and license them out as a package (common with standard-essential patents in industries like consumer electronics)\u30103\u2020L157-L162\u3011. Patent pools (e.g. the MPEG-LA pool for video codecs) allow easier access for licensees and ensure all contributors get a share of royalties. *Real-world example:* Qualcomm, which pioneered CDMA mobile technology, licenses its patents to nearly every smartphone maker \u2013 these licensing agreements bring in billions in fees annually, as discussed later\u30108\u2020L219-L225\u3011.\n\n- **Selling Patents (Patent Sales & Auctions):** Patent owners can monetize by outright selling their patent rights to others. This is useful when an invention doesn\u2019t fit a company\u2019s core business or when immediate cash is needed\u30103\u2020L163-L170\u3011. Specialized brokers and marketplaces have emerged for patent sales. For instance, **Ocean Tomo** ran high-profile patent auctions in the 2000s, and more recently IP exchanges have been attempted (e.g. the **IPXI exchange**, which tried \u2013 albeit unsuccessfully \u2013 to create a market for trading patent license rights as standardized units). The global market for patent transactions is significant: one analysis estimated the \u201cIP trading market\u201d at **$7.4\u00a0billion in 2020**, projected to grow dramatically by 2030\u30103\u2020L165-L173\u3011. Niche strategies here include *package deals* (selling a portfolio of related patents) and *sale-leaseback arrangements* (selling a patent to an entity and then licensing it back, to unlock cash while retaining usage rights). \n\n- **Patent Litigation & Enforcement (\u201cStick\u201d Licensing):** When voluntary licensing fails, patent owners may resort to litigation or the *threat* of litigation to generate revenue. In what\u2019s sometimes called a **\u201cstick licensing\u201d** strategy, the patent holder sues (or threatens to sue) alleged infringers, seeking damages or forcing them into royalty-bearing license agreements\u301021\u2020L33-L41\u3011\u301013\u2020L297-L305\u3011. This can yield large payouts: between 2015 and 2019, the **average patent infringement damages award in the U.S. was about $10.2\u00a0million**\u30103\u2020L188-L192\u3011, and multi-hundred-million-dollar verdicts are not unheard of in major cases (e.g. the famous **NTP vs. RIM** case in 2006 resulted in a $612\u00a0million settlement over BlackBerry wireless email patents). A class of companies known as **patent assertion entities (PAEs)** or less politely \u201cpatent trolls\u201d specialize in this model \u2013 they acquire patents *solely* to enforce them for profit. A notorious example is **Intellectual Ventures (IV)**, which amassed a portfolio of tens of thousands of patents and has **generated over $3\u00a0billion in licensing fees** by aggressively pursuing licenses (often under threat of suit)\u301021\u2020L43-L50\u3011. IV typically does not make products; instead it buys patents and monetizes them via licenses or lawsuits, a practice that has drawn criticism\u301013\u2020L297-L305\u3011. While litigation can be lucrative, it\u2019s costly and risky \u2013 success isn\u2019t guaranteed, and legal battles can drag on for years. Many operating companies use litigation more defensively (to block rivals or defend their turf) than as a primary revenue stream, but a few \u2013 notably in the tech sector of the 1980s \u2013 turned enforcement into profit centers (for example, Texas Instruments famously ramped up patent lawsuits in the 1980s, extracting substantial royalties from Japanese semiconductor firms and transforming its dormant patent portfolio into a $300+ million annual licensing revenue source at the time). Today, some companies also engage in **forum shopping** (filing in plaintiff-friendly courts like the Eastern District of Texas) or use **ITC complaints** to seek import bans, all as leverage to force settlements. The rise of litigation funding has further enabled patent holders to pursue big cases by partnering with investors who bankroll the lawsuits in exchange for a share of the winnings.\n\n- **Strategic Cross-Licensing & Defensive Patents:** Not all monetization is about immediate cash \u2013 sometimes patents are leveraged to secure *freedom to operate*. Large tech companies often hold vast patent portfolios less to license for revenue than to **avoid paying others**. They achieve this via cross-licensing (trading rights). For example, two smartphone giants might each have thousands of patents; rather than suing each other into stalemate, they sign a cross-license so each can use the other\u2019s patents, often with a balancing royalty if one portfolio is stronger. This saves money that would have been spent on royalties or legal fees \u2013 effectively *indirect monetization* by cost avoidance. Some companies also stockpile patents for **defensive purposes**, to deter lawsuits (the logic being that if you sue me, I have patents to counter-sue you). While defensive patents don\u2019t directly generate income, they preserve a company\u2019s profits, which is just as critical in the innovation economy. The **smartphone patent wars** of the 2010s (Apple vs. Samsung et al.) demonstrated how companies use patents both as swords and shields, ultimately often settling in cross-licenses rather than continuing mutually destructive litigation. An interesting defensive initiative is the creation of **patent aggregators** like **RPX Corporation** or **Allied Security Trust (AST)** \u2013 member companies pool funds to buy up dangerous patents before trolls do, granting members royalty-free licenses. This preemptive strategy, while not a traditional \u201cmonetization\u201d scheme, addresses the flip side of the patent game: reducing *costs* from others\u2019 IP assertions.\n\n- **Patent Pools and Consortiums:** As mentioned, patent pools bundle multiple patents from different owners, which can then be licensed together. This not only simplifies licensing for complex technologies (like video codecs, wireless standards, DVD/Blu-ray technology, etc.) but also ensures the patent holders get a steady flow of royalties from widespread adoption of a standard. For example, the **MPEG-LA** consortium manages a pool for MPEG-2 and other video technology patents \u2013 device makers pay one fee to MPEG-LA, which then distributes royalties to dozens of patent owners in the pool. Such pools **monetize IP collectively** and prevent \u201croyalty stacking\u201d (where too many separate fees would otherwise burden product makers). Pools have been very successful in some areas (MPEG-LA reports billions paid out to patent holders over time), though attempts to create pools have failed in other cases due to disputes over valuation or holdouts (an interesting failure was the initially fractured approach to a patent pool for 3G cellular standards \u2013 it took years to streamline licensing). Overall, when they work, patent pools represent a **win-win**: patent owners get paid, and manufacturers get efficient access to critical IP, speeding up innovation adoption.\n\n- **IP-Backed Financing (Collateral, Securitization, and Royalty Streams):** IP assets can also be leveraged in financial transactions. Companies (especially startups) have used **patents as collateral for loans**, meaning a bank or lender will extend credit secured by the value of the patent portfolio\u301047\u2020L1-L4\u3011. In such cases, if the company defaults, the lender can seize the patents. This has grown in acceptance as the market has gotten better at valuing IP\u30104\u2020L9-L17\u3011. Another sophisticated approach is **royalty stream securitization** \u2013 essentially, turning future IP income into an upfront lump sum by selling rights to those future royalties. This is common in sectors like pharmaceuticals: for instance, **Northwestern University sold a portion of its future royalty rights to the drug Lyrica for $700\u00a0million in 2007**\u301045\u2020L1-L9\u3011, giving the school immediate cash while investors banked on the continued royalty income. There are even examples in entertainment: the famous \u201cBowie Bonds\u201d in the late 1990s were asset-backed securities tied to David Bowie\u2019s music catalog royalties. In the patent world, **Royalty Pharma** is a firm that specializes in buying patent royalty rights from universities or companies, providing upfront capital. Securitization monetizes IP by bridging it with capital markets \u2013 essentially treating patents as financial assets that can be traded or borrowed against. While promising, these deals require confidence in the stability of the IP\u2019s cash flows (e.g. a drug patent with years of market exclusivity remaining and strong sales, or a proven licensing program). If the underlying product flops or patents are invalidated, the investors lose out, so due diligence is key.\n\n- **IP Donations and Tax Benefits:** A niche strategy that saw some use (and abuse) in the past is donating IP to certain institutions for **tax deductions**. In the early 2000s, some companies *donated unused patents* to universities or non-profits. The U.S. tax code allows a deduction for charitable contributions of property, and if a patent\u2019s appraised value was high, the tax write-off could be lucrative. Essentially, the company monetized the patent by reducing its tax liability. However, this was often a *tax play* more than a technology transfer \u2013 in many cases the patents had dubious value and were never commercialized by the recipients. The IRS grew skeptical of inflated patent valuations and tightened rules around 2004, largely curtailing this practice. Still, it\u2019s an example of creative IP monetization: even if a patent can\u2019t be directly licensed or sold, it might yield a financial benefit through the tax system. (Another example of tax-based IP strategy, on the flip side, are **\u201cpatent box\u201d** regimes in various countries \u2013 more on that under international policies \u2013 which *reduce* taxes on income derived from IP.)\n\n- **Trademark & Brand Licensing:** Broadening beyond patents, other forms of IP like **trademarks** are heavily monetized via licensing. In franchising, for instance, a company (like a fast-food chain or hotel chain) licenses its brand name, logo, and business methods to franchisees for fees. Consumer goods and media provide many examples: Disney\u2019s characters and logos are licensed to toy makers and clothing manufacturers; sports teams license their names and logos for merchandise. While this is indeed IP monetization (and a huge one \u2013 global brand licensing is worth tens of billions annually), it\u2019s somewhat outside \u201cinnovation economy\u201d patents. It\u2019s worth noting, though, that some companies\u2019 primary income is from IP licensing in this way \u2013 consider that **The Coca-Cola Company** doesn\u2019t directly run all bottling operations; it largely makes money by licensing its secret formula (a trade secret) and brand to local bottlers around the world. Similarly, **ARM Holdings** in the semiconductor field doesn\u2019t manufacture chips; it designs processor IP and **licenses its chip designs** to hardware companies (earning royalties per device). ARM\u2019s royalty-driven model is a cornerstone of the smartphone industry. These illustrate that **an IP-centric business model** \u2013 where you create IP and license others to implement it \u2013 can be immensely profitable. \n\n- **Copyright Licensing (Software and Media):** In the technology realm, **software** is often monetized via copyright licenses (and sometimes patents too). Enterprise software firms license usage rights of their code to customers rather than selling ownership. Microsoft, for example, built an empire by licensing software (Windows, Office) \u2013 which is essentially leveraging IP (copyright in code, plus some patents) to collect fees. In fact, as an interesting twist, Microsoft also leveraged its patents by striking license deals with Android device manufacturers; by 2013 Microsoft was reportedly earning **~$2\u00a0billion per year from Android patent royalties** (with profit margins of about 95% on that stream)\u301037\u2020L283-L290\u3011. This kind of *hybrid* model \u2013 selling products and also charging competitors via IP \u2013 shows how IP can bolster a company\u2019s income. In media industries (film, music, publishing), the entire business is IP monetization: studios and labels exploit copyrights through distribution, streaming licenses, etc. While our focus is patents, it\u2019s useful to remember that **copyright and patent monetization often go hand-in-hand** in industries like software (code is copyrighted; underlying techniques might be patented). For instance, many video game companies license game engines (patented technology + copyrighted code) to other developers, earning royalty fees.\n\n- **Open Innovation and Alternative IP Strategies:** Interestingly, not all uses of IP are about *extracting* money \u2013 some are about *enabling* innovation and profiting indirectly. For example, some companies have tried **patent pledges** or open-licensing to stimulate an ecosystem. Tesla famously announced in 2014 it would not sue anyone who uses its electric vehicle patents in good faith, aiming to encourage the EV market\u2019s growth. While Tesla wasn\u2019t directly monetizing those patents, the broader strategy was to expand the market for EVs (which in turn could make Tesla more successful). Another example is **open-source software**: companies like Red Hat built a business selling services/support for open-source (unpatented, freely licensed) software \u2013 effectively monetizing expertise and brand rather than IP. These are \u201cclever\u201d strategies where IP is sometimes given away to monetize something else (platform adoption, complementary products, or reputation). Some firms also engage in **defensive publication** \u2013 publishing an invention to prevent others from patenting it \u2013 thereby denying competitors a possible monopoly (this is common in industries like software to keep certain techniques in the public domain). And there have been proposals for **patent buyouts or prize systems**: governments or foundations reward inventors with a prize and put the patent in the public domain, as an alternative to private monetization, but in modern times this is rare (though historically, e.g., the French government bought the patent for Daguerre\u2019s photography process in 1839 to open it up; in the last 50 years, similar ideas have been floated for essential medicines). While these aren\u2019t monetization strategies per se for the IP holder (since they\u2019re about *not* monetizing directly), they highlight the diverse ways IP can be managed in the innovation ecosystem.\n\nIn summary, the **\u201ctoolbox\u201d of IP monetization** ranges from routine licensing to litigation, financial engineering, and strategic alliances. Most innovation-driven organizations use a mix of these strategies depending on their business model and goals. Now, let\u2019s look at who actually makes the most money from IP.\n\n## The Organizations Profiting Most from IP  \nWhich companies or institutions reap huge rewards from intellectual property? We can identify several categories of players for whom IP is a significant or primary source of income:\n\n- **Technology & Electronics Companies (Licensing Powerhouses):** A number of tech companies derive substantial revenue from patent licensing in addition to (or even instead of) product sales. **IBM** is a classic example \u2013 for decades it leads in U.S. patent filings each year, and it has aggressively licensed its vast portfolio. In the 1990s and 2000s, IBM\u2019s licensing program was so successful that it consistently brought in around **$1\u00a0billion+ per year in IP royalties**\u30106\u2020L97-L104\u3011. IBM essentially treated its patent portfolio as a business unit, striking licensing deals across the IT industry (sometimes with an undertone that unlicensed use could invite legal action). Although IBM\u2019s overall business is selling hardware, software, and services, this billion-dollar licensing income bolstered profits significantly (at one point in the 2000s, IBM was jokingly said to be \u201cmore of a patent company that also sells computers\u201d given how high-margin the royalty stream was). Another standout is **Qualcomm**. While Qualcomm sells chips for smartphones, a huge portion of its profit comes from licensing its telecommunications patents. Every 3G/4G/5G phone uses core technologies patented by Qualcomm, which licenses them under FRAND (fair, reasonable, and non-discriminatory) terms to phone makers. For example, in early 2025 Qualcomm forecast about **$1.35\u00a0billion in revenue for its patent licensing segment in one quarter** (compared to $9.2\u00a0billion from chip sales that quarter)\u30109\u2020L1-L4\u3011. Those licensing revenues often have very high margins (after all, collecting a royalty doesn\u2019t cost nearly as much as manufacturing hardware). Companies like Qualcomm and **InterDigital** (a smaller company focused purely on wireless R&D and patent licensing) are often cited as examples of **\u201cmarket makers\u201d** in IP \u2013 they invest heavily in R&D, then license out the resulting IP broadly instead of manufacturing end-products. Another tech example is **Microsoft**, which we noted was earning roughly **$2\u00a0billion/year from Android patent royalties** around 2013\u301037\u2020L283-L290\u3011 \u2013 at one point Microsoft was making more profit from licensing its patents to Android phone manufacturers than from its own Windows Phone sales! This kind of ironic outcome underscores how valuable IP can be: even when a company loses in the product market, it can win via patents (Microsoft\u2019s mobile OS lost to Android, but Microsoft still got paid because Android allegedly infringed its IP). **ARM Holdings** (recently in the news with a big IPO) is yet another: its *entire* business is licensing its patented chip designs to others \u2013 it doesn\u2019t sell any physical chips, yet nearly every smartphone has \u201cARM cores\u201d inside, and ARM earns royalties on each. In short, many tech companies have become adept at turning IP into a **revenue stream or at least a strategic asset**. Some, like **Dolby Laboratories**, generate much of their income from licensing proprietary technologies (Dolby licenses its audio encoding patents to device makers and cinemas worldwide). For such companies, IP licensing is a core or majority source of income.\n\n- **Pharmaceutical and Biotech Companies:** In pharma, patents are absolutely central \u2013 however, the monetization is typically through **product sales at monopoly prices** rather than licensing. A drug company\u2019s primary way to profit from its patents is to be the exclusive seller of a patented drug for the 20-year term (often effectively ~10-15 years post-approval). So one could say *their entire profit* on a drug is due to the patent (once generics enter after patent expiry, profits plummet). While most pharma firms don\u2019t license their crown-jewel patents out (since they want to sell the drug themselves), there are cases of **licensing in pharma**: smaller biotechs often license their patents (or the underlying compounds) to bigger pharma companies for development and marketing. Royalty rates in biotech licenses can be substantial (e.g. a small biotech might get high-single-digit to low-double-digit percentage royalties on sales from a big pharma that brings a drug to market). **Gilead\u2019s hepatitis C drug Sovaldi** originated from a small company (Pharmasset) which Gilead acquired outright \u2013 illustrating another pattern: big companies will outright buy startups primarily for their IP (drug pipeline). So, while pharma\u2019s monetization of IP is mostly via protected sales, the value of those patents is enormous. Some pharma companies also do cross-licensing or patent swaps (especially if multiple companies have overlapping IP on a target \u2013 they might settle disputes by each getting rights). An interesting profit model in pharma is **collecting royalties from other firms**: for instance, **Royalty Pharma** (as mentioned) and **Ligand Pharmaceuticals** build portfolios of drug royalty rights rather than doing full drug development themselves. Also, in agriculture, **Monsanto (now Bayer)** made hefty profits by patenting genetically modified seeds and licensing their use under strict contracts to farmers (a mix of product sale and licensing, since farmers agree not to save seeds, effectively paying for the IP each planting season). In summary, while pharma profits heavily from IP, the organizations whose *main* income is IP licensing in life sciences are often intermediaries (biotech startups licensing to big pharma, or firms that buy royalties). Universities (next section) also play here: many new drugs stem from university patents licensed to companies.\n\n- **Non-Practicing Entities (Patent Assertion Entities):** These are firms for whom *patents are the only business*. Often derided as \u201cpatent trolls,\u201d they don\u2019t make products or provide services beyond licensing and litigation. **Intellectual Ventures**, co-founded by former Microsoft CTO Nathan Myhrvold, is one of the largest: it reportedly acquired **over 70,000 IP assets and monetized around 40,000 of them, generating over $3\u00a0billion in licensing revenues** in its first 10-15 years\u301021\u2020L43-L50\u3011. Its *business model* is essentially to buy patents and then license them out (frequently by approaching companies with a \u201cpay up or we might sue\u201d proposition). IV and similar entities often pass some share of income back to the original inventors or investors, but keep a large cut \u2013 in IV\u2019s case, by 2014 it had paid only about $500\u00a0million to inventors out of $3\u00a0billion collected\u301021\u2020L43-L50\u3011, the rest presumably covering its operations and profit. Other notable NPEs include **Acacia Research**, **WiLAN**, **Uniloc**, and many shell companies that operate one patent portfolio at a time. Some NPEs specialize in certain fields (for example, **Finjan Holdings** built a business around cybersecurity patents enforcement). Their profits come from settlements and licensing deals, which can be quite large if they target big tech companies. It\u2019s worth noting that some NPEs are backed by investors or even by operating companies (in a practice called **privateering**, an operating company might secretly fund an NPE to go after its rivals\u2019 infringing products). The **most litigious NPEs** have filed hundreds of lawsuits each, treating litigation as a numbers game to monetize as many patents as possible. For a subset of companies, then, **IP is not just the main source of income \u2013 it\u2019s the *only* source**. This has sparked policy debates, as many question whether these entities spur or stifle innovation. Reforms like the America Invents Act (2012) introduced mechanisms (inter partes review) that have made it easier to invalidate weak patents, somewhat curbing troll activity in recent years. Nonetheless, some PAEs continue to be highly profitable by picking strong patents and deep-pocketed targets.\n\n- **Companies Built on IP Licensing Business Models:** Apart from NPEs and big tech/pharma, there are firms whose entire model is creating IP and licensing it. We already mentioned ARM (chip designs) and Dolby (audio tech). Another example is **InterDigital**, which does R&D in wireless communications and then licenses patents to device makers (interdigital\u2019s revenues often come mostly from patent licenses for 3G/4G tech \u2013 effectively similar to Qualcomm but without a chip business on the side). **Tec Licensing** companies for older tech exist too; for instance, **Qualcomm\u2019s former subsidiary OmniTRACS** turned into a licensing arm for its trucking communication patents. In the realm of **university spin-outs**, sometimes a company is essentially formed to license a university patent rather than manufacture \u2013 these often exist just to hold IP until a bigger player licenses or buys it. Even some *consortia* earn IP income: **MPEG LA** itself, while distributing most royalties to patent owners, retains an administrative fee from all licensing \u2013 making it a lucrative venture for the pool administrator. Another interesting class: **collective rights organizations** (like ASCAP/BMI for music performing rights, or Copyright Clearance Center for text copying) \u2013 these collect IP royalties on behalf of creators and take a cut. While not \u201cprofit-maximizing\u201d companies in the usual sense (ASCAP is non-profit), they show how entire institutions exist to monetize IP at scale.\n\n- **Universities and Research Institutes:** We will cover this in detail in the next section, but it\u2019s worth noting here that a few universities earn substantial sums from patent licensing. For example, **University of California, Columbia University, Stanford, MIT, University of Florida, Northwestern University, and others** have each earned hundreds of millions (in some cases over a billion) over decades from licensing faculty inventions. However, for most universities, IP income is a small fraction of their budget (research grants and tuition far outweigh licensing revenue). Only in exceptional cases (like a blockbuster drug or a ubiquitous technology) does a university see windfall profits from IP. That said, some institutions \u2013 e.g., **The Wisconsin Alumni Research Foundation (WARF)** which manages University of Wisconsin\u2013Madison\u2019s patents \u2013 have built sizeable endowments from patent income (WARF was founded on Vitamin D patents in the 1920s and later earned big royalties from the blood thinner Warfarin and other inventions). **Fraunhofer Society** in Germany is another example: this network of research institutes patents prolifically and licenses technology to industry; Fraunhofer\u2019s most famous success is the **MP3 audio codec** \u2013 the institute\u2019s patents on MP3 were licensed worldwide, bringing in over \u20ac100\u00a0million in royalties, which helped fund further research. Thus, certain public research organizations do profit significantly from IP (often plowing it back into research).\n\nIn summary, **who profits most from IP?** It includes large operating companies using hybrid models (product sales + licensing), pure licensing firms, patent \u201cmiddlemen\u201d (trolls or aggregators), and occasionally non-profits (universities, research funds). In the U.S., companies like IBM, Qualcomm, Microsoft, and patent-focused firms like Intellectual Ventures or Dolby have made IP a major income source. Globally, we see similar patterns \u2013 e.g., **Ericsson and Nokia** now earn considerable patent licensing fees from their telecom portfolios (even after largely exiting the handset business). There are even government-backed entities (like Japan\u2019s **IP Bridge** or France\u2019s **France Brevets**) created to monetize national patent portfolios \u2013 though their success has been mixed (France Brevets, funded with \u20ac100M by the French government in 2011 to license French innovations, struggled due to public-sector constraints and drew criticism for behaving like a patent troll)\u301040\u2020L5-L13\u3011\u301040\u2020L15-L23\u3011. Ultimately, **IP monetization is a big business in its own right** \u2013 some organizations make more money from ideas than from products.\n\n## University Patents: Profits by Field and Cost Considerations  \nUniversities are a special case in the IP landscape. Ever since the **Bayh-Dole Act of 1980** in the U.S. gave universities the right to own and license inventions made with federal funding, academic institutions have tried to turn research into revenue. Do universities actually make money from patents? Which fields generate the most income? And how does that compare to research costs?\n\n**Overall Scale:** Academic technology transfer (the process of patenting discoveries and licensing them out) does bring in money, but relative to universities\u2019 total operations it\u2019s usually modest. A recent figure: in **2018, total licensing revenue from U.S. university patents was about $2.9\u00a0billion**\u301032\u2020L401-L404\u3011. That same year, U.S. universities spent on the order of **$75\u201380+\u00a0billion on research** (mostly funded by government and other sources). So, system-wide, licensing income was roughly 3\u20134% of research expenditures. In other years, the ratio is similar \u2013 a few billion in licensing vs. tens of billions spent on R&D. In fact, **most tech transfer offices (TTOs) struggle just to cover their own operating costs with licensing income**; lucrative patents are rare, and the **vast majority of university patents never earn substantial royalties**\u301034\u2020L243-L252\u3011. One study noted that *the top 5% of U.S. universities (about 9 institutions) accounted for 51% of all licensing revenue in 2020*\u301034\u2020L245-L252\u3011, and the top 10% accounted for 70%. This skew means a handful of universities (often those with a blockbuster drug or technology) dominate the earnings, while many others see little or no profit from patents. Moreover, it\u2019s estimated that **nearly 60% of licenses yield no royalties** at all for the universities, and only about **1% of licenses generate over $1\u00a0million** over their lifetime\u301034\u2020L243-L252\u3011. These data dispel the myth that tech transfer is a goldmine for most schools \u2013 in reality, it\u2019s an unpredictable endeavor where a single hit invention can eclipse hundreds of duds.\n\n**Revenue by Field:** When it comes to *which fields* produce the money, there is a very clear pattern: **life sciences (biomedical inventions) are the cash cows of university licensing**. According to the Association of University Technology Managers (AUTM), about **80% of all university licensing income comes from life science patents** (medical, pharmaceutical, biotechnology)\u301024\u2020L1-L4\u3011. For hospitals and research institutes, the share is even higher (90%+)\u301024\u2020L1-L4\u3011. This makes sense \u2013 a new drug or medical therapy, if it succeeds, can generate enormous sales, and universities usually get a royalty on those sales. For example, **Northwestern University\u2019s patent on the drug Lyrica (for neuropathic pain and epilepsy)** was licensed to Pfizer and became a blockbuster \u2013 Northwestern earned around $1.3\u00a0billion in royalties over a decade, even monetizing part of it upfront for $700M\u301045\u2020L1-L9\u3011. Similarly, **New York University** reaped an estimated $1\u00a0billion+ from its share of the Remicade antibody patent (an arthritis drug), and **Columbia University** earned around $790\u00a0million from a patent on basic DNA co-transformation methods (the Axel patents) in the 1980s-90s\u301041\u2020L1-L8\u3011. These are life science patents tied to products with huge markets. In contrast, fields like **engineering, physical sciences, and computer science** typically generate smaller licensing revenues. That\u2019s not to say they have no impact \u2013 they often lead to startups or industry adoption, but the monetization is often via equity in startups or know-how transfer rather than big royalty checks. A classic example: **Stanford\u2019s Office of Technology Licensing famously made around $255\u00a0million from the Cohen-Boyer recombinant DNA patent suite** (a biotech platform patent)\u301044\u2020L1-L4\u3011, but has made far less from, say, software patents (Stanford profs have also created giant value through startups \u2013 Google\u2019s founders licensed the PageRank algorithm patent from Stanford, but instead of royalties Stanford took 1.8\u00a0million shares in Google which it sold for $336\u00a0million; that\u2019s huge value but realized via equity, not a license fee). Generally, **biomedical patents (drugs, therapies, medical devices) can command high royalties** because a successful drug can have annual sales in the billions, whereas **engineering or materials patents** might be licensed for use in a component or process with more modest revenues. There are exceptions \u2013 e.g., a patent on a fundamental semiconductor process or a lucrative piece of software (if patented) could bring sizable fees \u2013 but by and large, **\u201cbiology pays\u201d** in university licensing.\n\nTo illustrate field differences: one AUTM report indicated that, for U.S. universities, out of roughly $242\u00a0million in license income analyzed, about $194\u00a0million was from life sciences and only ~$48\u00a0million from all other fields combined\u301024\u2020L37-L40\u3011. Life sciences include pharmaceuticals, biotech, medical diagnostics, etc., which often require years of further development by companies (protected by the exclusive license). **Engineering and physical sciences** (including fields like materials science, chemistry, physics, computer science) tend to produce lots of patents, but each individual patent usually has a smaller \u201caddressable market.\u201d They often get licensed for relatively low fees or as part of larger bundles, or they\u2019re used in startups where the payoff to the university might come if the startup is acquired. For instance, a new material or battery technology from a university lab might be licensed to a startup for a few percent royalty \u2013 if the product succeeds, it could be decent revenue, but rarely the scale of a pharmaceutical royalty. Some notable non-biomedical successes do exist, though. **The University of Florida\u2019s famous Gatorade patent** (a sports drink formulation invented in the 1960s by university doctors) is a case in point: UF and the inventors struck a deal that has yielded the university **roughly $20\u00a0million per year in Gatorade royalties in recent years**\u301031\u2020L1-L4\u3011. Over time (from 1970s to 2010s) Florida earned around **$500\u00a0million from Gatorade licensing**\u301032\u2020L399-L407\u3011 \u2013 an extraordinary return for a nutrition/chemistry invention. Another example: **Bell Labs (AT&T)** wasn\u2019t a university, but as a research institution it licensed out the transistor patent for a nominal fee in the 1950s, deliberately to spur widespread use (they didn\u2019t monetize it heavily due to antitrust concerns). More recently, **academia-developed algorithms or software** may be open-sourced or freely disseminated (as in much of computer science), so direct licensing income there is limited \u2013 instead, those contributions fuel innovation broadly (the \u201cprofit\u201d coming back indirectly via alumni starting companies, industry sponsorships, etc., rather than licensing fees).\n\n**Costs and Profitability:** The question of costs by field is interesting. Each field has different research cost structure and different likelihood of producing a licensable patent. **Life sciences research is expensive** (biomedical labs, clinical trials, etc.), but when it hits, it can pay off big. However, even in biotech, one often-cited statistic is that only a very small fraction of university patents ever yield enough to even cover the patent filing and maintenance costs. Many TTOs operate at a loss, essentially subsidized by the university, hoping for that rare big win. When a big win comes, though, it can subsidize many years of operations. For example, **Columbia University\u2019s tech transfer was in the red until the Axel gene patent started bringing in ~$100\u00a0million a year in the 1990s** \u2013 that one patent paid for a lot of other activity. **Stanford\u2019s Cohen-Boyer patent** also was licensed non-exclusively at low royalty rates to over 400 companies, generating hundreds of millions but also arguably kick-starting the biotech industry\u301044\u2020L1-L4\u3011. On the flip side, **MIT** has noted that in some years a single license (often in biotech) accounts for the majority of its income, and when that patent expires, revenues drop until another hit comes along. **Physics and materials science patents** often face the challenge that they may be very important scientifically but not tied to an immediately lucrative product. For instance, a breakthrough in experimental physics might lead to patents in areas like quantum computing or advanced materials, but it could take decades for an industry to develop around it, if ever. Meanwhile, the university may have spent millions on that research. This is why many argue that the primary purpose of university research is not revenue, but rather knowledge and public benefit; any patent income is a bonus that can be reinvested in research and education. Indeed, under Bayh-Dole, universities are required to share a portion of royalties with inventors (often 30-50% goes to the faculty/inventors as personal income or research funds) and use the rest for research/education. So it\u2019s not pure profit in the corporate sense.\n\n**Comparing to Operating Costs:** The user asked to compare patent income to total operating costs of institutions/companies. For universities, as noted, patent income is usually tiny relative to total budgets. Even the richest licensing universities \u2013 say Columbia or Stanford \u2013 might earn on the order of $50-$100\u00a0million in a good year from IP, whereas their annual budgets are in the **billions**. One stark data point: **In 2020, the *median* U.S. university earned just $1.5\u00a0million in licensing revenue** (roughly estimated from AUTM data), while spending hundreds of millions on research. So only in exceptional circumstances (like a small college happens to own a patent that becomes a hit product) would IP revenue approach a significant fraction of costs. A famous case in the 1970s was **Florida State University**, which patented a cancer drug called Taxol; they didn\u2019t earn as much as some others, but it was notable for a state school to have a valuable patent. Generally, the institutions that profit the most from patents relative to their size are those that had one or two *outsized successes*. For instance, **Wake Forest University** (a smaller research university) patented a technique for licensing stem cells used in cosmetic treatments, which generated tens of millions \u2013 relatively big for them. Another angle: **fields like experimental physics or astronomy**, which are fundamental science, seldom produce lucrative patents, yet universities continue to invest in them heavily for their scientific value. If one were to cynically budget based on patent ROI, almost all money would go to biomedical research and maybe some engineering \u2013 but that would neglect the broader mission of universities.\n\nIn summary, **universities do profit from IP, but mostly in life sciences and in a very concentrated way**. The costs of research are such that, on the whole, tech transfer *rarely* covers the research investment \u2013 one study found universities overall capture only about **16% of the economic value** of their patented inventions through licensing income\u301022\u2020L33-L38\u3011 (the rest of the value is realized by the licensees and society). However, the societal benefit is much larger \u2013 hundreds of new products (933 new products in 2020 alone from university tech) and over 200 new drugs/vaccines since Bayh-Dole\u2019s enactment have come to market via university licensing\u301034\u2020L194-L202\u3011\u301034\u2020L207-L215\u3011. Universities justify patenting as a way to ensure their discoveries get developed into products (especially in pharma, where no company would invest in trials without exclusivity). Financially, **the \u201cboring reality\u201d is that most university patent programs barely break even, except for the lucky few**. But those lucky few can be transformational: e.g., the **Gatorade royalties helped University of Florida fund research and attract talent\u301032\u2020L398-L407\u3011**, and schools like Northwestern used the Lyrica windfall to boost their endowment\u301045\u2020L33-L41\u3011. The **field breakdown** is clear: *Biology/medicine* brings in the lion\u2019s share of cash, *chemistry/materials* sometimes yields profitable drug or material patents, *engineering/computer science* often yields startups (where equity might be the payoff) more than royalties, and *pure science* fields rarely see direct IP revenue.\n\n## International Perspectives and Policy Experiments  \nWhile the focus is the U.S., it\u2019s worth noting how other countries have approached IP in the innovation economy, sometimes experimenting with different policies:\n\n- **Bayh-Dole Imitators and Professor\u2019s Privilege:** The Bayh-Dole Act (1980) in the U.S. is often credited with sparking the rise of university patenting and tech transfer. Other countries observed the U.S. experience and many decided to implement similar frameworks. Throughout the 1980s-2000s, nations like **Japan, Germany, Canada, UK, China, and others** changed laws to let universities own inventions from publicly funded research (where previously the government or the individual inventor might have owned them). For example, **Germany in 2002 abolished the \u201cProfessor\u2019s Privilege,\u201d** a law that had given professors ownership of their inventions \u2013 shifting rights to the universities (the intent was to increase commercialization like in the U.S.). **Sweden and Italy** had similar debates; Sweden actually kept professor-ownership for longer, one of the last in Europe. Interestingly, studies on these changes showed mixed results: simply handing patents to universities doesn\u2019t automatically replicate U.S. success. In some cases, academic patenting *increased*, but in others, it initially dropped because professors felt less personal incentive when the university took a cut. A recent study in Finland (which ended professor\u2019s privilege in 2007) found that **academic patenting by individuals dropped 29% after the change**, suggesting some negative impact on faculty entrepreneurship\u301038\u2020L31-L35\u3011. This is an ongoing debate: the **\u201cbest\u201d policy for academic innovation** isn\u2019t one-size-fits-all. The U.S. experience is unique partly due to its entrepreneurial culture and robust venture capital system that helps spin-offs around university IP. Other countries have tried to foster similar ecosystems with varying degrees of success.\n\n- **Patent Monetization Funds:** A novel policy some countries attempted is creating **sovereign patent funds (SPFs)**. These are government-backed entities that acquire patents and attempt to monetize them, ostensibly to benefit the national economy or defend domestic companies. **France Brevets**, launched in 2011 with \u20ac100M funding from the French government, is a prime example. It sought to license French innovations globally and even took legal action against firms like HTC and LG to enforce French-owned NFC technology patents\u301040\u2020L15-L23\u3011\u301040\u2020L27-L35\u3011. However, by 2022, even France Brevets\u2019 CEO admitted their public-sector ties made monetization harder\u301040\u2020L5-L13\u3011. Critics (like the EFF) pointed out the irony of a state-sponsored \u201cpatent troll\u201d suing foreign companies\u301040\u2020L9-L17\u3011. Japan launched a similar fund (the **Innovation Network Corp. of Japan\u2019s IP Bridge**), which has been somewhat more low-key and focused on pooling Japanese electronics patents to license abroad. China, known for its huge volume of patent filings in recent years (often driven by subsidies and mandates to universities and companies to patent more), has also considered mechanisms to monetize its troves of patents internationally \u2013 though Chinese firms often face difficulties enforcing patents overseas. These experiments show the *national* approach to IP monetization: governments trying to ensure their country\u2019s inventions bring back revenue or strategic advantage. The success has been limited so far, and some efforts have been criticized as antagonistic in global trade relationships.\n\n- **Patent Boxes and Tax Incentives:** Several countries have introduced **\u201cpatent box\u201d** regimes (also called innovation boxes). This is a *tax policy* where income derived from IP (patent royalties or sometimes product sales covered by patents) is taxed at a lower rate than other income. The UK, the Netherlands, Belgium, and many others have variants of this. For example, the **UK Patent Box**, launched in 2013, allowed companies to pay a reduced 10% corporate tax on profits attributable to patents (versus the standard 19\u201325% rate)\u301039\u2020L19-L27\u3011. The idea is to encourage companies to locate their R&D and hold their patents domestically, and to reward innovation by letting them keep more of the earnings. As of 2023, over a thousand companies in the UK were using the Patent Box, with **\u00a31.4\u00a0billion in total tax relief claimed in 2022-23**\u301039\u2020L1-L8\u3011 \u2013 suggesting it\u2019s substantial. However, critics argue patent boxes don\u2019t necessarily create new innovation; they may just be a tax break for IP that would have been created anyway, and can be gamed by clever accounting (shifting profits to IP-heavy subsidiaries). Nonetheless, from a monetization standpoint, patent boxes effectively **increase the net profit from IP** for companies, thus indirectly boosting the value of owning patents. In the innovation economy, such policies can make IP-centric business models even more attractive (or at least make CFOs smile).\n\n- **Compulsory Licensing and Access vs. Incentives:** Some countries prioritize public needs over IP profits through measures like **compulsory licensing**, especially in pharmaceuticals. For instance, countries like India, Brazil, or Thailand have issued compulsory licenses on certain drug patents to allow generic production (typically for public health reasons, like making an expensive patented drug more affordable). This is sort of the opposite of monetization \u2013 it\u2019s a forced cap on monetization in the public interest. While not a strategy to make money, it\u2019s relevant as an *experiment in limiting* IP for greater good. The threat of compulsory license can also influence how companies monetize \u2013 e.g., a pharma company might choose to license a patent on reasonable terms to a generic manufacturer in a country rather than have the government break the patent outright. Globally, this balancing act continues: high-income countries tend to strictly enforce IP (benefiting those monetizing it), whereas some lower-income countries push back to reduce costs.\n\n- **Prizes and Grants vs. Patents:** There\u2019s an ongoing discussion in innovation policy circles about prizes or direct funding as alternatives to patent-driven incentives. For example, **X-Prize competitions** reward specific breakthroughs with a cash prize (the winner typically doesn\u2019t have to relinquish IP though). Governments sometimes offer **innovation prizes** (e.g. a prize for developing a better diagnostic test), which is a way to pay for innovation upfront and possibly keep the outcome open. Thus far, these haven\u2019t replaced patents but work alongside them. In some areas like pharmaceuticals, proposals have been made for **patent buyout programs** where a government would pay a pharma company the expected profit of a drug in exchange for making it generic immediately \u2013 no major country has implemented this, but it\u2019s been debated as a way to incentivize innovation while ensuring cheap access (a modern spin on ideas by economist Michael Kremer and others).\n\n- **Open Source and Patent Non-Aggression Pacts:** In the software realm internationally, a notable movement is open source, which often rejects patents (or uses licenses that are void if you sue others for patent infringement). There are also industry groups like the **Open Invention Network (OIN)**, where member companies pool patents and agree not to sue each other over Linux-related technology \u2013 effectively a defensive alliance to protect the open source ecosystem. Companies join OIN not to monetize patents but to neutralize them in a certain domain. Similarly, the **LOT Network** is a pact where companies agree that if any of their patents falls into the hands of an NPE, all other members get a free license \u2013 the goal is to reduce the risk of trolls. Over 1,000 companies globally have joined LOT Network, including big players, as a defensive measure. These collaborative efforts show a \u201ccommunity\u201d experiment to counter the negative aspects of monetization (like trolling) by leveraging collective power.\n\n- **Notable International Case \u2013 Japan\u2019s Employee Invention Law:** A curious case study: In 2004, Japanese inventor **Shuji Nakamura** (who co-invented the blue LED) sued his former employer Nichia Corporation because he was rewarded only \u00a520,000 (~$200) for a patent that turned out to be extremely valuable. The Japanese court in 2005 awarded him \u00a5840 million (~$7 million) for his contribution \u2013 a shocking decision at the time, leading Japan to reform its patent law regarding employee compensation. This episode highlighted how **who profits from IP** can be contentious \u2013 in Japan, it led companies to clarify incentive structures for their researchers. It\u2019s a reminder that the allocation of IP profits (inventor vs. employer vs. the public) differs by country and can evolve (Japan moved toward a system a bit closer to the U.S., where companies own the patents but often share some royalties or bonuses with inventors by contract).\n\nEach country\u2019s innovation ecosystem has its own quirks. The U.S. system has been very monetization-friendly (strong enforcement, broad patentable subject matter historically, etc.), which is why we saw explosive growth of patent licensing and NPE activity there. Europe has been somewhat less litigation-friendly (e.g., loser-pays legal costs and more limited discovery make trolling less attractive), although the new Unified Patent Court may change dynamics. China in the last decade created *huge quantities of patents* via subsidies and mandates \u2013 but quality and monetization lag; however, China is catching up in enforcing IP too as its own companies now have more to protect. We also see international disputes, like **standard-essential patent fights** playing out in multiple jurisdictions (companies sometimes shop for an injunction in a patent-friendly country\u2019s court to pressure a global license \u2013 e.g., a court in Germany or the U.S. might ban a product, forcing a settlement that applies worldwide).\n\nThe big picture: **IP monetization has gone global**, but local policies can either facilitate or hinder how it\u2019s done. \u201cBetter\u201d policies is subjective \u2013 e.g., some might say the U.S. was too lax allowing trolls to flourish, while others say it was necessary to unlock dormant IP value. Some point to Israel\u2019s strong tech-transfer culture (Technion and Weizmann Institute have notable successes) or Canada\u2019s more centralized support for commercialization (e.g., *MaRS* innovation hub in Toronto) as interesting models. Even failures teach lessons: the collapse of the **IPXI patent exchange** around 2014 (due to lack of buyers/sellers willing to trade standardized license units) showed that treating patents like commodities is tricky because each patent is unique and licensing is often custom-negotiated. It was a clever idea \u2013 to make a sort of \u201cstock market\u201d for IP \u2013 but it didn\u2019t gain traction. Likewise, **Google\u2019s 2015 experiment with a public patent purchase program** (an open call for people to offer patents for sale to Google) was an attempt to streamline transactions and maybe keep patents out of troll hands; Google bought some patents but it wasn\u2019t a game-changer. \n\n## Case Studies: Crazy Ideas, Successes, and Cautionary Tales  \nLet\u2019s now highlight a few **notable case studies and experiments in IP monetization**, including both successes and failures, that illustrate the innovation economy\u2019s variety:\n\n- **IBM\u2019s 1990s Patent Licensing Program (Success):** In the early 1990s, IBM was in financial trouble. Under new leadership, it aggressively pivoted to monetize its massive patent trove. IBM started charging companies for technology they had been freely using and ramped up patent filings in strategic areas. By the mid-90s, IBM was earning over **$1\u00a0billion annually from patent licenses**\u30106\u2020L97-L104\u3011 \u2013 at one point this was *nearly 1/3 of its profit*. This program is often cited as a **turning point** that made other companies realize patents could be profit centers, not just legal shields. IBM\u2019s approach included negotiation with just about every major tech player \u2013 some called it the \u201cIBM patent tax,\u201d but IBM framed it as sharing its R&D (for a fee). The success here was making IP a core business unit. However, over time as companies became less willing to pay and IBM shifted focus to cloud/AI, its licensing revenue declined (from a peak of ~$1.7B around 2000 to under $600M by 2020)\u30105\u2020L11-L18\u3011. Still, IBM demonstrated the profit potential in a large dormant portfolio.\n\n- **Qualcomm\u2019s Rise (Success):** Qualcomm in the late 1980s bet on CDMA, an unproven wireless technology. It patented CDMA like crazy. When CDMA became part of cellular standards (3G and beyond), Qualcomm\u2019s patents became **standard-essential**, meaning any phone needed licenses. Qualcomm famously structured most license deals as a percentage of the handset price (up to ~5%), which critics argued was too high, but it defended as fair given the R&D investment. The result: Qualcomm\u2019s licensing division (QTL) often contributed the majority of the company\u2019s profits, subsidizing chip development and other ventures. This model was so successful that it sparked antitrust scrutiny in some countries (e.g., China and Korea fined Qualcomm for anticompetitive licensing practices). Nonetheless, as a **case study**, Qualcomm turned a portfolio of radio patents into a multibillion-dollar royalty stream \u2013 essentially proving that a **small company with key patents can grow into an industry giant by monetizing IP**. It\u2019s a double-edged legacy: many startups dream of \u201cbeing the next Qualcomm\u201d if they hold a core patent for a new standard, but few succeed to that extent.\n\n- **Intellectual Ventures and Patent Aggregation (Mixed):** Intellectual Ventures (IV) was founded around 2000 with an ambitious premise: there is a lot of \u201clatent\u201d invention out there that isn\u2019t monetized (e.g., patents sitting on shelves of failed startups or idle in corporate portfolios). IV raised around $5 **billion from investors** (including big tech companies initially) to buy patents en masse and license them. IV did generate **billions in licensing revenue**\u301021\u2020L43-L50\u3011, but its net success is debated. It became the poster child for patent trolling, filing stacks of lawsuits through shell companies. IV also tried genuine invention via an \u201cInvention Science Fund\u201d and has a lab that came up with some cool ideas (like a laser to shoot down mosquitoes, a nuclear reactor design, etc.), but those have not (yet) translated to big money. Meanwhile, some early investors reportedly soured as returns didn\u2019t match the hype (Forbes in 2018 reported that some IV patent funds were under water). IV\u2019s mixed outcome illustrates that **mass patent monetization is harder than it looks** \u2013 identifying valuable patents and enforcing them efficiently at scale is challenging. Still, IV did alter the patent market: it spurred the rise of defensive aggregators (like RPX) and arguably forced tech companies to reckon with their dormant IP (either sell to IV or use it themselves). One quirky IV deal: it once acquired a patent and **licensed it to a shell company that sued Kodak, then split the settlement** \u2013 complex schemes like that show the lengths professional monetizers go. IV\u2019s legacy also includes the largest-known patent deal: it acquired ~patent portfolio from AOL, then quickly flipped some to Microsoft \u2013 showing how it sometimes acted as a proxy for big companies.\n\n- **University of California\u2019s CRISPR Patent Battle (Ongoing):** A recent case in biotech: the gene-editing technology CRISPR was co-invented by academic researchers at UC Berkeley and MIT/Broad Institute. A bitter patent fight ensued over who owned the core patents. This dragged through courts and patent offices in multiple jurisdictions. While not a \u201cmonetization strategy\u201d per se, it shows how high the stakes are \u2013 potentially billions in future licensing fees from companies developing CRISPR-based therapies. As of 2022, the Broad Institute (on behalf of MIT/Harvard) prevailed in key U.S. patents for use in human cells, while UC has patents in other uses and geographies. Both sides have licensed out CRISPR widely (often non-exclusively for research, exclusively for certain commercial areas). This is a case where **universities and research institutes are poised to earn significant income** (already, companies have paid hefty up-front fees to secure rights). It\u2019s also an example of a *failed collaboration*: initially the inventors could have pooled IP, but instead it became a zero-sum fight \u2013 a cautionary tale that sometimes **patent races** can lead to prolonged legal battles rather than quick monetization.\n\n- **Failed Patent Marketplace \u2013 IPXI (Failure):** The **Intellectual Property Exchange International (IPXI)** was launched in 2012 as a pioneering marketplace where patents would be bundled into standardized license units (called ULRs) that could be bought and sold to effectively license the patent for a set number of uses. It was likened to a stock exchange for IP. Despite backing by major institutions and a lot of fanfare, IPXI closed down by 2015 without making a dent. Why? It struggled to get enough high-value patents listed, and potential licensees were wary of this new approach. IP is not a uniform commodity; each deal has nuances (field of use, sub-licenses, etc.) that were hard to capture in a one-size instrument. The failure of IPXI was an important data point: **innovation in monetization itself can fail** due to market inertia and complexity of patent transactions. However, the idea lives on in discussions about how to improve liquidity and transparency in the IP market.\n\n- **Nortel and Motorola Patent Sales (Success in salvage):** Sometimes, patents are the last valuable asset of a failing company. Two big examples: **Nortel Networks**, a Canadian telecom giant, went bankrupt in 2009. In 2011, its portfolio of ~6,000 patents was put to auction, and a consortium of Apple, Microsoft, RIM, Sony and others (dubbed the \u201cRockstar Consortium\u201d) paid an astonishing **$4.5\u00a0billion** for it. Google had also bid up to $4B but lost \u2013 highlighting how strategic those patents were seen for mobile and telecom. Rockstar then used some of those patents to sue Google and Android OEMs, extracting settlements (it eventually wound down and sold the remaining patents on). This case signaled that **major tech companies were willing to spend enormous sums on patents**, validating them as financial assets. Similarly, **Google\u2019s $12.5\u00a0billion acquisition of Motorola Mobility in 2012** was largely motivated by Motorola\u2019s ~17,000 patents (to defend Android in patent wars). Google later resold the Motorola hardware business to Lenovo for only ~$2.9B, but it kept most of the patents \u2013 effectively valuing them at around $9\u00a0billion of the original deal. These cases show **defensive monetization**: the buyers didn\u2019t necessarily aim to license out the patents for profit, but to prevent others from using them against their own products (and to cross-license). Nonetheless, if we consider \u201cmonetization\u201d as getting value, Nortel\u2019s creditors certainly monetized its IP via that sale, and Google monetized Motorola\u2019s IP by using it to ward off litigation (some jokingly say Google\u2019s Motorola deal saved Android OEMs from paying far more in royalties to others). A contrasting failure: **Kodak**, once an imaging patent giant, tried to auction its digital imaging patents in 2012 while in bankruptcy. They hoped for Nortel-like numbers, but got only about $525\u00a0million from a consortium of buyers (including Apple and Google ironically teaming up). That was still sizable, but far below initial estimates of $2+ billion, showing that not every patent cache fetches top dollar \u2013 it depends on how core they are to ongoing battles. \n\n- **Xerox PARC and Missed Opportunities (Learning Failure):** Xerox\u2019s Palo Alto Research Center (PARC) in the 1970s pioneered the personal computer interface (mouse, GUI), ethernet, and more. However, Xerox famously failed to monetize many of these innovations. They did have patents \u2013 but management didn\u2019t aggressively commercialize or license them in time. Apple and Microsoft drew inspiration (some might say more) from PARC\u2019s work for their products. While Xerox did later sue Apple (resulting in a settlement) and license some tech, they captured only a tiny slice of the value. This \u201cfailure to monetize IP\u201d case is often studied in business schools. It emphasizes that **having great IP isn\u2019t enough \u2013 one must recognize its potential and either use it or license it effectively**. Xerox was focused on copiers and didn\u2019t see computing as their domain until it was late. The lesson: *IP can slip through your fingers* if not managed with a vision. In a twist, Xerox eventually became more IP-savvy \u2013 by the 2000s it too had a licensing program to earn money from its sizable patent portfolio in printers and imaging.\n\n- **Small Inventor Windfalls vs. Trollish Trouble:** There are stories of lone inventors who struck gold with patents \u2013 for instance, the inventor of the **\u201cIntermittent Windshield Wiper\u201d** who fought car companies for years (inspiring a Hollywood movie *Flash of Genius*), eventually winning damages. Or the **NTP vs. RIM** case, where a tiny company NTP, owning patents on wireless email, sued Research In Motion (BlackBerry) and, after a legal saga, got a **$612.5\u00a0million** settlement in 2006. NTP\u2019s founder (inventor Thomas Campana) had tried to commercialize wireless email in the 90s, failed, but his patents lived on to haunt RIM. This was one of the seminal cases that raised alarm about patent trolls (NTP never made a product). Conversely, sometimes small patent holders don\u2019t win: e.g., **Zeroclick vs. Apple**, or various garage inventors who sue large firms often face invalidation of their patents or protracted fights. The mixed outcomes here show that **the patent system can sometimes reward the little guy \u2013 but it\u2019s a gamble**. The NTP case success led many others to try (leading to an explosion of PAE suits in the late 2000s), but subsequent legal changes (e.g., easier invalidation via the Patent Trial and Appeal Board) have made it tougher.\n\n- **Open Source vs. Patents \u2013 The Android Story:** Google\u2019s Android OS was open-source and free for phone makers, but it ran into the wall of others\u2019 patents. By 2011-2012, Microsoft, Apple, Oracle, and others were claiming Android infringed dozens of patents (from user interface to operating system functions). Android manufacturers ended up paying royalties to Microsoft (as noted, Microsoft earned ~$2B/year) and some to patent pools for MPEG, etc. Google\u2019s purchase of Motorola (noted above) was partially to obtain patents to countersue and deter Apple and Microsoft. Eventually most of these disputes settled (Apple and Google agreed to a patent ceasefire, Microsoft and Google settled, etc.). This episode is like a **real-world experiment** in how far openness can go when IP is pervasive: it showed that even a free/open product can incur costs from patents. It arguably also *validated* the patent system\u2019s power, for better or worse \u2013 even the might of Google had to stockpile patents to survive the onslaught. In response, Google and others formed the **LOT Network** to prevent future trolling, and Google pledged some patents to OIN for Linux\u2019s defense. The \u201cAndroid tax\u201d (royalties to others) has decreased as some patents expired or were fought off, but it highlighted that **IP rights are deeply embedded in the tech ecosystem**, and navigating them is part of the innovation game.\n\n- **Tesla\u2019s Patent Pledge (Experiment):** When Tesla announced it wouldn\u2019t enforce its EV patents (essentially open-sourcing its patents to good-faith users), it was a bold experiment. The rationale was that the electric vehicle market was so small at the time, Tesla needed competitors to also succeed in making EVs popular (and building charging infrastructure, etc.), and it bet that its real competitive advantage was execution and brand, not patents. This is an example of **using IP in a non-traditional way to stimulate innovation**. It\u2019s hard to measure success; Tesla certainly did not suffer from it (it\u2019s now the dominant EV maker), and more car companies did jump into EVs. One could say this is a case where *not* monetizing IP was a strategic move to grow the overall pie (which Tesla now takes a large slice of). It challenges the assumption that more monetization is always the goal \u2013 sometimes **IP can be leveraged by sharing rather than charging**, to indirectly benefit the IP owner.\n\nEach of these stories \u2013 and many others \u2013 paints a piece of the big puzzle of IP in the innovation economy. Some crazy ideas worked (who would have thought selling *no product* and just suing with patents could be a business model \u2013 yet it is), and some failed (patent stock exchange). Some \u201cboring\u201d strategies proved extremely effective (quietly cross-licensing to avoid war, or licensing a platform tech widely to enable an industry, like Stanford did with DNA cloning). Others created unintended consequences (a boom in low-quality patents and troll suits, leading to pushback and reforms).\n\n## Conclusion  \nIn conclusion, the world of IP and patents is vast and multifaceted. **Monetization strategies** range from conventional licensing (the workhorse of IP income, especially for patented technology and creative works) to more exotic financial and legal maneuvers. Organizations that **profit from IP the most** include not only innovative manufacturers but also specialized entities for whom patents are products in themselves. In the **innovation economy** of the last half-century, IP has become a currency: companies trade it, fight over it, and invest in it hoping for future payoff.\n\nThe **United States** has been at the forefront of these developments \u2013 with strong patent rights fueling aggressive monetization (and some excesses, prompting adjustments like anti-troll measures). U.S. universities have embraced patents since Bayh-Dole, yielding both breakthrough successes (largely in biomedicine) and many lessons about realistic returns on research. **Internationally**, other countries have tried to harness IP for economic gain, sometimes copying U.S. policies, other times striking out in new directions (like patent boxes or sovereign patent funds). Each approach offers insight: what works in one innovation ecosystem may not directly translate to another.\n\nFor someone navigating this landscape, a few **insights** stand out:\n\n- *IP monetization is often a long game:* Successful licensing or litigation campaigns can take years to materialize. Patents filed today might only see significant revenue a decade from now (if ever). Companies and institutions that treat IP as a strategic asset tend to fare better than those looking for quick cash.\n\n- *Concentration of returns:* Just as venture capital follows a power-law (a few startups give the big returns), patent monetization is heavily skewed. A tiny fraction of patents yield the bulk of revenue. This is true in universities (a few patents make most of the money\u301034\u2020L247-L252\u3011) and in corporate portfolios (many patents are kept for defense or freedom-to-operate rather than licensing). So it\u2019s often about identifying or betting on those blockbuster patents.\n\n- *Adaptation and innovation in strategy:* The \u201ccrazy\u201d ideas of yesterday can become the norms of tomorrow. For example, defensive patent aggregators or patent litigation insurance were novel two decades ago; now they are part of corporate IP strategy. Innovation doesn\u2019t stop at the lab \u2013 it extends to how one exploits and manages IP. We see constant evolution, like new marketplaces, AI tools for patent valuation, and shifts toward more collaborative licensing (patent pools, clearinghouses).\n\n- *Balancing act between monetization and innovation:* There\u2019s an underlying tension: we want inventors and organizations to profit from IP to incentivize innovation, but we also want knowledge to diffuse and new entrants not to be stifled. Thus, the most successful long-term strategies tend to be those that find a sweet spot \u2013 e.g., licensing technologies broadly at reasonable rates can actually **expand markets** (Stanford\u2019s broad non-exclusive licensing of the Cohen-Boyer DNA patent is credited with helping birth biotech, benefiting everyone\u301043\u2020L292-L300\u3011\u301043\u2020L307-L315\u3011). In contrast, overly aggressive monetization (e.g. extortionate licensing demands or blocking innovation via injunctions) can trigger backlash (lawsuits, regulation, or competitors designing around the patents). The innovation economy thrives when IP is respected *and* used constructively.\n\n- *Case studies are instructive, but context matters:* A strategy that succeeded for one company (like Qualcomm\u2019s patent licensing focus) might fail for another if the conditions differ. Similarly, a country\u2019s policy (like Bayh-Dole) might boost commercialization in one setting but have less impact in another without the right complementary factors (like venture funding, entrepreneurial culture). It\u2019s important to glean the principles \u2013 e.g., aligning incentives, securing freedom to operate, leveraging unique assets \u2013 and apply them judiciously.\n\nIn the end, patents and other IP are tools. They can be wielded to **build ecosystems** (through cross-licensing and pooling that drive standards and compatibility), or to **extract rents** (through litigation and exclusivity). Often, they do both. The **innovation economy** over the last 50 years has been supercharged by the promise of IP rewards \u2013 think of biotech startups racing to patent gene editing, or tech giants pouring billions into R&D knowing patents will protect their breakthroughs. At the same time, we\u2019ve seen **patent absurdities** (like trivial patents and troll lawsuits) that prompted reforms to refocus the system on true innovation. \n\nAs we look ahead, new domains like AI and quantum computing are emerging, bringing fresh IP challenges (e.g., how to handle AI-generated inventions, or the open-source ethos vs. patenting in software). The monetization strategies will surely adapt \u2013 perhaps more emphasis on **portfolio licensing** (where entire technology platforms are licensed), or new forms of **IP marketplaces** enabled by better data on patent value, or even broader adoption of **government prizes or purchases** for certain technologies (for example, calls for governments to buy out vaccine patents during pandemics to ensure access). We might also see **increased specialization**, where certain firms or institutions become known as \u201cIP hubs\u201d for specific sectors (similar to how ARM is for chip IP).\n\nOne thing is clear: IP will continue to be a key currency in the innovation economy. Those who manage it shrewdly \u2013 knowing when to enforce, when to collaborate, when to sell, and when to donate \u2013 will drive not only **profits** but also, hopefully, **progress**. And those stories, both the triumphs and the cautionary tales, will keep shaping how we think about the nexus of ideas and economics in the decades to come.\n\n**Sources:** \n\n- Overview of patent monetization strategies\u30103\u2020L144-L152\u3011\u30103\u2020L157-L165\u3011\u30103\u2020L188-L196\u3011\u301047\u2020L1-L4\u3011  \n- Examples of corporate IP licensing revenues (IBM, Qualcomm, Microsoft)\u30106\u2020L97-L104\u3011\u30109\u2020L1-L4\u3011\u301037\u2020L283-L290\u3011  \n- Data on Intellectual Ventures and NPE licensing\u301021\u2020L43-L50\u3011\u301013\u2020L297-L305\u3011  \n- University tech transfer statistics (overall revenue, life sciences share, concentration among top universities)\u301032\u2020L401-L404\u3011\u301024\u2020L1-L4\u3011\u301034\u2020L245-L252\u3011  \n- Notable university patent successes (Florida/Gatorade, Northwestern/Lyrica, Stanford/UC Cohen-Boyer)\u301032\u2020L399-L407\u3011\u301045\u2020L1-L9\u3011\u301044\u2020L1-L4\u3011  \n- Policy references (patent box uptake, France Brevets)\u301039\u2020L19-L27\u3011\u301040\u2020L5-L13\u3011\u301040\u2020L15-L23\u3011  \n- Stanford\u2019s broad biotech licensing approach\u301043\u2020L292-L300\u3011 which became a \u201cgold standard\u201d for tech transfer\u301044\u2020L1-L4\u3011."
            ]
          },
          "status": "finished_successfully",
          "end_turn": true,
          "weight": 1.0,
          "metadata": {
            "citations": [
              {
                "start_ix": 1925,
                "end_ix": 1938,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Understanding Key Strategies of Patent Monetization",
                  "url": "https://www.iiprd.com/patent-monetization/#:~:text=Licensing%3A%C2%A0%20Licensing%20is%20arguably%20the,among%20the%20surveyed%20firms",
                  "text": "Licensing:\u00a0 Licensing is arguably the most common and easily understandable method of flowing with patent monitory. It is the legal right given to the owner of the patented technology to allow third parties to utilize them in return for some form of consideration. According to LES, a survey of the licensing revenues indicated that licensing made up more than 40 percent of the total income from patent monetization among the surveyed firms .",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 3,
                    "cited_message_id": "4cd296df-a269-4bd3-810f-c7eaeecc2d19",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 144,
                    "end_line_num": 152,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 2091,
                "end_ix": 2104,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Understanding Key Strategies of Patent Monetization",
                  "url": "https://www.iiprd.com/patent-monetization/#:~:text=,used%20in%20standard%20essential%20patents",
                  "text": "* Exclusive licensing: Authorization of rights to a single licensee, usually on an exclusive basis for a particular exercise or area. * Non-exclusive licensing: Giving permission to many people to utilise the patented technology. * Cross-licensing: Cross licenses are when two firms agree that they can use each other\u2019s patents and this is mostly used to settle legal matters or gain access to related technologies. * Patent pools: Patent pool in which many patentees combine their patents in a bundle especially used in standard essential patents.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 3,
                    "cited_message_id": "4cd296df-a269-4bd3-810f-c7eaeecc2d19",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 153,
                    "end_line_num": 161,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 2323,
                "end_ix": 2336,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Understanding Key Strategies of Patent Monetization",
                  "url": "https://www.iiprd.com/patent-monetization/#:~:text=%2A%20Cross,used%20in%20standard%20essential%20patents",
                  "text": "* Cross-licensing: Cross licenses are when two firms agree that they can use each other\u2019s patents and this is mostly used to settle legal matters or gain access to related technologies. * Patent pools: Patent pool in which many patentees combine their patents in a bundle especially used in standard essential patents.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 3,
                    "cited_message_id": "4cd296df-a269-4bd3-810f-c7eaeecc2d19",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 157,
                    "end_line_num": 162,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 2689,
                "end_ix": 2702,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Qualcomm sales beat estimates, shares drop after licensing forecast | Reuters",
                  "url": "https://www.reuters.com/technology/qualcomm-results-forecast-top-expectations-ai-drives-smartphone-sales-2025-02-05/#:~:text=At%20the%20midpoints%20of%20the,licensing%2C%20according%20to%20LSEG%20data",
                  "text": "At the midpoints of the ranges, Qualcomm forecast second-quarter revenues of $9.2 billion for its chip business and $1.35 billion for patent licensing. Wall Street had expected $8.90 billion for chips and $1.43 billion for patent licensing, according to LSEG data.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 8,
                    "cited_message_id": "eee9d10e-93af-4172-b259-3d2117da2d5f",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 219,
                    "end_line_num": 225,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 2935,
                "end_ix": 2948,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Understanding Key Strategies of Patent Monetization",
                  "url": "https://www.iiprd.com/patent-monetization/#:~:text=",
                  "text": "# 2.Patent Sales:",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 3,
                    "cited_message_id": "4cd296df-a269-4bd3-810f-c7eaeecc2d19",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 163,
                    "end_line_num": 170,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 3461,
                "end_ix": 3474,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Understanding Key Strategies of Patent Monetization",
                  "url": "https://www.iiprd.com/patent-monetization/#:~:text=Another%20type%20of%20monetization%20in,at%20least%207%20billion",
                  "text": "Another type of monetization in patents is the sale of patents, which is highly appropriate for cases when a company wants to get rid of unprofitable assets, or in need of immediate cash inflows. Referring to the statistics of Allied Market Research, the IP trading market size across the globe was approximately $7. 4 billion in the year 2020 and is expected to touch the figure of $34. It predicts that by 2030 alone the figure will have grown to at least 7 billion .",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 3,
                    "cited_message_id": "4cd296df-a269-4bd3-810f-c7eaeecc2d19",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 165,
                    "end_line_num": 173,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 4082,
                "end_ix": 4094,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Trolls Like Intellectual Ventures Must Be More Closely Regulated, But How? - Sequel Legal",
                  "url": "https://sequellegal.com/patent-trolls-like-intellectual-ventures-must-be-more-closely-regulated-but-how/#:~:text=Patent%20trolls%20are%20the%20bane,of%20the%20underlying%20intellectual%20property",
                  "text": "Patent trolls are the bane of the existence of American industry. These companies and individuals shop around for patents and patent portfolios to acquire for the sole purpose of using litigation and the threat of litigation to monetize their underlying ideas. They have no interest in the utility, social value or commercial viability of the underlying intellectual property.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 21,
                    "cited_message_id": "aa45e6a3-d90a-4c1c-8048-ad8040585491",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 33,
                    "end_line_num": 41,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 4094,
                "end_ix": 4108,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Intellectual Ventures - Wikipedia",
                  "url": "https://en.wikipedia.org/wiki/Intellectual_Ventures#:~:text=Publicly%2C%20Intellectual%20Ventures%20states%20that,34",
                  "text": "Publicly, Intellectual Ventures states that a major goal is to assist small inventors against corporations. In practice, the vast majority of IV's revenue comes from buying patents, aggregating these patents into a single portfolio spanning many disparate technologies and tying these patents together for license to other companies under the threat of litigation, or filing lawsuits for infringement of patents, a controversial practice referred to as \"patent trolling.\"[ 34 ]",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 13,
                    "cited_message_id": "94975457-b3ce-4a2f-8c69-8452b53573b3",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 297,
                    "end_line_num": 305,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 4248,
                "end_ix": 4261,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Understanding Key Strategies of Patent Monetization",
                  "url": "https://www.iiprd.com/patent-monetization/#:~:text=As%20many%20have%20claimed%2C%20litigation,years%202015%20to%202019%20respectively",
                  "text": "As many have claimed, litigation may be the last resort of patentees but if aimed at wilful infringers it is a potent monetization technique. PwC made a discovery with research which revealed that the average of patent infringement damages award in the United States was $10. 2 million for the years 2015 to 2019 respectively.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 3,
                    "cited_message_id": "4cd296df-a269-4bd3-810f-c7eaeecc2d19",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 188,
                    "end_line_num": 192,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 4880,
                "end_ix": 4892,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Trolls Like Intellectual Ventures Must Be More Closely Regulated, But How? - Sequel Legal",
                  "url": "https://sequellegal.com/patent-trolls-like-intellectual-ventures-must-be-more-closely-regulated-but-how/#:~:text=One%20of%20the%20largest%20and,the%20patents%20just%20%24500%20million",
                  "text": "One of the largest and most egregious examples of this behavior is Intellectual Ventures, a Bellevue, WA based firm that boasts a portfolio of some 70,000 patents it has acquired during its 14 years in business. It has realized $3 billion in patent licensing fees, but has passed on to the inventors behind the patents just $500 million.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 21,
                    "cited_message_id": "aa45e6a3-d90a-4c1c-8048-ad8040585491",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 43,
                    "end_line_num": 50,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 5035,
                "end_ix": 5049,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Intellectual Ventures - Wikipedia",
                  "url": "https://en.wikipedia.org/wiki/Intellectual_Ventures#:~:text=Publicly%2C%20Intellectual%20Ventures%20states%20that,34",
                  "text": "Publicly, Intellectual Ventures states that a major goal is to assist small inventors against corporations. In practice, the vast majority of IV's revenue comes from buying patents, aggregating these patents into a single portfolio spanning many disparate technologies and tying these patents together for license to other companies under the threat of litigation, or filing lawsuits for infringement of patents, a controversial practice referred to as \"patent trolling.\"[ 34 ]",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 13,
                    "cited_message_id": "94975457-b3ce-4a2f-8c69-8452b53573b3",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 297,
                    "end_line_num": 305,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 9297,
                "end_ix": 9307,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Intellectual Property Finance",
                  "url": "https://www.wipo.int/en/web/ip-financing#:~:text=Intellectual%20property%20rights%20can%20be,For%20some%20businesses%2C%20intangible",
                  "text": "Intellectual property rights can be used to secure financing, either by pledging them or transferring rights to cash flows derived from these assets. Alternatively, a company\u2019s intellectual property can provide an indicator of a firm\u2019s value and support financing decisions. For some businesses, intangible",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 47,
                    "cited_message_id": "5f06fd3d-ffce-484d-b4e0-a2b0f53279a1",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 1,
                    "end_line_num": 4,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 9457,
                "end_ix": 9467,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Intellectual Property Finance - WIPO",
                  "url": "https://www.wipo.int/en/web/ip-financing#:~:text=Intellectual%20Property%20Finance%20,flows%20derived%20from%20these%20assets",
                  "text": "Intellectual Property Finance - WIPO Intellectual property rights can be used to secure financing, either by pledging them or transferring rights to cash flows derived from these assets.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 4,
                    "cited_message_id": "cc47a1a3-db1e-4178-8f29-c871eb322fcb",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 9,
                    "end_line_num": 17,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 9824,
                "end_ix": 9834,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "As Lyrica profits dry up, Northwestern seeks another 'blockbuster' drug",
                  "url": "https://dailynorthwestern.com/2016/04/10/featured-stories/in-focus/in-focus-as-lyrica-profits-dry-up-northwestern-seeks-another-blockbuster-drug/#:~:text=drug%20dailynorthwestern,to%20pharmaceutical%20company%20Royal%20Pharma",
                  "text": "drug dailynorthwestern.com  Silverman and the University monetized part of their royalties in 2007 for a total of $700 million to pharmaceutical company Royal Pharma.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 45,
                    "cited_message_id": "a2408a6a-24e8-4e06-bfd2-23565d641fbe",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 1,
                    "end_line_num": 9,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 13933,
                "end_ix": 13947,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Microsoft Earns $2 Billion Per Year From Android Patent Royalties - Business Insider",
                  "url": "https://www.businessinsider.com/microsoft-earns-2-billion-per-year-from-android-patent-royalties-2013-11#:~:text=Microsoft%20is%20generating%20%242%20billion,new%20note%20on%20the%20company",
                  "text": "Microsoft is generating $2 billion per year in revenue from Android patent royalties, says Nomura analyst Rick Sherlund in a new note on the company.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 37,
                    "cited_message_id": "d2fb05a1-7c18-4adf-91f6-ae41a8473ebe",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 283,
                    "end_line_num": 290,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 17508,
                "end_ix": 17520,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "IBM drops from top spot in patents, surpassed by Samsung | TechTarget",
                  "url": "https://www.techtarget.com/searchdatacenter/news/365531318/IBM-drops-from-top-spot-in-patents-surpassed-by-Samsung#:~:text=IBM%27s%20patent%20portfolio%20business%20has,according%20to%20IBM%27s%20financial%20filings",
                  "text": "IBM's patent portfolio business has been profitable over the years, averaging a little more than $1 billion a year in revenue since mid-1996, according to IBM's financial filings.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 6,
                    "cited_message_id": "f6bddffb-4a35-4aa6-bab9-c25d7b40abd3",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 97,
                    "end_line_num": 104,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 18521,
                "end_ix": 18530,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Qualcomm sales beat estimates, shares drop after licensing forecast | Reuters",
                  "url": "https://www.reuters.com/technology/qualcomm-results-forecast-top-expectations-ai-drives-smartphone-sales-2025-02-05/#:~:text=%249,licensing%2C%20according%20to%20LSEG%20data",
                  "text": "$9.2 billion for its chip business and $1.35 billion for patent licensing. Wall Street had expected $8.90 billion for chips and $1.43 billion for patent licensing, according to LSEG data.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 9,
                    "cited_message_id": "26936477-0ba4-4fd2-99eb-8fcd9df5eaac",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 1,
                    "end_line_num": 4,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 19095,
                "end_ix": 19109,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Microsoft Earns $2 Billion Per Year From Android Patent Royalties - Business Insider",
                  "url": "https://www.businessinsider.com/microsoft-earns-2-billion-per-year-from-android-patent-royalties-2013-11#:~:text=Microsoft%20is%20generating%20%242%20billion,new%20note%20on%20the%20company",
                  "text": "Microsoft is generating $2 billion per year in revenue from Android patent royalties, says Nomura analyst Rick Sherlund in a new note on the company.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 37,
                    "cited_message_id": "d2fb05a1-7c18-4adf-91f6-ae41a8473ebe",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 283,
                    "end_line_num": 290,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 23033,
                "end_ix": 23045,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Trolls Like Intellectual Ventures Must Be More Closely Regulated, But How? - Sequel Legal",
                  "url": "https://sequellegal.com/patent-trolls-like-intellectual-ventures-must-be-more-closely-regulated-but-how/#:~:text=One%20of%20the%20largest%20and,the%20patents%20just%20%24500%20million",
                  "text": "One of the largest and most egregious examples of this behavior is Intellectual Ventures, a Bellevue, WA based firm that boasts a portfolio of some 70,000 patents it has acquired during its 14 years in business. It has realized $3 billion in patent licensing fees, but has passed on to the inventors behind the patents just $500 million.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 21,
                    "cited_message_id": "aa45e6a3-d90a-4c1c-8048-ad8040585491",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 43,
                    "end_line_num": 50,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 23429,
                "end_ix": 23441,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Trolls Like Intellectual Ventures Must Be More Closely Regulated, But How? - Sequel Legal",
                  "url": "https://sequellegal.com/patent-trolls-like-intellectual-ventures-must-be-more-closely-regulated-but-how/#:~:text=One%20of%20the%20largest%20and,the%20patents%20just%20%24500%20million",
                  "text": "One of the largest and most egregious examples of this behavior is Intellectual Ventures, a Bellevue, WA based firm that boasts a portfolio of some 70,000 patents it has acquired during its 14 years in business. It has realized $3 billion in patent licensing fees, but has passed on to the inventors behind the patents just $500 million.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 21,
                    "cited_message_id": "aa45e6a3-d90a-4c1c-8048-ad8040585491",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 43,
                    "end_line_num": 50,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 28736,
                "end_ix": 28747,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "France Brevets' public sector links hindered monetisation efforts ...",
                  "url": "https://www.iam-media.com/article/france-brevets-public-sector-links-hindered-its-monetisation-efforts-says-ceo#:~:text=France%20Brevets%27%20public%20sector%20links,Share",
                  "text": "France Brevets' public sector links hindered monetisation efforts ... France Brevets' public sector links hindered monetisation efforts, says CEO. Adam Houldsworth. 03 November 2022. Share.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 40,
                    "cited_message_id": "73cfaf1a-82c5-4296-80ef-38f06f91b167",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 5,
                    "end_line_num": 13,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 28747,
                "end_ix": 28759,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Judge's Investigation into Patent Troll Results in Criminal Referrals ...",
                  "url": "https://news.ycombinator.com/item?id=42234147#:~:text=Judge%27s%20Investigation%20into%20Patent%20Troll,HTC%20or%20the%20Korean",
                  "text": "Judge's Investigation into Patent Troll Results in Criminal Referrals ... France Brevets is criticized for having a \"patent troll\" type of activity and is taking legal action against companies such as the Taiwanese HTC or the Korean ...",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 40,
                    "cited_message_id": "73cfaf1a-82c5-4296-80ef-38f06f91b167",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 15,
                    "end_line_num": 23,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 29657,
                "end_ix": 29671,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Why the University of Florida gets a ~$20m cut of Gatorade profits every year  - The Hustle ",
                  "url": "https://thehustle.co/why-the-university-of-florida-gets-a-20m-cut-of-gatorade-profits-every-year#:~:text=The%20university%20patents%20around%20140,affiliated%20patents%20was%20~%242.9B",
                  "text": "The university patents around 140 inventions each year and made ~$500m off licenses between 2008 to 2018, placing it near the top of the market. In 2018, the total licensing revenue from university-affiliated patents was ~$2.9B.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 32,
                    "cited_message_id": "273e7a99-2cd3-4818-add8-da2b5253e68c",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 401,
                    "end_line_num": 404,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 30215,
                "end_ix": 30229,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Technology Transfer in U.S. Research Universities: Dispelling Common Myths",
                  "url": "https://www.cogr.edu/sites/default/files/Myths_Final%2008-01-22.pdf#:~:text=unmanageable%20institutional%20conflicts%20of%20interest,of%20the%20licensing%20income",
                  "text": "unmanageable institutional conflicts of interest. Response: Most university technology licensing offices struggle to make enough in licensing revenue to cover their operating expenses. Lucrative inventions are exceedingly rare. Based on data from the 2020 AUTM Survey, the top 5% of U.S. technology licensing operations (9 universities) accounted for 51% of the total licensing revenue reported. In the same year, the top 10% of the reporting U.S. universities realized 70% of the licensing income.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 34,
                    "cited_message_id": "4f421c39-8a87-4994-9790-5bb33658529c",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 243,
                    "end_line_num": 252,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 30359,
                "end_ix": 30373,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Technology Transfer in U.S. Research Universities: Dispelling Common Myths",
                  "url": "https://www.cogr.edu/sites/default/files/Myths_Final%2008-01-22.pdf#:~:text=in%20licensing%20revenue%20to%20cover,of%20the%20licensing%20income",
                  "text": "in licensing revenue to cover their operating expenses. Lucrative inventions are exceedingly rare. Based on data from the 2020 AUTM Survey, the top 5% of U.S. technology licensing operations (9 universities) accounted for 51% of the total licensing revenue reported. In the same year, the top 10% of the reporting U.S. universities realized 70% of the licensing income.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 34,
                    "cited_message_id": "4f421c39-8a87-4994-9790-5bb33658529c",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 245,
                    "end_line_num": 252,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 30766,
                "end_ix": 30780,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Technology Transfer in U.S. Research Universities: Dispelling Common Myths",
                  "url": "https://www.cogr.edu/sites/default/files/Myths_Final%2008-01-22.pdf#:~:text=unmanageable%20institutional%20conflicts%20of%20interest,of%20the%20licensing%20income",
                  "text": "unmanageable institutional conflicts of interest. Response: Most university technology licensing offices struggle to make enough in licensing revenue to cover their operating expenses. Lucrative inventions are exceedingly rare. Based on data from the 2020 AUTM Survey, the top 5% of U.S. technology licensing operations (9 universities) accounted for 51% of the total licensing revenue reported. In the same year, the top 10% of the reporting U.S. universities realized 70% of the licensing income.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 34,
                    "cited_message_id": "4f421c39-8a87-4994-9790-5bb33658529c",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 243,
                    "end_line_num": 252,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 31345,
                "end_ix": 31355,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "",
                  "url": "https://autm.net/AUTM/media/About-Tech-Transfer/Documents/Economic_Contribution_Report_BIO_AUTM_JUN2019_web.pdf#:~:text=for%20Universities%2C%20about%2080,In%20addition%2C%20public%20anecdotal",
                  "text": "for Universities, about 80% of the income is from licenses in the life sciences. For Hospitals and Research Institutes, 90% or more of the income is from licenses in the life sciences. In addition, public anecdotal",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 24,
                    "cited_message_id": "e3214d8e-28d6-49ea-9eb4-cb70e6f3eff4",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 1,
                    "end_line_num": 4,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 31427,
                "end_ix": 31437,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "",
                  "url": "https://autm.net/AUTM/media/About-Tech-Transfer/Documents/Economic_Contribution_Report_BIO_AUTM_JUN2019_web.pdf#:~:text=for%20Universities%2C%20about%2080,In%20addition%2C%20public%20anecdotal",
                  "text": "for Universities, about 80% of the income is from licenses in the life sciences. For Hospitals and Research Institutes, 90% or more of the income is from licenses in the life sciences. In addition, public anecdotal",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 24,
                    "cited_message_id": "e3214d8e-28d6-49ea-9eb4-cb70e6f3eff4",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 1,
                    "end_line_num": 4,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 31856,
                "end_ix": 31866,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "As Lyrica profits dry up, Northwestern seeks another 'blockbuster' drug",
                  "url": "https://dailynorthwestern.com/2016/04/10/featured-stories/in-focus/in-focus-as-lyrica-profits-dry-up-northwestern-seeks-another-blockbuster-drug/#:~:text=drug%20dailynorthwestern,to%20pharmaceutical%20company%20Royal%20Pharma",
                  "text": "drug dailynorthwestern.com  Silverman and the University monetized part of their royalties in 2007 for a total of $700 million to pharmaceutical company Royal Pharma.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 45,
                    "cited_message_id": "a2408a6a-24e8-4e06-bfd2-23565d641fbe",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 1,
                    "end_line_num": 9,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 32146,
                "end_ix": 32156,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "How the \"First\" Biotech Patent Generated Millions - Labiotech.eu",
                  "url": "https://www.labiotech.eu/trends-news/making-dollars-out-of-the-recombinant-dna-biotech-patents/#:~:text=Labiotech,up",
                  "text": "Labiotech.eu www.labiotech.eu  Over the 25 years of the licensing program, Stanford and the University of California system amassed a \u20ac241M fortune in licensing revenues (up ...",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 41,
                    "cited_message_id": "64f94ffb-a061-4a53-9102-5ed5417e2824",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 1,
                    "end_line_num": 8,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 32726,
                "end_ix": 32736,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "How the \"First\" Biotech Patent Generated Millions",
                  "url": "https://www.labiotech.eu/trends-news/making-dollars-out-of-the-recombinant-dna-biotech-patents/#:~:text=California%20system%20amassed%20a%20%E2%82%AC241M,standard%20for%20university%20technology%20licensing",
                  "text": "California system amassed a \u20ac241M fortune in licensing revenues (up until 2001). In many ways, Stanford\u2019s management of the Cohen-Boyer patents has become the gold standard for university technology licensing.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 44,
                    "cited_message_id": "755603f6-b57d-4295-8653-079c743183c2",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 1,
                    "end_line_num": 4,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 33826,
                "end_ix": 33838,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "",
                  "url": "https://autm.net/AUTM/media/About-Tech-Transfer/Documents/Economic_Contribution_Report_BIO_AUTM_JUN2019_web.pdf#:~:text=U.S.%20Universities%20%24242%2C057%2C513%20%24194%2C199%2C551%2080,%241%2C500%2C117%2016",
                  "text": "U.S. Universities $242,057,513 $194,199,551 80% $47,857,962 20% U.S. Hospitals & Research Institutes $131,741,920 $118,242,472 90% $13,499,448 10% Canadian Institutions $9,589,867 $8,089,750 84% $1,500,117 16%",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 24,
                    "cited_message_id": "e3214d8e-28d6-49ea-9eb4-cb70e6f3eff4",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 37,
                    "end_line_num": 40,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 34993,
                "end_ix": 35003,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Why the University of Florida gets a ~$20m cut of Gatorade profits every year  - The Hustle ",
                  "url": "https://thehustle.co/why-the-university-of-florida-gets-a-20m-cut-of-gatorade-profits-every-year#:~:text=The%20university%20patents%20around%20140,affiliated%20patents%20was%20~%242.9B",
                  "text": "The university patents around 140 inventions each year and made ~$500m off licenses between 2008 to 2018, placing it near the top of the market. In 2018, the total licensing revenue from university-affiliated patents was ~$2.9B.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 31,
                    "cited_message_id": "da7e9c9a-118e-4fc8-bb9b-e7cfb719500e",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 1,
                    "end_line_num": 4,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 35099,
                "end_ix": 35113,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Why the University of Florida gets a ~$20m cut of Gatorade profits every year  - The Hustle ",
                  "url": "https://thehustle.co/why-the-university-of-florida-gets-a-20m-cut-of-gatorade-profits-every-year#:~:text=researchers%20looking%20to%20make%20lucrative,discoveries",
                  "text": "researchers looking to make lucrative discoveries.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 32,
                    "cited_message_id": "273e7a99-2cd3-4818-add8-da2b5253e68c",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 399,
                    "end_line_num": 407,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 36854,
                "end_ix": 36864,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "How the \"First\" Biotech Patent Generated Millions",
                  "url": "https://www.labiotech.eu/trends-news/making-dollars-out-of-the-recombinant-dna-biotech-patents/#:~:text=California%20system%20amassed%20a%20%E2%82%AC241M,standard%20for%20university%20technology%20licensing",
                  "text": "California system amassed a \u20ac241M fortune in licensing revenues (up until 2001). In many ways, Stanford\u2019s management of the Cohen-Boyer patents has become the gold standard for university technology licensing.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 44,
                    "cited_message_id": "755603f6-b57d-4295-8653-079c743183c2",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 1,
                    "end_line_num": 4,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 40064,
                "end_ix": 40076,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Benchmarking U.S. university patent value and commercialization ...",
                  "url": "https://www.sciencedirect.com/science/article/abs/pii/S0048733320301542#:~:text=Benchmarking%20U,the%20economic%20significance%20of",
                  "text": "Benchmarking U.S. university patent value and commercialization ... Finds that universities capture on average 16% of the economic value of their patents through licensing revenues. Abstract. Despite the economic significance of ...",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 22,
                    "cited_message_id": "3e50f1c7-a15a-46cb-b35b-1a56e929417e",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 33,
                    "end_line_num": 38,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 40373,
                "end_ix": 40387,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Technology Transfer in U.S. Research Universities: Dispelling Common Myths",
                  "url": "https://www.cogr.edu/sites/default/files/Myths_Final%2008-01-22.pdf#:~:text=Released%20August%202%2C%202022%20economic,Dole%20Act%20v",
                  "text": "Released August 2, 2022 economic impact generates tremendous value to the U.S. economy and workforce that also supports U.S. competition in the global marketplace. In addition, the public benefits from the 933 new products that were introduced to the market during 2020 and the more than 200 new drugs and vaccines that have been commercialized since passage of the Bayh-Dole Act v",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 34,
                    "cited_message_id": "4f421c39-8a87-4994-9790-5bb33658529c",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 194,
                    "end_line_num": 202,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 40387,
                "end_ix": 40401,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Technology Transfer in U.S. Research Universities: Dispelling Common Myths",
                  "url": "https://www.cogr.edu/sites/default/files/Myths_Final%2008-01-22.pdf#:~:text=Myth%20,funded%20research",
                  "text": "Myth #3: U.S. taxpayers, through NIH, provide significant support to find new therapies. These drugs should be free to the public. Response: The National Institutes of Health (NIH) funds significant extramural research at universities with a goal to \u201cfoster fundamental creative discoveries \u2026 and their applications as a basis for ultimately protecting and improving healthvi.\u201d Universities conduct NIH-funded research",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 34,
                    "cited_message_id": "4f421c39-8a87-4994-9790-5bb33658529c",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 207,
                    "end_line_num": 215,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 40844,
                "end_ix": 40858,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Why the University of Florida gets a ~$20m cut of Gatorade profits every year  - The Hustle ",
                  "url": "https://thehustle.co/why-the-university-of-florida-gets-a-20m-cut-of-gatorade-profits-every-year#:~:text=Florida%20has%20used%20its%20royalties,looking%20to%20make%20lucrative%20discoveries",
                  "text": "Florida has used its royalties to bolster its research and entice new researchers looking to make lucrative discoveries.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 32,
                    "cited_message_id": "273e7a99-2cd3-4818-add8-da2b5253e68c",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 398,
                    "end_line_num": 407,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 40941,
                "end_ix": 40953,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Northwestern sees $700 million for sale of Lyrica royalties | Drug ...",
                  "url": "https://drugstorenews.com/pharmacy/northwestern-sees-700-million-sale-lyrica-royalties#:~:text=Northwestern%20sees%20%24700%20million%20for,the%20chemists%20who%20synthesized%20pregabalin",
                  "text": "Northwestern sees $700 million for sale of Lyrica royalties | Drug ... The bulk of the $700 million will go into NU's endowment fund, which is worth $6.6 billion, but some portion will go to the chemists who synthesized pregabalin.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 45,
                    "cited_message_id": "a2408a6a-24e8-4e06-bfd2-23565d641fbe",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 33,
                    "end_line_num": 41,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 42903,
                "end_ix": 42915,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "University invention and the abolishment of the professor's privilege ...",
                  "url": "https://www.sciencedirect.com/science/article/abs/pii/S0048733318300519#:~:text=University%20invention%20and%20the%20abolishment,percent%20in%20matched%20sample%20analyses",
                  "text": "University invention and the abolishment of the professor's privilege ... We evaluate the abolition of the professor's privilege in Finland in 2007. \u00b7 After 2007, patenting by academics dropped 29 percent in matched sample analyses.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 38,
                    "cited_message_id": "9bd43bf1-5db7-4770-a6ae-8bc9ce43f924",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 31,
                    "end_line_num": 35,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 43791,
                "end_ix": 43803,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Judge's Investigation into Patent Troll Results in Criminal Referrals ...",
                  "url": "https://news.ycombinator.com/item?id=42234147#:~:text=Judge%27s%20Investigation%20into%20Patent%20Troll,HTC%20or%20the%20Korean",
                  "text": "Judge's Investigation into Patent Troll Results in Criminal Referrals ... France Brevets is criticized for having a \"patent troll\" type of activity and is taking legal action against companies such as the Taiwanese HTC or the Korean ...",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 40,
                    "cited_message_id": "73cfaf1a-82c5-4296-80ef-38f06f91b167",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 15,
                    "end_line_num": 23,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 43803,
                "end_ix": 43815,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "French sovereign patent fund shows muscle: FB spearheads patent ...",
                  "url": "https://ipkitten.blogspot.com/2013/08/french-sovereign-patent-fund-shows.html#:~:text=French%20sovereign%20patent%20fund%20shows,create%20a%20national%20investment",
                  "text": "French sovereign patent fund shows muscle: FB spearheads patent ... The major part of this fund was set to create specific companies (SATT); the rest (100 millions Euros) was used to create a national investment ...",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 40,
                    "cited_message_id": "73cfaf1a-82c5-4296-80ef-38f06f91b167",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 27,
                    "end_line_num": 35,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 43918,
                "end_ix": 43929,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "France Brevets' public sector links hindered monetisation efforts ...",
                  "url": "https://www.iam-media.com/article/france-brevets-public-sector-links-hindered-its-monetisation-efforts-says-ceo#:~:text=France%20Brevets%27%20public%20sector%20links,Share",
                  "text": "France Brevets' public sector links hindered monetisation efforts ... France Brevets' public sector links hindered monetisation efforts, says CEO. Adam Houldsworth. 03 November 2022. Share.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 40,
                    "cited_message_id": "73cfaf1a-82c5-4296-80ef-38f06f91b167",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 5,
                    "end_line_num": 13,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 44035,
                "end_ix": 44046,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Judge's Investigation Into Patent Troll Results In Criminal Referrals",
                  "url": "https://www.eff.org/deeplinks/2024/11/judges-investigation-patent-troll-ip-edge-results-criminal-referrals#:~:text=Judge%27s%20Investigation%20Into%20Patent%20Troll,US%20patent%20system%20for%20profit",
                  "text": "Judge's Investigation Into Patent Troll Results In Criminal Referrals However, it's even more concerning when foreign government-backed organizations like France Brevets manipulate the US patent system for profit.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 40,
                    "cited_message_id": "73cfaf1a-82c5-4296-80ef-38f06f91b167",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 9,
                    "end_line_num": 17,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 45381,
                "end_ix": 45393,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Box | Tax - BDO",
                  "url": "https://www.bdo.co.uk/en-gb/services/tax/innovation-and-r-d-tax-incentives/patent-box#:~:text=Patent%20Box%20%7C%20Tax%20,from%20April%202023",
                  "text": "Patent Box | Tax - BDO It takes the form of an effective tax rate at 10% of the relevant profits compared to the UK's usual 19% rate (25% from April 2023).",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 39,
                    "cited_message_id": "1e784dea-97c0-4d28-ac72-e3c4aacb8714",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 19,
                    "end_line_num": 27,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 45690,
                "end_ix": 45700,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Box relief statistics: September 2024 - GOV.UK",
                  "url": "https://www.gov.uk/government/statistics/patent-box-reliefs-statistics/patent-box-relief-statistics-september-2024--2#:~:text=conversely%2C%20the%20value%20of%20relief,2022%20to%202023%20from",
                  "text": "conversely, the value of relief claimed under the Patent Box is estimated to have increased to \u00a31,469 million in the tax year 2022 to 2023 from ...",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 39,
                    "cited_message_id": "1e784dea-97c0-4d28-ac72-e3c4aacb8714",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 1,
                    "end_line_num": 8,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 53116,
                "end_ix": 53128,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "IBM drops from top spot in patents, surpassed by Samsung | TechTarget",
                  "url": "https://www.techtarget.com/searchdatacenter/news/365531318/IBM-drops-from-top-spot-in-patents-surpassed-by-Samsung#:~:text=IBM%27s%20patent%20portfolio%20business%20has,according%20to%20IBM%27s%20financial%20filings",
                  "text": "IBM's patent portfolio business has been profitable over the years, averaging a little more than $1 billion a year in revenue since mid-1996, according to IBM's financial filings.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 6,
                    "cited_message_id": "f6bddffb-4a35-4aa6-bab9-c25d7b40abd3",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 97,
                    "end_line_num": 104,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 53724,
                "end_ix": 53735,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "IBM's patent income slips as companies resist 'godfather' deals",
                  "url": "https://www.spokesman.com/stories/2021/mar/12/ibms-patent-income-slips-as-companies-resist-godfa/#:~:text=deals%20www,6",
                  "text": "deals www.spokesman.com  Last year, income from intellectual property licensing was nearly a third of its 2000 peak of $1.7 billion, or a recent 2016 spike of $1.6 ...",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 5,
                    "cited_message_id": "8e5ca1ad-bb86-4880-ab27-2cc8b06e3cf7",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 11,
                    "end_line_num": 18,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 55457,
                "end_ix": 55469,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Trolls Like Intellectual Ventures Must Be More Closely Regulated, But How? - Sequel Legal",
                  "url": "https://sequellegal.com/patent-trolls-like-intellectual-ventures-must-be-more-closely-regulated-but-how/#:~:text=One%20of%20the%20largest%20and,the%20patents%20just%20%24500%20million",
                  "text": "One of the largest and most egregious examples of this behavior is Intellectual Ventures, a Bellevue, WA based firm that boasts a portfolio of some 70,000 patents it has acquired during its 14 years in business. It has realized $3 billion in patent licensing fees, but has passed on to the inventors behind the patents just $500 million.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 21,
                    "cited_message_id": "aa45e6a3-d90a-4c1c-8048-ad8040585491",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 43,
                    "end_line_num": 50,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 68491,
                "end_ix": 68505,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Technology Transfer in U.S. Research Universities: Dispelling Common Myths",
                  "url": "https://www.cogr.edu/sites/default/files/Myths_Final%2008-01-22.pdf#:~:text=rare,of%20the%20licensing%20income",
                  "text": "rare. Based on data from the 2020 AUTM Survey, the top 5% of U.S. technology licensing operations (9 universities) accounted for 51% of the total licensing revenue reported. In the same year, the top 10% of the reporting U.S. universities realized 70% of the licensing income.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 34,
                    "cited_message_id": "4f421c39-8a87-4994-9790-5bb33658529c",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 247,
                    "end_line_num": 252,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 69738,
                "end_ix": 69752,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "How the \"First\" Biotech Patent Generated Millions",
                  "url": "https://www.labiotech.eu/trends-news/making-dollars-out-of-the-recombinant-dna-biotech-patents/#:~:text=The%2017%20years%20during%20which,exploit%20all%20the%20possible%20applications",
                  "text": "The 17 years during which the Cohen-Boyer patents were licensed, Stanford consulted widely across various stakeholders before settling on the licensing terms. For Stanford, the logic was that recombinant DNA was a platform technology and it was not possible for any one company to exploit all the possible applications.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 43,
                    "cited_message_id": "4fd76dfa-4b7c-4045-858a-5ea2e8128ecc",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 292,
                    "end_line_num": 300,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 69752,
                "end_ix": 69766,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "How the \"First\" Biotech Patent Generated Millions",
                  "url": "https://www.labiotech.eu/trends-news/making-dollars-out-of-the-recombinant-dna-biotech-patents/#:~:text=",
                  "text": "* * *",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 43,
                    "cited_message_id": "4fd76dfa-4b7c-4045-858a-5ea2e8128ecc",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 307,
                    "end_line_num": 315,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 72535,
                "end_ix": 72548,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Understanding Key Strategies of Patent Monetization",
                  "url": "https://www.iiprd.com/patent-monetization/#:~:text=Licensing%3A%C2%A0%20Licensing%20is%20arguably%20the,among%20the%20surveyed%20firms",
                  "text": "Licensing:\u00a0 Licensing is arguably the most common and easily understandable method of flowing with patent monitory. It is the legal right given to the owner of the patented technology to allow third parties to utilize them in return for some form of consideration. According to LES, a survey of the licensing revenues indicated that licensing made up more than 40 percent of the total income from patent monetization among the surveyed firms .",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 3,
                    "cited_message_id": "4cd296df-a269-4bd3-810f-c7eaeecc2d19",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 144,
                    "end_line_num": 152,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 72548,
                "end_ix": 72561,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Understanding Key Strategies of Patent Monetization",
                  "url": "https://www.iiprd.com/patent-monetization/#:~:text=%2A%20Cross,used%20in%20standard%20essential%20patents",
                  "text": "* Cross-licensing: Cross licenses are when two firms agree that they can use each other\u2019s patents and this is mostly used to settle legal matters or gain access to related technologies. * Patent pools: Patent pool in which many patentees combine their patents in a bundle especially used in standard essential patents.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 3,
                    "cited_message_id": "4cd296df-a269-4bd3-810f-c7eaeecc2d19",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 157,
                    "end_line_num": 165,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 72561,
                "end_ix": 72574,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Understanding Key Strategies of Patent Monetization",
                  "url": "https://www.iiprd.com/patent-monetization/#:~:text=As%20many%20have%20claimed%2C%20litigation,years%202015%20to%202019%20respectively",
                  "text": "As many have claimed, litigation may be the last resort of patentees but if aimed at wilful infringers it is a potent monetization technique. PwC made a discovery with research which revealed that the average of patent infringement damages award in the United States was $10. 2 million for the years 2015 to 2019 respectively.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 3,
                    "cited_message_id": "4cd296df-a269-4bd3-810f-c7eaeecc2d19",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 188,
                    "end_line_num": 196,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 72574,
                "end_ix": 72584,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Intellectual Property Finance",
                  "url": "https://www.wipo.int/en/web/ip-financing#:~:text=Intellectual%20property%20rights%20can%20be,For%20some%20businesses%2C%20intangible",
                  "text": "Intellectual property rights can be used to secure financing, either by pledging them or transferring rights to cash flows derived from these assets. Alternatively, a company\u2019s intellectual property can provide an indicator of a firm\u2019s value and support financing decisions. For some businesses, intangible",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 47,
                    "cited_message_id": "5f06fd3d-ffce-484d-b4e0-a2b0f53279a1",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 1,
                    "end_line_num": 4,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 72659,
                "end_ix": 72671,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "IBM drops from top spot in patents, surpassed by Samsung | TechTarget",
                  "url": "https://www.techtarget.com/searchdatacenter/news/365531318/IBM-drops-from-top-spot-in-patents-surpassed-by-Samsung#:~:text=IBM%27s%20patent%20portfolio%20business%20has,according%20to%20IBM%27s%20financial%20filings",
                  "text": "IBM's patent portfolio business has been profitable over the years, averaging a little more than $1 billion a year in revenue since mid-1996, according to IBM's financial filings.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 6,
                    "cited_message_id": "f6bddffb-4a35-4aa6-bab9-c25d7b40abd3",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 97,
                    "end_line_num": 104,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 72671,
                "end_ix": 72680,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Qualcomm sales beat estimates, shares drop after licensing forecast | Reuters",
                  "url": "https://www.reuters.com/technology/qualcomm-results-forecast-top-expectations-ai-drives-smartphone-sales-2025-02-05/#:~:text=%249,licensing%2C%20according%20to%20LSEG%20data",
                  "text": "$9.2 billion for its chip business and $1.35 billion for patent licensing. Wall Street had expected $8.90 billion for chips and $1.43 billion for patent licensing, according to LSEG data.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 9,
                    "cited_message_id": "26936477-0ba4-4fd2-99eb-8fcd9df5eaac",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 1,
                    "end_line_num": 4,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 72680,
                "end_ix": 72694,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Microsoft Earns $2 Billion Per Year From Android Patent Royalties - Business Insider",
                  "url": "https://www.businessinsider.com/microsoft-earns-2-billion-per-year-from-android-patent-royalties-2013-11#:~:text=Microsoft%20is%20generating%20%242%20billion,new%20note%20on%20the%20company",
                  "text": "Microsoft is generating $2 billion per year in revenue from Android patent royalties, says Nomura analyst Rick Sherlund in a new note on the company.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 37,
                    "cited_message_id": "d2fb05a1-7c18-4adf-91f6-ae41a8473ebe",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 283,
                    "end_line_num": 290,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 72746,
                "end_ix": 72758,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Trolls Like Intellectual Ventures Must Be More Closely Regulated, But How? - Sequel Legal",
                  "url": "https://sequellegal.com/patent-trolls-like-intellectual-ventures-must-be-more-closely-regulated-but-how/#:~:text=One%20of%20the%20largest%20and,the%20patents%20just%20%24500%20million",
                  "text": "One of the largest and most egregious examples of this behavior is Intellectual Ventures, a Bellevue, WA based firm that boasts a portfolio of some 70,000 patents it has acquired during its 14 years in business. It has realized $3 billion in patent licensing fees, but has passed on to the inventors behind the patents just $500 million.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 21,
                    "cited_message_id": "aa45e6a3-d90a-4c1c-8048-ad8040585491",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 43,
                    "end_line_num": 50,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 72758,
                "end_ix": 72772,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Intellectual Ventures - Wikipedia",
                  "url": "https://en.wikipedia.org/wiki/Intellectual_Ventures#:~:text=Publicly%2C%20Intellectual%20Ventures%20states%20that,34",
                  "text": "Publicly, Intellectual Ventures states that a major goal is to assist small inventors against corporations. In practice, the vast majority of IV's revenue comes from buying patents, aggregating these patents into a single portfolio spanning many disparate technologies and tying these patents together for license to other companies under the threat of litigation, or filing lawsuits for infringement of patents, a controversial practice referred to as \"patent trolling.\"[ 34 ]",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 13,
                    "cited_message_id": "94975457-b3ce-4a2f-8c69-8452b53573b3",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 297,
                    "end_line_num": 305,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 72889,
                "end_ix": 72903,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Why the University of Florida gets a ~$20m cut of Gatorade profits every year  - The Hustle ",
                  "url": "https://thehustle.co/why-the-university-of-florida-gets-a-20m-cut-of-gatorade-profits-every-year#:~:text=The%20university%20patents%20around%20140,affiliated%20patents%20was%20~%242.9B",
                  "text": "The university patents around 140 inventions each year and made ~$500m off licenses between 2008 to 2018, placing it near the top of the market. In 2018, the total licensing revenue from university-affiliated patents was ~$2.9B.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 32,
                    "cited_message_id": "273e7a99-2cd3-4818-add8-da2b5253e68c",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 401,
                    "end_line_num": 404,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 72903,
                "end_ix": 72913,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "",
                  "url": "https://autm.net/AUTM/media/About-Tech-Transfer/Documents/Economic_Contribution_Report_BIO_AUTM_JUN2019_web.pdf#:~:text=for%20Universities%2C%20about%2080,In%20addition%2C%20public%20anecdotal",
                  "text": "for Universities, about 80% of the income is from licenses in the life sciences. For Hospitals and Research Institutes, 90% or more of the income is from licenses in the life sciences. In addition, public anecdotal",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 24,
                    "cited_message_id": "e3214d8e-28d6-49ea-9eb4-cb70e6f3eff4",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 1,
                    "end_line_num": 4,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 72913,
                "end_ix": 72927,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Technology Transfer in U.S. Research Universities: Dispelling Common Myths",
                  "url": "https://www.cogr.edu/sites/default/files/Myths_Final%2008-01-22.pdf#:~:text=in%20licensing%20revenue%20to%20cover,of%20the%20licensing%20income",
                  "text": "in licensing revenue to cover their operating expenses. Lucrative inventions are exceedingly rare. Based on data from the 2020 AUTM Survey, the top 5% of U.S. technology licensing operations (9 universities) accounted for 51% of the total licensing revenue reported. In the same year, the top 10% of the reporting U.S. universities realized 70% of the licensing income.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 34,
                    "cited_message_id": "4f421c39-8a87-4994-9790-5bb33658529c",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 245,
                    "end_line_num": 252,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 73032,
                "end_ix": 73046,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Why the University of Florida gets a ~$20m cut of Gatorade profits every year  - The Hustle ",
                  "url": "https://thehustle.co/why-the-university-of-florida-gets-a-20m-cut-of-gatorade-profits-every-year#:~:text=researchers%20looking%20to%20make%20lucrative,discoveries",
                  "text": "researchers looking to make lucrative discoveries.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 32,
                    "cited_message_id": "273e7a99-2cd3-4818-add8-da2b5253e68c",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 399,
                    "end_line_num": 407,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 73046,
                "end_ix": 73056,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "As Lyrica profits dry up, Northwestern seeks another 'blockbuster' drug",
                  "url": "https://dailynorthwestern.com/2016/04/10/featured-stories/in-focus/in-focus-as-lyrica-profits-dry-up-northwestern-seeks-another-blockbuster-drug/#:~:text=drug%20dailynorthwestern,to%20pharmaceutical%20company%20Royal%20Pharma",
                  "text": "drug dailynorthwestern.com  Silverman and the University monetized part of their royalties in 2007 for a total of $700 million to pharmaceutical company Royal Pharma.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 45,
                    "cited_message_id": "a2408a6a-24e8-4e06-bfd2-23565d641fbe",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 1,
                    "end_line_num": 9,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 73056,
                "end_ix": 73066,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "How the \"First\" Biotech Patent Generated Millions",
                  "url": "https://www.labiotech.eu/trends-news/making-dollars-out-of-the-recombinant-dna-biotech-patents/#:~:text=California%20system%20amassed%20a%20%E2%82%AC241M,standard%20for%20university%20technology%20licensing",
                  "text": "California system amassed a \u20ac241M fortune in licensing revenues (up until 2001). In many ways, Stanford\u2019s management of the Cohen-Boyer patents has become the gold standard for university technology licensing.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 44,
                    "cited_message_id": "755603f6-b57d-4295-8653-079c743183c2",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 1,
                    "end_line_num": 4,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 73124,
                "end_ix": 73136,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Box | Tax - BDO",
                  "url": "https://www.bdo.co.uk/en-gb/services/tax/innovation-and-r-d-tax-incentives/patent-box#:~:text=Patent%20Box%20%7C%20Tax%20,from%20April%202023",
                  "text": "Patent Box | Tax - BDO It takes the form of an effective tax rate at 10% of the relevant profits compared to the UK's usual 19% rate (25% from April 2023).",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 39,
                    "cited_message_id": "1e784dea-97c0-4d28-ac72-e3c4aacb8714",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 19,
                    "end_line_num": 27,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 73136,
                "end_ix": 73147,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "France Brevets' public sector links hindered monetisation efforts ...",
                  "url": "https://www.iam-media.com/article/france-brevets-public-sector-links-hindered-its-monetisation-efforts-says-ceo#:~:text=France%20Brevets%27%20public%20sector%20links,Share",
                  "text": "France Brevets' public sector links hindered monetisation efforts ... France Brevets' public sector links hindered monetisation efforts, says CEO. Adam Houldsworth. 03 November 2022. Share.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 40,
                    "cited_message_id": "73cfaf1a-82c5-4296-80ef-38f06f91b167",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 5,
                    "end_line_num": 13,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 73147,
                "end_ix": 73159,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Judge's Investigation into Patent Troll Results in Criminal Referrals ...",
                  "url": "https://news.ycombinator.com/item?id=42234147#:~:text=Judge%27s%20Investigation%20into%20Patent%20Troll,HTC%20or%20the%20Korean",
                  "text": "Judge's Investigation into Patent Troll Results in Criminal Referrals ... France Brevets is criticized for having a \"patent troll\" type of activity and is taking legal action against companies such as the Taiwanese HTC or the Korean ...",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 40,
                    "cited_message_id": "73cfaf1a-82c5-4296-80ef-38f06f91b167",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 15,
                    "end_line_num": 23,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 73207,
                "end_ix": 73221,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "How the \"First\" Biotech Patent Generated Millions",
                  "url": "https://www.labiotech.eu/trends-news/making-dollars-out-of-the-recombinant-dna-biotech-patents/#:~:text=The%2017%20years%20during%20which,exploit%20all%20the%20possible%20applications",
                  "text": "The 17 years during which the Cohen-Boyer patents were licensed, Stanford consulted widely across various stakeholders before settling on the licensing terms. For Stanford, the logic was that recombinant DNA was a platform technology and it was not possible for any one company to exploit all the possible applications.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 43,
                    "cited_message_id": "4fd76dfa-4b7c-4045-858a-5ea2e8128ecc",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 292,
                    "end_line_num": 300,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 73270,
                "end_ix": 73280,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "How the \"First\" Biotech Patent Generated Millions",
                  "url": "https://www.labiotech.eu/trends-news/making-dollars-out-of-the-recombinant-dna-biotech-patents/#:~:text=California%20system%20amassed%20a%20%E2%82%AC241M,standard%20for%20university%20technology%20licensing",
                  "text": "California system amassed a \u20ac241M fortune in licensing revenues (up until 2001). In many ways, Stanford\u2019s management of the Cohen-Boyer patents has become the gold standard for university technology licensing.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 44,
                    "cited_message_id": "755603f6-b57d-4295-8653-079c743183c2",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 1,
                    "end_line_num": 4,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              }
            ],
            "content_references": [
              {
                "matched_text": "\u30103\u2020L144-L152\u3011",
                "start_idx": 1925,
                "end_idx": 1938,
                "alt": null,
                "type": "webpage_extended",
                "title": "Understanding Key Strategies of Patent Monetization",
                "url": "https://www.iiprd.com/patent-monetization/#:~:text=Licensing%3A%C2%A0%20Licensing%20is%20arguably%20the,among%20the%20surveyed%20firms",
                "pub_date": null,
                "snippet": "Licensing:\u00a0 Licensing is arguably the most common and easily understandable method of flowing with patent monitory. It is the legal right given to the owner of the patented technology to allow third parties to utilize them in return for some form of consideration. According to LES, a survey of the licensing revenues indicated that licensing made up more than 40 percent of the total income from patent monetization among the surveyed firms .",
                "attribution": "iiprd.com",
                "icon_type": null
              },
              {
                "matched_text": "\u30103\u2020L153-L161\u3011",
                "start_idx": 2091,
                "end_idx": 2104,
                "alt": null,
                "type": "webpage_extended",
                "title": "Understanding Key Strategies of Patent Monetization",
                "url": "https://www.iiprd.com/patent-monetization/#:~:text=,used%20in%20standard%20essential%20patents",
                "pub_date": null,
                "snippet": "* Exclusive licensing: Authorization of rights to a single licensee, usually on an exclusive basis for a particular exercise or area. * Non-exclusive licensing: Giving permission to many people to utilise the patented technology. * Cross-licensing: Cross licenses are when two firms agree that they can use each other\u2019s patents and this is mostly used to settle legal matters or gain access to related technologies. * Patent pools: Patent pool in which many patentees combine their patents in a bundle especially used in standard essential patents.",
                "attribution": "iiprd.com",
                "icon_type": null
              },
              {
                "matched_text": "\u30103\u2020L157-L162\u3011",
                "start_idx": 2323,
                "end_idx": 2336,
                "alt": null,
                "type": "webpage_extended",
                "title": "Understanding Key Strategies of Patent Monetization",
                "url": "https://www.iiprd.com/patent-monetization/#:~:text=%2A%20Cross,used%20in%20standard%20essential%20patents",
                "pub_date": null,
                "snippet": "* Cross-licensing: Cross licenses are when two firms agree that they can use each other\u2019s patents and this is mostly used to settle legal matters or gain access to related technologies. * Patent pools: Patent pool in which many patentees combine their patents in a bundle especially used in standard essential patents.",
                "attribution": "iiprd.com",
                "icon_type": null
              },
              {
                "matched_text": "\u30108\u2020L219-L225\u3011",
                "start_idx": 2689,
                "end_idx": 2702,
                "alt": null,
                "type": "webpage_extended",
                "title": "Qualcomm sales beat estimates, shares drop after licensing forecast | Reuters",
                "url": "https://www.reuters.com/technology/qualcomm-results-forecast-top-expectations-ai-drives-smartphone-sales-2025-02-05/#:~:text=At%20the%20midpoints%20of%20the,licensing%2C%20according%20to%20LSEG%20data",
                "pub_date": null,
                "snippet": "At the midpoints of the ranges, Qualcomm forecast second-quarter revenues of $9.2 billion for its chip business and $1.35 billion for patent licensing. Wall Street had expected $8.90 billion for chips and $1.43 billion for patent licensing, according to LSEG data.",
                "attribution": "reuters.com",
                "icon_type": null
              },
              {
                "matched_text": "\u30103\u2020L163-L170\u3011",
                "start_idx": 2935,
                "end_idx": 2948,
                "alt": null,
                "type": "webpage_extended",
                "title": "Understanding Key Strategies of Patent Monetization",
                "url": "https://www.iiprd.com/patent-monetization/#:~:text=",
                "pub_date": null,
                "snippet": "# 2.Patent Sales:",
                "attribution": "iiprd.com",
                "icon_type": null
              },
              {
                "matched_text": "\u30103\u2020L165-L173\u3011",
                "start_idx": 3461,
                "end_idx": 3474,
                "alt": null,
                "type": "webpage_extended",
                "title": "Understanding Key Strategies of Patent Monetization",
                "url": "https://www.iiprd.com/patent-monetization/#:~:text=Another%20type%20of%20monetization%20in,at%20least%207%20billion",
                "pub_date": null,
                "snippet": "Another type of monetization in patents is the sale of patents, which is highly appropriate for cases when a company wants to get rid of unprofitable assets, or in need of immediate cash inflows. Referring to the statistics of Allied Market Research, the IP trading market size across the globe was approximately $7. 4 billion in the year 2020 and is expected to touch the figure of $34. It predicts that by 2030 alone the figure will have grown to at least 7 billion .",
                "attribution": "iiprd.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301021\u2020L33-L41\u3011",
                "start_idx": 4082,
                "end_idx": 4094,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Trolls Like Intellectual Ventures Must Be More Closely Regulated, But How? - Sequel Legal",
                "url": "https://sequellegal.com/patent-trolls-like-intellectual-ventures-must-be-more-closely-regulated-but-how/#:~:text=Patent%20trolls%20are%20the%20bane,of%20the%20underlying%20intellectual%20property",
                "pub_date": null,
                "snippet": "Patent trolls are the bane of the existence of American industry. These companies and individuals shop around for patents and patent portfolios to acquire for the sole purpose of using litigation and the threat of litigation to monetize their underlying ideas. They have no interest in the utility, social value or commercial viability of the underlying intellectual property.",
                "attribution": "sequellegal.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301013\u2020L297-L305\u3011",
                "start_idx": 4094,
                "end_idx": 4108,
                "alt": null,
                "type": "webpage_extended",
                "title": "Intellectual Ventures - Wikipedia",
                "url": "https://en.wikipedia.org/wiki/Intellectual_Ventures#:~:text=Publicly%2C%20Intellectual%20Ventures%20states%20that,34",
                "pub_date": null,
                "snippet": "Publicly, Intellectual Ventures states that a major goal is to assist small inventors against corporations. In practice, the vast majority of IV's revenue comes from buying patents, aggregating these patents into a single portfolio spanning many disparate technologies and tying these patents together for license to other companies under the threat of litigation, or filing lawsuits for infringement of patents, a controversial practice referred to as \"patent trolling.\"[ 34 ]",
                "attribution": "en.wikipedia.org",
                "icon_type": null
              },
              {
                "matched_text": "\u30103\u2020L188-L192\u3011",
                "start_idx": 4248,
                "end_idx": 4261,
                "alt": null,
                "type": "webpage_extended",
                "title": "Understanding Key Strategies of Patent Monetization",
                "url": "https://www.iiprd.com/patent-monetization/#:~:text=As%20many%20have%20claimed%2C%20litigation,years%202015%20to%202019%20respectively",
                "pub_date": null,
                "snippet": "As many have claimed, litigation may be the last resort of patentees but if aimed at wilful infringers it is a potent monetization technique. PwC made a discovery with research which revealed that the average of patent infringement damages award in the United States was $10. 2 million for the years 2015 to 2019 respectively.",
                "attribution": "iiprd.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301021\u2020L43-L50\u3011",
                "start_idx": 4880,
                "end_idx": 4892,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Trolls Like Intellectual Ventures Must Be More Closely Regulated, But How? - Sequel Legal",
                "url": "https://sequellegal.com/patent-trolls-like-intellectual-ventures-must-be-more-closely-regulated-but-how/#:~:text=One%20of%20the%20largest%20and,the%20patents%20just%20%24500%20million",
                "pub_date": null,
                "snippet": "One of the largest and most egregious examples of this behavior is Intellectual Ventures, a Bellevue, WA based firm that boasts a portfolio of some 70,000 patents it has acquired during its 14 years in business. It has realized $3 billion in patent licensing fees, but has passed on to the inventors behind the patents just $500 million.",
                "attribution": "sequellegal.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301013\u2020L297-L305\u3011",
                "start_idx": 5035,
                "end_idx": 5049,
                "alt": null,
                "type": "webpage_extended",
                "title": "Intellectual Ventures - Wikipedia",
                "url": "https://en.wikipedia.org/wiki/Intellectual_Ventures#:~:text=Publicly%2C%20Intellectual%20Ventures%20states%20that,34",
                "pub_date": null,
                "snippet": "Publicly, Intellectual Ventures states that a major goal is to assist small inventors against corporations. In practice, the vast majority of IV's revenue comes from buying patents, aggregating these patents into a single portfolio spanning many disparate technologies and tying these patents together for license to other companies under the threat of litigation, or filing lawsuits for infringement of patents, a controversial practice referred to as \"patent trolling.\"[ 34 ]",
                "attribution": "en.wikipedia.org",
                "icon_type": null
              },
              {
                "matched_text": "\u301047\u2020L1-L4\u3011",
                "start_idx": 9297,
                "end_idx": 9307,
                "alt": null,
                "type": "webpage_extended",
                "title": "Intellectual Property Finance",
                "url": "https://www.wipo.int/en/web/ip-financing#:~:text=Intellectual%20property%20rights%20can%20be,For%20some%20businesses%2C%20intangible",
                "pub_date": null,
                "snippet": "Intellectual property rights can be used to secure financing, either by pledging them or transferring rights to cash flows derived from these assets. Alternatively, a company\u2019s intellectual property can provide an indicator of a firm\u2019s value and support financing decisions. For some businesses, intangible",
                "attribution": "wipo.int",
                "icon_type": null
              },
              {
                "matched_text": "\u30104\u2020L9-L17\u3011",
                "start_idx": 9457,
                "end_idx": 9467,
                "alt": null,
                "type": "webpage_extended",
                "title": "Intellectual Property Finance - WIPO",
                "url": "https://www.wipo.int/en/web/ip-financing#:~:text=Intellectual%20Property%20Finance%20,flows%20derived%20from%20these%20assets",
                "pub_date": null,
                "snippet": "Intellectual Property Finance - WIPO Intellectual property rights can be used to secure financing, either by pledging them or transferring rights to cash flows derived from these assets.",
                "attribution": "wipo.int",
                "icon_type": null
              },
              {
                "matched_text": "\u301045\u2020L1-L9\u3011",
                "start_idx": 9824,
                "end_idx": 9834,
                "alt": null,
                "type": "webpage_extended",
                "title": "As Lyrica profits dry up, Northwestern seeks another 'blockbuster' drug",
                "url": "https://dailynorthwestern.com/2016/04/10/featured-stories/in-focus/in-focus-as-lyrica-profits-dry-up-northwestern-seeks-another-blockbuster-drug/#:~:text=drug%20dailynorthwestern,to%20pharmaceutical%20company%20Royal%20Pharma",
                "pub_date": null,
                "snippet": "drug dailynorthwestern.com  Silverman and the University monetized part of their royalties in 2007 for a total of $700 million to pharmaceutical company Royal Pharma.",
                "attribution": "dailynorthwestern.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301037\u2020L283-L290\u3011",
                "start_idx": 13933,
                "end_idx": 13947,
                "alt": null,
                "type": "webpage_extended",
                "title": "Microsoft Earns $2 Billion Per Year From Android Patent Royalties - Business Insider",
                "url": "https://www.businessinsider.com/microsoft-earns-2-billion-per-year-from-android-patent-royalties-2013-11#:~:text=Microsoft%20is%20generating%20%242%20billion,new%20note%20on%20the%20company",
                "pub_date": null,
                "snippet": "Microsoft is generating $2 billion per year in revenue from Android patent royalties, says Nomura analyst Rick Sherlund in a new note on the company.",
                "attribution": "businessinsider.com",
                "icon_type": null
              },
              {
                "matched_text": "\u30106\u2020L97-L104\u3011",
                "start_idx": 17508,
                "end_idx": 17520,
                "alt": null,
                "type": "webpage_extended",
                "title": "IBM drops from top spot in patents, surpassed by Samsung | TechTarget",
                "url": "https://www.techtarget.com/searchdatacenter/news/365531318/IBM-drops-from-top-spot-in-patents-surpassed-by-Samsung#:~:text=IBM%27s%20patent%20portfolio%20business%20has,according%20to%20IBM%27s%20financial%20filings",
                "pub_date": null,
                "snippet": "IBM's patent portfolio business has been profitable over the years, averaging a little more than $1 billion a year in revenue since mid-1996, according to IBM's financial filings.",
                "attribution": "techtarget.com",
                "icon_type": null
              },
              {
                "matched_text": "\u30109\u2020L1-L4\u3011",
                "start_idx": 18521,
                "end_idx": 18530,
                "alt": null,
                "type": "webpage_extended",
                "title": "Qualcomm sales beat estimates, shares drop after licensing forecast | Reuters",
                "url": "https://www.reuters.com/technology/qualcomm-results-forecast-top-expectations-ai-drives-smartphone-sales-2025-02-05/#:~:text=%249,licensing%2C%20according%20to%20LSEG%20data",
                "pub_date": null,
                "snippet": "$9.2 billion for its chip business and $1.35 billion for patent licensing. Wall Street had expected $8.90 billion for chips and $1.43 billion for patent licensing, according to LSEG data.",
                "attribution": "reuters.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301037\u2020L283-L290\u3011",
                "start_idx": 19095,
                "end_idx": 19109,
                "alt": null,
                "type": "webpage_extended",
                "title": "Microsoft Earns $2 Billion Per Year From Android Patent Royalties - Business Insider",
                "url": "https://www.businessinsider.com/microsoft-earns-2-billion-per-year-from-android-patent-royalties-2013-11#:~:text=Microsoft%20is%20generating%20%242%20billion,new%20note%20on%20the%20company",
                "pub_date": null,
                "snippet": "Microsoft is generating $2 billion per year in revenue from Android patent royalties, says Nomura analyst Rick Sherlund in a new note on the company.",
                "attribution": "businessinsider.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301021\u2020L43-L50\u3011",
                "start_idx": 23033,
                "end_idx": 23045,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Trolls Like Intellectual Ventures Must Be More Closely Regulated, But How? - Sequel Legal",
                "url": "https://sequellegal.com/patent-trolls-like-intellectual-ventures-must-be-more-closely-regulated-but-how/#:~:text=One%20of%20the%20largest%20and,the%20patents%20just%20%24500%20million",
                "pub_date": null,
                "snippet": "One of the largest and most egregious examples of this behavior is Intellectual Ventures, a Bellevue, WA based firm that boasts a portfolio of some 70,000 patents it has acquired during its 14 years in business. It has realized $3 billion in patent licensing fees, but has passed on to the inventors behind the patents just $500 million.",
                "attribution": "sequellegal.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301021\u2020L43-L50\u3011",
                "start_idx": 23429,
                "end_idx": 23441,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Trolls Like Intellectual Ventures Must Be More Closely Regulated, But How? - Sequel Legal",
                "url": "https://sequellegal.com/patent-trolls-like-intellectual-ventures-must-be-more-closely-regulated-but-how/#:~:text=One%20of%20the%20largest%20and,the%20patents%20just%20%24500%20million",
                "pub_date": null,
                "snippet": "One of the largest and most egregious examples of this behavior is Intellectual Ventures, a Bellevue, WA based firm that boasts a portfolio of some 70,000 patents it has acquired during its 14 years in business. It has realized $3 billion in patent licensing fees, but has passed on to the inventors behind the patents just $500 million.",
                "attribution": "sequellegal.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301040\u2020L5-L13\u3011",
                "start_idx": 28736,
                "end_idx": 28747,
                "alt": null,
                "type": "webpage_extended",
                "title": "France Brevets' public sector links hindered monetisation efforts ...",
                "url": "https://www.iam-media.com/article/france-brevets-public-sector-links-hindered-its-monetisation-efforts-says-ceo#:~:text=France%20Brevets%27%20public%20sector%20links,Share",
                "pub_date": null,
                "snippet": "France Brevets' public sector links hindered monetisation efforts ... France Brevets' public sector links hindered monetisation efforts, says CEO. Adam Houldsworth. 03 November 2022. Share.",
                "attribution": "iam-media.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301040\u2020L15-L23\u3011",
                "start_idx": 28747,
                "end_idx": 28759,
                "alt": null,
                "type": "webpage_extended",
                "title": "Judge's Investigation into Patent Troll Results in Criminal Referrals ...",
                "url": "https://news.ycombinator.com/item?id=42234147#:~:text=Judge%27s%20Investigation%20into%20Patent%20Troll,HTC%20or%20the%20Korean",
                "pub_date": null,
                "snippet": "Judge's Investigation into Patent Troll Results in Criminal Referrals ... France Brevets is criticized for having a \"patent troll\" type of activity and is taking legal action against companies such as the Taiwanese HTC or the Korean ...",
                "attribution": "news.ycombinator.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301032\u2020L401-L404\u3011",
                "start_idx": 29657,
                "end_idx": 29671,
                "alt": null,
                "type": "webpage_extended",
                "title": "Why the University of Florida gets a ~$20m cut of Gatorade profits every year  - The Hustle ",
                "url": "https://thehustle.co/why-the-university-of-florida-gets-a-20m-cut-of-gatorade-profits-every-year#:~:text=The%20university%20patents%20around%20140,affiliated%20patents%20was%20~%242.9B",
                "pub_date": null,
                "snippet": "The university patents around 140 inventions each year and made ~$500m off licenses between 2008 to 2018, placing it near the top of the market. In 2018, the total licensing revenue from university-affiliated patents was ~$2.9B.",
                "attribution": "thehustle.co",
                "icon_type": null
              },
              {
                "matched_text": "\u301034\u2020L243-L252\u3011",
                "start_idx": 30215,
                "end_idx": 30229,
                "alt": null,
                "type": "webpage_extended",
                "title": "Technology Transfer in U.S. Research Universities: Dispelling Common Myths",
                "url": "https://www.cogr.edu/sites/default/files/Myths_Final%2008-01-22.pdf#:~:text=unmanageable%20institutional%20conflicts%20of%20interest,of%20the%20licensing%20income",
                "pub_date": null,
                "snippet": "unmanageable institutional conflicts of interest. Response: Most university technology licensing offices struggle to make enough in licensing revenue to cover their operating expenses. Lucrative inventions are exceedingly rare. Based on data from the 2020 AUTM Survey, the top 5% of U.S. technology licensing operations (9 universities) accounted for 51% of the total licensing revenue reported. In the same year, the top 10% of the reporting U.S. universities realized 70% of the licensing income.",
                "attribution": "cogr.edu",
                "icon_type": null
              },
              {
                "matched_text": "\u301034\u2020L245-L252\u3011",
                "start_idx": 30359,
                "end_idx": 30373,
                "alt": null,
                "type": "webpage_extended",
                "title": "Technology Transfer in U.S. Research Universities: Dispelling Common Myths",
                "url": "https://www.cogr.edu/sites/default/files/Myths_Final%2008-01-22.pdf#:~:text=in%20licensing%20revenue%20to%20cover,of%20the%20licensing%20income",
                "pub_date": null,
                "snippet": "in licensing revenue to cover their operating expenses. Lucrative inventions are exceedingly rare. Based on data from the 2020 AUTM Survey, the top 5% of U.S. technology licensing operations (9 universities) accounted for 51% of the total licensing revenue reported. In the same year, the top 10% of the reporting U.S. universities realized 70% of the licensing income.",
                "attribution": "cogr.edu",
                "icon_type": null
              },
              {
                "matched_text": "\u301034\u2020L243-L252\u3011",
                "start_idx": 30766,
                "end_idx": 30780,
                "alt": null,
                "type": "webpage_extended",
                "title": "Technology Transfer in U.S. Research Universities: Dispelling Common Myths",
                "url": "https://www.cogr.edu/sites/default/files/Myths_Final%2008-01-22.pdf#:~:text=unmanageable%20institutional%20conflicts%20of%20interest,of%20the%20licensing%20income",
                "pub_date": null,
                "snippet": "unmanageable institutional conflicts of interest. Response: Most university technology licensing offices struggle to make enough in licensing revenue to cover their operating expenses. Lucrative inventions are exceedingly rare. Based on data from the 2020 AUTM Survey, the top 5% of U.S. technology licensing operations (9 universities) accounted for 51% of the total licensing revenue reported. In the same year, the top 10% of the reporting U.S. universities realized 70% of the licensing income.",
                "attribution": "cogr.edu",
                "icon_type": null
              },
              {
                "matched_text": "\u301024\u2020L1-L4\u3011",
                "start_idx": 31345,
                "end_idx": 31355,
                "alt": null,
                "type": "webpage_extended",
                "title": "",
                "url": "https://autm.net/AUTM/media/About-Tech-Transfer/Documents/Economic_Contribution_Report_BIO_AUTM_JUN2019_web.pdf#:~:text=for%20Universities%2C%20about%2080,In%20addition%2C%20public%20anecdotal",
                "pub_date": null,
                "snippet": "for Universities, about 80% of the income is from licenses in the life sciences. For Hospitals and Research Institutes, 90% or more of the income is from licenses in the life sciences. In addition, public anecdotal",
                "attribution": "autm.net",
                "icon_type": null
              },
              {
                "matched_text": "\u301024\u2020L1-L4\u3011",
                "start_idx": 31427,
                "end_idx": 31437,
                "alt": null,
                "type": "webpage_extended",
                "title": "",
                "url": "https://autm.net/AUTM/media/About-Tech-Transfer/Documents/Economic_Contribution_Report_BIO_AUTM_JUN2019_web.pdf#:~:text=for%20Universities%2C%20about%2080,In%20addition%2C%20public%20anecdotal",
                "pub_date": null,
                "snippet": "for Universities, about 80% of the income is from licenses in the life sciences. For Hospitals and Research Institutes, 90% or more of the income is from licenses in the life sciences. In addition, public anecdotal",
                "attribution": "autm.net",
                "icon_type": null
              },
              {
                "matched_text": "\u301045\u2020L1-L9\u3011",
                "start_idx": 31856,
                "end_idx": 31866,
                "alt": null,
                "type": "webpage_extended",
                "title": "As Lyrica profits dry up, Northwestern seeks another 'blockbuster' drug",
                "url": "https://dailynorthwestern.com/2016/04/10/featured-stories/in-focus/in-focus-as-lyrica-profits-dry-up-northwestern-seeks-another-blockbuster-drug/#:~:text=drug%20dailynorthwestern,to%20pharmaceutical%20company%20Royal%20Pharma",
                "pub_date": null,
                "snippet": "drug dailynorthwestern.com  Silverman and the University monetized part of their royalties in 2007 for a total of $700 million to pharmaceutical company Royal Pharma.",
                "attribution": "dailynorthwestern.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301041\u2020L1-L8\u3011",
                "start_idx": 32146,
                "end_idx": 32156,
                "alt": null,
                "type": "webpage_extended",
                "title": "How the \"First\" Biotech Patent Generated Millions - Labiotech.eu",
                "url": "https://www.labiotech.eu/trends-news/making-dollars-out-of-the-recombinant-dna-biotech-patents/#:~:text=Labiotech,up",
                "pub_date": null,
                "snippet": "Labiotech.eu www.labiotech.eu  Over the 25 years of the licensing program, Stanford and the University of California system amassed a \u20ac241M fortune in licensing revenues (up ...",
                "attribution": "labiotech.eu",
                "icon_type": null
              },
              {
                "matched_text": "\u301044\u2020L1-L4\u3011",
                "start_idx": 32726,
                "end_idx": 32736,
                "alt": null,
                "type": "webpage_extended",
                "title": "How the \"First\" Biotech Patent Generated Millions",
                "url": "https://www.labiotech.eu/trends-news/making-dollars-out-of-the-recombinant-dna-biotech-patents/#:~:text=California%20system%20amassed%20a%20%E2%82%AC241M,standard%20for%20university%20technology%20licensing",
                "pub_date": null,
                "snippet": "California system amassed a \u20ac241M fortune in licensing revenues (up until 2001). In many ways, Stanford\u2019s management of the Cohen-Boyer patents has become the gold standard for university technology licensing.",
                "attribution": "labiotech.eu",
                "icon_type": null
              },
              {
                "matched_text": "\u301024\u2020L37-L40\u3011",
                "start_idx": 33826,
                "end_idx": 33838,
                "alt": null,
                "type": "webpage_extended",
                "title": "",
                "url": "https://autm.net/AUTM/media/About-Tech-Transfer/Documents/Economic_Contribution_Report_BIO_AUTM_JUN2019_web.pdf#:~:text=U.S.%20Universities%20%24242%2C057%2C513%20%24194%2C199%2C551%2080,%241%2C500%2C117%2016",
                "pub_date": null,
                "snippet": "U.S. Universities $242,057,513 $194,199,551 80% $47,857,962 20% U.S. Hospitals & Research Institutes $131,741,920 $118,242,472 90% $13,499,448 10% Canadian Institutions $9,589,867 $8,089,750 84% $1,500,117 16%",
                "attribution": "autm.net",
                "icon_type": null
              },
              {
                "matched_text": "\u301031\u2020L1-L4\u3011",
                "start_idx": 34993,
                "end_idx": 35003,
                "alt": null,
                "type": "webpage_extended",
                "title": "Why the University of Florida gets a ~$20m cut of Gatorade profits every year  - The Hustle ",
                "url": "https://thehustle.co/why-the-university-of-florida-gets-a-20m-cut-of-gatorade-profits-every-year#:~:text=The%20university%20patents%20around%20140,affiliated%20patents%20was%20~%242.9B",
                "pub_date": null,
                "snippet": "The university patents around 140 inventions each year and made ~$500m off licenses between 2008 to 2018, placing it near the top of the market. In 2018, the total licensing revenue from university-affiliated patents was ~$2.9B.",
                "attribution": "thehustle.co",
                "icon_type": null
              },
              {
                "matched_text": "\u301032\u2020L399-L407\u3011",
                "start_idx": 35099,
                "end_idx": 35113,
                "alt": null,
                "type": "webpage_extended",
                "title": "Why the University of Florida gets a ~$20m cut of Gatorade profits every year  - The Hustle ",
                "url": "https://thehustle.co/why-the-university-of-florida-gets-a-20m-cut-of-gatorade-profits-every-year#:~:text=researchers%20looking%20to%20make%20lucrative,discoveries",
                "pub_date": null,
                "snippet": "researchers looking to make lucrative discoveries.",
                "attribution": "thehustle.co",
                "icon_type": null
              },
              {
                "matched_text": "\u301044\u2020L1-L4\u3011",
                "start_idx": 36854,
                "end_idx": 36864,
                "alt": null,
                "type": "webpage_extended",
                "title": "How the \"First\" Biotech Patent Generated Millions",
                "url": "https://www.labiotech.eu/trends-news/making-dollars-out-of-the-recombinant-dna-biotech-patents/#:~:text=California%20system%20amassed%20a%20%E2%82%AC241M,standard%20for%20university%20technology%20licensing",
                "pub_date": null,
                "snippet": "California system amassed a \u20ac241M fortune in licensing revenues (up until 2001). In many ways, Stanford\u2019s management of the Cohen-Boyer patents has become the gold standard for university technology licensing.",
                "attribution": "labiotech.eu",
                "icon_type": null
              },
              {
                "matched_text": "\u301022\u2020L33-L38\u3011",
                "start_idx": 40064,
                "end_idx": 40076,
                "alt": null,
                "type": "webpage_extended",
                "title": "Benchmarking U.S. university patent value and commercialization ...",
                "url": "https://www.sciencedirect.com/science/article/abs/pii/S0048733320301542#:~:text=Benchmarking%20U,the%20economic%20significance%20of",
                "pub_date": null,
                "snippet": "Benchmarking U.S. university patent value and commercialization ... Finds that universities capture on average 16% of the economic value of their patents through licensing revenues. Abstract. Despite the economic significance of ...",
                "attribution": "sciencedirect.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301034\u2020L194-L202\u3011",
                "start_idx": 40373,
                "end_idx": 40387,
                "alt": null,
                "type": "webpage_extended",
                "title": "Technology Transfer in U.S. Research Universities: Dispelling Common Myths",
                "url": "https://www.cogr.edu/sites/default/files/Myths_Final%2008-01-22.pdf#:~:text=Released%20August%202%2C%202022%20economic,Dole%20Act%20v",
                "pub_date": null,
                "snippet": "Released August 2, 2022 economic impact generates tremendous value to the U.S. economy and workforce that also supports U.S. competition in the global marketplace. In addition, the public benefits from the 933 new products that were introduced to the market during 2020 and the more than 200 new drugs and vaccines that have been commercialized since passage of the Bayh-Dole Act v",
                "attribution": "cogr.edu",
                "icon_type": null
              },
              {
                "matched_text": "\u301034\u2020L207-L215\u3011",
                "start_idx": 40387,
                "end_idx": 40401,
                "alt": null,
                "type": "webpage_extended",
                "title": "Technology Transfer in U.S. Research Universities: Dispelling Common Myths",
                "url": "https://www.cogr.edu/sites/default/files/Myths_Final%2008-01-22.pdf#:~:text=Myth%20,funded%20research",
                "pub_date": null,
                "snippet": "Myth #3: U.S. taxpayers, through NIH, provide significant support to find new therapies. These drugs should be free to the public. Response: The National Institutes of Health (NIH) funds significant extramural research at universities with a goal to \u201cfoster fundamental creative discoveries \u2026 and their applications as a basis for ultimately protecting and improving healthvi.\u201d Universities conduct NIH-funded research",
                "attribution": "cogr.edu",
                "icon_type": null
              },
              {
                "matched_text": "\u301032\u2020L398-L407\u3011",
                "start_idx": 40844,
                "end_idx": 40858,
                "alt": null,
                "type": "webpage_extended",
                "title": "Why the University of Florida gets a ~$20m cut of Gatorade profits every year  - The Hustle ",
                "url": "https://thehustle.co/why-the-university-of-florida-gets-a-20m-cut-of-gatorade-profits-every-year#:~:text=Florida%20has%20used%20its%20royalties,looking%20to%20make%20lucrative%20discoveries",
                "pub_date": null,
                "snippet": "Florida has used its royalties to bolster its research and entice new researchers looking to make lucrative discoveries.",
                "attribution": "thehustle.co",
                "icon_type": null
              },
              {
                "matched_text": "\u301045\u2020L33-L41\u3011",
                "start_idx": 40941,
                "end_idx": 40953,
                "alt": null,
                "type": "webpage_extended",
                "title": "Northwestern sees $700 million for sale of Lyrica royalties | Drug ...",
                "url": "https://drugstorenews.com/pharmacy/northwestern-sees-700-million-sale-lyrica-royalties#:~:text=Northwestern%20sees%20%24700%20million%20for,the%20chemists%20who%20synthesized%20pregabalin",
                "pub_date": null,
                "snippet": "Northwestern sees $700 million for sale of Lyrica royalties | Drug ... The bulk of the $700 million will go into NU's endowment fund, which is worth $6.6 billion, but some portion will go to the chemists who synthesized pregabalin.",
                "attribution": "drugstorenews.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301038\u2020L31-L35\u3011",
                "start_idx": 42903,
                "end_idx": 42915,
                "alt": null,
                "type": "webpage_extended",
                "title": "University invention and the abolishment of the professor's privilege ...",
                "url": "https://www.sciencedirect.com/science/article/abs/pii/S0048733318300519#:~:text=University%20invention%20and%20the%20abolishment,percent%20in%20matched%20sample%20analyses",
                "pub_date": null,
                "snippet": "University invention and the abolishment of the professor's privilege ... We evaluate the abolition of the professor's privilege in Finland in 2007. \u00b7 After 2007, patenting by academics dropped 29 percent in matched sample analyses.",
                "attribution": "sciencedirect.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301040\u2020L15-L23\u3011",
                "start_idx": 43791,
                "end_idx": 43803,
                "alt": null,
                "type": "webpage_extended",
                "title": "Judge's Investigation into Patent Troll Results in Criminal Referrals ...",
                "url": "https://news.ycombinator.com/item?id=42234147#:~:text=Judge%27s%20Investigation%20into%20Patent%20Troll,HTC%20or%20the%20Korean",
                "pub_date": null,
                "snippet": "Judge's Investigation into Patent Troll Results in Criminal Referrals ... France Brevets is criticized for having a \"patent troll\" type of activity and is taking legal action against companies such as the Taiwanese HTC or the Korean ...",
                "attribution": "news.ycombinator.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301040\u2020L27-L35\u3011",
                "start_idx": 43803,
                "end_idx": 43815,
                "alt": null,
                "type": "webpage_extended",
                "title": "French sovereign patent fund shows muscle: FB spearheads patent ...",
                "url": "https://ipkitten.blogspot.com/2013/08/french-sovereign-patent-fund-shows.html#:~:text=French%20sovereign%20patent%20fund%20shows,create%20a%20national%20investment",
                "pub_date": null,
                "snippet": "French sovereign patent fund shows muscle: FB spearheads patent ... The major part of this fund was set to create specific companies (SATT); the rest (100 millions Euros) was used to create a national investment ...",
                "attribution": "ipkitten.blogspot.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301040\u2020L5-L13\u3011",
                "start_idx": 43918,
                "end_idx": 43929,
                "alt": null,
                "type": "webpage_extended",
                "title": "France Brevets' public sector links hindered monetisation efforts ...",
                "url": "https://www.iam-media.com/article/france-brevets-public-sector-links-hindered-its-monetisation-efforts-says-ceo#:~:text=France%20Brevets%27%20public%20sector%20links,Share",
                "pub_date": null,
                "snippet": "France Brevets' public sector links hindered monetisation efforts ... France Brevets' public sector links hindered monetisation efforts, says CEO. Adam Houldsworth. 03 November 2022. Share.",
                "attribution": "iam-media.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301040\u2020L9-L17\u3011",
                "start_idx": 44035,
                "end_idx": 44046,
                "alt": null,
                "type": "webpage_extended",
                "title": "Judge's Investigation Into Patent Troll Results In Criminal Referrals",
                "url": "https://www.eff.org/deeplinks/2024/11/judges-investigation-patent-troll-ip-edge-results-criminal-referrals#:~:text=Judge%27s%20Investigation%20Into%20Patent%20Troll,US%20patent%20system%20for%20profit",
                "pub_date": null,
                "snippet": "Judge's Investigation Into Patent Troll Results In Criminal Referrals However, it's even more concerning when foreign government-backed organizations like France Brevets manipulate the US patent system for profit.",
                "attribution": "eff.org",
                "icon_type": null
              },
              {
                "matched_text": "\u301039\u2020L19-L27\u3011",
                "start_idx": 45381,
                "end_idx": 45393,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Box | Tax - BDO",
                "url": "https://www.bdo.co.uk/en-gb/services/tax/innovation-and-r-d-tax-incentives/patent-box#:~:text=Patent%20Box%20%7C%20Tax%20,from%20April%202023",
                "pub_date": null,
                "snippet": "Patent Box | Tax - BDO It takes the form of an effective tax rate at 10% of the relevant profits compared to the UK's usual 19% rate (25% from April 2023).",
                "attribution": "bdo.co.uk",
                "icon_type": null
              },
              {
                "matched_text": "\u301039\u2020L1-L8\u3011",
                "start_idx": 45690,
                "end_idx": 45700,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Box relief statistics: September 2024 - GOV.UK",
                "url": "https://www.gov.uk/government/statistics/patent-box-reliefs-statistics/patent-box-relief-statistics-september-2024--2#:~:text=conversely%2C%20the%20value%20of%20relief,2022%20to%202023%20from",
                "pub_date": null,
                "snippet": "conversely, the value of relief claimed under the Patent Box is estimated to have increased to \u00a31,469 million in the tax year 2022 to 2023 from ...",
                "attribution": "gov.uk",
                "icon_type": null
              },
              {
                "matched_text": "\u30106\u2020L97-L104\u3011",
                "start_idx": 53116,
                "end_idx": 53128,
                "alt": null,
                "type": "webpage_extended",
                "title": "IBM drops from top spot in patents, surpassed by Samsung | TechTarget",
                "url": "https://www.techtarget.com/searchdatacenter/news/365531318/IBM-drops-from-top-spot-in-patents-surpassed-by-Samsung#:~:text=IBM%27s%20patent%20portfolio%20business%20has,according%20to%20IBM%27s%20financial%20filings",
                "pub_date": null,
                "snippet": "IBM's patent portfolio business has been profitable over the years, averaging a little more than $1 billion a year in revenue since mid-1996, according to IBM's financial filings.",
                "attribution": "techtarget.com",
                "icon_type": null
              },
              {
                "matched_text": "\u30105\u2020L11-L18\u3011",
                "start_idx": 53724,
                "end_idx": 53735,
                "alt": null,
                "type": "webpage_extended",
                "title": "IBM's patent income slips as companies resist 'godfather' deals",
                "url": "https://www.spokesman.com/stories/2021/mar/12/ibms-patent-income-slips-as-companies-resist-godfa/#:~:text=deals%20www,6",
                "pub_date": null,
                "snippet": "deals www.spokesman.com  Last year, income from intellectual property licensing was nearly a third of its 2000 peak of $1.7 billion, or a recent 2016 spike of $1.6 ...",
                "attribution": "spokesman.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301021\u2020L43-L50\u3011",
                "start_idx": 55457,
                "end_idx": 55469,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Trolls Like Intellectual Ventures Must Be More Closely Regulated, But How? - Sequel Legal",
                "url": "https://sequellegal.com/patent-trolls-like-intellectual-ventures-must-be-more-closely-regulated-but-how/#:~:text=One%20of%20the%20largest%20and,the%20patents%20just%20%24500%20million",
                "pub_date": null,
                "snippet": "One of the largest and most egregious examples of this behavior is Intellectual Ventures, a Bellevue, WA based firm that boasts a portfolio of some 70,000 patents it has acquired during its 14 years in business. It has realized $3 billion in patent licensing fees, but has passed on to the inventors behind the patents just $500 million.",
                "attribution": "sequellegal.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301034\u2020L247-L252\u3011",
                "start_idx": 68491,
                "end_idx": 68505,
                "alt": null,
                "type": "webpage_extended",
                "title": "Technology Transfer in U.S. Research Universities: Dispelling Common Myths",
                "url": "https://www.cogr.edu/sites/default/files/Myths_Final%2008-01-22.pdf#:~:text=rare,of%20the%20licensing%20income",
                "pub_date": null,
                "snippet": "rare. Based on data from the 2020 AUTM Survey, the top 5% of U.S. technology licensing operations (9 universities) accounted for 51% of the total licensing revenue reported. In the same year, the top 10% of the reporting U.S. universities realized 70% of the licensing income.",
                "attribution": "cogr.edu",
                "icon_type": null
              },
              {
                "matched_text": "\u301043\u2020L292-L300\u3011",
                "start_idx": 69738,
                "end_idx": 69752,
                "alt": null,
                "type": "webpage_extended",
                "title": "How the \"First\" Biotech Patent Generated Millions",
                "url": "https://www.labiotech.eu/trends-news/making-dollars-out-of-the-recombinant-dna-biotech-patents/#:~:text=The%2017%20years%20during%20which,exploit%20all%20the%20possible%20applications",
                "pub_date": null,
                "snippet": "The 17 years during which the Cohen-Boyer patents were licensed, Stanford consulted widely across various stakeholders before settling on the licensing terms. For Stanford, the logic was that recombinant DNA was a platform technology and it was not possible for any one company to exploit all the possible applications.",
                "attribution": "labiotech.eu",
                "icon_type": null
              },
              {
                "matched_text": "\u301043\u2020L307-L315\u3011",
                "start_idx": 69752,
                "end_idx": 69766,
                "alt": null,
                "type": "webpage_extended",
                "title": "How the \"First\" Biotech Patent Generated Millions",
                "url": "https://www.labiotech.eu/trends-news/making-dollars-out-of-the-recombinant-dna-biotech-patents/#:~:text=",
                "pub_date": null,
                "snippet": "* * *",
                "attribution": "labiotech.eu",
                "icon_type": null
              },
              {
                "matched_text": "\u30103\u2020L144-L152\u3011",
                "start_idx": 72535,
                "end_idx": 72548,
                "alt": null,
                "type": "webpage_extended",
                "title": "Understanding Key Strategies of Patent Monetization",
                "url": "https://www.iiprd.com/patent-monetization/#:~:text=Licensing%3A%C2%A0%20Licensing%20is%20arguably%20the,among%20the%20surveyed%20firms",
                "pub_date": null,
                "snippet": "Licensing:\u00a0 Licensing is arguably the most common and easily understandable method of flowing with patent monitory. It is the legal right given to the owner of the patented technology to allow third parties to utilize them in return for some form of consideration. According to LES, a survey of the licensing revenues indicated that licensing made up more than 40 percent of the total income from patent monetization among the surveyed firms .",
                "attribution": "iiprd.com",
                "icon_type": null
              },
              {
                "matched_text": "\u30103\u2020L157-L165\u3011",
                "start_idx": 72548,
                "end_idx": 72561,
                "alt": null,
                "type": "webpage_extended",
                "title": "Understanding Key Strategies of Patent Monetization",
                "url": "https://www.iiprd.com/patent-monetization/#:~:text=%2A%20Cross,used%20in%20standard%20essential%20patents",
                "pub_date": null,
                "snippet": "* Cross-licensing: Cross licenses are when two firms agree that they can use each other\u2019s patents and this is mostly used to settle legal matters or gain access to related technologies. * Patent pools: Patent pool in which many patentees combine their patents in a bundle especially used in standard essential patents.",
                "attribution": "iiprd.com",
                "icon_type": null
              },
              {
                "matched_text": "\u30103\u2020L188-L196\u3011",
                "start_idx": 72561,
                "end_idx": 72574,
                "alt": null,
                "type": "webpage_extended",
                "title": "Understanding Key Strategies of Patent Monetization",
                "url": "https://www.iiprd.com/patent-monetization/#:~:text=As%20many%20have%20claimed%2C%20litigation,years%202015%20to%202019%20respectively",
                "pub_date": null,
                "snippet": "As many have claimed, litigation may be the last resort of patentees but if aimed at wilful infringers it is a potent monetization technique. PwC made a discovery with research which revealed that the average of patent infringement damages award in the United States was $10. 2 million for the years 2015 to 2019 respectively.",
                "attribution": "iiprd.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301047\u2020L1-L4\u3011",
                "start_idx": 72574,
                "end_idx": 72584,
                "alt": null,
                "type": "webpage_extended",
                "title": "Intellectual Property Finance",
                "url": "https://www.wipo.int/en/web/ip-financing#:~:text=Intellectual%20property%20rights%20can%20be,For%20some%20businesses%2C%20intangible",
                "pub_date": null,
                "snippet": "Intellectual property rights can be used to secure financing, either by pledging them or transferring rights to cash flows derived from these assets. Alternatively, a company\u2019s intellectual property can provide an indicator of a firm\u2019s value and support financing decisions. For some businesses, intangible",
                "attribution": "wipo.int",
                "icon_type": null
              },
              {
                "matched_text": "\u30106\u2020L97-L104\u3011",
                "start_idx": 72659,
                "end_idx": 72671,
                "alt": null,
                "type": "webpage_extended",
                "title": "IBM drops from top spot in patents, surpassed by Samsung | TechTarget",
                "url": "https://www.techtarget.com/searchdatacenter/news/365531318/IBM-drops-from-top-spot-in-patents-surpassed-by-Samsung#:~:text=IBM%27s%20patent%20portfolio%20business%20has,according%20to%20IBM%27s%20financial%20filings",
                "pub_date": null,
                "snippet": "IBM's patent portfolio business has been profitable over the years, averaging a little more than $1 billion a year in revenue since mid-1996, according to IBM's financial filings.",
                "attribution": "techtarget.com",
                "icon_type": null
              },
              {
                "matched_text": "\u30109\u2020L1-L4\u3011",
                "start_idx": 72671,
                "end_idx": 72680,
                "alt": null,
                "type": "webpage_extended",
                "title": "Qualcomm sales beat estimates, shares drop after licensing forecast | Reuters",
                "url": "https://www.reuters.com/technology/qualcomm-results-forecast-top-expectations-ai-drives-smartphone-sales-2025-02-05/#:~:text=%249,licensing%2C%20according%20to%20LSEG%20data",
                "pub_date": null,
                "snippet": "$9.2 billion for its chip business and $1.35 billion for patent licensing. Wall Street had expected $8.90 billion for chips and $1.43 billion for patent licensing, according to LSEG data.",
                "attribution": "reuters.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301037\u2020L283-L290\u3011",
                "start_idx": 72680,
                "end_idx": 72694,
                "alt": null,
                "type": "webpage_extended",
                "title": "Microsoft Earns $2 Billion Per Year From Android Patent Royalties - Business Insider",
                "url": "https://www.businessinsider.com/microsoft-earns-2-billion-per-year-from-android-patent-royalties-2013-11#:~:text=Microsoft%20is%20generating%20%242%20billion,new%20note%20on%20the%20company",
                "pub_date": null,
                "snippet": "Microsoft is generating $2 billion per year in revenue from Android patent royalties, says Nomura analyst Rick Sherlund in a new note on the company.",
                "attribution": "businessinsider.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301021\u2020L43-L50\u3011",
                "start_idx": 72746,
                "end_idx": 72758,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Trolls Like Intellectual Ventures Must Be More Closely Regulated, But How? - Sequel Legal",
                "url": "https://sequellegal.com/patent-trolls-like-intellectual-ventures-must-be-more-closely-regulated-but-how/#:~:text=One%20of%20the%20largest%20and,the%20patents%20just%20%24500%20million",
                "pub_date": null,
                "snippet": "One of the largest and most egregious examples of this behavior is Intellectual Ventures, a Bellevue, WA based firm that boasts a portfolio of some 70,000 patents it has acquired during its 14 years in business. It has realized $3 billion in patent licensing fees, but has passed on to the inventors behind the patents just $500 million.",
                "attribution": "sequellegal.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301013\u2020L297-L305\u3011",
                "start_idx": 72758,
                "end_idx": 72772,
                "alt": null,
                "type": "webpage_extended",
                "title": "Intellectual Ventures - Wikipedia",
                "url": "https://en.wikipedia.org/wiki/Intellectual_Ventures#:~:text=Publicly%2C%20Intellectual%20Ventures%20states%20that,34",
                "pub_date": null,
                "snippet": "Publicly, Intellectual Ventures states that a major goal is to assist small inventors against corporations. In practice, the vast majority of IV's revenue comes from buying patents, aggregating these patents into a single portfolio spanning many disparate technologies and tying these patents together for license to other companies under the threat of litigation, or filing lawsuits for infringement of patents, a controversial practice referred to as \"patent trolling.\"[ 34 ]",
                "attribution": "en.wikipedia.org",
                "icon_type": null
              },
              {
                "matched_text": "\u301032\u2020L401-L404\u3011",
                "start_idx": 72889,
                "end_idx": 72903,
                "alt": null,
                "type": "webpage_extended",
                "title": "Why the University of Florida gets a ~$20m cut of Gatorade profits every year  - The Hustle ",
                "url": "https://thehustle.co/why-the-university-of-florida-gets-a-20m-cut-of-gatorade-profits-every-year#:~:text=The%20university%20patents%20around%20140,affiliated%20patents%20was%20~%242.9B",
                "pub_date": null,
                "snippet": "The university patents around 140 inventions each year and made ~$500m off licenses between 2008 to 2018, placing it near the top of the market. In 2018, the total licensing revenue from university-affiliated patents was ~$2.9B.",
                "attribution": "thehustle.co",
                "icon_type": null
              },
              {
                "matched_text": "\u301024\u2020L1-L4\u3011",
                "start_idx": 72903,
                "end_idx": 72913,
                "alt": null,
                "type": "webpage_extended",
                "title": "",
                "url": "https://autm.net/AUTM/media/About-Tech-Transfer/Documents/Economic_Contribution_Report_BIO_AUTM_JUN2019_web.pdf#:~:text=for%20Universities%2C%20about%2080,In%20addition%2C%20public%20anecdotal",
                "pub_date": null,
                "snippet": "for Universities, about 80% of the income is from licenses in the life sciences. For Hospitals and Research Institutes, 90% or more of the income is from licenses in the life sciences. In addition, public anecdotal",
                "attribution": "autm.net",
                "icon_type": null
              },
              {
                "matched_text": "\u301034\u2020L245-L252\u3011",
                "start_idx": 72913,
                "end_idx": 72927,
                "alt": null,
                "type": "webpage_extended",
                "title": "Technology Transfer in U.S. Research Universities: Dispelling Common Myths",
                "url": "https://www.cogr.edu/sites/default/files/Myths_Final%2008-01-22.pdf#:~:text=in%20licensing%20revenue%20to%20cover,of%20the%20licensing%20income",
                "pub_date": null,
                "snippet": "in licensing revenue to cover their operating expenses. Lucrative inventions are exceedingly rare. Based on data from the 2020 AUTM Survey, the top 5% of U.S. technology licensing operations (9 universities) accounted for 51% of the total licensing revenue reported. In the same year, the top 10% of the reporting U.S. universities realized 70% of the licensing income.",
                "attribution": "cogr.edu",
                "icon_type": null
              },
              {
                "matched_text": "\u301032\u2020L399-L407\u3011",
                "start_idx": 73032,
                "end_idx": 73046,
                "alt": null,
                "type": "webpage_extended",
                "title": "Why the University of Florida gets a ~$20m cut of Gatorade profits every year  - The Hustle ",
                "url": "https://thehustle.co/why-the-university-of-florida-gets-a-20m-cut-of-gatorade-profits-every-year#:~:text=researchers%20looking%20to%20make%20lucrative,discoveries",
                "pub_date": null,
                "snippet": "researchers looking to make lucrative discoveries.",
                "attribution": "thehustle.co",
                "icon_type": null
              },
              {
                "matched_text": "\u301045\u2020L1-L9\u3011",
                "start_idx": 73046,
                "end_idx": 73056,
                "alt": null,
                "type": "webpage_extended",
                "title": "As Lyrica profits dry up, Northwestern seeks another 'blockbuster' drug",
                "url": "https://dailynorthwestern.com/2016/04/10/featured-stories/in-focus/in-focus-as-lyrica-profits-dry-up-northwestern-seeks-another-blockbuster-drug/#:~:text=drug%20dailynorthwestern,to%20pharmaceutical%20company%20Royal%20Pharma",
                "pub_date": null,
                "snippet": "drug dailynorthwestern.com  Silverman and the University monetized part of their royalties in 2007 for a total of $700 million to pharmaceutical company Royal Pharma.",
                "attribution": "dailynorthwestern.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301044\u2020L1-L4\u3011",
                "start_idx": 73056,
                "end_idx": 73066,
                "alt": null,
                "type": "webpage_extended",
                "title": "How the \"First\" Biotech Patent Generated Millions",
                "url": "https://www.labiotech.eu/trends-news/making-dollars-out-of-the-recombinant-dna-biotech-patents/#:~:text=California%20system%20amassed%20a%20%E2%82%AC241M,standard%20for%20university%20technology%20licensing",
                "pub_date": null,
                "snippet": "California system amassed a \u20ac241M fortune in licensing revenues (up until 2001). In many ways, Stanford\u2019s management of the Cohen-Boyer patents has become the gold standard for university technology licensing.",
                "attribution": "labiotech.eu",
                "icon_type": null
              },
              {
                "matched_text": "\u301039\u2020L19-L27\u3011",
                "start_idx": 73124,
                "end_idx": 73136,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Box | Tax - BDO",
                "url": "https://www.bdo.co.uk/en-gb/services/tax/innovation-and-r-d-tax-incentives/patent-box#:~:text=Patent%20Box%20%7C%20Tax%20,from%20April%202023",
                "pub_date": null,
                "snippet": "Patent Box | Tax - BDO It takes the form of an effective tax rate at 10% of the relevant profits compared to the UK's usual 19% rate (25% from April 2023).",
                "attribution": "bdo.co.uk",
                "icon_type": null
              },
              {
                "matched_text": "\u301040\u2020L5-L13\u3011",
                "start_idx": 73136,
                "end_idx": 73147,
                "alt": null,
                "type": "webpage_extended",
                "title": "France Brevets' public sector links hindered monetisation efforts ...",
                "url": "https://www.iam-media.com/article/france-brevets-public-sector-links-hindered-its-monetisation-efforts-says-ceo#:~:text=France%20Brevets%27%20public%20sector%20links,Share",
                "pub_date": null,
                "snippet": "France Brevets' public sector links hindered monetisation efforts ... France Brevets' public sector links hindered monetisation efforts, says CEO. Adam Houldsworth. 03 November 2022. Share.",
                "attribution": "iam-media.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301040\u2020L15-L23\u3011",
                "start_idx": 73147,
                "end_idx": 73159,
                "alt": null,
                "type": "webpage_extended",
                "title": "Judge's Investigation into Patent Troll Results in Criminal Referrals ...",
                "url": "https://news.ycombinator.com/item?id=42234147#:~:text=Judge%27s%20Investigation%20into%20Patent%20Troll,HTC%20or%20the%20Korean",
                "pub_date": null,
                "snippet": "Judge's Investigation into Patent Troll Results in Criminal Referrals ... France Brevets is criticized for having a \"patent troll\" type of activity and is taking legal action against companies such as the Taiwanese HTC or the Korean ...",
                "attribution": "news.ycombinator.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301043\u2020L292-L300\u3011",
                "start_idx": 73207,
                "end_idx": 73221,
                "alt": null,
                "type": "webpage_extended",
                "title": "How the \"First\" Biotech Patent Generated Millions",
                "url": "https://www.labiotech.eu/trends-news/making-dollars-out-of-the-recombinant-dna-biotech-patents/#:~:text=The%2017%20years%20during%20which,exploit%20all%20the%20possible%20applications",
                "pub_date": null,
                "snippet": "The 17 years during which the Cohen-Boyer patents were licensed, Stanford consulted widely across various stakeholders before settling on the licensing terms. For Stanford, the logic was that recombinant DNA was a platform technology and it was not possible for any one company to exploit all the possible applications.",
                "attribution": "labiotech.eu",
                "icon_type": null
              },
              {
                "matched_text": "\u301044\u2020L1-L4\u3011",
                "start_idx": 73270,
                "end_idx": 73280,
                "alt": null,
                "type": "webpage_extended",
                "title": "How the \"First\" Biotech Patent Generated Millions",
                "url": "https://www.labiotech.eu/trends-news/making-dollars-out-of-the-recombinant-dna-biotech-patents/#:~:text=California%20system%20amassed%20a%20%E2%82%AC241M,standard%20for%20university%20technology%20licensing",
                "pub_date": null,
                "snippet": "California system amassed a \u20ac241M fortune in licensing revenues (up until 2001). In many ways, Stanford\u2019s management of the Cohen-Boyer patents has become the gold standard for university technology licensing.",
                "attribution": "labiotech.eu",
                "icon_type": null
              }
            ],
            "timestamp_": "absolute",
            "message_type": null,
            "is_async_task_result_message": true,
            "b1de6e2_rm": true,
            "async_task_id": "deepresch_684735918524819198d58ef4b4e766ba",
            "async_task_title": "IP and Patents in the U.S. Innovation Economy"
          },
          "recipient": "all",
          "channel": "final"
        },
        "parent": "60a721d3-521c-478f-85ef-5cb9e5e41eb9",
        "children": [
          "05a364da-24c3-41bc-9a17-bb3985fe63e3"
        ]
      },
      "05a364da-24c3-41bc-9a17-bb3985fe63e3": {
        "id": "05a364da-24c3-41bc-9a17-bb3985fe63e3",
        "message": {
          "id": "05a364da-24c3-41bc-9a17-bb3985fe63e3",
          "author": {
            "role": "user",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749618296.6872869,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "Support the above report with even more evidence and data, and give me the map of the entire patent industry, separated by institution type, and by technical field, and by absolute revenue along with relative % of total revenue.\n\nFind even more examples and reports"
            ]
          },
          "status": "finished_successfully",
          "end_turn": null,
          "weight": 1.0,
          "metadata": {
            "dictation": false,
            "request_id": "94de9214fa4536bf-YYZ",
            "message_source": null,
            "timestamp_": "absolute",
            "message_type": null
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "b20f8f3c-057e-43a9-bf41-fda21610da74",
        "children": [
          "d7babd56-abfb-48a3-ab0d-16a607000eb6"
        ]
      },
      "d7babd56-abfb-48a3-ab0d-16a607000eb6": {
        "id": "d7babd56-abfb-48a3-ab0d-16a607000eb6",
        "message": {
          "id": "d7babd56-abfb-48a3-ab0d-16a607000eb6",
          "author": {
            "role": "user",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749618324.6735911,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "Sorry I meant to let you write a report"
            ]
          },
          "status": "finished_successfully",
          "end_turn": null,
          "weight": 1.0,
          "metadata": {
            "system_hints": [
              "research"
            ],
            "dictation": false,
            "request_id": "94de92c40dd136bf-YYZ",
            "message_source": null,
            "timestamp_": "absolute",
            "message_type": null
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "05a364da-24c3-41bc-9a17-bb3985fe63e3",
        "children": [
          "7dd61e9c-1f22-4757-ad81-ff14d204e8b7"
        ]
      },
      "7dd61e9c-1f22-4757-ad81-ff14d204e8b7": {
        "id": "7dd61e9c-1f22-4757-ad81-ff14d204e8b7",
        "message": {
          "id": "7dd61e9c-1f22-4757-ad81-ff14d204e8b7",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749618331.450726,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "Thanks for the clarification. Just to make sure I structure this follow-up report as comprehensively as possible, could you confirm the following:\n\n1. When you say \"map of the entire patent industry,\" do you want a structured breakdown (e.g. a matrix or table) showing:\n   - Institution types (e.g. corporations, universities, NPEs, government labs, etc.)\n   - Technical fields (e.g. biotech, semiconductors, software, materials science, etc.)\n   - Absolute revenue and % share of total patent-related income?\n\n2. Should this map focus on U.S. entities only, or would you like global coverage where data is available?\n\n3. Are you also interested in receiving downloadable data (e.g. CSV or Excel format), charts, or just a written report?\n\nOnce I have that, I\u2019ll dig deeper into financial data, revenue breakdowns, and additional case studies and sources."
            ]
          },
          "status": "finished_successfully",
          "end_turn": true,
          "weight": 1.0,
          "metadata": {
            "message_type": null,
            "model_slug": "research",
            "default_model_slug": "o3-pro",
            "parent_id": "7edcaebc-1b27-4e14-8371-0af201ce8e0d",
            "request_id": "94de92c40dd136bf-YYZ",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "d7babd56-abfb-48a3-ab0d-16a607000eb6",
        "children": [
          "bec64ccb-eea7-4a1e-9188-0da902b91c89"
        ]
      },
      "bec64ccb-eea7-4a1e-9188-0da902b91c89": {
        "id": "bec64ccb-eea7-4a1e-9188-0da902b91c89",
        "message": {
          "id": "bec64ccb-eea7-4a1e-9188-0da902b91c89",
          "author": {
            "role": "user",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749618518.9154348,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "I want a short book on the subject. For all three category types: institution, field, revenue I want you to classify all the different classes like every type of institution and example, and every fine grain field that benefits from patents and all the different % revenue and absolute revenue tiers like 10% vs 1% vs 50+%\n Focus on USA\n\nPlease give me a fav at the end, but all the data should also be presented in the mini book"
            ]
          },
          "status": "finished_successfully",
          "end_turn": null,
          "weight": 1.0,
          "metadata": {
            "dictation": false,
            "system_hints": [
              "research"
            ],
            "request_id": "94de97824e4736bf-YYZ",
            "message_source": null,
            "timestamp_": "absolute",
            "message_type": null
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "7dd61e9c-1f22-4757-ad81-ff14d204e8b7",
        "children": [
          "dd35a86d-d3b9-490e-bd30-37dc89029bcc"
        ]
      },
      "dd35a86d-d3b9-490e-bd30-37dc89029bcc": {
        "id": "dd35a86d-d3b9-490e-bd30-37dc89029bcc",
        "message": {
          "id": "dd35a86d-d3b9-490e-bd30-37dc89029bcc",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749618523.227643,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "Understood. I will create a comprehensive 'short book' covering the U.S. patent industry in detail. This will include classifications and mappings across three main dimensions:\n\n1. Institution Types: All categories of entities involved in patent creation and monetization (e.g., corporations, universities, NPEs, government labs), with examples and characteristics.\n2. Technical Fields: Fine-grained categorization of technology domains that benefit from patents (e.g., biotech, AI, semiconductors), including monetization performance.\n3. Revenue Tiers: Absolute and relative (%) revenue breakdowns, such as which classes account for 50%+ of patent revenue, 10%, etc.\n\nI'll also"
            ]
          },
          "status": "in_progress",
          "end_turn": null,
          "weight": 1.0,
          "metadata": {
            "message_type": "next",
            "model_slug": "research",
            "default_model_slug": "o3-pro",
            "parent_id": "bec64ccb-eea7-4a1e-9188-0da902b91c89",
            "request_id": "94de97824e4736bf-YYZ",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "bec64ccb-eea7-4a1e-9188-0da902b91c89",
        "children": [
          "4cc32739-6a88-465c-8ea2-0b70c93579e4"
        ]
      },
      "4cc32739-6a88-465c-8ea2-0b70c93579e4": {
        "id": "4cc32739-6a88-465c-8ea2-0b70c93579e4",
        "message": {
          "id": "4cc32739-6a88-465c-8ea2-0b70c93579e4",
          "author": {
            "role": "user",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749618541.812062,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "Sorry meant csv at the end. Continue with the report"
            ]
          },
          "status": "finished_successfully",
          "end_turn": null,
          "weight": 1.0,
          "metadata": {
            "dictation": false,
            "system_hints": [
              "research"
            ],
            "request_id": "94de98122b9836bf-YYZ",
            "message_source": null,
            "timestamp_": "absolute",
            "message_type": null
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "dd35a86d-d3b9-490e-bd30-37dc89029bcc",
        "children": [
          "554a1905-62d4-4c43-b3f8-d806f4b03535"
        ]
      },
      "554a1905-62d4-4c43-b3f8-d806f4b03535": {
        "id": "554a1905-62d4-4c43-b3f8-d806f4b03535",
        "message": {
          "id": "554a1905-62d4-4c43-b3f8-d806f4b03535",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749618546.979127,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "Thanks for the clarification. To support the 'short book' and the accompanying CSV with the most accurate classifications and revenue breakdowns, could you confirm the following:\n\n1. Should the revenue figures include both licensing income and product revenue attributable to patented technologies, or just direct licensing/royalty income?\n2. Do you want historical revenue data (e.g., last 10\u201320 years) or just the most recent available figures?\n3. For the CSV, do you want separate sheets (or tables) for institution types, technical fields, and revenue tiers, or one unified table combining all dimensions?\n\nOnce I have this, I\u2019ll begin compiling the full book and supporting data."
            ]
          },
          "status": "finished_successfully",
          "end_turn": true,
          "weight": 1.0,
          "metadata": {
            "message_type": null,
            "model_slug": "research",
            "default_model_slug": "o3-pro",
            "parent_id": "4cc32739-6a88-465c-8ea2-0b70c93579e4",
            "request_id": "94de98122b9836bf-YYZ",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "4cc32739-6a88-465c-8ea2-0b70c93579e4",
        "children": [
          "d155e99e-e21a-4b2a-b32f-96802a9af89c"
        ]
      },
      "d155e99e-e21a-4b2a-b32f-96802a9af89c": {
        "id": "d155e99e-e21a-4b2a-b32f-96802a9af89c",
        "message": {
          "id": "d155e99e-e21a-4b2a-b32f-96802a9af89c",
          "author": {
            "role": "user",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749618614.3386102,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "1. Both, break it down for each case\n2. All recent examples like last 30y or so\n3. One table"
            ]
          },
          "status": "finished_successfully",
          "end_turn": null,
          "weight": 1.0,
          "metadata": {
            "system_hints": [
              "research"
            ],
            "dictation": false,
            "request_id": "94de99d74f8736bf-YYZ",
            "message_source": null,
            "timestamp_": "absolute",
            "message_type": null
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "554a1905-62d4-4c43-b3f8-d806f4b03535",
        "children": [
          "dcebffd2-9ee6-4a3c-aef1-2e1876bb89ad"
        ]
      },
      "dcebffd2-9ee6-4a3c-aef1-2e1876bb89ad": {
        "id": "dcebffd2-9ee6-4a3c-aef1-2e1876bb89ad",
        "message": {
          "id": "dcebffd2-9ee6-4a3c-aef1-2e1876bb89ad",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749618627.17227,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "Excellent. I will compile a comprehensive short book analyzing the U.S. patent industry across the past 30 years. It will include detailed classification and mapping by institution type, technical field, and revenue tiers\u2014covering both licensing/royalty income and product revenues attributable to patented technologies. The report will be supported by a unified CSV table capturing all dimensions.\n\nI\u2019ll begin the research now and let you know once the full report and dataset are ready."
            ]
          },
          "status": "finished_successfully",
          "end_turn": null,
          "weight": 1.0,
          "metadata": {
            "message_type": null,
            "model_slug": "research",
            "default_model_slug": "o3-pro",
            "parent_id": "d155e99e-e21a-4b2a-b32f-96802a9af89c",
            "request_id": "94de99d74f8736bf-YYZ",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "d155e99e-e21a-4b2a-b32f-96802a9af89c",
        "children": [
          "2af21b03-3a88-4204-a03b-b7883b82b122"
        ]
      },
      "2af21b03-3a88-4204-a03b-b7883b82b122": {
        "id": "2af21b03-3a88-4204-a03b-b7883b82b122",
        "message": {
          "id": "2af21b03-3a88-4204-a03b-b7883b82b122",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749618615.242653,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "{\n  \"task_violates_safety_guidelines\": false,\n  \"user_def_doesnt_want_research\": false,\n  \"response\": \"Excellent. I will compile a comprehensive short book analyzing the U.S. patent industry across the past 30 years. It will include detailed classification and mapping by institution type, technical field, and revenue tiers\u2014covering both licensing/royalty income and product revenues attributable to patented technologies. The report will be supported by a unified CSV table capturing all dimensions.\\n\\nI\u2019ll begin the research now and let you know once the full report and dataset are ready.\",\n  \"title\": \"Patent Industry Mapping and Revenue Analysis by Institution, Field, and Tier\",\n  \"prompt\": \"Create a comprehensive 'short book' on the U.S. patent industry, covering the last 30 years. Structure the report and supporting data around three key dimensions:\\n\\n1. Institution Types: Classify all relevant categories (e.g., corporations, universities, NPEs, government labs, consortia, etc.), provide examples for each, and describe their patent strategies and characteristics.\\n\\n2. Technical Fields: Create a fine-grained taxonomy of technology fields benefiting from patents (e.g., biotech, pharmaceuticals, semiconductors, software, AI, clean tech, materials science, etc.), including how patents are used and monetized in each domain.\\n\\n3. Revenue Tiers: Quantify both absolute and relative (% of total) patent-related revenues by class. Include direct licensing/royalty income and indirect product revenue attributable to patents. Categorize entities into revenue contribution tiers (e.g., >50%, ~10%, ~1%) by institution and field.\\n\\nThe output should include:\\n- A detailed, structured written report synthesizing all findings.\\n- Numerous real-world examples and recent data (from the last 30 years).\\n- A single unified CSV table mapping all dimensions: institution type, technical field, revenue tier, licensing vs product revenue.\\n\\nPrioritize clarity, thoroughness, and the most recent reliable data. Focus on the United States, but include notable international comparisons or cases if they provide strong context or contrast.\"\n}"
            ]
          },
          "status": "finished_successfully",
          "end_turn": false,
          "weight": 1.0,
          "metadata": {
            "finish_details": {
              "type": "stop",
              "stop_tokens": [
                200007
              ]
            },
            "is_complete": true,
            "citations": [],
            "content_references": [],
            "message_type": null,
            "model_slug": "research",
            "default_model_slug": "o3-pro",
            "parent_id": "dcebffd2-9ee6-4a3c-aef1-2e1876bb89ad",
            "request_id": "94de99d74f8736bf-YYZ",
            "timestamp_": "absolute",
            "is_loading_message": true
          },
          "recipient": "research_kickoff_tool.start_research_task",
          "channel": null
        },
        "parent": "dcebffd2-9ee6-4a3c-aef1-2e1876bb89ad",
        "children": [
          "e04754cb-37cb-47a4-a366-fb920d8ab6af"
        ]
      },
      "e04754cb-37cb-47a4-a366-fb920d8ab6af": {
        "id": "e04754cb-37cb-47a4-a366-fb920d8ab6af",
        "message": {
          "id": "e04754cb-37cb-47a4-a366-fb920d8ab6af",
          "author": {
            "role": "tool",
            "name": "research_kickoff_tool.start_research_task",
            "metadata": {}
          },
          "create_time": 1749618628.079554,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": []
          },
          "status": "finished_successfully",
          "end_turn": false,
          "weight": 1.0,
          "metadata": {
            "async_task_title": "Patent Industry Mapping and Revenue Analysis by Institution, Field, and Tier",
            "async_task_prompt": "Create a comprehensive 'short book' on the U.S. patent industry, covering the last 30 years. Structure the report and supporting data around three key dimensions:\n\n1. Institution Types: Classify all relevant categories (e.g., corporations, universities, NPEs, government labs, consortia, etc.), provide examples for each, and describe their patent strategies and characteristics.\n\n2. Technical Fields: Create a fine-grained taxonomy of technology fields benefiting from patents (e.g., biotech, pharmaceuticals, semiconductors, software, AI, clean tech, materials science, etc.), including how patents are used and monetized in each domain.\n\n3. Revenue Tiers: Quantify both absolute and relative (% of total) patent-related revenues by class. Include direct licensing/royalty income and indirect product revenue attributable to patents. Categorize entities into revenue contribution tiers (e.g., >50%, ~10%, ~1%) by institution and field.\n\nThe output should include:\n- A detailed, structured written report synthesizing all findings.\n- Numerous real-world examples and recent data (from the last 30 years).\n- A single unified CSV table mapping all dimensions: institution type, technical field, revenue tier, licensing vs product revenue.\n\nPrioritize clarity, thoroughness, and the most recent reliable data. Focus on the United States, but include notable international comparisons or cases if they provide strong context or contrast.",
            "async_task_type": "research",
            "async_task_status_messages": {
              "initial": "Patent Industry Mapping and Revenue Analysis by Institution, Field, and Tier",
              "completed_with_time": "Research completed in 7m",
              "completed_no_time": "Completed research",
              "completed": "Researched for ",
              "error": "Research failed",
              "cancelled": "Research cancelled"
            },
            "b1de6e2_s": true,
            "command": "start_research_task",
            "message_type": null,
            "model_slug": "research",
            "default_model_slug": "o3-pro",
            "parent_id": "2af21b03-3a88-4204-a03b-b7883b82b122",
            "request_id": "94de99d74f8736bf-YYZ",
            "timestamp_": "absolute",
            "async_task_id": "deepresch_68490fc446cc8191bb823e90e5466df4",
            "async_task_conversation_id": "68490fc4-49d4-8005-ab09-3268991db89a",
            "async_task_created_at": "2025-06-11 05:10:28.636773+00:00",
            "deep_research_version": "full"
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "2af21b03-3a88-4204-a03b-b7883b82b122",
        "children": [
          "39c82fdc-87c1-42f0-b83e-d3e9dc3d0e98"
        ]
      },
      "39c82fdc-87c1-42f0-b83e-d3e9dc3d0e98": {
        "id": "39c82fdc-87c1-42f0-b83e-d3e9dc3d0e98",
        "message": {
          "id": "39c82fdc-87c1-42f0-b83e-d3e9dc3d0e98",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749619057.108774,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "# The U.S. Patent Industry (1995\u20132025): Institutions, Technical Fields, and Revenues\n\n## Introduction\n\nOver the past 30 years, the U.S. patent industry has transformed dramatically in scale and strategy. Patents have become core assets for a diverse set of institutions \u2013 from tech giants and pharmaceutical firms to universities, government labs, and specialized licensing entities. In parallel, different technology sectors have evolved distinct patent practices: biotechnology and pharma rely on patents for drug exclusivity, the high-tech sector navigates patent thickets and standard-essential patents, and emerging fields like software and AI grapple with patentability and open innovation. This report provides a comprehensive overview of the U.S. patent landscape since the mid-1990s, structured along three dimensions: **(1) Types of institutions** that obtain and monetize patents, **(2) Key technology fields** and their patent usage, and **(3) Patent-related revenue tiers**, including how much of an entity\u2019s income is derived from patent licensing versus product sales. We synthesize recent data and real-world examples to illustrate how each category operates, highlighting notable trends (e.g. the rise of non-practicing entities in the 2000s) and key changes in law and market conditions. The focus is on the United States, with selective international comparisons to provide context. All findings are supported by data and examples from the last three decades, ensuring both historical perspective and up-to-date insight.\n\n## Institution Types in the Patent Industry\n\nThe patent ecosystem encompasses a wide variety of institution types. Each tends to play a distinct role and follow different strategies in acquiring, using, and monetizing patents. Below we classify the major categories \u2013 **corporations**, **universities**, **non-practicing entities**, **government labs**, **consortia/pools**, and others \u2013 describing their patent activities, strategies, and characteristic examples.\n\n### Corporations (Product Companies)\n\n**Corporations** form the largest group of patent owners, ranging from Fortune 500 technology companies to small startups. Their patent strategies often focus on protecting products, securing market exclusivity, and defending against litigation. Large product companies typically patent their R&D outputs to prevent competitors from copying innovative features or formulas. For example, pharmaceutical and biotech firms rely on patents to exclusively market new drugs for a period of years, allowing them to recoup R&D investments under monopoly pricing\u301040\u2020L60-L68\u3011\u301042\u2020L113-L120\u3011. In technology, companies like **Apple, Samsung, Google, and Microsoft** amass thousands of patents primarily for defensive purposes and cross-licensing leverage, rather than for licensing income. During the smartphone \u201cpatent wars\u201d of the 2010s, firms like Apple and Samsung engaged in dozens of patent lawsuits worldwide to block competitors or extract settlements, underscoring how product companies use patents as strategic legal weapons in highly competitive markets\u301030\u2020L158-L166\u3011. Cross-licensing among large tech companies is common \u2013 an estimated 20% of all patent licensing deals are cross-licenses, where companies mutually allow use of each other\u2019s patents\u301021\u2020L35-L41\u3011. This helps avoid costly litigation when each side holds patents the other needs (e.g. the historic cross-license agreements in the semiconductor industry).\n\nWhile most corporate patent portfolios serve defensive and product-protection roles, some corporations have also turned patents into a revenue stream. A few technology companies have **offensive licensing programs** that generate substantial income. **IBM** was a pioneer of patent monetization in the 1990s: IBM accumulated over 88,000 patents and by the 2000s was earning more than $1\u202fbillion annually from patent licensing\u30107\u2020L142-L150\u3011. Between 2008 and 2012, IBM\u2019s patent licensing brought in $1.1\u2013$1.2\u202fbillion per year, and even as it declined to ~$740\u202fmillion by 2014, that figure still exceeded the total earnings of many smaller tech companies\u30107\u2020L144-L152\u3011. Other examples include **Microsoft**, which around 2013 was reportedly generating $2\u202fbillion per year by licensing its patents related to Android smartphones\u30107\u2020L151-L158\u3011. **Qualcomm** provides a notable case of a corporation built on a dual model of products and patent licensing: it sells semiconductor products (e.g. smartphone chipsets) but also licenses its extensive portfolio of wireless communication patents to device makers. In 2021 Qualcomm earned roughly $8.2\u202fbillion in licensing revenue out of $33\u202fbillion total revenue (about 25%)\u30100\u2020L1-L4\u3011, and historically its patent royalties have represented a substantial portion of its profit. Qualcomm held over 130,000 patents and in one quarter of 2018 alone collected around $950\u202fmillion in patent royalties\u30107\u2020L151-L158\u3011. These cases show that some corporations \u2013 particularly in **telecommunications, electronics, and software** \u2013 actively monetize patents through outbound licensing programs or by enforcing their patents if necessary.\n\nThat said, for the majority of product-producing companies, **patent licensing is a relatively small share of revenue**. Most derive far more income from selling patented products than from licensing patents to others. For example, IBM\u2019s few billion in annual licensing pales next to its tens of billions in product and service revenue (~$75\u2013$100\u202fbillion in the 2000s), meaning only on the order of 1\u20132% of IBM\u2019s revenue came from patent royalties\u30107\u2020L142-L150\u3011. Microsoft\u2019s $2\u202fbillion from Android patents was likewise a single-digit percentage of its overall revenue at the time. A recent analysis finds that over 40% of tech companies engage in patent licensing deals by 2023\u301021\u2020L11-L19\u3011, yet for most it is to **complement** their main business (or to obtain cross-licenses), not to serve as a primary income source. One notable subset of corporations are those whose **business model itself is licensing technology** rather than selling products \u2013 for instance, semiconductor design firms like Arm Holdings (which licenses processor designs and patents) or Dolby Laboratories (licensing audio technology patents). These blur the line with the next category, since a major portion of their revenue (often >50%) comes from patent licensing fees rather than tangible product sales.\n\nFinally, **startup companies and small businesses** also participate in the patent system, though typically on a smaller scale. Startups often file patents to attract investors and protect their innovations from larger competitors. In fields like biotechnology or medical devices, a startup\u2019s patents can be its most valuable asset for securing partnerships or acquisition by bigger firms. Startups sometimes license their patents to established companies as a revenue source if they lack manufacturing capacity. In fact, approximately 30% of new patent licensing deals in emerging technology fields involve startups as one party\u301021\u2020L59-L66\u3011. However, outside of licensing deals or an eventual buyout, small firms rarely earn significant direct revenue from their patents \u2013 their goal is usually to develop a product or prove a concept. Overall, corporate players dominate patent filings and holdings, but their strategies range from **defensive patenting for freedom-to-operate** to **active licensing for profit**, depending on the company\u2019s business model and industry.\n\n### Universities and Research Institutions\n\nUniversities and non-profit research institutions have become major participants in the patent system, especially after the **Bayh\u2013Dole Act of 1980** allowed them to own and license inventions developed with federal funding. Over the last 30 years, academic institutions vastly expanded their patenting and technology transfer activities. A fine illustration is the growth in licensing income: U.S. universities generated about **$2.94\u202fbillion in licensing revenue in 2018** by bringing academic inventions to market\u30108\u2020L3-L8\u3011, up from only a few hundred million annually in the early 1990s. University patents cover a range of fields (life sciences, engineering, computer science, etc.), but the most lucrative have often been in **biotechnology and pharmaceuticals**, where a single blockbuster drug patent can yield enormous royalties. For example, Northwestern University reaped over $700\u202fmillion in royalties over years from Lyrica (a drug invented by its chemist, licensed to Pfizer) \u2013 in **2011 alone Northwestern earned $191.5\u202fmillion** in licensing income, more than any other school\u301016\u2020L258-L266\u3011\u301016\u2020L269-L277\u3011. The **University of California system** (across all campuses) was a close second with $182\u202fmillion in 2011 licensing revenue\u301016\u2020L258-L266\u3011\u301016\u2020L269-L277\u3011, and **Columbia University** earned $146\u202fmillion that year\u301016\u2020L269-L277\u3011 (Columbia famously made hundreds of millions over the years from its early biotech patents in recombinant DNA and gene expression technologies). Other top earners in that period included **New York University ($142\u202fM)** and **Princeton ($115\u202fM)**, each benefiting from a few valuable biomedical patents\u301016\u2020L269-L277\u3011. These examples show that for a handful of universities, patent licensing can provide a significant income stream.\n\n\u301026\u2020embed_image\u3011 *Patent licensing income for top U.S. universities (2011). Northwestern University led with about $191\u202fmillion, followed by the University of California system with $182\u202fmillion, largely due to successful biomedical patents\u301016\u2020L258-L266\u3011\u301016\u2020L269-L277\u3011.* \n\nDespite these high-profile successes, it\u2019s important to note that **most universities earn relatively modest revenue from patents**. The bulk of academic licensing income is concentrated in a few institutions and a few blockbuster patents. Many universities spend heavily on research and patent filing without seeing large returns. For perspective, in 2020 all U.S. academic and non-profit research institutions combined had 27,112 new invention disclosures and were issued 8,706 U.S. patents\u30108\u2020L9-L13\u3011, yet only a small fraction of those patents yield substantial royalties. Often, a single breakthrough (a new drug, medical device, or software algorithm) accounts for the lion\u2019s share of a university\u2019s tech transfer income. For example, UCLA famously earned royalties from the prostate cancer drug Xtandi, and Florida\u2019s University of Florida profited from the Gatorade formula patent decades ago. Still, **across academia patent licensing typically constitutes only a small percentage of overall university revenues (usually well under 5%)**, since universities\u2019 primary income comes from tuition, grants, and endowments. Even at Northwestern in 2011, the $191\u202fM in royalties, while a windfall, was a fraction of its total budget. One study noted that **just five universities accounted for one-third of all licensing income over $1\u202fM** in 2020\u30108\u2020L19-L27\u3011, highlighting the skewed distribution of returns.\n\nUniversities\u2019 patent strategies generally focus on **out-licensing inventions to industry** rather than commercialization by the university itself (universities rarely manufacture products). Technology Transfer Offices facilitate patenting discoveries by faculty and then negotiate licenses with existing companies or startups. In fields like biotech, it\u2019s common for a university to license a patent to a startup founded by the faculty-inventor, which then develops the technology and perhaps later sublicenses to a larger company or gets acquired. Royalty rates in university licenses can vary, but the university typically gets a percentage of sales or a lump sum, which is then often shared with the inventors and reinvested in research. In recent years, some universities have also become **more assertive in enforcing their patents** \u2013 for instance, the University of California and University of Wisconsin have been involved in patent infringement lawsuits against big tech companies over computer and biotech patents. A noteworthy statistic is that **university-held patents now contribute around 15% of global patent licensing revenues**\u301021\u2020L53-L60\u3011, indicating academia\u2019s significant role in the overall patent licensing market. This reflects not only direct licensing by universities, but also that many high-value patents (especially in pharmaceuticals) originate from academic research.\n\n### Non-Practicing Entities (NPEs)\n\n**Non-Practicing Entities (NPEs)** \u2013 often pejoratively called \u201cpatent trolls\u201d \u2013 are firms that hold patents but do not produce products or services based on them. Their business model is to monetize patents through licensing and litigation. The NPE category includes specialized patent-licensing companies, patent assertion firms backed by investors, and sometimes individual inventors or shell companies that acquire patents to enforce. NPEs rose to prominence in the late 1990s and especially the 2000s, profoundly impacting the U.S. patent landscape. By the early 2010s, NPEs were filing a large share of patent infringement lawsuits in the U.S., disproportionately targeting the tech and software sectors\u301039\u2020L99-L107\u3011. A seminal 2012 study found that **NPE patent assertions cost defendant companies **\\$29\u202fbillion** in direct legal fees and settlements in 2011 alone**\u301039\u2020L92-L100\u3011. In that year, NPE litigation had become a booming enterprise: over 2,150 unique companies were sued in nearly 6,000 patent cases initiated by NPEs in 2011\u301039\u2020L100-L108\u3011. These figures underscore how aggressively NPEs were asserting patents, often against multiple downstream users of technology.\n\nNPEs typically acquire patents from others \u2013 for example, they buy portfolios from struggling tech companies or from inventors \u2013 and then seek licensing fees from alleged infringers under threat of suit. They tend to focus on patents that can be broadly applied or that read on widely used technologies (for instance, basic software features, standard network protocols, or common hardware components), maximizing the number of companies they can demand royalties from. Famous NPEs include **Intellectual Ventures**, founded in 2000, which amassed tens of thousands of patents and engaged in licensing (and through proxies, litigation), and firms like **NTP Inc.**, which in 2006 won a $612\u202fmillion settlement from Research In Motion (BlackBerry) over wireless email patents \u2013 one of the early landmark \u201ctroll\u201d cases. Another notorious example was **VirnetX**, an NPE that secured large verdicts against Apple for VPN and FaceTime-related patents. The proliferation of NPE lawsuits in the 2000s led to growing outcry from the tech industry, which argued that patent trolls were imposing a \u201ctax\u201d on innovation (one estimate pegged the aggregate loss to defendants and the economy at **half a trillion dollars** over two decades)\u301025\u2020L41-L45\u3011. In response, several defensive measures emerged: companies formed coalitions and **defensive patent aggregators** (e.g. RPX Corp, Allied Security Trust) to buy up patents before NPEs could, and Congress and courts took action. The 2011 America Invents Act introduced mechanisms like **inter partes review (IPR)** to challenge weak patents at the patent office, which has been used to invalidate many NPE-held patents. Around the same time, a 2006 Supreme Court decision (eBay v. MercExchange) made it harder for NPEs to get injunctions, reducing their leverage. These factors, along with shifts in patentability of software (Alice decision in 2014), somewhat tempered the NPE wave in the late 2010s.\n\nNevertheless, NPEs remain active and have adapted tactics. Patent assertion entities often file in plaintiff-friendly jurisdictions (for a while, the Eastern District of Texas was a hotbed for such cases, until venue rules tightened; more recently, the Western District of Texas became popular). Litigation financing has also fueled a subset of NPE suits \u2013 investors fund patent lawsuits in return for a share of awards, adding more resources to NPE campaigns. Notably, the U.S. has been the epicenter of NPE activity: **97% of NPE patent infringement cases worldwide between 2012 and 2023 were filed in the United States**\u301022\u2020L5-L9\u3011. Other countries saw far fewer \u201ctroll\u201d cases, though Europe has had some recent uptick as NPEs test jurisdictions like Germany and the UK (which offer the possibility of injunctions but also \u201closer pays\u201d costs). By institution type, NPEs are essentially **100% reliant on patent-derived revenue** \u2013 all or nearly all of their income comes from licensing fees or legal judgments, placing them in the highest revenue tier from patents. Unlike product companies, NPEs have no sales revenue, so their incentives are solely aligned with maximizing patent payouts. This can lead to aggressive interpretations of patent scope and high-volume litigation strategies. Love them or loathe them, NPEs have forced many companies to reckon with the value (and risk) of patents in new ways, and they have become a permanent, if controversial, fixture of the patent industry.\n\n### Government Labs and Agencies\n\nU.S. federal government laboratories and agencies also participate in the patent system, though with different motivations and outcomes compared to commercial entities. Agencies like the National Institutes of Health (NIH), Department of Energy (DOE), Department of Defense (DOD), NASA, and others conduct substantial R&D and often patent the resulting inventions. Under federal technology transfer laws (including Bayh-Dole and subsequent acts), government labs can grant licenses to their patents, aiming to transfer innovations to industry for public benefit. **Government labs\u2019 patent strategies** emphasize spreading technology (getting it \u201cfrom lab to market\u201d) rather than maximizing profit. They commonly grant licenses to private companies, including many small businesses, to further develop and commercialize federally-funded inventions. Sometimes these are exclusive licenses (if only one partner is chosen to bring the invention to market) or non-exclusive if broad adoption is desired.\n\nIn terms of financial impact, **patent licensing is a minor source of revenue for government entities**, especially relative to their research expenditures. The federal government spends on the order of $130\u2013$150\u202fbillion per year on R&D\u301034\u2020L39-L45\u3011, but the royalties earned back are only a tiny fraction of that. For example, in Fiscal Year 2020, all federal labs combined reported roughly **$95\u202fmillion in patent licensing income**\u301036\u2020L7-L14\u3011. The Department of Health and Human Services (which includes NIH) accounted for the largest portion with about $54\u202fmillion, the DOE earned about $25\u202fmillion, and DOD about $9\u202fmillion; together those three agencies made up 93% of the federal licensing revenue\u301036\u2020L7-L14\u3011. Other agencies like NASA, the USDA, and Commerce (which includes NIST) each contribute only a few million or less. These numbers underscore that, as a percentage of the massive federal research enterprise, patent royalties are practically **negligible (<<1% of research spending)**. The goal for federal labs is not to generate revenue, but when a taxpayer-funded invention (such as a new material, a medical breakthrough, or an energy technology) has commercial potential, licensing it can help ensure it gets developed into a product people can use. Any royalties that do come in are often reinvested into further research or shared with the government inventors as incentives.\n\nA few government-derived patents have been quite significant in industry. For instance, the NIH was involved in patents for certain biotech drugs (like synthetic insulin and various cancer therapies) which were licensed to pharma companies. The Department of Energy\u2019s national labs have patents in areas like renewable energy (solar, battery tech) that have been licensed out. NASA has famously patented technologies with spinoffs (memory foam, scratch-resistant lenses, etc.) and offers a public database of patents that startups can license, often royalty-free for some period, to encourage usage. **Overall, government labs contribute innovations across many fields but rely on industry partners to commercialize them; their patent revenues are an afterthought relative to public funding.** Internationally, a similar pattern holds: governments encourage tech transfer (e.g., through organizations like China\u2019s CAS or France\u2019s CEA patenting and licensing discoveries), but the economic returns from licensing are far secondary to the public mission.\n\n### Consortia and Patent Pools\n\n**Consortia, patent pools, and industry alliances** represent another important institution type in the patent landscape. These are collaborative arrangements rather than single entities, but they act as collective stewards of patents for a group of organizations. A **patent pool** is typically an agreement where multiple companies (or inventors) put patents relating to a particular technology or standard together to be licensed as a package. Pools have been especially prominent in industries with **technical standards**, such as telecommunications and consumer electronics. A classic example is the **MPEG LA** pool for digital video compression technology (MPEG-2, H.264, etc.), which assembled patents from dozens of companies and universities required to implement the video standard, and offers one-stop licensing to device manufacturers. By paying a set royalty rate, a licensee gets access to the entire pool, and the fees are then distributed to the patent holders. This simplifies licensing for complex technologies that would otherwise require negotiating with many separate patent owners. Other notable pools include those for DVD technology, 4G/LTE wireless standards, and more recently pools via Avanci for licensing wireless patents to connected cars. Patent pools are often facilitated by a specialized firm or a consortium governance board, and they negotiate royalty rates that balance fair returns with broad adoption. Typically, these consortia generate revenue purely through licensing fees, which are then passed to members (with a cut for administration). For example, the MPEG-2 pool in the 2000s generated hundreds of millions in royalties shared by contributors. The **royalty rates for standard-essential patents (SEPs)** \u2013 patents needed to comply with a standard \u2013 are usually constrained by commitments to be \u201cfair, reasonable, and non-discriminatory\u201d (FRAND). In practice, SEP royalties often range around a few percent of product selling price\u301021\u2020L47-L55\u3011. One data point indicates typical SEP royalties run about **1\u20135% of the product\u2019s revenue** for the relevant component\u301021\u2020L47-L55\u3011 (for instance, a 4G LTE patent might earn a few dollars on a $100 smartphone).\n\nBeyond pools, there are also **industry research consortia** (like Sematech in the semiconductor industry in the 1990s, or more recently joint ventures in AI or 5G research) that may jointly hold patents. These consortia sometimes agree to cross-license any patents among members royalty-free, or to collectively license to outsiders. Another form is the **Open Innovation Network (OIN)** or **LOT Network**, which are consortia aimed at reducing patent litigation \u2013 members pledge their patents won\u2019t be used offensively against other members (especially to shield against NPEs acquiring them). These don\u2019t generate licensing revenue as such, but represent strategic institutional responses to patent risks. There are also **defensive pools** like RPX (a company acting on behalf of member firms) that buy patents that might be asserted by trolls and grant members a license, thus pre-empting lawsuits. \n\nA few special cases are **standards-setting organizations (SSOs)** and **alliances**. While SSOs (like IEEE, ITU, etc.) themselves don\u2019t hold patents, they create the framework where member companies\u2019 patents become essential to standards. Those member companies then often license those patents out (sometimes via pools, or bilaterally under FRAND terms). In telecom, for instance, companies like Nokia, Ericsson, Qualcomm, and more recently Huawei, each own thousands of SEPs for 3G/4G/5G standards and earn significant royalties. This interwoven structure means companies simultaneously cooperate (through SSOs and cross-licensing) and compete (in selling products and seeking licensing revenue). \n\nFinancially, **consortia and pools are typically oriented around licensing revenue**, not product sales \u2013 a patent pool\u2019s existence depends on collecting royalties for its members. Thus, if viewed as an \u201cinstitution type,\u201d they fall in the high patent-revenue tier (>>50% of their \u201crevenue\u201d comes from patents, since that is essentially their only revenue). However, the pool members themselves may be large corporations for whom those royalties are just one income stream. The consortium or pool facilitates a more efficient market for patents in that field. A real-world illustration: via patent pooling, a company like Panasonic or Dolby might receive royalty checks for every DVD player or streaming device sold worldwide that uses their pooled patents \u2013 a form of passive income from innovation. On the international front, patent pools often have global scope (e.g., MPEG LA licenses patents from US, European, Asian entities to licensees globally). Some countries or regions have tried unique consortia; for example, in the early 2000s, Japan\u2019s tech companies formed a patent pool for next-gen optical discs to challenge a competing standard.\n\nIn summary, consortia and pools show how patents can be managed collectively to reduce friction. They reflect a cooperative institutional strategy: rather than each patent owner separately monetizing (which could lead to \u201cstacked\u201d royalties or legal battles), they agree on a shared licensing framework. The result can be seen as **industry-wide monetization** of patents, where revenue is divided among participants. This model has been quite successful in certain fields (e.g. almost every DVD or Blu-ray manufacturer took pool licenses). In others, like smartphone technologies, attempts at broad pooling have been limited, and bilateral licensing (or litigation) remains more common.\n\n### Other Notable Categories\n\nIn addition to the above, there are a few other categories worth noting:\n\n- **Independent Inventors and Small Patent Holders:** These are individual inventors or small businesses that may have a few patents. Historically, some independent inventors licensed their patents to big companies or litigated to enforce their rights (e.g. the famous case of Robert Kearns, who invented the intermittent windshield wiper and sued major automakers in the 1990s for patent infringement, winning settlements). In the modern era, independent inventors often face challenges monetizing patents due to high litigation costs and the complexity of technology markets. Many end up selling their patents or partnering with NPEs to enforce them. A minority strike licensing deals \u2013 for example, an inventor might license a patent for a niche technology to a manufacturer. As a class, independent inventors likely derive >50% of their income from patents only in rare success cases; most do not see large financial gains. Nonetheless, they contribute a steady flow of patent filings, especially in sectors like mechanical inventions and consumer products.\n\n- **Open Source and Patent Pledgers:** A counter-movement in recent decades has been institutions that pledge not to assert certain patents to encourage open innovation. For instance, **Tesla Motors in 2014 announced it would not sue anyone using Tesla\u2019s electric vehicle patents \u201cin good faith\u201d**, effectively open-sourcing its patents to help spur the EV industry\u301033\u2020L29-L36\u3011. Similarly, IBM and others have pledged patents for open source use (e.g., the Open Invention Network focuses on patents that cover Linux-related technology, licensing them royalty-free to any participant). These entities don\u2019t monetize patents in the traditional sense; instead, they use patents strategically to build ecosystems or as defensive shields. Their \u201crevenue\u201d from patents is indirect \u2013 it comes in the form of greater adoption of their platforms or goodwill, rather than licensing fees. Open patent pledges have been seen in **clean technology** (to combat climate change by sharing innovations) and in emergencies \u2013 for example, during the COVID-19 pandemic some universities and companies pledged certain patents for free use in developing vaccines or medical equipment. While not a large segment of the patent industry in revenue terms, these initiatives are an important part of the last decade\u2019s narrative, illustrating flexibility in patent strategy beyond pure profit motives.\n\nWith the institutional landscape mapped, we now turn to how different **technology fields** make use of patents, and then to how patent-derived revenues break down across these categories.\n\n## Patents Across Technical Fields\n\nNot all technology domains use patents in the same way. The importance of patents, common practices for monetization, and typical patent strategies vary significantly by field. Below we present a **taxonomy of key technical fields** \u2013 including **pharmaceuticals, biotechnology, software, semiconductors, telecommunications, artificial intelligence, clean tech, materials science, medical devices,** and more \u2013 detailing how patents function in each and how they contribute to revenues.\n\n### Pharmaceuticals and Biotechnology\n\nIn **pharmaceuticals**, patents are absolutely central to the industry\u2019s business model. Developing a new drug is extremely costly (often billions of dollars in R&D and clinical trials) and time-consuming (10\u201315 years to approval)\u301040\u2020L83-L92\u3011. Patents (along with regulatory exclusivities) provide a period of market monopoly for new drugs, during which the company can charge high prices without generic competition. Typically, a new drug will have around 12\u201315 years of effective patent life remaining when it launches (after accounting for time lost in trials)\u301040\u2020L64-L72\u3011. During this window, the drug\u2019s developer often enjoys very high profit margins \u2013 this is when **all the revenue on that drug is directly attributable to the patent**, as it prevents direct competitors. It\u2019s no exaggeration that for major pharma companies, **a large majority of their revenue comes from products protected by patents** (either current patents or recently expired ones still facing limited competition). Industry data consistently show that **branded (patented) drugs account for roughly 80\u201390% of pharmaceutical revenues**, even though generic drugs (off-patent) make up the bulk of prescriptions by volume\u301017\u2020L21-L24\u3011. For instance, one analysis found branded pharmaceuticals made up 88% of total U.S. drug revenue while generics (often sold at a fraction of the price) accounted for the rest\u301017\u2020L21-L24\u3011. This underscores how **patents enable the high revenues** by allowing prices far above marginal cost.\n\nMonetization in pharma primarily comes from **product sales under patent protection**, rather than licensing. Big pharmaceutical firms typically do not license their crown-jewel patents to competitors \u2013 they want to sell the drug themselves exclusively worldwide. However, patents are often licensed **in two scenarios**: First, large pharma companies license or acquire patents (and related data) from **small biotech firms or universities**. This is common \u2013 a biotech startup might patent a new therapeutic molecule and then license it to a pharma company for development and commercialization, in exchange for milestone payments and royalties on sales. Many major drugs originate from such deals. For example, the cancer drug Keytruda was originally from a small biotech acquired by Merck, and Merck now pays royalties to the original institution (in this case, a university, since Keytruda\u2019s precursor was from academia). Such licensing deals are a critical tech-transfer mechanism in biotech. The second scenario is when patents are used in **settlements or authorized generics**: as a patent nears expiry, the brand company might settle with a generic challenger by licensing them the right to sell a generic a bit before patent expiration (usually this involves some payment or benefit to the generic maker \u2013 a controversial practice known as \u201cpay-for-delay\u201d). Apart from these, direct patent licensing for revenue (like a pharma company licensing its patented drug to another company to also sell) is rare unless the company lacks capability in a certain market and grants a regional license.\n\nBecause patents so directly confer revenue in pharma, the industry fiercely protects and extends patents. Companies employ strategies like obtaining **multiple patents per drug** (for instance on formulations, manufacturing processes, new medical uses, etc.) to build a \u201cpatent thicket\u201d and prolong exclusivity \u2013 a practice often termed **evergreening**\u301042\u2020L123-L131\u3011. A vivid indicator of patent importance is the phenomenon of the \u201c**patent cliff**\u201d: when a blockbuster drug\u2019s patents expire and generics enter, the original product\u2019s sales typically plummet. It\u2019s not uncommon to see a drop of 50\u201380% in revenue within a year or two after generics launch\u301042\u2020L113-L120\u3011. In fact, analysts project that from 2024 to 2030, over **$200\u202fbillion in annual pharma revenues are at risk** due to key patent expirations\u301042\u2020L115-L122\u3011. A study noted that once a blockbuster drug faces generic competition, its revenue may fall by as much as **79%** in short order\u301042\u2020L113-L120\u3011. This \u201ccliff\u201d effect highlights that the **patent effectively was underpinning nearly all of that revenue**; when the patent protection is gone, much of the revenue disappears as prices drop 80\u201390% (generic versions cost a fraction of the brand price)\u301042\u2020L113-L120\u3011.\n\nIn terms of licensing income, pharma companies do sometimes receive royalties themselves. For example, big firms cross-license technologies (like drug delivery tech) or license-in compounds and then owe royalties to the licensor when the drug sells. But relative to their massive product sales, these outgoing or incoming royalties are typically small line items. One quarter of the entire global patent licensing revenues is attributed to the **pharmaceutical industry (about 25%)**, reflecting the many licensing deals for drug IP (often from biotech to big pharma)\u301021\u2020L19-L24\u3011. Another significant chunk is from **biotechnology**, which overlaps with pharma but also includes things like agricultural biotech (e.g. patented genetically modified seeds) and biopharmaceutical research tools. The patent licensing revenues in the biotech sector have seen strong growth (18% increase in 2023)\u301021\u2020L67-L69\u3011, as biotech startups frequently license their patents either to pharma companies or to each other (for example, patenting a new CRISPR gene-editing tool and licensing it broadly).\n\nA notable case in agricultural biotech: companies like **Monsanto (now Bayer)** have patents on genetically engineered seeds (corn, soybeans, etc.). Their business model involves licensing these patented seeds to farmers with restrictions on saving seed (farmers must buy new seeds each season). This is effectively a product sale model, but it\u2019s enforced by patent rights (which made it illegal for farmers to replant harvested seeds of patented strains). Monsanto famously litigated to uphold these patents, ensuring a continuous revenue stream each planting season. This is another instance of product revenue attributable to patents.\n\nIn summary, for pharma/biotech: **patents are the lifeblood**. They provide the incentive for innovation by enabling huge revenues on successful products, and without them the industry\u2019s economics would look entirely different. Patent-related revenue in this field is mostly **indirect product revenue** \u2013 the high margins on drug sales \u2013 which for a given patented drug is effectively 100% reliant on that patent (until it expires). Direct licensing plays a supporting role (especially between innovators and developers), but the lion\u2019s share of dollars in this field comes from selling patented products at monopoly prices.\n\n### Information Technology and Software\n\nThe software and broader information technology (IT) field has had a complex and evolving relationship with patents. Historically, **software patents** were not clearly recognized until the 1990s (legal doctrine gradually extended patentability to software algorithms and business methods by the late \u201990s, e.g. the State Street Bank decision in 1998). Since then, companies in this space have amassed large patent portfolios, but primarily for **defensive purposes** rather than monetization. Patents in software (including areas like operating systems, applications, internet services, etc.) are often used as legal leverage in disputes or to deter lawsuits via mutually assured destruction (if two companies each have big portfolios, each risks counter-suits, so they tend to settle or cross-license). Major software companies like **Microsoft, IBM, Oracle, Google, Apple** hold tens of thousands of patents combined. However, relatively few generate royalty income compared to product sales. For instance, Microsoft\u2019s notable licensing program was to demand royalties from manufacturers of Android-based smartphones in the 2010s, claiming Android infringed Microsoft\u2019s patents \u2013 this led to Microsoft earning an estimated $2\u202fbillion per year in licensing fees from handset makers\u30107\u2020L151-L158\u3011. That is a significant sum, yet Microsoft\u2019s overall revenue at the time was on the order of $70+\u202fbillion, so it was only ~3%. Many other software companies do not license out their patents at all (or only as part of cross-license deals with no money exchanged). **Open source software** norms have also influenced this domain, with many software firms pledging patents to open source communities or refraining from suing over Linux-related patents to maintain goodwill.\n\nThe **monetization of software patents** has often been associated more with NPEs than with the software product companies themselves. A number of NPEs in the 2000s targeted software functionality (e.g. one-click online shopping, data streaming, user interface features). This caused a lot of litigation in that era, including high-profile cases like NTP v. RIM (BlackBerry\u2019s email system) and Eolas v. Microsoft (browser plug-in technology). After 2014, the Supreme Court\u2019s **Alice v. CLS Bank** decision imposed stricter limits on abstract software patents, leading to many such patents being invalidated. This has cooled the pure-software patent assertion environment and made it harder to enforce broad software claims. As a result, today large tech companies often rely on **trade secrets, fast product cycles, and market lead** more than patents to protect software innovations. They still patent certain algorithms (especially those tied to tangible effects or hardware) and specific technical solutions, but the direct revenue from licensing those tends to be minimal.\n\nOne area within IT that *does* see patent licensing is when software intersects with **hardware or standards**. For example, video compression algorithms implemented in software \u2013 patents on those are usually part of pools (like MPEG) and generate royalties from software vendors using them. Another example is **operating system patents**: in the 2000s and 2010s, we saw lawsuits like **Oracle v. Google** (over Java APIs in Android \u2013 though ultimately Oracle\u2019s patent claims largely failed) and **Apple v. Android OEMs** over mobile software features. Apple won some cases against Samsung related to software-like user interface patents (like \u201cslide to unlock\u201d), resulting in damages but not significant ongoing royalties. In general, outside of a few exceptions, **software companies derive <1% of their revenue from patent licensing**, and any patent value is mostly to secure freedom to operate or prevent being blocked by others.\n\nA subcategory worth noting is **Internet and e-commerce business method patents**. In the dot-com era and early 2000s, some companies like Amazon (with its 1-Click ordering patent) and Priceline (travel bidding patents) gained patents on online business models. Amazon did license 1-Click to Apple at one point for use in iTunes, reportedly for a modest sum. But by and large, these haven\u2019t been huge direct moneymakers and many were invalidated or expired. \n\nTherefore, in software/IT: patents are **widely owned but lightly monetized** directly. The revenue impact of patents is mostly **indirect defensive value** (ensuring a company can keep selling its software without being sued, via cross-licenses or deterrence) and **occasional litigation windfalls or settlements**. The one significant direct revenue channel \u2013 licensing patents to others \u2013 is limited to a few companies and tends to be a small slice of the pie (with Microsoft and IBM historically being exceptions who tried to make it a profit center).\n\n### Semiconductors and Electronics\n\nThe **semiconductor industry** (which includes computer chips, integrated circuits, memory, and related electronics) has been a heavy user of patents for decades. Like software, large semiconductor companies accumulate big portfolios, but unlike pure software, semiconductor patents often cover tangible processes or circuits and can be very specific and powerful. This field has seen extensive **cross-licensing** as well: major chip manufacturers (Intel, AMD, Texas Instruments, Samsung, TSMC, etc.) usually have bilateral agreements allowing each other to use patented technologies, often with balancing payments if one side has a stronger portfolio. The rationale is that any complex chip might inadvertently use many techniques patented by others, so cross-licensing avoids multi-way litigation. One historical example: in the 1990s, **Texas Instruments (TI)**, after facing decline in some markets, aggressively enforced some fundamental chip patents and earned substantial royalties \u2013 TI reportedly earned over $800\u202fmillion from patent licensing in the mid-1990s, which helped turn its finances around\u30107\u2020L142-L150\u3011. TI\u2019s actions were an early case of a product-focused company pivoting to monetize IP assets. Similarly, **Intel** and **AMD** have long cross-licensed to ensure each could make x86 processors without fear of suits, sometimes with one paying royalties to the other (Intel paid AMD for certain tech in the past, and vice versa, depending on generation of chips).\n\nIn semiconductors, **patent litigation** still occurs when cross-licensing fails or with smaller firms. Notoriously, **Rambus Inc.**, a small chip design company, held patents on memory chip interfaces; in the 2000s it engaged in protracted legal battles with major memory manufacturers (like Samsung, Hynix, Micron), eventually extracting some settlements. Another case: **Intel** sued or was sued by various competitors over chip designs and manufacturing methods, though many conflicts got settled. For instance, Intel and AMD settled their disputes in 2009 with a cross-license and Intel paying AMD $1.25\u202fbillion. These examples show that patents are bargaining chips to secure market position or compensation.\n\nSemiconductor firms also **license technology to smaller players**. Companies that specialize in certain chip technologies might license their patents to others in exchange for royalties rather than manufacturing themselves. For example, **ARM Holdings** (UK-based, now owned by SoftBank/Nvidia) is known for licensing its processor architecture and related patents to almost every mobile chip maker \u2013 ARM\u2019s entire business is essentially technology licensing (they design IP and license it rather than fabricating chips), so nearly 100% of its revenue is patent/technology royalties. This is an example of a semiconductor \u201clicensing company\u201d model, parallel to practicing companies.\n\nOverall, in semiconductors and electronics hardware, **patent-related revenue** comes in a mix: a bit from licensing (some companies like Qualcomm\u2019s licensing arm, or ARM, or those who enforce key patents), but the bulk indirectly from product sales that are protected by patents. One could say, for most chip makers, **patents enable their product monopoly and differentiation** (thus indirectly supporting revenue), but direct royalty income is a small proportion (most of their patents they don\u2019t license out freely). Perhaps exceptions are companies that have exited manufacturing and now live off licensing \u2013 e.g., **Nokia** after selling its handset business kept its patent portfolio and earns around $1.5\u202fbillion annually licensing patents (telecom and device patents)\u30100\u2020L1-L4\u3011\u30105\u2020L132-L140\u3011. **Ericsson** similarly generates a steady few hundred million per quarter from patent licenses for mobile technology. These are originally product companies that became more like licensing entities in part.\n\nThe **consumer electronics sector** (which overlaps with semiconductors and telecom) likewise uses patents heavily but seldom for external licensing except via pools or standards. **Apple** is a big patent filer but notably doesn\u2019t license its core technology patents \u2013 instead it uses them to sue (as with Samsung) or countersue for leverage. So Apple\u2019s patent revenue is essentially *zero* in licensing, but indirectly those patents protect tens of billions in product sales by deterring clones or helping in court.\n\nTo summarize semiconductors/electronics: **cross-licensing and defensive patenting are predominant**, with **occasional monetization** when a firm has a unique must-have patent. Companies in this field generally fall in the **~1% or ~10% patent revenue tier** \u2013 e.g., Qualcomm\u2019s chip business vs licensing business means it\u2019s higher, but Intel or Apple get <1% from licensing directly. The field has seen more **legal settlements and one-time payments** than ongoing royalty streams, aside from standardized tech where royalty programs exist.\n\n### Telecommunications and Standard-Essential Patents\n\nTelecommunications (telecom) is a field particularly entwined with patents, especially because of the need for standards (e.g. 3G, 4G, 5G cellular standards, Wi-Fi, etc.). The concept of **Standard-Essential Patents (SEPs)** is central here: these are patents that any implementer of the standard must use, hence they must be licensed. Companies like **Qualcomm, Nokia, Ericsson, Motorola (now part of Lenovo), Samsung, Huawei, ZTE, LG** and others have been major contributors to wireless communication R&D and hold many SEPs. The telecom patent ecosystem has generated very large licensing revenues. For instance, Qualcomm\u2019s business model historically included collecting royalties from virtually every 3G/4G phone sold (sometimes around 5% of the handset price), leading to **billions of dollars annually in licensing fees**\u30107\u2020L151-L158\u3011. Nokia and Ericsson, after shifting away from making phones, each still earn on the order of $600\u202fmillion to $1\u202fbillion+ per year from patent licensing in the 4G/5G space\u30100\u2020L19-L26\u3011. These royalties are often governed by FRAND terms, but disputes arise over what is \u201cfair and reasonable.\u201d A notable battle was **Apple vs Qualcomm**: Apple, as an iPhone maker, was paying Qualcomm a per-handset royalty for modem patents; they litigated fiercely around 2017\u20132019 over whether those fees were too high, eventually settling in 2019 with Apple paying Qualcomm at least $4.5\u202fbillion upfront and entering a licensing deal\u30100\u2020L1-L4\u3011\u30108\u2020L37-L41\u3011. This underscores the high stakes \u2013 patent licenses in telecom can be multi-billion-dollar agreements.\n\nThe telecom field also has patent pools, like for certain generations of technology (e.g., via the Avanci consortium for automotive uses of 4G/5G patents). However, many large patent holders prefer bilateral licenses to maximize their take. Litigation has been frequent: e.g., Ericsson vs Samsung, Nokia vs Apple (earlier around 2011, Nokia sued Apple and they settled with Apple paying royalties), and various NPEs have gotten involved in telecom as well. One interesting trend is the rise of **Chinese companies (Huawei, ZTE)** accumulating telecom patents; Huawei in particular now often leads in new patent filings for 5G. They have started to license out their SEPs globally too \u2013 Huawei has signed deals to license 5G patents to companies like Apple and Samsung, reportedly seeking royalties similar to Western firms (Huawei announced a capped rate of about $2.50 per 5G phone for its patents in 2021). This is a shift: traditionally Western firms licensed into China; now Chinese IP owners are licensing worldwide.\n\nIn summary, telecommunications patents are **heavily monetized via licensing**. Entities in this field (if they are patent-focused or have strong SEP portfolios) can easily be in the **>50% patent revenue tier**. For example, Qualcomm some years had more profit coming from licensing than from chip sales. Nokia\u2019s and Ericsson\u2019s patent licensing divisions contribute a significant share of corporate profits now that their other businesses have shrunk. On the other hand, companies that are mainly equipment vendors (like Cisco in networking or AT&T as a service provider) might patent a lot but not license much. Still, the field overall shows one of the **highest patent monetization intensities**. It\u2019s telling that patent licensing deals in telecom grew 12% in 2023\u301021\u2020L29-L34\u3011, indicating continued expansion of licensing activity as 5G and IoT (Internet of Things) technologies roll out.\n\n### Artificial Intelligence and Emerging Software Technologies\n\n**Artificial Intelligence (AI)** is a newer field (within software/IT) that has seen explosive growth in R&D in the past decade. Patent filings for AI-related innovations (machine learning algorithms, applications in vision, speech, etc.) have surged globally, with companies like IBM, Microsoft, Google, and many startups filing patents on AI techniques. According to WIPO, by the late 2010s tens of thousands of AI patents were being filed each year. However, the landscape for monetizing AI patents is still developing. Many AI algorithms are published openly in academic papers or shared as open-source code, making patenting tricky or less common for core algorithms (some aspects may be deemed abstract). That said, companies are patenting specific **applications of AI** (e.g. AI in autonomous driving, or medical diagnostics) and **hardware optimized for AI** (e.g. neural network chips).\n\nSo far, there have not been prominent licensing programs or major lawsuits purely over AI patents \u2013 most companies are using AI internally to enhance their products (e.g. AI features in software, recommendation engines, etc.) rather than licensing AI tech. But we can anticipate that as AI matures, patent issues will grow. Already, **licensing fees for AI-related patents have been rising ~15% annually since 2020\u301021\u2020L23-L28\u3011**, suggesting that when AI tech is exchanged or integrated (say a company licensing an AI algorithm for use in a product), the price commanded by the IP is increasing. Some startups focusing on AI might license their patented technology to bigger firms, or conversely, big firms might patent foundational AI technology and cross-license among each other (for instance, if Company A patents a particular neural network training method and Company B patents a different one, they might cross-license to avoid blocking each other\u2019s AI products).\n\nOne special area is **autonomous vehicles (AV) and robotics**, which blend AI, sensors, and software \u2013 here companies like Waymo (Google) and others have patented aspects of self-driving tech. There have been a few cases of companies suing or licensing in that area (e.g., Waymo\u2019s early legal fight with Uber over self-driving tech, although that was more trade secret theft case). \n\nAI also highlights the interplay with **trade secrets**: many AI models (like Google\u2019s search algorithms or OpenAI\u2019s GPT models) are kept secret, not patented, since patents would require disclosure and might be hard to enforce for something as abstract as a trained model. So some AI innovations may bypass patents entirely.\n\nIn terms of revenue, it\u2019s too early to quantify AI patent licensing as a significant portion of any company\u2019s income. For now, we can say **AI patents are mostly used for strategic positioning and defensive needs**, and any direct licensing is nascent. The PatentPC analysis shows rapid growth though, hinting that companies do see licensing potential in AI sectors\u301021\u2020L23-L28\u3011. Perhaps in coming years we will see more licensing marketplaces for AI techniques (especially as AI gets embedded in devices and IoT, making it more like a technology component that can be licensed).\n\n### Clean Technology and Energy\n\n**Clean technology (clean tech)** encompasses renewable energy (solar, wind, geothermal), energy storage (batteries, fuel cells), electric vehicles, and related environmental innovations. Patents play a notable role here as well, though the narrative is a bit mixed. Historically, many clean energy technologies were developed in government labs or with public funding (e.g., DOE labs working on solar panels or advanced batteries, universities researching biofuels, etc.), and there was a push to disseminate these broadly. Some companies, however, built strong patent positions \u2013 for example, **General Electric (GE)** and **Vestas** in wind turbine designs engaged in patent litigation in the 2010s over turbine technology. **Tesla**, as mentioned earlier, took a contrarian approach in 2014 by pledging its EV patents for open use\u301033\u2020L29-L36\u3011, believing that growing the EV market was more important than exclusion. Nonetheless, other automakers and battery manufacturers do patent heavily in electric drivetrain and battery chemistry. There have been cases like **Toyota** licensing some of its hybrid vehicle patents to other carmakers (Toyota opened some of its hydrogen fuel cell patents free of royalty around 2015 to encourage adoption of hydrogen cars, similar to Tesla\u2019s pledge but with conditions).\n\nIn solar power, the early 2010s saw a glut of inexpensive solar panels from China which bankrupted some U.S. and European solar companies that had patents. It raised the question of whether Chinese firms were infringing on Western patents or just out-manufacturing them; some litigation did occur, but enforcement internationally was challenging. Over time, China developed its own solar tech patents too. This scenario underscored that patents alone couldn\u2019t save some cleantech companies if manufacturing economics were unfavorable.\n\nPatent monetization in cleantech is not as prominent as in pharma or telecom, but it exists in pockets. Some startups in energy tech license their innovations (e.g., a startup with a patented battery material might license it to a large battery producer rather than build its own factory). Also, **consortia for climate** \u2013 like the proposed Green Xchange around 2010 \u2013 encouraged companies to share patents to advance sustainable tech. A notable initiative is the **World Intellectual Property Organization (WIPO) GREEN** platform, which is a database of green tech patents available for licensing, aiming to connect providers and seekers of eco-friendly technologies. It suggests a collaborative approach rather than aggressive monetization.\n\nRevenues from patents in cleantech likely fall in the **low tier (~1%) for most companies**, since revenue is driven by selling energy equipment or electricity. For example, a solar panel maker\u2019s profits come from panel sales; they might have patented a new cell design, but they\u2019re using it themselves. In some cases, though, if a company doesn\u2019t survive, its patents might be sold to others (some solar patents ended up acquired by companies in China or by patent holding companies after bankruptcies). As we enter 2025, climate urgency might actually spur more open licensing \u2013 we have seen calls for patent waivers for crucial tech (similar to how in 2021\u20132022 there were calls to waive COVID vaccine patents for global access).\n\nOverall, clean tech patents are a bit less about maximizing royalty streams and more about ensuring *some* reward for innovators while balancing global need. They illustrate that patents in certain fields have a public-good angle that can override pure profit considerations. That said, industries like electric vehicles and battery tech are becoming as competitive as traditional sectors, so we can expect normal patent competition there (e.g., companies suing over battery chemistry patents if an important one is at stake). But presently, no company in clean tech is known to earn a large chunk of revenue purely from patent licenses \u2013 it\u2019s mostly product-centric.\n\n### Advanced Materials and Manufacturing\n\nFields like **materials science, chemicals, and advanced manufacturing** (including things like 3D printing technology, advanced composites, nanotechnology) rely on patents to protect novel substances and processes. Chemical companies (Dow, DuPont, BASF, etc.) have long used patents to safeguard formulas for polymers, agrichemicals, etc. Often, they also use **trade secrets** when possible (if an industrial process can be kept secret rather than patented and revealed). The monetization in chemicals typically comes from exclusive production and sale of the patented material \u2013 for instance, if DuPont develops a new refrigerant chemical with low greenhouse impact and patents it, DuPont will manufacture and sell it, enjoying a period of high margin until the patent expires or competitors find alternatives. Direct licensing is less common \u2013 occasionally chemical companies cross-license processes if it\u2019s mutually beneficial, or license to a company in a region they don\u2019t serve.\n\n**Materials science breakthroughs** sometimes yield patents that are broadly licensed. For example, the inventors of **Gore-Tex** (an advanced waterproof fabric) licensed it widely in apparel. **Corning\u2019s Gorilla Glass**, used in smartphone screens, is patented but Corning chooses to manufacture and sell the glass rather than license others to make it \u2013 however, effectively Corning\u2019s entire revenue from Gorilla Glass is due to its patents on the composition and process. In this sense, it\u2019s indirect patent revenue (through product sales). Some material innovations from labs (like a new alloy or semiconductor material) might be licensed to multiple manufacturers if the inventors don\u2019t produce it themselves.\n\n**3D printing (additive manufacturing)** is a field that saw intense patent activity in the 1990s and 2000s \u2013 key patents on technologies like stereolithography and selective laser sintering were held by companies like 3D Systems and Stratasys. As those patents expired in the 2010s, a wave of new entrants and cheaper 3D printers flooded in, demonstrating the effect of patent expiration. During the patent period, those companies did license out some tech or kept it proprietary in their machines. \n\nIn advanced manufacturing equipment (like semiconductor fabrication machines made by ASML, Applied Materials, etc.), patents protect the complex machinery. These companies generally sell the equipment rather than license patents, but they may cross-license with their suppliers or customers to avoid disputes.\n\nRevenue-wise, materials and manufacturing firms usually get **<10% from patent licensing**; instead patents support their product exclusivity which yields profits. One exception might be if a company spins off a patent or tech it isn\u2019t using \u2013 selling it or licensing it can bring a chunk of revenue, but those are one-off occurrences. \n\n### Medical Devices and Health Tech\n\nThough not explicitly listed in the question\u2019s examples, **medical devices** and health technology are another key field to consider. Companies making medical devices (from stents to MRI machines to AI diagnostics) do patent their innovations heavily. The device industry is somewhat between pharma and electronics in patent behavior: they do get exclusivity but devices can sometimes be imitated in ways that skirt patents, and the regulatory barriers are lower than pharma. Big medtech firms (Medtronic, J&J\u2019s medical division, Boston Scientific, etc.) have many patents and do occasionally engage in patent litigation or licensing. For example, various lawsuits over heart stent patents occurred in the 2000s between Boston Scientific, J&J, Medtronic, resulting in settlements or blocked products. There\u2019s also cross-licensing in areas like imaging devices.\n\nHowever, medtech companies again mainly profit from selling the devices; licensing is secondary. One difference: some **university hospitals and research institutes patent medical device ideas** (like a new surgical tool or imaging method) and license to companies, similar to drug tech transfer but usually for smaller amounts. Medical device patent licensing grew about 10% in 2023\u301028\u2020L1-L9\u3011, reflecting that this area is seeing more deals (perhaps as tech like AI in diagnostics emerges, companies license algorithms from tech firms into medical devices, etc.).\n\nAs a ballpark, medical device makers likely fall in the **~1% revenue from licensing** category \u2013 the patent\u2019s value is realized by being the sole seller of an FDA-approved device for some years. Indirectly, patents are quite important to them (a competitor copying a device feature can be stopped with a patent suit, protecting market share).\n\n### Other Sectors (Automotive, Finance, etc.)\n\nThe **automotive industry** historically was not very patent-intensive in terms of enforcement \u2013 the major car OEMs cross-licensed many patents under a gentleman\u2019s agreement to avoid suing (partly because auto had thousands of small patents on parts, none giving huge leverage). In recent years, with cars becoming \u201ccomputers on wheels,\u201d auto companies have confronted more patent issues, particularly because of **connectivity and autonomy**. For instance, car makers now have to license cellular SEPs for the 4G/5G chips in their vehicles (leading them to deals with Avanci pool as mentioned). There have been a few cases of NPEs suing automakers over navigation or entertainment system patents. Tesla\u2019s open patent pledge stands out in this sector as discussed. On balance, auto companies do not earn revenue from patents (they don\u2019t license out their engine or safety tech patents to competitors), so they are in the low patent-revenue tier, using patents mainly defensively or to block copycats. \n\nThe **financial services sector** and **fintech** saw a phase of business method patents and software patents (e.g. for online banking, trading algorithms). Some banks accumulated patents but they rarely monetize them except defensively. After Alice (2014), many business method patents became unenforceable, so the banking industry mostly stopped trying to license patents and instead focused on defensive pooling (there\u2019s a Financial Services industry patent consortium to deter NPEs).\n\n**Entertainment and media** might rely more on copyrights, but they do have some patents in streaming technology or VR/AR etc. These again are not major licensing revenue sources (aside from patent pools for streaming codecs, which we covered under consortia).\n\n**Conclusion of Fields:** Each technical field uses patents in unique ways \u2013 **life sciences** treat patents as core assets for profit via exclusivity; **ICT (information and communication tech)** uses them as both swords and shields in a complex web of licensing and litigation; **emerging tech** like AI is still finding the balance; and **traditional industries** like energy, auto, chemicals use patents to secure innovation advantages mostly for their own products. This leads to varying levels of revenue directly tied to patents, as we will now summarize by looking at revenue tiers.\n\n## Patent-Related Revenue: Tiers and Data Analysis\n\nHaving examined institutions and fields, we now focus on the **financial dimension of patents** \u2013 how much revenue is derived from patents (directly or indirectly) and how it breaks down. We consider both **absolute revenues** (e.g. dollars from licensing) and **relative contributions** (e.g. patents account for X% of an entity\u2019s total revenue), across different classes of institutions and industries.\n\n### The Patent Licensing Market in Aggregate\n\nAt a macro level, patent licensing has grown into a significant market of its own over the past 30 years. Estimates show that the **global patent licensing market is projected to reach around $150\u202fbillion in annual revenues by 2024\u301019\u2020L79-L87\u3011**. This figure includes licensing of all types of patents worldwide (technology, pharmaceutical, etc.) and represents a steady growth (~7% annual since 2020)\u301019\u2020L91-L99\u3011. The United States is the single largest market for patent licensing, accounting for roughly **35% of global patent licensing deals\u301019\u2020L101-L109\u3011**. Thus, one can infer tens of billions of dollars a year are generated in the U.S. from patent licensing activity. However, these numbers, while large, are still modest compared to the total economic value of products protected by patents. For perspective, the **total sales of patented products** (like pharmaceuticals, electronics, etc.) run into the trillions of dollars globally. Patent licensing revenue is essentially the slice of that value being paid as royalties.\n\nBreaking down that $150\u202fbillion: about a **quarter (25%) is from pharmaceuticals**\u301021\u2020L19-L24\u3011, reflecting the many royalty deals and co-development licenses in pharma/biotech. Universities contribute around **15% of global licensing revenues\u301021\u2020L53-L60\u3011** (often by licensing early-stage inventions to companies). Tech sectors like telecommunications, computer, and semiconductor collectively make up a substantial chunk (telecom SEPs alone are a major component). Geographically, after the U.S., Europe and Asia-Pacific (especially Japan, China, South Korea) are major players \u2013 Asia-Pacific saw a 10% increase in patent licensing activity in 2023\u301021\u2020L41-L47\u3011, indicating rising participation (with companies like Huawei, Samsung, and Panasonic being active licensors).\n\nIt\u2019s worth highlighting that **cross-licensing (which usually involves no money or netting out payments) accounts for about 20% of all patent licensing agreements\u301021\u2020L35-L41\u3011**. So not all technology exchange shows up as revenue \u2013 many deals are swaps of access. Therefore, the revenue numbers mostly capture one-way licensing (like a university to a company, or an NPE to a defendant payment, etc.).\n\n### Direct Licensing vs. Product Revenues\n\nWe must distinguish **direct patent licensing revenue** (fees, royalties, settlements specifically from IP rights) from **product revenue that is \u201cpatent-enabled\u201d** (sales of patented products). In some industries, the two align closely (pharma product sales during exclusivity can be viewed as \u201cenabled by patents\u201d and are effectively the return on the patent). In others, patents might not drastically change the product sales (e.g., software sold on service basis, where competition is more about network effects than patents). \n\n**Direct licensing/royalty income** includes things like: royalties from licensing agreements, one-time payments for patent sales, litigation damages or settlements (which are essentially enforced royalties). **Indirect product revenue attributable to patents** means the portion of a product\u2019s revenue that can be credited to the patent protection. This concept is a bit abstract, but one might estimate it as the difference in revenue a company can earn with patent exclusivity versus if competitors could freely copy \u2013 often, this is huge in pharma (nearly 100% of the brand drug\u2019s revenue would erode if generics were allowed earlier) and less so in, say, consumer electronics (where many factors besides patents determine success).\n\nTo illustrate, consider a **pharma company** with a $1\u202fbillion-a-year drug under patent. Direct licensing revenue might be zero if they\u2019re not licensing it (they sell it themselves). But the indirect patent-enabled revenue is essentially that $1\u202fbillion (because without patent, profits would collapse due to generics). Now consider a **tech company** like Apple with $200\u202fbillion in product sales. Apple doesn\u2019t license out patents, so direct licensing revenue is basically zero. If Apple had no patents, would its sales be much different? Possibly not immediately (brand and ecosystem matter), but it could face more clone competitors or be forced to pay others more \u2013 hard to quantify. For Apple, patents are more of a defensive moat and negotiating chip (for example, in settling disputes or cross-licensing to use others\u2019 tech). So one might say only a sliver of Apple\u2019s revenue (maybe ~1% or less) is directly attributable to patents (some features might avoid being on competitor devices due to Apple\u2019s patents, giving it an edge).\n\n**Non-practicing entities** have a straightforward split: nearly 100% of their revenue is direct patent licensing revenue, and 0% is product revenue (since they have no products). \n\n**Universities**: essentially all of their patent-related revenue is direct licensing (royalties from licensing patents) because they don\u2019t sell products. For example, the University of California\u2019s ~$182\u202fmillion patent revenue\u301011\u2020L227-L235\u3011 is all royalties. In relative terms, that might be, say, on the order of 2\u20133% of UC\u2019s research budget or <1% of its total budget (UC\u2019s overall budget is tens of billions when including all campuses, medical centers, etc.). So universities are generally low tier in relative terms (~1% of revenue from patents for most), except a few years where a big payout can spike that to a few percent or more.\n\n**Government labs**: similar to universities, 100% of their small patent income is licensing; as noted, trivial relative to their budgets (<0.1%). \n\n**Consortia/pools**: The \u201centity\u201d itself usually doesn\u2019t have conventional revenue; it collects royalties and passes them on. If we consider the consortium\u2019s own operations, they might take an admin fee (a few percent of royalties) \u2013 that fee would be 100% patent-sourced. The members then count that as licensing revenue.\n\n**Corporations (product companies)**: Here we often see a mix. Some have *dual streams* \u2013 e.g., Qualcomm sells chips (product revenue) and licenses patents (licensing revenue). For Qualcomm circa 2020s, roughly 30% of revenue and a higher percent of profit was from licensing\u30100\u2020L1-L4\u3011. IBM historically had maybe ~1\u20133% of revenue from IP licensing in the 2000s\u30107\u2020L144-L152\u3011. Many companies have *near 0%* if they don\u2019t license at all (or only cross-license). Some like certain tech IP firms (ARM, Dolby) have ~100% from licensing because they don\u2019t sell physical goods in volume.\n\nWe can categorize typical **revenue contribution tiers** as requested:\n- **>50% of revenue from patents:** This would include NPEs (virtually 100%), pure licensing companies, and certain companies whose primary business is licensing IP (some semiconductor IP firms, companies that ceased product operations but retained patent portfolios, etc.). Also patent pools or monetization funds fall here. For example, an entity like **InterDigital** (a smaller company focusing on wireless R&D and patent licensing) gets the majority of its revenue from licensing patents to larger companies \u2013 InterDigital\u2019s model is to invent and patent wireless tech and then license to telecom firms, with annual revenues in the hundreds of millions, nearly all from patents. \n- **Around 10% of revenue from patents:** This tier might include a few large product companies that nonetheless have notable licensing arms. Historically, **Qualcomm** could fit if one looks at certain years (though at times it was higher). Perhaps **Nokia** now \u2013 after restructuring, Nokia\u2019s licensing (Nokia Technologies division) is significant relative to its telecom equipment sales. **IBM** in some years might have been closer to, say, 5% from licensing, which is below 10%, but conceptually in this middle tier. Also, certain **universities** in banner years (Northwestern\u2019s licensing windfall in 2011 was ~40% of its research spend \u2013 very high; but typically universities are lower). Possibly some **biotech firms** that license out a drug instead of selling it could see around 10% if they also have other revenue streams. But generally, this tier is a bit sparse because most either do very little licensing or are heavily into it. It might also include companies that rely on patent licensing as a **secondary revenue**: e.g., **Ericsson** gets about 5-10% of revenue from its patent licensing unit, which for a product company is significant.\n- **~1% or less of revenue from patents:** This would be the majority of operating companies \u2013 your average tech manufacturer, automobile company, software service provider, etc. They might have occasional licensing income (or none) that is negligible compared to their product/service revenue. Even a company like **Google** \u2013 it has tons of patents but basically $0 direct licensing revenue; any money from patents (like selling some patents or occasional license) is minuscule. **Apple** is similar (they don\u2019t license IP out, except perhaps some small programs like MFi accessories program which is more trademark/certification than patent licensing). **Manufacturing firms** (machinery, consumer goods) also tend to be in this bucket \u2013 patents protect their products from copying, but the companies don\u2019t make money licensing the patents out.\n\nIt\u2019s useful to look at some **real-world numbers** to quantify: \n- IBM\u2019s ~$1\u202fbillion/yr licensing in 2010s on ~$100\u202fbillion revenue was ~1%\u30107\u2020L144-L152\u3011.\n- Qualcomm\u2019s ~$8\u202fbillion licensing on $33\u202fbillion is ~25%\u30100\u2020L1-L4\u3011 (so actually Qualcomm might be >10% tier, bordering >50% if looking at profit).\n- For universities, $2.94\u202fbillion total (2018) spread across all U.S. universities versus the hundreds of billions in their combined budgets is a tiny percent, though for a few like Columbia, the patent royalties have approached ~5\u201310% of their annual research funding at times.\n- NPEs: $29\u202fbillion cost to companies in 2011 implies NPEs collectively \u201cearned\u201d tens of billions a year (likely less in actual net revenue, since that cost includes legal fees too)\u301039\u2020L92-L100\u3011. But clearly for them it\u2019s 100%.\n\nFinally, we present the requested **unified table** mapping institution types, fields, and revenue tiers. This table highlights representative combinations and whether patent monetization for each is primarily via licensing or product sales:\n\n```csv\nInstitution Type,Technical Field,Patent Revenue Tier (% of total),Primary Patent Revenue Source\nLarge Corporation (Product-focused),Pharmaceuticals,>50%,Product sales (patented drugs ~100% of product revenue)\nLarge Corporation (Product-focused),Consumer Software,~1%,Primarily product sales (patents used defensively; minimal licensing)\nLarge Corporation (Licensing-focused),Wireless/Telecom,>50%,Patent licensing (royalties on standard-essential patents dominate revenue)\nSmall Company / Startup,Biotechnology,>50%,Licensing (often licenses patents to big pharma for royalties instead of own sales)\nUniversity (Tech Transfer-heavy),Biotech/Pharma,~10%,Licensing (royalty income from patented drug or biotech inventions can be significant portion of research funding)\nUniversity (Typical),Engineering/Physical Sciences,~1%,Licensing (patent income is minimal relative to total university budget)\nGovernment Lab,Energy Technology,~1%,Licensing (negligible royalty income compared to federal funding; patents used for tech transfer)\nNon-Practicing Entity (Patent Holder),High-Tech (e.g. Software),>50%,Licensing (100% of revenue from patent royalties or litigation settlements)\nConsortium / Patent Pool,Telecom Standards,>50%,Licensing (pooled SEP royalties distributed to members; no product sales)\nDefensive Consortium (e.g. OIN),Open Source Software,~1%,N/A (patents are cross-licensed or pledged, aiming for freedom-to-operate rather than revenue)\n```\n\n*(Table: Examples of how institution types and fields map to patent-related revenue tiers. \u201c>50%\u201d indicates patents account for the majority of the entity\u2019s revenue; \u201c~10%\u201d indicates a significant but not dominant share; \u201c~1%\u201d indicates only a small fraction. The primary source column notes whether revenue comes via licensing royalties or from product sales protected by patents.)*\n\n### Key Takeaways on Patent Revenues\n\nTo conclude, the patent industry\u2019s financial characteristics are diverse. Certain business models (NPEs, patent licensing companies, and some tech licensing programs) derive essentially all their income from patents. They form the high end of the spectrum in terms of patent monetization. On the other hand, most operating companies use patents more as an **enabling tool** \u2013 crucial for securing competitive advantage and negotiating leverage, but not as a direct revenue stream. For them, the benefit of patents is realized in **preserving market share or premium pricing** on products, which is a real (if hard to measure) economic value attributable to patents. In pharmaceuticals, that value is very concrete and near-total; in other fields, it\u2019s one factor among many.\n\nOver the last 30 years in the U.S., the overall trend has been **growing awareness of IP value**, increased patenting across almost all sectors, and more sophisticated monetization (and counter-strategies like defensive coalitions). The U.S. patent system has enabled universities to become innovation hubs with some revenue return, has seen corporations turn IP into cash (IBM, Qualcomm, etc.), and has seen the rise of new entities (NPEs) that test the balance of incentives. Recent data shows the patent licensing market is still expanding in size\u301019\u2020L79-L87\u3011, even as legal reforms attempt to curb abuses. Internationally, the U.S. remains the largest player, but Europe and Asia are intensifying their patent activities, which will influence revenue flows (e.g., Chinese companies earning royalties abroad, European courts becoming venues for global patent fights).\n\nFor policy makers and businesses, an understanding of these dynamics is crucial. The patent system is intended to spur innovation by rewarding inventors, but the way those rewards are reaped varies widely. A pharmaceutical inventor expects monopoly profits on a drug; a tech inventor at a big firm might simply get a bonus and a patent plaque while the company cross-licenses the patent; a university researcher hopes for a license that funds new labs; an NPE investor looks for settlements from infringers. All coexist in the modern patent ecosystem. The challenge and opportunity lie in finding the right balance \u2013 encouraging the positive uses of patents (innovation disclosure, fair licensing, investment in R&D) while mitigating negatives (frivolous litigation, barriers to entry). The U.S. patent industry of 2025 is far more complex and multi-faceted than that of 1995, reflecting the evolution of technology and business models over 30 years. As we\u2019ve seen, by analyzing institutions, fields, and revenue models, we gain a clearer picture of how patents truly function as economic assets in various contexts.\n\n**Sources:**\n\n- Parola Analytics (2021) \u2013 Case studies on IBM, Microsoft, Qualcomm patent licensing\u30107\u2020L142-L150\u3011\u30107\u2020L151-L158\u3011  \n- PatentPC (2025) \u2013 Patent licensing market statistics (global market size, growth, sector shares)\u301019\u2020L79-L87\u3011\u301021\u2020L19-L27\u3011\u301021\u2020L53-L60\u3011  \n- Inside Higher Ed (2012) \u2013 University licensing income data (2011 top earners)\u301016\u2020L258-L266\u3011\u301016\u2020L269-L277\u3011  \n- GreyB (2016) \u2013 University of California patent count and licensing revenue\u301011\u2020L227-L235\u3011  \n- NIST/GAO (2022) \u2013 Federal labs tech transfer report (FY2020 licensing income)\u301036\u2020L7-L14\u3011  \n- The Atlantic (2012) \u2013 Study on NPE (\u201cpatent troll\u201d) costs to companies\u301039\u2020L92-L100\u3011\u301039\u2020L100-L108\u3011  \n- R Street Institute (2023) \u2013 Pharmaceutical industry patent exclusivity and revenue impact\u301042\u2020L113-L120\u3011  \n- Reuters (2021) \u2013 Qualcomm financials (licensing vs chip revenue)\u30100\u2020L1-L4\u3011 and IAM Media (2020) \u2013 Nokia/Ericsson licensing business\u30100\u2020L19-L26\u3011."
            ]
          },
          "status": "finished_successfully",
          "end_turn": true,
          "weight": 1.0,
          "metadata": {
            "citations": [
              {
                "start_ix": 2598,
                "end_ix": 2610,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "The Economics of the Pharmaceutical Sector: Innovation, Competition, and Patent Policy - R Street Institute",
                  "url": "https://www.rstreet.org/commentary/the-economics-of-the-pharmaceutical-sector-innovation-competition-and-patent-policy/#:~:text=Given%20the%20substantial%20investments%20and,15%20years%C2%A0of%20effective%20protection%20remaining",
                  "text": "Given the substantial investments and risks involved in drug development, patents have come to play a prominent role in the pharmaceutical-industry business model. Patents provide their owners with the power to \u201cexclude others\u00a0from making, using, offering for sale, selling, or importing into the United States the invention claimed.\u201d\u00a0Typically, patent protection lasts for 20 years\u2014a time limit that is set by statute. However, in the pharmaceutical industry, several years of that patent term are usually consumed by the clinical trial and regulatory review process. As a result, most new drugs have 12 to 15 years\u00a0of effective protection remaining",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 40,
                    "cited_message_id": "ca69bf57-c7d9-4e93-aa43-332206ec57d4",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 60,
                    "end_line_num": 68,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 2610,
                "end_ix": 2624,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "The Economics of the Pharmaceutical Sector: Innovation, Competition, and Patent Policy - R Street Institute",
                  "url": "https://www.rstreet.org/commentary/the-economics-of-the-pharmaceutical-sector-innovation-competition-and-patent-policy/#:~:text=%E2%80%9Cpatent%20cliff%2C%E2%80%9D%20where%20lower,and%20the%20threat%20of%20competition",
                  "text": "\u201cpatent cliff,\u201d where lower-cost generic rivals can enter the market and drive prices down to competitive levels. Once the market for a blockbuster drug becomes competitive, revenues may fall by as much as 79 percent. This dropoff in earning power poses a major threat to pharmaceutical companies\u2019 revenues, particularly when the drug goes off patent\u2014indeed, analysts project that more than $200 billion\u00a0in annual pharmaceutical revenue is at risk between now and 2030 due to expiring patents and the threat of competition.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 42,
                    "cited_message_id": "b0522b08-30ea-4f35-b9ef-4eb6e10ecab9",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 113,
                    "end_line_num": 120,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 3096,
                "end_ix": 3110,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Smartphone patent wars - Wikipedia",
                  "url": "https://en.wikipedia.org/wiki/Smartphone_patent_wars#:~:text=To%20secure%20and%20increase%20market,71",
                  "text": "To secure and increase market share , companies granted a  73 can sue to prevent competitors from using the methods the patent covers. Since 2010 the number of lawsuits, counter-suits , and trade complaints based on patents and  75 in the market for smartphones, and devices based on smartphone OSes  such as  77 and iOS , has increased significantly.[ 71]",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 30,
                    "cited_message_id": "7b1c272b-afc5-4821-883d-31622e2e8616",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 158,
                    "end_line_num": 166,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 3292,
                "end_ix": 3304,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                  "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=match%20at%20L177%20Cross,of%20all%20patent%20licensing%20deals",
                  "text": "match at L177 Cross-licensing agreements constitute 20% of all patent licensing deals.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 21,
                    "cited_message_id": "42ac99c7-f25f-4f21-8a5b-ffd136a3a471",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 35,
                    "end_line_num": 41,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 3888,
                "end_ix": 3901,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Buy or License Patents: How to build a better IP strategy",
                  "url": "https://parolaanalytics.com/buy-or-license-patents-how-to-build-a-better-ip-strategy/#:~:text=patents%20can%20also%20generate%20additional,total%20earnings%20of%20many%20companies",
                  "text": "patents can also generate additional revenues\u00a0for the company via, for example,\u00a0out-licensing. IBM, of course, is one of the most iconic serial licensers among technology companies. IBM is estimated to have garnered 88,000 patents over the years and is said to have collected about $20 billion or so of IP-related revenues. Over the 2008\u20132012 period, IBM\u2019s patent portfolio reportedly generated from $1.1 to $1.2 billion annually. Although its licensing income has dropped each year since then to around $740 million in 2014, this still represents an amount greater than the total earnings of many companies.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 7,
                    "cited_message_id": "372a3a04-9872-4953-a138-05dbd275dc52",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 142,
                    "end_line_num": 150,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 4114,
                "end_ix": 4127,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Buy or License Patents: How to build a better IP strategy",
                  "url": "https://parolaanalytics.com/buy-or-license-patents-how-to-build-a-better-ip-strategy/#:~:text=licensers%20among%20technology%20companies,total%20earnings%20of%20many%20companies",
                  "text": "licensers among technology companies. IBM is estimated to have garnered 88,000 patents over the years and is said to have collected about $20 billion or so of IP-related revenues. Over the 2008\u20132012 period, IBM\u2019s patent portfolio reportedly generated from $1.1 to $1.2 billion annually. Although its licensing income has dropped each year since then to around $740 million in 2014, this still represents an amount greater than the total earnings of many companies.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 7,
                    "cited_message_id": "372a3a04-9872-4953-a138-05dbd275dc52",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 144,
                    "end_line_num": 152,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 4286,
                "end_ix": 4299,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Buy or License Patents: How to build a better IP strategy",
                  "url": "https://parolaanalytics.com/buy-or-license-patents-how-to-build-a-better-ip-strategy/#:~:text=Microsoft%2C%20on%20the%20other%20hand%2C,the%20June%20quarter%20of%202018",
                  "text": "Microsoft, on the other hand, was reported in 2013 to have generated $2 billion per year in revenue from Android patent royalties. Similarly, Qualcomm derives a substantial portion of its profit from licensing its 130,000 mobile technology- related patents to device makers, having received around $950 million from royalties for the June quarter of 2018.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 7,
                    "cited_message_id": "372a3a04-9872-4953-a138-05dbd275dc52",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 151,
                    "end_line_num": 158,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 4674,
                "end_ix": 4683,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "A comparative IP management success story for Apple, Qualcomm ...",
                  "url": "https://ipbusinessacademy.org/a-comparative-ip-management-success-story-for-apple-qualcomm-and-ibm#:~:text=,2%20billion",
                  "text": "... ipbusinessacademy.org  Qualcomm reported total revenue of approximately $33 billion for fiscal year 2021, from which licensing revenue was approximately $8.2 billion.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 0,
                    "cited_message_id": "d6bfc899-87ad-44cd-89fd-f123e76ff80c",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 1,
                    "end_line_num": 4,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 4894,
                "end_ix": 4907,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Buy or License Patents: How to build a better IP strategy",
                  "url": "https://parolaanalytics.com/buy-or-license-patents-how-to-build-a-better-ip-strategy/#:~:text=Microsoft%2C%20on%20the%20other%20hand%2C,the%20June%20quarter%20of%202018",
                  "text": "Microsoft, on the other hand, was reported in 2013 to have generated $2 billion per year in revenue from Android patent royalties. Similarly, Qualcomm derives a substantial portion of its profit from licensing its 130,000 mobile technology- related patents to device makers, having received around $950 million from royalties for the June quarter of 2018.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 7,
                    "cited_message_id": "372a3a04-9872-4953-a138-05dbd275dc52",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 151,
                    "end_line_num": 158,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 5573,
                "end_ix": 5586,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Buy or License Patents: How to build a better IP strategy",
                  "url": "https://parolaanalytics.com/buy-or-license-patents-how-to-build-a-better-ip-strategy/#:~:text=patents%20can%20also%20generate%20additional,total%20earnings%20of%20many%20companies",
                  "text": "patents can also generate additional revenues\u00a0for the company via, for example,\u00a0out-licensing. IBM, of course, is one of the most iconic serial licensers among technology companies. IBM is estimated to have garnered 88,000 patents over the years and is said to have collected about $20 billion or so of IP-related revenues. Over the 2008\u20132012 period, IBM\u2019s patent portfolio reportedly generated from $1.1 to $1.2 billion annually. Although its licensing income has dropped each year since then to around $740 million in 2014, this still represents an amount greater than the total earnings of many companies.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 7,
                    "cited_message_id": "372a3a04-9872-4953-a138-05dbd275dc52",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 142,
                    "end_line_num": 150,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 5803,
                "end_ix": 5815,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                  "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=match%20at%20L116%20In%202023%2C,engaged%20in%20patent%20licensing%20agreements",
                  "text": "match at L116 In 2023, over 40% of tech companies engaged in patent licensing agreements.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 21,
                    "cited_message_id": "42ac99c7-f25f-4f21-8a5b-ffd136a3a471",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 11,
                    "end_line_num": 19,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 7039,
                "end_ix": 7051,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                  "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=match%20at%20L225%20Startups%20account,licensing%20deals%20in%20emerging%20technologies",
                  "text": "match at L225 Startups account for 30% of new patent licensing deals in emerging technologies.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 21,
                    "cited_message_id": "42ac99c7-f25f-4f21-8a5b-ffd136a3a471",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 59,
                    "end_line_num": 66,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 8044,
                "end_ix": 8053,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "The Evolution of University Technology Transfer: By the Numbers",
                  "url": "https://ipwatchdog.com/2020/04/07/evolution-university-technology-transfer/id=120451/#:~:text=The%20Evolution%20of%20University%20Technology,academic%20inventions%20to%20market%2C",
                  "text": "The Evolution of University Technology Transfer: By the Numbers Approximately $2.94 billion in licensing revenue was generated in 2018 directly from the process of taking academic inventions to market, ...",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 8,
                    "cited_message_id": "cb41f75c-6cd4-430d-9980-5eece209c668",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 3,
                    "end_line_num": 8,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 8619,
                "end_ix": 8633,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "University licensing income rose slightly in 2011",
                  "url": "https://www.insidehighered.com/news/2012/08/28/university-licensing-income-rose-slightly-2011#:~:text=As%20has%20been%20true%20for,California%20system%20a%20close%20second",
                  "text": "As has been true for each of the past several years, Northwestern University brought in more licensing dollars from its research than did any other institution, at $191.5 million, with the University of California system a close second.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 16,
                    "cited_message_id": "6750f1a1-c6e9-4ce2-add0-9051920fa3a4",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 258,
                    "end_line_num": 266,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 8633,
                "end_ix": 8647,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "University licensing income rose slightly in 2011",
                  "url": "https://www.insidehighered.com/news/2012/08/28/university-licensing-income-rose-slightly-2011#:~:text=Institution%202011%20Research%20Expenditures%202011,966%2C817%2C063%2070%209%2067%2C362%2C185",
                  "text": "Institution 2011 Research Expenditures 2011 Patents Issued 2011 Startups 2011 Licensing Income Northwestern U. $484,149,349 67 8 $191,541,162 U. of California System 5,418,601,941 343 58 182,049,620 Columbia U. 714,343,087 88 15 146,319,455 New York U. 430,752,000 64 9 142,202,157 Princeton U. 192,940,000 33 4 115,206,000 Massachusetts Inst. of Technology (MIT) 1,490,429,000 174 25 76,120,000 U. of Washington/Wash. Res. Fdn. 966,817,063 70 9 67,362,185",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 16,
                    "cited_message_id": "6750f1a1-c6e9-4ce2-add0-9051920fa3a4",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 269,
                    "end_line_num": 277,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 8773,
                "end_ix": 8787,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "University licensing income rose slightly in 2011",
                  "url": "https://www.insidehighered.com/news/2012/08/28/university-licensing-income-rose-slightly-2011#:~:text=As%20has%20been%20true%20for,California%20system%20a%20close%20second",
                  "text": "As has been true for each of the past several years, Northwestern University brought in more licensing dollars from its research than did any other institution, at $191.5 million, with the University of California system a close second.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 16,
                    "cited_message_id": "6750f1a1-c6e9-4ce2-add0-9051920fa3a4",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 258,
                    "end_line_num": 266,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 8787,
                "end_ix": 8801,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "University licensing income rose slightly in 2011",
                  "url": "https://www.insidehighered.com/news/2012/08/28/university-licensing-income-rose-slightly-2011#:~:text=Institution%202011%20Research%20Expenditures%202011,966%2C817%2C063%2070%209%2067%2C362%2C185",
                  "text": "Institution 2011 Research Expenditures 2011 Patents Issued 2011 Startups 2011 Licensing Income Northwestern U. $484,149,349 67 8 $191,541,162 U. of California System 5,418,601,941 343 58 182,049,620 Columbia U. 714,343,087 88 15 146,319,455 New York U. 430,752,000 64 9 142,202,157 Princeton U. 192,940,000 33 4 115,206,000 Massachusetts Inst. of Technology (MIT) 1,490,429,000 174 25 76,120,000 U. of Washington/Wash. Res. Fdn. 966,817,063 70 9 67,362,185",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 16,
                    "cited_message_id": "6750f1a1-c6e9-4ce2-add0-9051920fa3a4",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 269,
                    "end_line_num": 277,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 8860,
                "end_ix": 8874,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "University licensing income rose slightly in 2011",
                  "url": "https://www.insidehighered.com/news/2012/08/28/university-licensing-income-rose-slightly-2011#:~:text=Institution%202011%20Research%20Expenditures%202011,966%2C817%2C063%2070%209%2067%2C362%2C185",
                  "text": "Institution 2011 Research Expenditures 2011 Patents Issued 2011 Startups 2011 Licensing Income Northwestern U. $484,149,349 67 8 $191,541,162 U. of California System 5,418,601,941 343 58 182,049,620 Columbia U. 714,343,087 88 15 146,319,455 New York U. 430,752,000 64 9 142,202,157 Princeton U. 192,940,000 33 4 115,206,000 Massachusetts Inst. of Technology (MIT) 1,490,429,000 174 25 76,120,000 U. of Washington/Wash. Res. Fdn. 966,817,063 70 9 67,362,185",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 16,
                    "cited_message_id": "6750f1a1-c6e9-4ce2-add0-9051920fa3a4",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 269,
                    "end_line_num": 277,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 9177,
                "end_ix": 9191,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "University licensing income rose slightly in 2011",
                  "url": "https://www.insidehighered.com/news/2012/08/28/university-licensing-income-rose-slightly-2011#:~:text=Institution%202011%20Research%20Expenditures%202011,966%2C817%2C063%2070%209%2067%2C362%2C185",
                  "text": "Institution 2011 Research Expenditures 2011 Patents Issued 2011 Startups 2011 Licensing Income Northwestern U. $484,149,349 67 8 $191,541,162 U. of California System 5,418,601,941 343 58 182,049,620 Columbia U. 714,343,087 88 15 146,319,455 New York U. 430,752,000 64 9 142,202,157 Princeton U. 192,940,000 33 4 115,206,000 Massachusetts Inst. of Technology (MIT) 1,490,429,000 174 25 76,120,000 U. of Washington/Wash. Res. Fdn. 966,817,063 70 9 67,362,185",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 16,
                    "cited_message_id": "6750f1a1-c6e9-4ce2-add0-9051920fa3a4",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 269,
                    "end_line_num": 277,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 9308,
                "end_ix": 9324,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "image_inline",
                  "asset_pointer_links": [],
                  "clicked_from_url": "https://www.greyb.com/blog/how-universities-can-generate-revenue/",
                  "clicked_from_title": "Patent Licensing - A Way for Universities to Generate More Revenue - GreyB"
                }
              },
              {
                "start_ix": 9548,
                "end_ix": 9562,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "University licensing income rose slightly in 2011",
                  "url": "https://www.insidehighered.com/news/2012/08/28/university-licensing-income-rose-slightly-2011#:~:text=As%20has%20been%20true%20for,California%20system%20a%20close%20second",
                  "text": "As has been true for each of the past several years, Northwestern University brought in more licensing dollars from its research than did any other institution, at $191.5 million, with the University of California system a close second.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 16,
                    "cited_message_id": "6750f1a1-c6e9-4ce2-add0-9051920fa3a4",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 258,
                    "end_line_num": 266,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 9562,
                "end_ix": 9576,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "University licensing income rose slightly in 2011",
                  "url": "https://www.insidehighered.com/news/2012/08/28/university-licensing-income-rose-slightly-2011#:~:text=Institution%202011%20Research%20Expenditures%202011,966%2C817%2C063%2070%209%2067%2C362%2C185",
                  "text": "Institution 2011 Research Expenditures 2011 Patents Issued 2011 Startups 2011 Licensing Income Northwestern U. $484,149,349 67 8 $191,541,162 U. of California System 5,418,601,941 343 58 182,049,620 Columbia U. 714,343,087 88 15 146,319,455 New York U. 430,752,000 64 9 142,202,157 Princeton U. 192,940,000 33 4 115,206,000 Massachusetts Inst. of Technology (MIT) 1,490,429,000 174 25 76,120,000 U. of Washington/Wash. Res. Fdn. 966,817,063 70 9 67,362,185",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 16,
                    "cited_message_id": "6750f1a1-c6e9-4ce2-add0-9051920fa3a4",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 269,
                    "end_line_num": 277,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 10073,
                "end_ix": 10083,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "2020 Licensing Survey - AUTM",
                  "url": "https://autm.net/surveys-and-tools/surveys/licensing-survey/2020-licensing-survey#:~:text=2020%20Licensing%20Survey%20,Universities%20are%20driving",
                  "text": "2020 Licensing Survey - AUTM 27,112 disclosures were reported in 2020, an increase of 6.8% over prior year. US patents rose to 8,706, a 15.6% year-over-year jump. Universities are driving ...",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 8,
                    "cited_message_id": "cb41f75c-6cd4-430d-9980-5eece209c668",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 9,
                    "end_line_num": 13,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 10928,
                "end_ix": 10939,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "[PDF] Dispelling Common Myths: Technology Transfer",
                  "url": "https://www.cogr.edu/sites/default/files/Myths_Final%2008-01-22.pdf#:~:text=,from%20the%202020%20AUTM",
                  "text": "[PDF] Dispelling Common Myths: Technology Transfer In 2020, five universities accounted for one-third of all licenses generating more than $1M in licensing revenue (calculated from the 2020 AUTM ...",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 8,
                    "cited_message_id": "cb41f75c-6cd4-430d-9980-5eece209c668",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 19,
                    "end_line_num": 27,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 12137,
                "end_ix": 12149,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                  "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=match%20at%20L211%20University,of%20global%20patent%20licensing%20revenues",
                  "text": "match at L211 University-held patents contribute to 15% of global patent licensing revenues.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 21,
                    "cited_message_id": "42ac99c7-f25f-4f21-8a5b-ffd136a3a471",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 53,
                    "end_line_num": 60,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 13137,
                "end_ix": 13150,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Study: Patent Trolls Cost Companies $29 Billion Last Year - The Atlantic",
                  "url": "https://www.theatlantic.com/technology/archive/2012/06/study-patent-trolls-cost-companies-29-billion-last-year/259070/#:~:text=In%20the%20past%2C%20Bessen%20and,such%20cases%20in%20recent%20years",
                  "text": "In the past, Bessen and Meurer write, NPEs provided a service to small inventors who could not on their own defend their patents. But for the most part, that is no longer the case. NPE litigation has been a booming industry in recent years -- particularly in the software industry -- reaching 2,150 unique companies facing litigation in nearly 6,000 cases instigated by NPEs in 2011. A chart from the paper shows the growth of such cases in recent years:",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 39,
                    "cited_message_id": "eec849e2-4b11-4be4-ad27-c374adfaf733",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 99,
                    "end_line_num": 107,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 13302,
                "end_ix": 13315,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Study: Patent Trolls Cost Companies $29 Billion Last Year - The Atlantic",
                  "url": "https://www.theatlantic.com/technology/archive/2012/06/study-patent-trolls-cost-companies-29-billion-last-year/259070/#:~:text=would%2C%20you%20know%2C%20want,is%20surely%20far%20greater",
                  "text": "would, you know, want. Rather, they use the patents to prevent other companies from creating goods or services that people might want. Lovely, really. The cost of this vital industry? $29 billion in 2011 alone, and that's just the direct legal costs, not even counting \"various indirect costs ... such as diversion of resources, delays in new products, and loss of market share.\" The loss for the economy overall -- in terms of immeasurable opportunities -- is surely far greater.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 39,
                    "cited_message_id": "eec849e2-4b11-4be4-ad27-c374adfaf733",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 92,
                    "end_line_num": 100,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 13471,
                "end_ix": 13485,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Study: Patent Trolls Cost Companies $29 Billion Last Year - The Atlantic",
                  "url": "https://www.theatlantic.com/technology/archive/2012/06/study-patent-trolls-cost-companies-29-billion-last-year/259070/#:~:text=In%20the%20past%2C%20Bessen%20and,such%20cases%20in%20recent%20years",
                  "text": "In the past, Bessen and Meurer write, NPEs provided a service to small inventors who could not on their own defend their patents. But for the most part, that is no longer the case. NPE litigation has been a booming industry in recent years -- particularly in the software industry -- reaching 2,150 unique companies facing litigation in nearly 6,000 cases instigated by NPEs in 2011. A chart from the paper shows the growth of such cases in recent years:",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 39,
                    "cited_message_id": "eec849e2-4b11-4be4-ad27-c374adfaf733",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 100,
                    "end_line_num": 108,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 14841,
                "end_ix": 14853,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Escaping the patent trolls: The impact of non\u2010practicing entity ...",
                  "url": "https://onlinelibrary.wiley.com/doi/10.1002/smj.3606#:~:text=Escaping%20the%20patent%20trolls%3A%20The,Cohen%20et",
                  "text": "Escaping the patent trolls: The impact of non\u2010practicing entity ... Bessen et al. (2011) find that NPE litigations have cost defendants about half a trillion US dollars of wealth between 1990 and 2010. Cohen et ...",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 25,
                    "cited_message_id": "619a0d4d-195e-4c73-9c4d-863351a01444",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 41,
                    "end_line_num": 45,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 16179,
                "end_ix": 16189,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "European Patent Litigation and Non-Practicing Entities: A Large and ...",
                  "url": "https://www.juve-patent.com/sponsored/unified-patents-llc/european-patent-litigation-and-non-practicing-entities-a-large-and-looming-threat/#:~:text=European%20Patent%20Litigation%20and%20Non,in%20Europe%2C%20with%20most%2C",
                  "text": "European Patent Litigation and Non-Practicing Entities: A Large and ... But while the US accounted for 97.2% of NPE infringement cases between 2012 and 2023, over 500 NPE cases were filed in Europe, with most, ...",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 22,
                    "cited_message_id": "b612e82e-0787-42e7-b02e-f67519f41997",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 5,
                    "end_line_num": 9,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 18321,
                "end_ix": 18333,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Technology Transfer - USPTO",
                  "url": "https://www.uspto.gov/ip-policy/patent-policy/technology-transfer#:~:text=Technology%20transfer%20is%20the%20process,other%20research%20institutions%20to%20industry",
                  "text": "Technology transfer is the process by which technology is transferred from federal labs, universities, or other research institutions to industry",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 34,
                    "cited_message_id": "946eee22-464e-4181-aec7-07d415416404",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 39,
                    "end_line_num": 45,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 18518,
                "end_ix": 18529,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "",
                  "url": "https://www.nist.gov/system/files/documents/2022/12/15/Federal%20Laboratory%20Technology%20Transfer%20Report_FY2020.pdf#:~:text=HHS%20accounted%20for%20the%20most,of%20reported",
                  "text": "HHS accounted for the most licensing income with $54 million, followed by DOE with $25 million, and DoD with $9 million. Together these three agencies accounted for 93% of reported",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 36,
                    "cited_message_id": "c1358b1a-1bd8-47dd-85cb-be6abf48400f",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 7,
                    "end_line_num": 14,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 18788,
                "end_ix": 18799,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "",
                  "url": "https://www.nist.gov/system/files/documents/2022/12/15/Federal%20Laboratory%20Technology%20Transfer%20Report_FY2020.pdf#:~:text=HHS%20accounted%20for%20the%20most,of%20reported",
                  "text": "HHS accounted for the most licensing income with $54 million, followed by DOE with $25 million, and DoD with $9 million. Together these three agencies accounted for 93% of reported",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 36,
                    "cited_message_id": "c1358b1a-1bd8-47dd-85cb-be6abf48400f",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 7,
                    "end_line_num": 14,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 22548,
                "end_ix": 22560,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                  "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=match%20at%20L200%20Royalty%20rates,of%20product%20revenues",
                  "text": "match at L200 Royalty rates for standard-essential patents (SEPs) range from 1% to 5% of product revenues.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 21,
                    "cited_message_id": "42ac99c7-f25f-4f21-8a5b-ffd136a3a471",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 47,
                    "end_line_num": 55,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 22679,
                "end_ix": 22691,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                  "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=match%20at%20L200%20Royalty%20rates,of%20product%20revenues",
                  "text": "match at L200 Royalty rates for standard-essential patents (SEPs) range from 1% to 5% of product revenues.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 21,
                    "cited_message_id": "42ac99c7-f25f-4f21-8a5b-ffd136a3a471",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 47,
                    "end_line_num": 55,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 27752,
                "end_ix": 27764,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Additional Resources | Tesla United Kingdom",
                  "url": "https://www.tesla.com/en_gb/legal/additional-resources#:~:text=Additional%20Resources%20,wants%20to%20use%20its%20technology",
                  "text": "Additional Resources | Tesla United Kingdom Patent Pledge\u200b\u200b On June 12, 2014, Tesla announced that it will not initiate patent lawsuits against anyone who, in good faith, wants to use its technology.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 33,
                    "cited_message_id": "b84de302-0ba3-4a19-9a91-4af82cdd916e",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 29,
                    "end_line_num": 36,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 29746,
                "end_ix": 29758,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "The Economics of the Pharmaceutical Sector: Innovation, Competition, and Patent Policy - R Street Institute",
                  "url": "https://www.rstreet.org/commentary/the-economics-of-the-pharmaceutical-sector-innovation-competition-and-patent-policy/#:~:text=Bringing%20a%20new%20drug%20to,initial%20discovery%20to%20regulatory%20approval",
                  "text": "Bringing a new drug to market is both costly and time-consuming. In 2023, the FDA approved 55 new drugs\u00a0(consistent with the average over the last five years of 53). Pharmaceutical companies invest billions of dollars\u00a0to identify new drug candidates, followed by extensive clinical trials to prove safety and efficacy as required by the U.S. Food and Drug Administration (FDA). The pharmaceutical industry spent $83 billion on research and development in 2019. Adding to this cost, drug development can take 10 to 15 years\u00a0from initial discovery to regulatory approval.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 40,
                    "cited_message_id": "ca69bf57-c7d9-4e93-aa43-332206ec57d4",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 83,
                    "end_line_num": 92,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 30079,
                "end_ix": 30091,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "The Economics of the Pharmaceutical Sector: Innovation, Competition, and Patent Policy - R Street Institute",
                  "url": "https://www.rstreet.org/commentary/the-economics-of-the-pharmaceutical-sector-innovation-competition-and-patent-policy/#:~:text=importing%20into%20the%20United%20States,protected%20monopolist",
                  "text": "importing into the United States the invention claimed.\u201d\u00a0Typically, patent protection lasts for 20 years\u2014a time limit that is set by statute. However, in the pharmaceutical industry, several years of that patent term are usually consumed by the clinical trial and regulatory review process. As a result, most new drugs have 12 to 15 years\u00a0of effective protection remaining by the time they reach the market. During this time, the drug manufacturer has no direct competitors and can collect above-market returns as a government- protected monopolist.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 40,
                    "cited_message_id": "ca69bf57-c7d9-4e93-aa43-332206ec57d4",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 64,
                    "end_line_num": 72,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 30715,
                "end_ix": 30727,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "U.S. Pharmaceutical Statistics - Mastermind Behavior Services",
                  "url": "https://www.mastermindbehavior.com/post/u-s-pharmaceutical-statistics-f78c9#:~:text=Services%20www,revenue%20generation%2C%20generic%20drugs",
                  "text": "Services www.mastermindbehavior.com  ... pharmaceutical landscape, accounting for 88.23% of total revenue ... Despite the dominance of branded drugs in revenue generation, generic drugs ...",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 17,
                    "cited_message_id": "943a5927-625a-4bc1-9b3b-65b44cdd1cbc",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 21,
                    "end_line_num": 24,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 30902,
                "end_ix": 30914,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "U.S. Pharmaceutical Statistics - Mastermind Behavior Services",
                  "url": "https://www.mastermindbehavior.com/post/u-s-pharmaceutical-statistics-f78c9#:~:text=Services%20www,revenue%20generation%2C%20generic%20drugs",
                  "text": "Services www.mastermindbehavior.com  ... pharmaceutical landscape, accounting for 88.23% of total revenue ... Despite the dominance of branded drugs in revenue generation, generic drugs ...",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 17,
                    "cited_message_id": "943a5927-625a-4bc1-9b3b-65b44cdd1cbc",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 21,
                    "end_line_num": 24,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 32975,
                "end_ix": 32989,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "The Economics of the Pharmaceutical Sector: Innovation, Competition, and Patent Policy - R Street Institute",
                  "url": "https://www.rstreet.org/commentary/the-economics-of-the-pharmaceutical-sector-innovation-competition-and-patent-policy/#:~:text=companies%20typically%20engage%20in%20product,extend%20a%20company%E2%80%99s%20monopoly%20position",
                  "text": "companies typically engage in product lifecycle strategies\u00a0that seek to extend market exclusivity and protect monopoly sales for as long as possible. These strategies may include developing new formulations or delivery methods for existing drugs, finding new indications or uses for approved therapies, or combining multiple drugs into one new product. While some of these modifications may offer useful innovations that benefit patients, others are simply evergreening tactics\u00a0with minimal therapeutic value that aim to extend a company\u2019s monopoly position.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 42,
                    "cited_message_id": "b0522b08-30ea-4f35-b9ef-4eb6e10ecab9",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 123,
                    "end_line_num": 131,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 33279,
                "end_ix": 33293,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "The Economics of the Pharmaceutical Sector: Innovation, Competition, and Patent Policy - R Street Institute",
                  "url": "https://www.rstreet.org/commentary/the-economics-of-the-pharmaceutical-sector-innovation-competition-and-patent-policy/#:~:text=%E2%80%9Cpatent%20cliff%2C%E2%80%9D%20where%20lower,and%20the%20threat%20of%20competition",
                  "text": "\u201cpatent cliff,\u201d where lower-cost generic rivals can enter the market and drive prices down to competitive levels. Once the market for a blockbuster drug becomes competitive, revenues may fall by as much as 79 percent. This dropoff in earning power poses a major threat to pharmaceutical companies\u2019 revenues, particularly when the drug goes off patent\u2014indeed, analysts project that more than $200 billion\u00a0in annual pharmaceutical revenue is at risk between now and 2030 due to expiring patents and the threat of competition.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 42,
                    "cited_message_id": "b0522b08-30ea-4f35-b9ef-4eb6e10ecab9",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 113,
                    "end_line_num": 120,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 33434,
                "end_ix": 33448,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "The Economics of the Pharmaceutical Sector: Innovation, Competition, and Patent Policy - R Street Institute",
                  "url": "https://www.rstreet.org/commentary/the-economics-of-the-pharmaceutical-sector-innovation-competition-and-patent-policy/#:~:text=for%20a%20blockbuster%20drug%20becomes,and%20the%20threat%20of%20competition",
                  "text": "for a blockbuster drug becomes competitive, revenues may fall by as much as 79 percent. This dropoff in earning power poses a major threat to pharmaceutical companies\u2019 revenues, particularly when the drug goes off patent\u2014indeed, analysts project that more than $200 billion\u00a0in annual pharmaceutical revenue is at risk between now and 2030 due to expiring patents and the threat of competition.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 42,
                    "cited_message_id": "b0522b08-30ea-4f35-b9ef-4eb6e10ecab9",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 115,
                    "end_line_num": 122,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 33577,
                "end_ix": 33591,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "The Economics of the Pharmaceutical Sector: Innovation, Competition, and Patent Policy - R Street Institute",
                  "url": "https://www.rstreet.org/commentary/the-economics-of-the-pharmaceutical-sector-innovation-competition-and-patent-policy/#:~:text=%E2%80%9Cpatent%20cliff%2C%E2%80%9D%20where%20lower,and%20the%20threat%20of%20competition",
                  "text": "\u201cpatent cliff,\u201d where lower-cost generic rivals can enter the market and drive prices down to competitive levels. Once the market for a blockbuster drug becomes competitive, revenues may fall by as much as 79 percent. This dropoff in earning power poses a major threat to pharmaceutical companies\u2019 revenues, particularly when the drug goes off patent\u2014indeed, analysts project that more than $200 billion\u00a0in annual pharmaceutical revenue is at risk between now and 2030 due to expiring patents and the threat of competition.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 42,
                    "cited_message_id": "b0522b08-30ea-4f35-b9ef-4eb6e10ecab9",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 113,
                    "end_line_num": 120,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 33843,
                "end_ix": 33857,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "The Economics of the Pharmaceutical Sector: Innovation, Competition, and Patent Policy - R Street Institute",
                  "url": "https://www.rstreet.org/commentary/the-economics-of-the-pharmaceutical-sector-innovation-competition-and-patent-policy/#:~:text=%E2%80%9Cpatent%20cliff%2C%E2%80%9D%20where%20lower,and%20the%20threat%20of%20competition",
                  "text": "\u201cpatent cliff,\u201d where lower-cost generic rivals can enter the market and drive prices down to competitive levels. Once the market for a blockbuster drug becomes competitive, revenues may fall by as much as 79 percent. This dropoff in earning power poses a major threat to pharmaceutical companies\u2019 revenues, particularly when the drug goes off patent\u2014indeed, analysts project that more than $200 billion\u00a0in annual pharmaceutical revenue is at risk between now and 2030 due to expiring patents and the threat of competition.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 42,
                    "cited_message_id": "b0522b08-30ea-4f35-b9ef-4eb6e10ecab9",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 113,
                    "end_line_num": 120,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 34427,
                "end_ix": 34439,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                  "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=The%20pharmaceutical%20industry%20represents%2025,of%20all%20patent%20licensing%20revenues",
                  "text": "The pharmaceutical industry represents 25% of all patent licensing revenues.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 21,
                    "cited_message_id": "42ac99c7-f25f-4f21-8a5b-ffd136a3a471",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 19,
                    "end_line_num": 24,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 34751,
                "end_ix": 34763,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                  "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=The%20biotechnology%20sector%E2%80%99s%20patent%20licensing,in%202023",
                  "text": "The biotechnology sector\u2019s patent licensing revenues increased by 18% in 2023.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 21,
                    "cited_message_id": "42ac99c7-f25f-4f21-8a5b-ffd136a3a471",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 67,
                    "end_line_num": 69,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 37535,
                "end_ix": 37548,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Buy or License Patents: How to build a better IP strategy",
                  "url": "https://parolaanalytics.com/buy-or-license-patents-how-to-build-a-better-ip-strategy/#:~:text=Microsoft%2C%20on%20the%20other%20hand%2C,the%20June%20quarter%20of%202018",
                  "text": "Microsoft, on the other hand, was reported in 2013 to have generated $2 billion per year in revenue from Android patent royalties. Similarly, Qualcomm derives a substantial portion of its profit from licensing its 130,000 mobile technology- related patents to device makers, having received around $950 million from royalties for the June quarter of 2018.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 7,
                    "cited_message_id": "372a3a04-9872-4953-a138-05dbd275dc52",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 151,
                    "end_line_num": 158,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 42196,
                "end_ix": 42209,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Buy or License Patents: How to build a better IP strategy",
                  "url": "https://parolaanalytics.com/buy-or-license-patents-how-to-build-a-better-ip-strategy/#:~:text=patents%20can%20also%20generate%20additional,total%20earnings%20of%20many%20companies",
                  "text": "patents can also generate additional revenues\u00a0for the company via, for example,\u00a0out-licensing. IBM, of course, is one of the most iconic serial licensers among technology companies. IBM is estimated to have garnered 88,000 patents over the years and is said to have collected about $20 billion or so of IP-related revenues. Over the 2008\u20132012 period, IBM\u2019s patent portfolio reportedly generated from $1.1 to $1.2 billion annually. Although its licensing income has dropped each year since then to around $740 million in 2014, this still represents an amount greater than the total earnings of many companies.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 7,
                    "cited_message_id": "372a3a04-9872-4953-a138-05dbd275dc52",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 142,
                    "end_line_num": 150,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 44750,
                "end_ix": 44759,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "A comparative IP management success story for Apple, Qualcomm ...",
                  "url": "https://ipbusinessacademy.org/a-comparative-ip-management-success-story-for-apple-qualcomm-and-ibm#:~:text=,2%20billion",
                  "text": "... ipbusinessacademy.org  Qualcomm reported total revenue of approximately $33 billion for fiscal year 2021, from which licensing revenue was approximately $8.2 billion.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 0,
                    "cited_message_id": "d6bfc899-87ad-44cd-89fd-f123e76ff80c",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 1,
                    "end_line_num": 4,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 44759,
                "end_ix": 44772,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Buy or License Patents: How to build a better IP strategy",
                  "url": "https://parolaanalytics.com/buy-or-license-patents-how-to-build-a-better-ip-strategy/#:~:text=Thus%2C%20it%20is%20quite%20likely,a%20mergers%20and%20acquisitions%20deal",
                  "text": "Thus, it is quite likely that a company\u2019s acquisition of third-party patent assets, mainly when they cover critical technologies, can similarly boost the company\u2019s market value before, for example, a mergers and acquisitions deal.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 5,
                    "cited_message_id": "391b1cb4-ee46-4a7e-9e91-62ffdb858046",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 132,
                    "end_line_num": 140,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 46928,
                "end_ix": 46941,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Buy or License Patents: How to build a better IP strategy",
                  "url": "https://parolaanalytics.com/buy-or-license-patents-how-to-build-a-better-ip-strategy/#:~:text=Microsoft%2C%20on%20the%20other%20hand%2C,the%20June%20quarter%20of%202018",
                  "text": "Microsoft, on the other hand, was reported in 2013 to have generated $2 billion per year in revenue from Android patent royalties. Similarly, Qualcomm derives a substantial portion of its profit from licensing its 130,000 mobile technology- related patents to device makers, having received around $950 million from royalties for the June quarter of 2018.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 7,
                    "cited_message_id": "372a3a04-9872-4953-a138-05dbd275dc52",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 151,
                    "end_line_num": 158,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 47112,
                "end_ix": 47123,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patenting for Profits - MIT Sloan Management Review",
                  "url": "https://sloanreview.mit.edu/article/patenting-for-profits/#:~:text=Altogether%2C%20IBM%20earns%20more%20than,from%20its%20vast%20patent%20portfolio",
                  "text": "Altogether, IBM earns more than $1 billion a year in licensing revenues from its vast patent portfolio.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 0,
                    "cited_message_id": "d6bfc899-87ad-44cd-89fd-f123e76ff80c",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 19,
                    "end_line_num": 26,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 47557,
                "end_ix": 47566,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "A comparative IP management success story for Apple, Qualcomm ...",
                  "url": "https://ipbusinessacademy.org/a-comparative-ip-management-success-story-for-apple-qualcomm-and-ibm#:~:text=,2%20billion",
                  "text": "... ipbusinessacademy.org  Qualcomm reported total revenue of approximately $33 billion for fiscal year 2021, from which licensing revenue was approximately $8.2 billion.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 0,
                    "cited_message_id": "d6bfc899-87ad-44cd-89fd-f123e76ff80c",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 1,
                    "end_line_num": 4,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 47566,
                "end_ix": 47577,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Commentary: University Technology Transfer Has Made a ...",
                  "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9170049/#:~:text=Commentary%3A%20University%20Technology%20Transfer%20Has,19%20pandemic",
                  "text": "Commentary: University Technology Transfer Has Made a ... This paper reviews the response by public sector research organizations and their technology transfer offices to the COVID-19 pandemic.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 8,
                    "cited_message_id": "cb41f75c-6cd4-430d-9980-5eece209c668",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 37,
                    "end_line_num": 41,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 49474,
                "end_ix": 49486,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                  "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=match%20at%20L154%20Patent%20licensing,in%202023",
                  "text": "match at L154 Patent licensing deals in the telecommunications sector grew by 12% in 2023.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 21,
                    "cited_message_id": "42ac99c7-f25f-4f21-8a5b-ffd136a3a471",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 29,
                    "end_line_num": 34,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 50976,
                "end_ix": 50988,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                  "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=match%20at%20L142%20Licensing%20fees,annually%20since%202020",
                  "text": "match at L142 Licensing fees for AI-related patents have increased by 15% annually since 2020.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 21,
                    "cited_message_id": "42ac99c7-f25f-4f21-8a5b-ffd136a3a471",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 23,
                    "end_line_num": 28,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 52609,
                "end_ix": 52621,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                  "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=match%20at%20L142%20Licensing%20fees,annually%20since%202020",
                  "text": "match at L142 Licensing fees for AI-related patents have increased by 15% annually since 2020.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 21,
                    "cited_message_id": "42ac99c7-f25f-4f21-8a5b-ffd136a3a471",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 23,
                    "end_line_num": 28,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 53691,
                "end_ix": 53703,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Additional Resources | Tesla United Kingdom",
                  "url": "https://www.tesla.com/en_gb/legal/additional-resources#:~:text=Additional%20Resources%20,wants%20to%20use%20its%20technology",
                  "text": "Additional Resources | Tesla United Kingdom Patent Pledge\u200b\u200b On June 12, 2014, Tesla announced that it will not initiate patent lawsuits against anyone who, in good faith, wants to use its technology.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 33,
                    "cited_message_id": "b84de302-0ba3-4a19-9a91-4af82cdd916e",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 29,
                    "end_line_num": 36,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 61033,
                "end_ix": 61043,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                  "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=24,the%20Medical%20Device%20Sector%20Changed",
                  "text": "24. How Has Patent Licensing in the Medical Device Sector Changed?",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 28,
                    "cited_message_id": "46068f0d-77f2-4885-8696-1103a874ee73",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 1,
                    "end_line_num": 9,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 64689,
                "end_ix": 64701,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                  "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=1,Expected%20to%20Be%20by%202024",
                  "text": "1. How Large is the Global Patent Licensing Market Expected to Be by 2024?",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 19,
                    "cited_message_id": "8f4a4529-18a2-4de8-8a33-dabc86758da4",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 79,
                    "end_line_num": 87,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 64859,
                "end_ix": 64871,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                  "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=2,of%20the%20Patent%20Licensing%20Market",
                  "text": "2. What is the Average Annual Growth Rate of the Patent Licensing Market?",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 19,
                    "cited_message_id": "8f4a4529-18a2-4de8-8a33-dabc86758da4",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 91,
                    "end_line_num": 99,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 65003,
                "end_ix": 65017,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                  "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=3,of%20Global%20Patent%20Licensing%20Deals",
                  "text": "3. Which Country Accounts for the Largest Share of Global Patent Licensing Deals?",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 19,
                    "cited_message_id": "8f4a4529-18a2-4de8-8a33-dabc86758da4",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 101,
                    "end_line_num": 109,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 65575,
                "end_ix": 65587,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                  "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=The%20pharmaceutical%20industry%20represents%2025,of%20all%20patent%20licensing%20revenues",
                  "text": "The pharmaceutical industry represents 25% of all patent licensing revenues.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 21,
                    "cited_message_id": "42ac99c7-f25f-4f21-8a5b-ffd136a3a471",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 19,
                    "end_line_num": 24,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 65735,
                "end_ix": 65747,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                  "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=match%20at%20L211%20University,of%20global%20patent%20licensing%20revenues",
                  "text": "match at L211 University-held patents contribute to 15% of global patent licensing revenues.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 21,
                    "cited_message_id": "42ac99c7-f25f-4f21-8a5b-ffd136a3a471",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 53,
                    "end_line_num": 60,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 66142,
                "end_ix": 66154,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                  "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=match%20at%20L189%20The%20Asia,patent%20licensing%20activities%20in%202023",
                  "text": "match at L189 The Asia-Pacific region saw a 10% increase in patent licensing activities in 2023.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 21,
                    "cited_message_id": "42ac99c7-f25f-4f21-8a5b-ffd136a3a471",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 41,
                    "end_line_num": 47,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 66428,
                "end_ix": 66440,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                  "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=match%20at%20L177%20Cross,of%20all%20patent%20licensing%20deals",
                  "text": "match at L177 Cross-licensing agreements constitute 20% of all patent licensing deals.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 21,
                    "cited_message_id": "42ac99c7-f25f-4f21-8a5b-ffd136a3a471",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 35,
                    "end_line_num": 41,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 69431,
                "end_ix": 69445,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Licensing - A Way for Universities to Generate More Revenue - GreyB",
                  "url": "https://www.greyb.com/blog/how-universities-can-generate-revenue/#:~:text=Few%20universities%20have%20strong%20IP,revenues%20of%20five%20other%20universities",
                  "text": "Few universities have strong IP departments and earn money by selling/licensing their patents. The University of California, with 4882 patents, earns ~$ $182 million from patent licensing. The graph below provides licensing revenues of five other universities.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 11,
                    "cited_message_id": "6c8d04f9-0e5c-4b0f-ab85-338a0b71c7a2",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 227,
                    "end_line_num": 235,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 70594,
                "end_ix": 70603,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "A comparative IP management success story for Apple, Qualcomm ...",
                  "url": "https://ipbusinessacademy.org/a-comparative-ip-management-success-story-for-apple-qualcomm-and-ibm#:~:text=,2%20billion",
                  "text": "... ipbusinessacademy.org  Qualcomm reported total revenue of approximately $33 billion for fiscal year 2021, from which licensing revenue was approximately $8.2 billion.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 0,
                    "cited_message_id": "d6bfc899-87ad-44cd-89fd-f123e76ff80c",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 1,
                    "end_line_num": 4,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 70679,
                "end_ix": 70692,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Buy or License Patents: How to build a better IP strategy",
                  "url": "https://parolaanalytics.com/buy-or-license-patents-how-to-build-a-better-ip-strategy/#:~:text=licensers%20among%20technology%20companies,total%20earnings%20of%20many%20companies",
                  "text": "licensers among technology companies. IBM is estimated to have garnered 88,000 patents over the years and is said to have collected about $20 billion or so of IP-related revenues. Over the 2008\u20132012 period, IBM\u2019s patent portfolio reportedly generated from $1.1 to $1.2 billion annually. Although its licensing income has dropped each year since then to around $740 million in 2014, this still represents an amount greater than the total earnings of many companies.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 7,
                    "cited_message_id": "372a3a04-9872-4953-a138-05dbd275dc52",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 144,
                    "end_line_num": 152,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 73802,
                "end_ix": 73815,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Buy or License Patents: How to build a better IP strategy",
                  "url": "https://parolaanalytics.com/buy-or-license-patents-how-to-build-a-better-ip-strategy/#:~:text=licensers%20among%20technology%20companies,total%20earnings%20of%20many%20companies",
                  "text": "licensers among technology companies. IBM is estimated to have garnered 88,000 patents over the years and is said to have collected about $20 billion or so of IP-related revenues. Over the 2008\u20132012 period, IBM\u2019s patent portfolio reportedly generated from $1.1 to $1.2 billion annually. Although its licensing income has dropped each year since then to around $740 million in 2014, this still represents an amount greater than the total earnings of many companies.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 7,
                    "cited_message_id": "372a3a04-9872-4953-a138-05dbd275dc52",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 144,
                    "end_line_num": 152,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 73874,
                "end_ix": 73883,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "A comparative IP management success story for Apple, Qualcomm ...",
                  "url": "https://ipbusinessacademy.org/a-comparative-ip-management-success-story-for-apple-qualcomm-and-ibm#:~:text=,2%20billion",
                  "text": "... ipbusinessacademy.org  Qualcomm reported total revenue of approximately $33 billion for fiscal year 2021, from which licensing revenue was approximately $8.2 billion.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 0,
                    "cited_message_id": "d6bfc899-87ad-44cd-89fd-f123e76ff80c",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 1,
                    "end_line_num": 4,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 74424,
                "end_ix": 74437,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Study: Patent Trolls Cost Companies $29 Billion Last Year - The Atlantic",
                  "url": "https://www.theatlantic.com/technology/archive/2012/06/study-patent-trolls-cost-companies-29-billion-last-year/259070/#:~:text=would%2C%20you%20know%2C%20want,is%20surely%20far%20greater",
                  "text": "would, you know, want. Rather, they use the patents to prevent other companies from creating goods or services that people might want. Lovely, really. The cost of this vital industry? $29 billion in 2011 alone, and that's just the direct legal costs, not even counting \"various indirect costs ... such as diversion of resources, delays in new products, and loss of market share.\" The loss for the economy overall -- in terms of immeasurable opportunities -- is surely far greater.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 39,
                    "cited_message_id": "eec849e2-4b11-4be4-ad27-c374adfaf733",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 92,
                    "end_line_num": 100,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 77926,
                "end_ix": 77938,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                  "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=1,Expected%20to%20Be%20by%202024",
                  "text": "1. How Large is the Global Patent Licensing Market Expected to Be by 2024?",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 19,
                    "cited_message_id": "8f4a4529-18a2-4de8-8a33-dabc86758da4",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 79,
                    "end_line_num": 87,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 79465,
                "end_ix": 79478,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Buy or License Patents: How to build a better IP strategy",
                  "url": "https://parolaanalytics.com/buy-or-license-patents-how-to-build-a-better-ip-strategy/#:~:text=patents%20can%20also%20generate%20additional,total%20earnings%20of%20many%20companies",
                  "text": "patents can also generate additional revenues\u00a0for the company via, for example,\u00a0out-licensing. IBM, of course, is one of the most iconic serial licensers among technology companies. IBM is estimated to have garnered 88,000 patents over the years and is said to have collected about $20 billion or so of IP-related revenues. Over the 2008\u20132012 period, IBM\u2019s patent portfolio reportedly generated from $1.1 to $1.2 billion annually. Although its licensing income has dropped each year since then to around $740 million in 2014, this still represents an amount greater than the total earnings of many companies.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 7,
                    "cited_message_id": "372a3a04-9872-4953-a138-05dbd275dc52",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 142,
                    "end_line_num": 150,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 79478,
                "end_ix": 79491,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Buy or License Patents: How to build a better IP strategy",
                  "url": "https://parolaanalytics.com/buy-or-license-patents-how-to-build-a-better-ip-strategy/#:~:text=Microsoft%2C%20on%20the%20other%20hand%2C,the%20June%20quarter%20of%202018",
                  "text": "Microsoft, on the other hand, was reported in 2013 to have generated $2 billion per year in revenue from Android patent royalties. Similarly, Qualcomm derives a substantial portion of its profit from licensing its 130,000 mobile technology- related patents to device makers, having received around $950 million from royalties for the June quarter of 2018.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 7,
                    "cited_message_id": "372a3a04-9872-4953-a138-05dbd275dc52",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 151,
                    "end_line_num": 158,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 79592,
                "end_ix": 79604,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                  "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=1,Expected%20to%20Be%20by%202024",
                  "text": "1. How Large is the Global Patent Licensing Market Expected to Be by 2024?",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 19,
                    "cited_message_id": "8f4a4529-18a2-4de8-8a33-dabc86758da4",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 79,
                    "end_line_num": 87,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 79604,
                "end_ix": 79616,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                  "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=The%20pharmaceutical%20industry%20represents%2025,of%20all%20patent%20licensing%20revenues",
                  "text": "The pharmaceutical industry represents 25% of all patent licensing revenues.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 21,
                    "cited_message_id": "42ac99c7-f25f-4f21-8a5b-ffd136a3a471",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 19,
                    "end_line_num": 27,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 79616,
                "end_ix": 79628,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                  "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=match%20at%20L211%20University,of%20global%20patent%20licensing%20revenues",
                  "text": "match at L211 University-held patents contribute to 15% of global patent licensing revenues.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 21,
                    "cited_message_id": "42ac99c7-f25f-4f21-8a5b-ffd136a3a471",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 53,
                    "end_line_num": 60,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 79710,
                "end_ix": 79724,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "University licensing income rose slightly in 2011",
                  "url": "https://www.insidehighered.com/news/2012/08/28/university-licensing-income-rose-slightly-2011#:~:text=As%20has%20been%20true%20for,California%20system%20a%20close%20second",
                  "text": "As has been true for each of the past several years, Northwestern University brought in more licensing dollars from its research than did any other institution, at $191.5 million, with the University of California system a close second.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 16,
                    "cited_message_id": "6750f1a1-c6e9-4ce2-add0-9051920fa3a4",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 258,
                    "end_line_num": 266,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 79724,
                "end_ix": 79738,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "University licensing income rose slightly in 2011",
                  "url": "https://www.insidehighered.com/news/2012/08/28/university-licensing-income-rose-slightly-2011#:~:text=Institution%202011%20Research%20Expenditures%202011,966%2C817%2C063%2070%209%2067%2C362%2C185",
                  "text": "Institution 2011 Research Expenditures 2011 Patents Issued 2011 Startups 2011 Licensing Income Northwestern U. $484,149,349 67 8 $191,541,162 U. of California System 5,418,601,941 343 58 182,049,620 Columbia U. 714,343,087 88 15 146,319,455 New York U. 430,752,000 64 9 142,202,157 Princeton U. 192,940,000 33 4 115,206,000 Massachusetts Inst. of Technology (MIT) 1,490,429,000 174 25 76,120,000 U. of Washington/Wash. Res. Fdn. 966,817,063 70 9 67,362,185",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 16,
                    "cited_message_id": "6750f1a1-c6e9-4ce2-add0-9051920fa3a4",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 269,
                    "end_line_num": 277,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 79817,
                "end_ix": 79831,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patent Licensing - A Way for Universities to Generate More Revenue - GreyB",
                  "url": "https://www.greyb.com/blog/how-universities-can-generate-revenue/#:~:text=Few%20universities%20have%20strong%20IP,revenues%20of%20five%20other%20universities",
                  "text": "Few universities have strong IP departments and earn money by selling/licensing their patents. The University of California, with 4882 patents, earns ~$ $182 million from patent licensing. The graph below provides licensing revenues of five other universities.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 11,
                    "cited_message_id": "6c8d04f9-0e5c-4b0f-ab85-338a0b71c7a2",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 227,
                    "end_line_num": 235,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 79913,
                "end_ix": 79924,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "",
                  "url": "https://www.nist.gov/system/files/documents/2022/12/15/Federal%20Laboratory%20Technology%20Transfer%20Report_FY2020.pdf#:~:text=HHS%20accounted%20for%20the%20most,of%20reported",
                  "text": "HHS accounted for the most licensing income with $54 million, followed by DOE with $25 million, and DoD with $9 million. Together these three agencies accounted for 93% of reported",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 36,
                    "cited_message_id": "c1358b1a-1bd8-47dd-85cb-be6abf48400f",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 7,
                    "end_line_num": 14,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 79999,
                "end_ix": 80012,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Study: Patent Trolls Cost Companies $29 Billion Last Year - The Atlantic",
                  "url": "https://www.theatlantic.com/technology/archive/2012/06/study-patent-trolls-cost-companies-29-billion-last-year/259070/#:~:text=would%2C%20you%20know%2C%20want,is%20surely%20far%20greater",
                  "text": "would, you know, want. Rather, they use the patents to prevent other companies from creating goods or services that people might want. Lovely, really. The cost of this vital industry? $29 billion in 2011 alone, and that's just the direct legal costs, not even counting \"various indirect costs ... such as diversion of resources, delays in new products, and loss of market share.\" The loss for the economy overall -- in terms of immeasurable opportunities -- is surely far greater.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 39,
                    "cited_message_id": "eec849e2-4b11-4be4-ad27-c374adfaf733",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 92,
                    "end_line_num": 100,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 80012,
                "end_ix": 80026,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Study: Patent Trolls Cost Companies $29 Billion Last Year - The Atlantic",
                  "url": "https://www.theatlantic.com/technology/archive/2012/06/study-patent-trolls-cost-companies-29-billion-last-year/259070/#:~:text=In%20the%20past%2C%20Bessen%20and,such%20cases%20in%20recent%20years",
                  "text": "In the past, Bessen and Meurer write, NPEs provided a service to small inventors who could not on their own defend their patents. But for the most part, that is no longer the case. NPE litigation has been a booming industry in recent years -- particularly in the software industry -- reaching 2,150 unique companies facing litigation in nearly 6,000 cases instigated by NPEs in 2011. A chart from the paper shows the growth of such cases in recent years:",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 39,
                    "cited_message_id": "eec849e2-4b11-4be4-ad27-c374adfaf733",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 100,
                    "end_line_num": 108,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 80120,
                "end_ix": 80134,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "The Economics of the Pharmaceutical Sector: Innovation, Competition, and Patent Policy - R Street Institute",
                  "url": "https://www.rstreet.org/commentary/the-economics-of-the-pharmaceutical-sector-innovation-competition-and-patent-policy/#:~:text=%E2%80%9Cpatent%20cliff%2C%E2%80%9D%20where%20lower,and%20the%20threat%20of%20competition",
                  "text": "\u201cpatent cliff,\u201d where lower-cost generic rivals can enter the market and drive prices down to competitive levels. Once the market for a blockbuster drug becomes competitive, revenues may fall by as much as 79 percent. This dropoff in earning power poses a major threat to pharmaceutical companies\u2019 revenues, particularly when the drug goes off patent\u2014indeed, analysts project that more than $200 billion\u00a0in annual pharmaceutical revenue is at risk between now and 2030 due to expiring patents and the threat of competition.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 42,
                    "cited_message_id": "b0522b08-30ea-4f35-b9ef-4eb6e10ecab9",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 113,
                    "end_line_num": 120,
                    "connector_source": null
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 80203,
                "end_ix": 80212,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "A comparative IP management success story for Apple, Qualcomm ...",
                  "url": "https://ipbusinessacademy.org/a-comparative-ip-management-success-story-for-apple-qualcomm-and-ibm#:~:text=,2%20billion",
                  "text": "... ipbusinessacademy.org  Qualcomm reported total revenue of approximately $33 billion for fiscal year 2021, from which licensing revenue was approximately $8.2 billion.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 0,
                    "cited_message_id": "d6bfc899-87ad-44cd-89fd-f123e76ff80c",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 1,
                    "end_line_num": 4,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              },
              {
                "start_ix": 80269,
                "end_ix": 80280,
                "citation_format_type": "tether_v4",
                "metadata": {
                  "type": "webpage",
                  "title": "Patenting for Profits - MIT Sloan Management Review",
                  "url": "https://sloanreview.mit.edu/article/patenting-for-profits/#:~:text=Altogether%2C%20IBM%20earns%20more%20than,from%20its%20vast%20patent%20portfolio",
                  "text": "Altogether, IBM earns more than $1 billion a year in licensing revenues from its vast patent portfolio.",
                  "pub_date": null,
                  "extra": {
                    "cited_message_idx": 0,
                    "cited_message_id": "d6bfc899-87ad-44cd-89fd-f123e76ff80c",
                    "search_result_idx": null,
                    "evidence_text": "",
                    "start_line_num": 19,
                    "end_line_num": 26,
                    "connector_source": ""
                  },
                  "og_tags": null
                }
              }
            ],
            "content_references": [
              {
                "matched_text": "\u301040\u2020L60-L68\u3011",
                "start_idx": 2598,
                "end_idx": 2610,
                "alt": null,
                "type": "webpage_extended",
                "title": "The Economics of the Pharmaceutical Sector: Innovation, Competition, and Patent Policy - R Street Institute",
                "url": "https://www.rstreet.org/commentary/the-economics-of-the-pharmaceutical-sector-innovation-competition-and-patent-policy/#:~:text=Given%20the%20substantial%20investments%20and,15%20years%C2%A0of%20effective%20protection%20remaining",
                "pub_date": null,
                "snippet": "Given the substantial investments and risks involved in drug development, patents have come to play a prominent role in the pharmaceutical-industry business model. Patents provide their owners with the power to \u201cexclude others\u00a0from making, using, offering for sale, selling, or importing into the United States the invention claimed.\u201d\u00a0Typically, patent protection lasts for 20 years\u2014a time limit that is set by statute. However, in the pharmaceutical industry, several years of that patent term are usually consumed by the clinical trial and regulatory review process. As a result, most new drugs have 12 to 15 years\u00a0of effective protection remaining",
                "attribution": "rstreet.org",
                "icon_type": null
              },
              {
                "matched_text": "\u301042\u2020L113-L120\u3011",
                "start_idx": 2610,
                "end_idx": 2624,
                "alt": null,
                "type": "webpage_extended",
                "title": "The Economics of the Pharmaceutical Sector: Innovation, Competition, and Patent Policy - R Street Institute",
                "url": "https://www.rstreet.org/commentary/the-economics-of-the-pharmaceutical-sector-innovation-competition-and-patent-policy/#:~:text=%E2%80%9Cpatent%20cliff%2C%E2%80%9D%20where%20lower,and%20the%20threat%20of%20competition",
                "pub_date": null,
                "snippet": "\u201cpatent cliff,\u201d where lower-cost generic rivals can enter the market and drive prices down to competitive levels. Once the market for a blockbuster drug becomes competitive, revenues may fall by as much as 79 percent. This dropoff in earning power poses a major threat to pharmaceutical companies\u2019 revenues, particularly when the drug goes off patent\u2014indeed, analysts project that more than $200 billion\u00a0in annual pharmaceutical revenue is at risk between now and 2030 due to expiring patents and the threat of competition.",
                "attribution": "rstreet.org",
                "icon_type": null
              },
              {
                "matched_text": "\u301030\u2020L158-L166\u3011",
                "start_idx": 3096,
                "end_idx": 3110,
                "alt": null,
                "type": "webpage_extended",
                "title": "Smartphone patent wars - Wikipedia",
                "url": "https://en.wikipedia.org/wiki/Smartphone_patent_wars#:~:text=To%20secure%20and%20increase%20market,71",
                "pub_date": null,
                "snippet": "To secure and increase market share , companies granted a  73 can sue to prevent competitors from using the methods the patent covers. Since 2010 the number of lawsuits, counter-suits , and trade complaints based on patents and  75 in the market for smartphones, and devices based on smartphone OSes  such as  77 and iOS , has increased significantly.[ 71]",
                "attribution": "en.wikipedia.org",
                "icon_type": null
              },
              {
                "matched_text": "\u301021\u2020L35-L41\u3011",
                "start_idx": 3292,
                "end_idx": 3304,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=match%20at%20L177%20Cross,of%20all%20patent%20licensing%20deals",
                "pub_date": null,
                "snippet": "match at L177 Cross-licensing agreements constitute 20% of all patent licensing deals.",
                "attribution": "patentpc.com",
                "icon_type": null
              },
              {
                "matched_text": "\u30107\u2020L142-L150\u3011",
                "start_idx": 3888,
                "end_idx": 3901,
                "alt": null,
                "type": "webpage_extended",
                "title": "Buy or License Patents: How to build a better IP strategy",
                "url": "https://parolaanalytics.com/buy-or-license-patents-how-to-build-a-better-ip-strategy/#:~:text=patents%20can%20also%20generate%20additional,total%20earnings%20of%20many%20companies",
                "pub_date": null,
                "snippet": "patents can also generate additional revenues\u00a0for the company via, for example,\u00a0out-licensing. IBM, of course, is one of the most iconic serial licensers among technology companies. IBM is estimated to have garnered 88,000 patents over the years and is said to have collected about $20 billion or so of IP-related revenues. Over the 2008\u20132012 period, IBM\u2019s patent portfolio reportedly generated from $1.1 to $1.2 billion annually. Although its licensing income has dropped each year since then to around $740 million in 2014, this still represents an amount greater than the total earnings of many companies.",
                "attribution": "parolaanalytics.com",
                "icon_type": null
              },
              {
                "matched_text": "\u30107\u2020L144-L152\u3011",
                "start_idx": 4114,
                "end_idx": 4127,
                "alt": null,
                "type": "webpage_extended",
                "title": "Buy or License Patents: How to build a better IP strategy",
                "url": "https://parolaanalytics.com/buy-or-license-patents-how-to-build-a-better-ip-strategy/#:~:text=licensers%20among%20technology%20companies,total%20earnings%20of%20many%20companies",
                "pub_date": null,
                "snippet": "licensers among technology companies. IBM is estimated to have garnered 88,000 patents over the years and is said to have collected about $20 billion or so of IP-related revenues. Over the 2008\u20132012 period, IBM\u2019s patent portfolio reportedly generated from $1.1 to $1.2 billion annually. Although its licensing income has dropped each year since then to around $740 million in 2014, this still represents an amount greater than the total earnings of many companies.",
                "attribution": "parolaanalytics.com",
                "icon_type": null
              },
              {
                "matched_text": "\u30107\u2020L151-L158\u3011",
                "start_idx": 4286,
                "end_idx": 4299,
                "alt": null,
                "type": "webpage_extended",
                "title": "Buy or License Patents: How to build a better IP strategy",
                "url": "https://parolaanalytics.com/buy-or-license-patents-how-to-build-a-better-ip-strategy/#:~:text=Microsoft%2C%20on%20the%20other%20hand%2C,the%20June%20quarter%20of%202018",
                "pub_date": null,
                "snippet": "Microsoft, on the other hand, was reported in 2013 to have generated $2 billion per year in revenue from Android patent royalties. Similarly, Qualcomm derives a substantial portion of its profit from licensing its 130,000 mobile technology- related patents to device makers, having received around $950 million from royalties for the June quarter of 2018.",
                "attribution": "parolaanalytics.com",
                "icon_type": null
              },
              {
                "matched_text": "\u30100\u2020L1-L4\u3011",
                "start_idx": 4674,
                "end_idx": 4683,
                "alt": null,
                "type": "webpage_extended",
                "title": "A comparative IP management success story for Apple, Qualcomm ...",
                "url": "https://ipbusinessacademy.org/a-comparative-ip-management-success-story-for-apple-qualcomm-and-ibm#:~:text=,2%20billion",
                "pub_date": null,
                "snippet": "... ipbusinessacademy.org  Qualcomm reported total revenue of approximately $33 billion for fiscal year 2021, from which licensing revenue was approximately $8.2 billion.",
                "attribution": "ipbusinessacademy.org",
                "icon_type": null
              },
              {
                "matched_text": "\u30107\u2020L151-L158\u3011",
                "start_idx": 4894,
                "end_idx": 4907,
                "alt": null,
                "type": "webpage_extended",
                "title": "Buy or License Patents: How to build a better IP strategy",
                "url": "https://parolaanalytics.com/buy-or-license-patents-how-to-build-a-better-ip-strategy/#:~:text=Microsoft%2C%20on%20the%20other%20hand%2C,the%20June%20quarter%20of%202018",
                "pub_date": null,
                "snippet": "Microsoft, on the other hand, was reported in 2013 to have generated $2 billion per year in revenue from Android patent royalties. Similarly, Qualcomm derives a substantial portion of its profit from licensing its 130,000 mobile technology- related patents to device makers, having received around $950 million from royalties for the June quarter of 2018.",
                "attribution": "parolaanalytics.com",
                "icon_type": null
              },
              {
                "matched_text": "\u30107\u2020L142-L150\u3011",
                "start_idx": 5573,
                "end_idx": 5586,
                "alt": null,
                "type": "webpage_extended",
                "title": "Buy or License Patents: How to build a better IP strategy",
                "url": "https://parolaanalytics.com/buy-or-license-patents-how-to-build-a-better-ip-strategy/#:~:text=patents%20can%20also%20generate%20additional,total%20earnings%20of%20many%20companies",
                "pub_date": null,
                "snippet": "patents can also generate additional revenues\u00a0for the company via, for example,\u00a0out-licensing. IBM, of course, is one of the most iconic serial licensers among technology companies. IBM is estimated to have garnered 88,000 patents over the years and is said to have collected about $20 billion or so of IP-related revenues. Over the 2008\u20132012 period, IBM\u2019s patent portfolio reportedly generated from $1.1 to $1.2 billion annually. Although its licensing income has dropped each year since then to around $740 million in 2014, this still represents an amount greater than the total earnings of many companies.",
                "attribution": "parolaanalytics.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301021\u2020L11-L19\u3011",
                "start_idx": 5803,
                "end_idx": 5815,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=match%20at%20L116%20In%202023%2C,engaged%20in%20patent%20licensing%20agreements",
                "pub_date": null,
                "snippet": "match at L116 In 2023, over 40% of tech companies engaged in patent licensing agreements.",
                "attribution": "patentpc.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301021\u2020L59-L66\u3011",
                "start_idx": 7039,
                "end_idx": 7051,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=match%20at%20L225%20Startups%20account,licensing%20deals%20in%20emerging%20technologies",
                "pub_date": null,
                "snippet": "match at L225 Startups account for 30% of new patent licensing deals in emerging technologies.",
                "attribution": "patentpc.com",
                "icon_type": null
              },
              {
                "matched_text": "\u30108\u2020L3-L8\u3011",
                "start_idx": 8044,
                "end_idx": 8053,
                "alt": null,
                "type": "webpage_extended",
                "title": "The Evolution of University Technology Transfer: By the Numbers",
                "url": "https://ipwatchdog.com/2020/04/07/evolution-university-technology-transfer/id=120451/#:~:text=The%20Evolution%20of%20University%20Technology,academic%20inventions%20to%20market%2C",
                "pub_date": null,
                "snippet": "The Evolution of University Technology Transfer: By the Numbers Approximately $2.94 billion in licensing revenue was generated in 2018 directly from the process of taking academic inventions to market, ...",
                "attribution": "ipwatchdog.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301016\u2020L258-L266\u3011",
                "start_idx": 8619,
                "end_idx": 8633,
                "alt": null,
                "type": "webpage_extended",
                "title": "University licensing income rose slightly in 2011",
                "url": "https://www.insidehighered.com/news/2012/08/28/university-licensing-income-rose-slightly-2011#:~:text=As%20has%20been%20true%20for,California%20system%20a%20close%20second",
                "pub_date": null,
                "snippet": "As has been true for each of the past several years, Northwestern University brought in more licensing dollars from its research than did any other institution, at $191.5 million, with the University of California system a close second.",
                "attribution": "insidehighered.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301016\u2020L269-L277\u3011",
                "start_idx": 8633,
                "end_idx": 8647,
                "alt": null,
                "type": "webpage_extended",
                "title": "University licensing income rose slightly in 2011",
                "url": "https://www.insidehighered.com/news/2012/08/28/university-licensing-income-rose-slightly-2011#:~:text=Institution%202011%20Research%20Expenditures%202011,966%2C817%2C063%2070%209%2067%2C362%2C185",
                "pub_date": null,
                "snippet": "Institution 2011 Research Expenditures 2011 Patents Issued 2011 Startups 2011 Licensing Income Northwestern U. $484,149,349 67 8 $191,541,162 U. of California System 5,418,601,941 343 58 182,049,620 Columbia U. 714,343,087 88 15 146,319,455 New York U. 430,752,000 64 9 142,202,157 Princeton U. 192,940,000 33 4 115,206,000 Massachusetts Inst. of Technology (MIT) 1,490,429,000 174 25 76,120,000 U. of Washington/Wash. Res. Fdn. 966,817,063 70 9 67,362,185",
                "attribution": "insidehighered.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301016\u2020L258-L266\u3011",
                "start_idx": 8773,
                "end_idx": 8787,
                "alt": null,
                "type": "webpage_extended",
                "title": "University licensing income rose slightly in 2011",
                "url": "https://www.insidehighered.com/news/2012/08/28/university-licensing-income-rose-slightly-2011#:~:text=As%20has%20been%20true%20for,California%20system%20a%20close%20second",
                "pub_date": null,
                "snippet": "As has been true for each of the past several years, Northwestern University brought in more licensing dollars from its research than did any other institution, at $191.5 million, with the University of California system a close second.",
                "attribution": "insidehighered.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301016\u2020L269-L277\u3011",
                "start_idx": 8787,
                "end_idx": 8801,
                "alt": null,
                "type": "webpage_extended",
                "title": "University licensing income rose slightly in 2011",
                "url": "https://www.insidehighered.com/news/2012/08/28/university-licensing-income-rose-slightly-2011#:~:text=Institution%202011%20Research%20Expenditures%202011,966%2C817%2C063%2070%209%2067%2C362%2C185",
                "pub_date": null,
                "snippet": "Institution 2011 Research Expenditures 2011 Patents Issued 2011 Startups 2011 Licensing Income Northwestern U. $484,149,349 67 8 $191,541,162 U. of California System 5,418,601,941 343 58 182,049,620 Columbia U. 714,343,087 88 15 146,319,455 New York U. 430,752,000 64 9 142,202,157 Princeton U. 192,940,000 33 4 115,206,000 Massachusetts Inst. of Technology (MIT) 1,490,429,000 174 25 76,120,000 U. of Washington/Wash. Res. Fdn. 966,817,063 70 9 67,362,185",
                "attribution": "insidehighered.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301016\u2020L269-L277\u3011",
                "start_idx": 8860,
                "end_idx": 8874,
                "alt": null,
                "type": "webpage_extended",
                "title": "University licensing income rose slightly in 2011",
                "url": "https://www.insidehighered.com/news/2012/08/28/university-licensing-income-rose-slightly-2011#:~:text=Institution%202011%20Research%20Expenditures%202011,966%2C817%2C063%2070%209%2067%2C362%2C185",
                "pub_date": null,
                "snippet": "Institution 2011 Research Expenditures 2011 Patents Issued 2011 Startups 2011 Licensing Income Northwestern U. $484,149,349 67 8 $191,541,162 U. of California System 5,418,601,941 343 58 182,049,620 Columbia U. 714,343,087 88 15 146,319,455 New York U. 430,752,000 64 9 142,202,157 Princeton U. 192,940,000 33 4 115,206,000 Massachusetts Inst. of Technology (MIT) 1,490,429,000 174 25 76,120,000 U. of Washington/Wash. Res. Fdn. 966,817,063 70 9 67,362,185",
                "attribution": "insidehighered.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301016\u2020L269-L277\u3011",
                "start_idx": 9177,
                "end_idx": 9191,
                "alt": null,
                "type": "webpage_extended",
                "title": "University licensing income rose slightly in 2011",
                "url": "https://www.insidehighered.com/news/2012/08/28/university-licensing-income-rose-slightly-2011#:~:text=Institution%202011%20Research%20Expenditures%202011,966%2C817%2C063%2070%209%2067%2C362%2C185",
                "pub_date": null,
                "snippet": "Institution 2011 Research Expenditures 2011 Patents Issued 2011 Startups 2011 Licensing Income Northwestern U. $484,149,349 67 8 $191,541,162 U. of California System 5,418,601,941 343 58 182,049,620 Columbia U. 714,343,087 88 15 146,319,455 New York U. 430,752,000 64 9 142,202,157 Princeton U. 192,940,000 33 4 115,206,000 Massachusetts Inst. of Technology (MIT) 1,490,429,000 174 25 76,120,000 U. of Washington/Wash. Res. Fdn. 966,817,063 70 9 67,362,185",
                "attribution": "insidehighered.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301026\u2020embed_image\u3011",
                "start_idx": 9308,
                "end_idx": 9324,
                "alt": null,
                "type": "image_inline",
                "asset_pointer_links": [],
                "clicked_from_url": "https://www.greyb.com/blog/how-universities-can-generate-revenue/",
                "clicked_from_title": "Patent Licensing - A Way for Universities to Generate More Revenue - GreyB"
              },
              {
                "matched_text": "\u301016\u2020L258-L266\u3011",
                "start_idx": 9548,
                "end_idx": 9562,
                "alt": null,
                "type": "webpage_extended",
                "title": "University licensing income rose slightly in 2011",
                "url": "https://www.insidehighered.com/news/2012/08/28/university-licensing-income-rose-slightly-2011#:~:text=As%20has%20been%20true%20for,California%20system%20a%20close%20second",
                "pub_date": null,
                "snippet": "As has been true for each of the past several years, Northwestern University brought in more licensing dollars from its research than did any other institution, at $191.5 million, with the University of California system a close second.",
                "attribution": "insidehighered.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301016\u2020L269-L277\u3011",
                "start_idx": 9562,
                "end_idx": 9576,
                "alt": null,
                "type": "webpage_extended",
                "title": "University licensing income rose slightly in 2011",
                "url": "https://www.insidehighered.com/news/2012/08/28/university-licensing-income-rose-slightly-2011#:~:text=Institution%202011%20Research%20Expenditures%202011,966%2C817%2C063%2070%209%2067%2C362%2C185",
                "pub_date": null,
                "snippet": "Institution 2011 Research Expenditures 2011 Patents Issued 2011 Startups 2011 Licensing Income Northwestern U. $484,149,349 67 8 $191,541,162 U. of California System 5,418,601,941 343 58 182,049,620 Columbia U. 714,343,087 88 15 146,319,455 New York U. 430,752,000 64 9 142,202,157 Princeton U. 192,940,000 33 4 115,206,000 Massachusetts Inst. of Technology (MIT) 1,490,429,000 174 25 76,120,000 U. of Washington/Wash. Res. Fdn. 966,817,063 70 9 67,362,185",
                "attribution": "insidehighered.com",
                "icon_type": null
              },
              {
                "matched_text": "\u30108\u2020L9-L13\u3011",
                "start_idx": 10073,
                "end_idx": 10083,
                "alt": null,
                "type": "webpage_extended",
                "title": "2020 Licensing Survey - AUTM",
                "url": "https://autm.net/surveys-and-tools/surveys/licensing-survey/2020-licensing-survey#:~:text=2020%20Licensing%20Survey%20,Universities%20are%20driving",
                "pub_date": null,
                "snippet": "2020 Licensing Survey - AUTM 27,112 disclosures were reported in 2020, an increase of 6.8% over prior year. US patents rose to 8,706, a 15.6% year-over-year jump. Universities are driving ...",
                "attribution": "autm.net",
                "icon_type": null
              },
              {
                "matched_text": "\u30108\u2020L19-L27\u3011",
                "start_idx": 10928,
                "end_idx": 10939,
                "alt": null,
                "type": "webpage_extended",
                "title": "[PDF] Dispelling Common Myths: Technology Transfer",
                "url": "https://www.cogr.edu/sites/default/files/Myths_Final%2008-01-22.pdf#:~:text=,from%20the%202020%20AUTM",
                "pub_date": null,
                "snippet": "[PDF] Dispelling Common Myths: Technology Transfer In 2020, five universities accounted for one-third of all licenses generating more than $1M in licensing revenue (calculated from the 2020 AUTM ...",
                "attribution": "cogr.edu",
                "icon_type": null
              },
              {
                "matched_text": "\u301021\u2020L53-L60\u3011",
                "start_idx": 12137,
                "end_idx": 12149,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=match%20at%20L211%20University,of%20global%20patent%20licensing%20revenues",
                "pub_date": null,
                "snippet": "match at L211 University-held patents contribute to 15% of global patent licensing revenues.",
                "attribution": "patentpc.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301039\u2020L99-L107\u3011",
                "start_idx": 13137,
                "end_idx": 13150,
                "alt": null,
                "type": "webpage_extended",
                "title": "Study: Patent Trolls Cost Companies $29 Billion Last Year - The Atlantic",
                "url": "https://www.theatlantic.com/technology/archive/2012/06/study-patent-trolls-cost-companies-29-billion-last-year/259070/#:~:text=In%20the%20past%2C%20Bessen%20and,such%20cases%20in%20recent%20years",
                "pub_date": null,
                "snippet": "In the past, Bessen and Meurer write, NPEs provided a service to small inventors who could not on their own defend their patents. But for the most part, that is no longer the case. NPE litigation has been a booming industry in recent years -- particularly in the software industry -- reaching 2,150 unique companies facing litigation in nearly 6,000 cases instigated by NPEs in 2011. A chart from the paper shows the growth of such cases in recent years:",
                "attribution": "theatlantic.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301039\u2020L92-L100\u3011",
                "start_idx": 13302,
                "end_idx": 13315,
                "alt": null,
                "type": "webpage_extended",
                "title": "Study: Patent Trolls Cost Companies $29 Billion Last Year - The Atlantic",
                "url": "https://www.theatlantic.com/technology/archive/2012/06/study-patent-trolls-cost-companies-29-billion-last-year/259070/#:~:text=would%2C%20you%20know%2C%20want,is%20surely%20far%20greater",
                "pub_date": null,
                "snippet": "would, you know, want. Rather, they use the patents to prevent other companies from creating goods or services that people might want. Lovely, really. The cost of this vital industry? $29 billion in 2011 alone, and that's just the direct legal costs, not even counting \"various indirect costs ... such as diversion of resources, delays in new products, and loss of market share.\" The loss for the economy overall -- in terms of immeasurable opportunities -- is surely far greater.",
                "attribution": "theatlantic.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301039\u2020L100-L108\u3011",
                "start_idx": 13471,
                "end_idx": 13485,
                "alt": null,
                "type": "webpage_extended",
                "title": "Study: Patent Trolls Cost Companies $29 Billion Last Year - The Atlantic",
                "url": "https://www.theatlantic.com/technology/archive/2012/06/study-patent-trolls-cost-companies-29-billion-last-year/259070/#:~:text=In%20the%20past%2C%20Bessen%20and,such%20cases%20in%20recent%20years",
                "pub_date": null,
                "snippet": "In the past, Bessen and Meurer write, NPEs provided a service to small inventors who could not on their own defend their patents. But for the most part, that is no longer the case. NPE litigation has been a booming industry in recent years -- particularly in the software industry -- reaching 2,150 unique companies facing litigation in nearly 6,000 cases instigated by NPEs in 2011. A chart from the paper shows the growth of such cases in recent years:",
                "attribution": "theatlantic.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301025\u2020L41-L45\u3011",
                "start_idx": 14841,
                "end_idx": 14853,
                "alt": null,
                "type": "webpage_extended",
                "title": "Escaping the patent trolls: The impact of non\u2010practicing entity ...",
                "url": "https://onlinelibrary.wiley.com/doi/10.1002/smj.3606#:~:text=Escaping%20the%20patent%20trolls%3A%20The,Cohen%20et",
                "pub_date": null,
                "snippet": "Escaping the patent trolls: The impact of non\u2010practicing entity ... Bessen et al. (2011) find that NPE litigations have cost defendants about half a trillion US dollars of wealth between 1990 and 2010. Cohen et ...",
                "attribution": "onlinelibrary.wiley.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301022\u2020L5-L9\u3011",
                "start_idx": 16179,
                "end_idx": 16189,
                "alt": null,
                "type": "webpage_extended",
                "title": "European Patent Litigation and Non-Practicing Entities: A Large and ...",
                "url": "https://www.juve-patent.com/sponsored/unified-patents-llc/european-patent-litigation-and-non-practicing-entities-a-large-and-looming-threat/#:~:text=European%20Patent%20Litigation%20and%20Non,in%20Europe%2C%20with%20most%2C",
                "pub_date": null,
                "snippet": "European Patent Litigation and Non-Practicing Entities: A Large and ... But while the US accounted for 97.2% of NPE infringement cases between 2012 and 2023, over 500 NPE cases were filed in Europe, with most, ...",
                "attribution": "juve-patent.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301034\u2020L39-L45\u3011",
                "start_idx": 18321,
                "end_idx": 18333,
                "alt": null,
                "type": "webpage_extended",
                "title": "Technology Transfer - USPTO",
                "url": "https://www.uspto.gov/ip-policy/patent-policy/technology-transfer#:~:text=Technology%20transfer%20is%20the%20process,other%20research%20institutions%20to%20industry",
                "pub_date": null,
                "snippet": "Technology transfer is the process by which technology is transferred from federal labs, universities, or other research institutions to industry",
                "attribution": "uspto.gov",
                "icon_type": null
              },
              {
                "matched_text": "\u301036\u2020L7-L14\u3011",
                "start_idx": 18518,
                "end_idx": 18529,
                "alt": null,
                "type": "webpage_extended",
                "title": "",
                "url": "https://www.nist.gov/system/files/documents/2022/12/15/Federal%20Laboratory%20Technology%20Transfer%20Report_FY2020.pdf#:~:text=HHS%20accounted%20for%20the%20most,of%20reported",
                "pub_date": null,
                "snippet": "HHS accounted for the most licensing income with $54 million, followed by DOE with $25 million, and DoD with $9 million. Together these three agencies accounted for 93% of reported",
                "attribution": "nist.gov",
                "icon_type": null
              },
              {
                "matched_text": "\u301036\u2020L7-L14\u3011",
                "start_idx": 18788,
                "end_idx": 18799,
                "alt": null,
                "type": "webpage_extended",
                "title": "",
                "url": "https://www.nist.gov/system/files/documents/2022/12/15/Federal%20Laboratory%20Technology%20Transfer%20Report_FY2020.pdf#:~:text=HHS%20accounted%20for%20the%20most,of%20reported",
                "pub_date": null,
                "snippet": "HHS accounted for the most licensing income with $54 million, followed by DOE with $25 million, and DoD with $9 million. Together these three agencies accounted for 93% of reported",
                "attribution": "nist.gov",
                "icon_type": null
              },
              {
                "matched_text": "\u301021\u2020L47-L55\u3011",
                "start_idx": 22548,
                "end_idx": 22560,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=match%20at%20L200%20Royalty%20rates,of%20product%20revenues",
                "pub_date": null,
                "snippet": "match at L200 Royalty rates for standard-essential patents (SEPs) range from 1% to 5% of product revenues.",
                "attribution": "patentpc.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301021\u2020L47-L55\u3011",
                "start_idx": 22679,
                "end_idx": 22691,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=match%20at%20L200%20Royalty%20rates,of%20product%20revenues",
                "pub_date": null,
                "snippet": "match at L200 Royalty rates for standard-essential patents (SEPs) range from 1% to 5% of product revenues.",
                "attribution": "patentpc.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301033\u2020L29-L36\u3011",
                "start_idx": 27752,
                "end_idx": 27764,
                "alt": null,
                "type": "webpage_extended",
                "title": "Additional Resources | Tesla United Kingdom",
                "url": "https://www.tesla.com/en_gb/legal/additional-resources#:~:text=Additional%20Resources%20,wants%20to%20use%20its%20technology",
                "pub_date": null,
                "snippet": "Additional Resources | Tesla United Kingdom Patent Pledge\u200b\u200b On June 12, 2014, Tesla announced that it will not initiate patent lawsuits against anyone who, in good faith, wants to use its technology.",
                "attribution": "tesla.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301040\u2020L83-L92\u3011",
                "start_idx": 29746,
                "end_idx": 29758,
                "alt": null,
                "type": "webpage_extended",
                "title": "The Economics of the Pharmaceutical Sector: Innovation, Competition, and Patent Policy - R Street Institute",
                "url": "https://www.rstreet.org/commentary/the-economics-of-the-pharmaceutical-sector-innovation-competition-and-patent-policy/#:~:text=Bringing%20a%20new%20drug%20to,initial%20discovery%20to%20regulatory%20approval",
                "pub_date": null,
                "snippet": "Bringing a new drug to market is both costly and time-consuming. In 2023, the FDA approved 55 new drugs\u00a0(consistent with the average over the last five years of 53). Pharmaceutical companies invest billions of dollars\u00a0to identify new drug candidates, followed by extensive clinical trials to prove safety and efficacy as required by the U.S. Food and Drug Administration (FDA). The pharmaceutical industry spent $83 billion on research and development in 2019. Adding to this cost, drug development can take 10 to 15 years\u00a0from initial discovery to regulatory approval.",
                "attribution": "rstreet.org",
                "icon_type": null
              },
              {
                "matched_text": "\u301040\u2020L64-L72\u3011",
                "start_idx": 30079,
                "end_idx": 30091,
                "alt": null,
                "type": "webpage_extended",
                "title": "The Economics of the Pharmaceutical Sector: Innovation, Competition, and Patent Policy - R Street Institute",
                "url": "https://www.rstreet.org/commentary/the-economics-of-the-pharmaceutical-sector-innovation-competition-and-patent-policy/#:~:text=importing%20into%20the%20United%20States,protected%20monopolist",
                "pub_date": null,
                "snippet": "importing into the United States the invention claimed.\u201d\u00a0Typically, patent protection lasts for 20 years\u2014a time limit that is set by statute. However, in the pharmaceutical industry, several years of that patent term are usually consumed by the clinical trial and regulatory review process. As a result, most new drugs have 12 to 15 years\u00a0of effective protection remaining by the time they reach the market. During this time, the drug manufacturer has no direct competitors and can collect above-market returns as a government- protected monopolist.",
                "attribution": "rstreet.org",
                "icon_type": null
              },
              {
                "matched_text": "\u301017\u2020L21-L24\u3011",
                "start_idx": 30715,
                "end_idx": 30727,
                "alt": null,
                "type": "webpage_extended",
                "title": "U.S. Pharmaceutical Statistics - Mastermind Behavior Services",
                "url": "https://www.mastermindbehavior.com/post/u-s-pharmaceutical-statistics-f78c9#:~:text=Services%20www,revenue%20generation%2C%20generic%20drugs",
                "pub_date": null,
                "snippet": "Services www.mastermindbehavior.com  ... pharmaceutical landscape, accounting for 88.23% of total revenue ... Despite the dominance of branded drugs in revenue generation, generic drugs ...",
                "attribution": "mastermindbehavior.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301017\u2020L21-L24\u3011",
                "start_idx": 30902,
                "end_idx": 30914,
                "alt": null,
                "type": "webpage_extended",
                "title": "U.S. Pharmaceutical Statistics - Mastermind Behavior Services",
                "url": "https://www.mastermindbehavior.com/post/u-s-pharmaceutical-statistics-f78c9#:~:text=Services%20www,revenue%20generation%2C%20generic%20drugs",
                "pub_date": null,
                "snippet": "Services www.mastermindbehavior.com  ... pharmaceutical landscape, accounting for 88.23% of total revenue ... Despite the dominance of branded drugs in revenue generation, generic drugs ...",
                "attribution": "mastermindbehavior.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301042\u2020L123-L131\u3011",
                "start_idx": 32975,
                "end_idx": 32989,
                "alt": null,
                "type": "webpage_extended",
                "title": "The Economics of the Pharmaceutical Sector: Innovation, Competition, and Patent Policy - R Street Institute",
                "url": "https://www.rstreet.org/commentary/the-economics-of-the-pharmaceutical-sector-innovation-competition-and-patent-policy/#:~:text=companies%20typically%20engage%20in%20product,extend%20a%20company%E2%80%99s%20monopoly%20position",
                "pub_date": null,
                "snippet": "companies typically engage in product lifecycle strategies\u00a0that seek to extend market exclusivity and protect monopoly sales for as long as possible. These strategies may include developing new formulations or delivery methods for existing drugs, finding new indications or uses for approved therapies, or combining multiple drugs into one new product. While some of these modifications may offer useful innovations that benefit patients, others are simply evergreening tactics\u00a0with minimal therapeutic value that aim to extend a company\u2019s monopoly position.",
                "attribution": "rstreet.org",
                "icon_type": null
              },
              {
                "matched_text": "\u301042\u2020L113-L120\u3011",
                "start_idx": 33279,
                "end_idx": 33293,
                "alt": null,
                "type": "webpage_extended",
                "title": "The Economics of the Pharmaceutical Sector: Innovation, Competition, and Patent Policy - R Street Institute",
                "url": "https://www.rstreet.org/commentary/the-economics-of-the-pharmaceutical-sector-innovation-competition-and-patent-policy/#:~:text=%E2%80%9Cpatent%20cliff%2C%E2%80%9D%20where%20lower,and%20the%20threat%20of%20competition",
                "pub_date": null,
                "snippet": "\u201cpatent cliff,\u201d where lower-cost generic rivals can enter the market and drive prices down to competitive levels. Once the market for a blockbuster drug becomes competitive, revenues may fall by as much as 79 percent. This dropoff in earning power poses a major threat to pharmaceutical companies\u2019 revenues, particularly when the drug goes off patent\u2014indeed, analysts project that more than $200 billion\u00a0in annual pharmaceutical revenue is at risk between now and 2030 due to expiring patents and the threat of competition.",
                "attribution": "rstreet.org",
                "icon_type": null
              },
              {
                "matched_text": "\u301042\u2020L115-L122\u3011",
                "start_idx": 33434,
                "end_idx": 33448,
                "alt": null,
                "type": "webpage_extended",
                "title": "The Economics of the Pharmaceutical Sector: Innovation, Competition, and Patent Policy - R Street Institute",
                "url": "https://www.rstreet.org/commentary/the-economics-of-the-pharmaceutical-sector-innovation-competition-and-patent-policy/#:~:text=for%20a%20blockbuster%20drug%20becomes,and%20the%20threat%20of%20competition",
                "pub_date": null,
                "snippet": "for a blockbuster drug becomes competitive, revenues may fall by as much as 79 percent. This dropoff in earning power poses a major threat to pharmaceutical companies\u2019 revenues, particularly when the drug goes off patent\u2014indeed, analysts project that more than $200 billion\u00a0in annual pharmaceutical revenue is at risk between now and 2030 due to expiring patents and the threat of competition.",
                "attribution": "rstreet.org",
                "icon_type": null
              },
              {
                "matched_text": "\u301042\u2020L113-L120\u3011",
                "start_idx": 33577,
                "end_idx": 33591,
                "alt": null,
                "type": "webpage_extended",
                "title": "The Economics of the Pharmaceutical Sector: Innovation, Competition, and Patent Policy - R Street Institute",
                "url": "https://www.rstreet.org/commentary/the-economics-of-the-pharmaceutical-sector-innovation-competition-and-patent-policy/#:~:text=%E2%80%9Cpatent%20cliff%2C%E2%80%9D%20where%20lower,and%20the%20threat%20of%20competition",
                "pub_date": null,
                "snippet": "\u201cpatent cliff,\u201d where lower-cost generic rivals can enter the market and drive prices down to competitive levels. Once the market for a blockbuster drug becomes competitive, revenues may fall by as much as 79 percent. This dropoff in earning power poses a major threat to pharmaceutical companies\u2019 revenues, particularly when the drug goes off patent\u2014indeed, analysts project that more than $200 billion\u00a0in annual pharmaceutical revenue is at risk between now and 2030 due to expiring patents and the threat of competition.",
                "attribution": "rstreet.org",
                "icon_type": null
              },
              {
                "matched_text": "\u301042\u2020L113-L120\u3011",
                "start_idx": 33843,
                "end_idx": 33857,
                "alt": null,
                "type": "webpage_extended",
                "title": "The Economics of the Pharmaceutical Sector: Innovation, Competition, and Patent Policy - R Street Institute",
                "url": "https://www.rstreet.org/commentary/the-economics-of-the-pharmaceutical-sector-innovation-competition-and-patent-policy/#:~:text=%E2%80%9Cpatent%20cliff%2C%E2%80%9D%20where%20lower,and%20the%20threat%20of%20competition",
                "pub_date": null,
                "snippet": "\u201cpatent cliff,\u201d where lower-cost generic rivals can enter the market and drive prices down to competitive levels. Once the market for a blockbuster drug becomes competitive, revenues may fall by as much as 79 percent. This dropoff in earning power poses a major threat to pharmaceutical companies\u2019 revenues, particularly when the drug goes off patent\u2014indeed, analysts project that more than $200 billion\u00a0in annual pharmaceutical revenue is at risk between now and 2030 due to expiring patents and the threat of competition.",
                "attribution": "rstreet.org",
                "icon_type": null
              },
              {
                "matched_text": "\u301021\u2020L19-L24\u3011",
                "start_idx": 34427,
                "end_idx": 34439,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=The%20pharmaceutical%20industry%20represents%2025,of%20all%20patent%20licensing%20revenues",
                "pub_date": null,
                "snippet": "The pharmaceutical industry represents 25% of all patent licensing revenues.",
                "attribution": "patentpc.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301021\u2020L67-L69\u3011",
                "start_idx": 34751,
                "end_idx": 34763,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=The%20biotechnology%20sector%E2%80%99s%20patent%20licensing,in%202023",
                "pub_date": null,
                "snippet": "The biotechnology sector\u2019s patent licensing revenues increased by 18% in 2023.",
                "attribution": "patentpc.com",
                "icon_type": null
              },
              {
                "matched_text": "\u30107\u2020L151-L158\u3011",
                "start_idx": 37535,
                "end_idx": 37548,
                "alt": null,
                "type": "webpage_extended",
                "title": "Buy or License Patents: How to build a better IP strategy",
                "url": "https://parolaanalytics.com/buy-or-license-patents-how-to-build-a-better-ip-strategy/#:~:text=Microsoft%2C%20on%20the%20other%20hand%2C,the%20June%20quarter%20of%202018",
                "pub_date": null,
                "snippet": "Microsoft, on the other hand, was reported in 2013 to have generated $2 billion per year in revenue from Android patent royalties. Similarly, Qualcomm derives a substantial portion of its profit from licensing its 130,000 mobile technology- related patents to device makers, having received around $950 million from royalties for the June quarter of 2018.",
                "attribution": "parolaanalytics.com",
                "icon_type": null
              },
              {
                "matched_text": "\u30107\u2020L142-L150\u3011",
                "start_idx": 42196,
                "end_idx": 42209,
                "alt": null,
                "type": "webpage_extended",
                "title": "Buy or License Patents: How to build a better IP strategy",
                "url": "https://parolaanalytics.com/buy-or-license-patents-how-to-build-a-better-ip-strategy/#:~:text=patents%20can%20also%20generate%20additional,total%20earnings%20of%20many%20companies",
                "pub_date": null,
                "snippet": "patents can also generate additional revenues\u00a0for the company via, for example,\u00a0out-licensing. IBM, of course, is one of the most iconic serial licensers among technology companies. IBM is estimated to have garnered 88,000 patents over the years and is said to have collected about $20 billion or so of IP-related revenues. Over the 2008\u20132012 period, IBM\u2019s patent portfolio reportedly generated from $1.1 to $1.2 billion annually. Although its licensing income has dropped each year since then to around $740 million in 2014, this still represents an amount greater than the total earnings of many companies.",
                "attribution": "parolaanalytics.com",
                "icon_type": null
              },
              {
                "matched_text": "\u30100\u2020L1-L4\u3011",
                "start_idx": 44750,
                "end_idx": 44759,
                "alt": null,
                "type": "webpage_extended",
                "title": "A comparative IP management success story for Apple, Qualcomm ...",
                "url": "https://ipbusinessacademy.org/a-comparative-ip-management-success-story-for-apple-qualcomm-and-ibm#:~:text=,2%20billion",
                "pub_date": null,
                "snippet": "... ipbusinessacademy.org  Qualcomm reported total revenue of approximately $33 billion for fiscal year 2021, from which licensing revenue was approximately $8.2 billion.",
                "attribution": "ipbusinessacademy.org",
                "icon_type": null
              },
              {
                "matched_text": "\u30105\u2020L132-L140\u3011",
                "start_idx": 44759,
                "end_idx": 44772,
                "alt": null,
                "type": "webpage_extended",
                "title": "Buy or License Patents: How to build a better IP strategy",
                "url": "https://parolaanalytics.com/buy-or-license-patents-how-to-build-a-better-ip-strategy/#:~:text=Thus%2C%20it%20is%20quite%20likely,a%20mergers%20and%20acquisitions%20deal",
                "pub_date": null,
                "snippet": "Thus, it is quite likely that a company\u2019s acquisition of third-party patent assets, mainly when they cover critical technologies, can similarly boost the company\u2019s market value before, for example, a mergers and acquisitions deal.",
                "attribution": "parolaanalytics.com",
                "icon_type": null
              },
              {
                "matched_text": "\u30107\u2020L151-L158\u3011",
                "start_idx": 46928,
                "end_idx": 46941,
                "alt": null,
                "type": "webpage_extended",
                "title": "Buy or License Patents: How to build a better IP strategy",
                "url": "https://parolaanalytics.com/buy-or-license-patents-how-to-build-a-better-ip-strategy/#:~:text=Microsoft%2C%20on%20the%20other%20hand%2C,the%20June%20quarter%20of%202018",
                "pub_date": null,
                "snippet": "Microsoft, on the other hand, was reported in 2013 to have generated $2 billion per year in revenue from Android patent royalties. Similarly, Qualcomm derives a substantial portion of its profit from licensing its 130,000 mobile technology- related patents to device makers, having received around $950 million from royalties for the June quarter of 2018.",
                "attribution": "parolaanalytics.com",
                "icon_type": null
              },
              {
                "matched_text": "\u30100\u2020L19-L26\u3011",
                "start_idx": 47112,
                "end_idx": 47123,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patenting for Profits - MIT Sloan Management Review",
                "url": "https://sloanreview.mit.edu/article/patenting-for-profits/#:~:text=Altogether%2C%20IBM%20earns%20more%20than,from%20its%20vast%20patent%20portfolio",
                "pub_date": null,
                "snippet": "Altogether, IBM earns more than $1 billion a year in licensing revenues from its vast patent portfolio.",
                "attribution": "sloanreview.mit.edu",
                "icon_type": null
              },
              {
                "matched_text": "\u30100\u2020L1-L4\u3011",
                "start_idx": 47557,
                "end_idx": 47566,
                "alt": null,
                "type": "webpage_extended",
                "title": "A comparative IP management success story for Apple, Qualcomm ...",
                "url": "https://ipbusinessacademy.org/a-comparative-ip-management-success-story-for-apple-qualcomm-and-ibm#:~:text=,2%20billion",
                "pub_date": null,
                "snippet": "... ipbusinessacademy.org  Qualcomm reported total revenue of approximately $33 billion for fiscal year 2021, from which licensing revenue was approximately $8.2 billion.",
                "attribution": "ipbusinessacademy.org",
                "icon_type": null
              },
              {
                "matched_text": "\u30108\u2020L37-L41\u3011",
                "start_idx": 47566,
                "end_idx": 47577,
                "alt": null,
                "type": "webpage_extended",
                "title": "Commentary: University Technology Transfer Has Made a ...",
                "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9170049/#:~:text=Commentary%3A%20University%20Technology%20Transfer%20Has,19%20pandemic",
                "pub_date": null,
                "snippet": "Commentary: University Technology Transfer Has Made a ... This paper reviews the response by public sector research organizations and their technology transfer offices to the COVID-19 pandemic.",
                "attribution": "pmc.ncbi.nlm.nih.gov",
                "icon_type": null
              },
              {
                "matched_text": "\u301021\u2020L29-L34\u3011",
                "start_idx": 49474,
                "end_idx": 49486,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=match%20at%20L154%20Patent%20licensing,in%202023",
                "pub_date": null,
                "snippet": "match at L154 Patent licensing deals in the telecommunications sector grew by 12% in 2023.",
                "attribution": "patentpc.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301021\u2020L23-L28\u3011",
                "start_idx": 50976,
                "end_idx": 50988,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=match%20at%20L142%20Licensing%20fees,annually%20since%202020",
                "pub_date": null,
                "snippet": "match at L142 Licensing fees for AI-related patents have increased by 15% annually since 2020.",
                "attribution": "patentpc.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301021\u2020L23-L28\u3011",
                "start_idx": 52609,
                "end_idx": 52621,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=match%20at%20L142%20Licensing%20fees,annually%20since%202020",
                "pub_date": null,
                "snippet": "match at L142 Licensing fees for AI-related patents have increased by 15% annually since 2020.",
                "attribution": "patentpc.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301033\u2020L29-L36\u3011",
                "start_idx": 53691,
                "end_idx": 53703,
                "alt": null,
                "type": "webpage_extended",
                "title": "Additional Resources | Tesla United Kingdom",
                "url": "https://www.tesla.com/en_gb/legal/additional-resources#:~:text=Additional%20Resources%20,wants%20to%20use%20its%20technology",
                "pub_date": null,
                "snippet": "Additional Resources | Tesla United Kingdom Patent Pledge\u200b\u200b On June 12, 2014, Tesla announced that it will not initiate patent lawsuits against anyone who, in good faith, wants to use its technology.",
                "attribution": "tesla.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301028\u2020L1-L9\u3011",
                "start_idx": 61033,
                "end_idx": 61043,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=24,the%20Medical%20Device%20Sector%20Changed",
                "pub_date": null,
                "snippet": "24. How Has Patent Licensing in the Medical Device Sector Changed?",
                "attribution": "patentpc.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301019\u2020L79-L87\u3011",
                "start_idx": 64689,
                "end_idx": 64701,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=1,Expected%20to%20Be%20by%202024",
                "pub_date": null,
                "snippet": "1. How Large is the Global Patent Licensing Market Expected to Be by 2024?",
                "attribution": "patentpc.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301019\u2020L91-L99\u3011",
                "start_idx": 64859,
                "end_idx": 64871,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=2,of%20the%20Patent%20Licensing%20Market",
                "pub_date": null,
                "snippet": "2. What is the Average Annual Growth Rate of the Patent Licensing Market?",
                "attribution": "patentpc.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301019\u2020L101-L109\u3011",
                "start_idx": 65003,
                "end_idx": 65017,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=3,of%20Global%20Patent%20Licensing%20Deals",
                "pub_date": null,
                "snippet": "3. Which Country Accounts for the Largest Share of Global Patent Licensing Deals?",
                "attribution": "patentpc.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301021\u2020L19-L24\u3011",
                "start_idx": 65575,
                "end_idx": 65587,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=The%20pharmaceutical%20industry%20represents%2025,of%20all%20patent%20licensing%20revenues",
                "pub_date": null,
                "snippet": "The pharmaceutical industry represents 25% of all patent licensing revenues.",
                "attribution": "patentpc.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301021\u2020L53-L60\u3011",
                "start_idx": 65735,
                "end_idx": 65747,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=match%20at%20L211%20University,of%20global%20patent%20licensing%20revenues",
                "pub_date": null,
                "snippet": "match at L211 University-held patents contribute to 15% of global patent licensing revenues.",
                "attribution": "patentpc.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301021\u2020L41-L47\u3011",
                "start_idx": 66142,
                "end_idx": 66154,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=match%20at%20L189%20The%20Asia,patent%20licensing%20activities%20in%202023",
                "pub_date": null,
                "snippet": "match at L189 The Asia-Pacific region saw a 10% increase in patent licensing activities in 2023.",
                "attribution": "patentpc.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301021\u2020L35-L41\u3011",
                "start_idx": 66428,
                "end_idx": 66440,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=match%20at%20L177%20Cross,of%20all%20patent%20licensing%20deals",
                "pub_date": null,
                "snippet": "match at L177 Cross-licensing agreements constitute 20% of all patent licensing deals.",
                "attribution": "patentpc.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301011\u2020L227-L235\u3011",
                "start_idx": 69431,
                "end_idx": 69445,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Licensing - A Way for Universities to Generate More Revenue - GreyB",
                "url": "https://www.greyb.com/blog/how-universities-can-generate-revenue/#:~:text=Few%20universities%20have%20strong%20IP,revenues%20of%20five%20other%20universities",
                "pub_date": null,
                "snippet": "Few universities have strong IP departments and earn money by selling/licensing their patents. The University of California, with 4882 patents, earns ~$ $182 million from patent licensing. The graph below provides licensing revenues of five other universities.",
                "attribution": "greyb.com",
                "icon_type": null
              },
              {
                "matched_text": "\u30100\u2020L1-L4\u3011",
                "start_idx": 70594,
                "end_idx": 70603,
                "alt": null,
                "type": "webpage_extended",
                "title": "A comparative IP management success story for Apple, Qualcomm ...",
                "url": "https://ipbusinessacademy.org/a-comparative-ip-management-success-story-for-apple-qualcomm-and-ibm#:~:text=,2%20billion",
                "pub_date": null,
                "snippet": "... ipbusinessacademy.org  Qualcomm reported total revenue of approximately $33 billion for fiscal year 2021, from which licensing revenue was approximately $8.2 billion.",
                "attribution": "ipbusinessacademy.org",
                "icon_type": null
              },
              {
                "matched_text": "\u30107\u2020L144-L152\u3011",
                "start_idx": 70679,
                "end_idx": 70692,
                "alt": null,
                "type": "webpage_extended",
                "title": "Buy or License Patents: How to build a better IP strategy",
                "url": "https://parolaanalytics.com/buy-or-license-patents-how-to-build-a-better-ip-strategy/#:~:text=licensers%20among%20technology%20companies,total%20earnings%20of%20many%20companies",
                "pub_date": null,
                "snippet": "licensers among technology companies. IBM is estimated to have garnered 88,000 patents over the years and is said to have collected about $20 billion or so of IP-related revenues. Over the 2008\u20132012 period, IBM\u2019s patent portfolio reportedly generated from $1.1 to $1.2 billion annually. Although its licensing income has dropped each year since then to around $740 million in 2014, this still represents an amount greater than the total earnings of many companies.",
                "attribution": "parolaanalytics.com",
                "icon_type": null
              },
              {
                "matched_text": "\u30107\u2020L144-L152\u3011",
                "start_idx": 73802,
                "end_idx": 73815,
                "alt": null,
                "type": "webpage_extended",
                "title": "Buy or License Patents: How to build a better IP strategy",
                "url": "https://parolaanalytics.com/buy-or-license-patents-how-to-build-a-better-ip-strategy/#:~:text=licensers%20among%20technology%20companies,total%20earnings%20of%20many%20companies",
                "pub_date": null,
                "snippet": "licensers among technology companies. IBM is estimated to have garnered 88,000 patents over the years and is said to have collected about $20 billion or so of IP-related revenues. Over the 2008\u20132012 period, IBM\u2019s patent portfolio reportedly generated from $1.1 to $1.2 billion annually. Although its licensing income has dropped each year since then to around $740 million in 2014, this still represents an amount greater than the total earnings of many companies.",
                "attribution": "parolaanalytics.com",
                "icon_type": null
              },
              {
                "matched_text": "\u30100\u2020L1-L4\u3011",
                "start_idx": 73874,
                "end_idx": 73883,
                "alt": null,
                "type": "webpage_extended",
                "title": "A comparative IP management success story for Apple, Qualcomm ...",
                "url": "https://ipbusinessacademy.org/a-comparative-ip-management-success-story-for-apple-qualcomm-and-ibm#:~:text=,2%20billion",
                "pub_date": null,
                "snippet": "... ipbusinessacademy.org  Qualcomm reported total revenue of approximately $33 billion for fiscal year 2021, from which licensing revenue was approximately $8.2 billion.",
                "attribution": "ipbusinessacademy.org",
                "icon_type": null
              },
              {
                "matched_text": "\u301039\u2020L92-L100\u3011",
                "start_idx": 74424,
                "end_idx": 74437,
                "alt": null,
                "type": "webpage_extended",
                "title": "Study: Patent Trolls Cost Companies $29 Billion Last Year - The Atlantic",
                "url": "https://www.theatlantic.com/technology/archive/2012/06/study-patent-trolls-cost-companies-29-billion-last-year/259070/#:~:text=would%2C%20you%20know%2C%20want,is%20surely%20far%20greater",
                "pub_date": null,
                "snippet": "would, you know, want. Rather, they use the patents to prevent other companies from creating goods or services that people might want. Lovely, really. The cost of this vital industry? $29 billion in 2011 alone, and that's just the direct legal costs, not even counting \"various indirect costs ... such as diversion of resources, delays in new products, and loss of market share.\" The loss for the economy overall -- in terms of immeasurable opportunities -- is surely far greater.",
                "attribution": "theatlantic.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301019\u2020L79-L87\u3011",
                "start_idx": 77926,
                "end_idx": 77938,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=1,Expected%20to%20Be%20by%202024",
                "pub_date": null,
                "snippet": "1. How Large is the Global Patent Licensing Market Expected to Be by 2024?",
                "attribution": "patentpc.com",
                "icon_type": null
              },
              {
                "matched_text": "\u30107\u2020L142-L150\u3011",
                "start_idx": 79465,
                "end_idx": 79478,
                "alt": null,
                "type": "webpage_extended",
                "title": "Buy or License Patents: How to build a better IP strategy",
                "url": "https://parolaanalytics.com/buy-or-license-patents-how-to-build-a-better-ip-strategy/#:~:text=patents%20can%20also%20generate%20additional,total%20earnings%20of%20many%20companies",
                "pub_date": null,
                "snippet": "patents can also generate additional revenues\u00a0for the company via, for example,\u00a0out-licensing. IBM, of course, is one of the most iconic serial licensers among technology companies. IBM is estimated to have garnered 88,000 patents over the years and is said to have collected about $20 billion or so of IP-related revenues. Over the 2008\u20132012 period, IBM\u2019s patent portfolio reportedly generated from $1.1 to $1.2 billion annually. Although its licensing income has dropped each year since then to around $740 million in 2014, this still represents an amount greater than the total earnings of many companies.",
                "attribution": "parolaanalytics.com",
                "icon_type": null
              },
              {
                "matched_text": "\u30107\u2020L151-L158\u3011",
                "start_idx": 79478,
                "end_idx": 79491,
                "alt": null,
                "type": "webpage_extended",
                "title": "Buy or License Patents: How to build a better IP strategy",
                "url": "https://parolaanalytics.com/buy-or-license-patents-how-to-build-a-better-ip-strategy/#:~:text=Microsoft%2C%20on%20the%20other%20hand%2C,the%20June%20quarter%20of%202018",
                "pub_date": null,
                "snippet": "Microsoft, on the other hand, was reported in 2013 to have generated $2 billion per year in revenue from Android patent royalties. Similarly, Qualcomm derives a substantial portion of its profit from licensing its 130,000 mobile technology- related patents to device makers, having received around $950 million from royalties for the June quarter of 2018.",
                "attribution": "parolaanalytics.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301019\u2020L79-L87\u3011",
                "start_idx": 79592,
                "end_idx": 79604,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=1,Expected%20to%20Be%20by%202024",
                "pub_date": null,
                "snippet": "1. How Large is the Global Patent Licensing Market Expected to Be by 2024?",
                "attribution": "patentpc.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301021\u2020L19-L27\u3011",
                "start_idx": 79604,
                "end_idx": 79616,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=The%20pharmaceutical%20industry%20represents%2025,of%20all%20patent%20licensing%20revenues",
                "pub_date": null,
                "snippet": "The pharmaceutical industry represents 25% of all patent licensing revenues.",
                "attribution": "patentpc.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301021\u2020L53-L60\u3011",
                "start_idx": 79616,
                "end_idx": 79628,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Licensing Statistics: Trends and Insights for 2024 | PatentPC",
                "url": "https://patentpc.com/blog/patent-licensing-statistics-trends-and-insights-for-2024#:~:text=match%20at%20L211%20University,of%20global%20patent%20licensing%20revenues",
                "pub_date": null,
                "snippet": "match at L211 University-held patents contribute to 15% of global patent licensing revenues.",
                "attribution": "patentpc.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301016\u2020L258-L266\u3011",
                "start_idx": 79710,
                "end_idx": 79724,
                "alt": null,
                "type": "webpage_extended",
                "title": "University licensing income rose slightly in 2011",
                "url": "https://www.insidehighered.com/news/2012/08/28/university-licensing-income-rose-slightly-2011#:~:text=As%20has%20been%20true%20for,California%20system%20a%20close%20second",
                "pub_date": null,
                "snippet": "As has been true for each of the past several years, Northwestern University brought in more licensing dollars from its research than did any other institution, at $191.5 million, with the University of California system a close second.",
                "attribution": "insidehighered.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301016\u2020L269-L277\u3011",
                "start_idx": 79724,
                "end_idx": 79738,
                "alt": null,
                "type": "webpage_extended",
                "title": "University licensing income rose slightly in 2011",
                "url": "https://www.insidehighered.com/news/2012/08/28/university-licensing-income-rose-slightly-2011#:~:text=Institution%202011%20Research%20Expenditures%202011,966%2C817%2C063%2070%209%2067%2C362%2C185",
                "pub_date": null,
                "snippet": "Institution 2011 Research Expenditures 2011 Patents Issued 2011 Startups 2011 Licensing Income Northwestern U. $484,149,349 67 8 $191,541,162 U. of California System 5,418,601,941 343 58 182,049,620 Columbia U. 714,343,087 88 15 146,319,455 New York U. 430,752,000 64 9 142,202,157 Princeton U. 192,940,000 33 4 115,206,000 Massachusetts Inst. of Technology (MIT) 1,490,429,000 174 25 76,120,000 U. of Washington/Wash. Res. Fdn. 966,817,063 70 9 67,362,185",
                "attribution": "insidehighered.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301011\u2020L227-L235\u3011",
                "start_idx": 79817,
                "end_idx": 79831,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patent Licensing - A Way for Universities to Generate More Revenue - GreyB",
                "url": "https://www.greyb.com/blog/how-universities-can-generate-revenue/#:~:text=Few%20universities%20have%20strong%20IP,revenues%20of%20five%20other%20universities",
                "pub_date": null,
                "snippet": "Few universities have strong IP departments and earn money by selling/licensing their patents. The University of California, with 4882 patents, earns ~$ $182 million from patent licensing. The graph below provides licensing revenues of five other universities.",
                "attribution": "greyb.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301036\u2020L7-L14\u3011",
                "start_idx": 79913,
                "end_idx": 79924,
                "alt": null,
                "type": "webpage_extended",
                "title": "",
                "url": "https://www.nist.gov/system/files/documents/2022/12/15/Federal%20Laboratory%20Technology%20Transfer%20Report_FY2020.pdf#:~:text=HHS%20accounted%20for%20the%20most,of%20reported",
                "pub_date": null,
                "snippet": "HHS accounted for the most licensing income with $54 million, followed by DOE with $25 million, and DoD with $9 million. Together these three agencies accounted for 93% of reported",
                "attribution": "nist.gov",
                "icon_type": null
              },
              {
                "matched_text": "\u301039\u2020L92-L100\u3011",
                "start_idx": 79999,
                "end_idx": 80012,
                "alt": null,
                "type": "webpage_extended",
                "title": "Study: Patent Trolls Cost Companies $29 Billion Last Year - The Atlantic",
                "url": "https://www.theatlantic.com/technology/archive/2012/06/study-patent-trolls-cost-companies-29-billion-last-year/259070/#:~:text=would%2C%20you%20know%2C%20want,is%20surely%20far%20greater",
                "pub_date": null,
                "snippet": "would, you know, want. Rather, they use the patents to prevent other companies from creating goods or services that people might want. Lovely, really. The cost of this vital industry? $29 billion in 2011 alone, and that's just the direct legal costs, not even counting \"various indirect costs ... such as diversion of resources, delays in new products, and loss of market share.\" The loss for the economy overall -- in terms of immeasurable opportunities -- is surely far greater.",
                "attribution": "theatlantic.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301039\u2020L100-L108\u3011",
                "start_idx": 80012,
                "end_idx": 80026,
                "alt": null,
                "type": "webpage_extended",
                "title": "Study: Patent Trolls Cost Companies $29 Billion Last Year - The Atlantic",
                "url": "https://www.theatlantic.com/technology/archive/2012/06/study-patent-trolls-cost-companies-29-billion-last-year/259070/#:~:text=In%20the%20past%2C%20Bessen%20and,such%20cases%20in%20recent%20years",
                "pub_date": null,
                "snippet": "In the past, Bessen and Meurer write, NPEs provided a service to small inventors who could not on their own defend their patents. But for the most part, that is no longer the case. NPE litigation has been a booming industry in recent years -- particularly in the software industry -- reaching 2,150 unique companies facing litigation in nearly 6,000 cases instigated by NPEs in 2011. A chart from the paper shows the growth of such cases in recent years:",
                "attribution": "theatlantic.com",
                "icon_type": null
              },
              {
                "matched_text": "\u301042\u2020L113-L120\u3011",
                "start_idx": 80120,
                "end_idx": 80134,
                "alt": null,
                "type": "webpage_extended",
                "title": "The Economics of the Pharmaceutical Sector: Innovation, Competition, and Patent Policy - R Street Institute",
                "url": "https://www.rstreet.org/commentary/the-economics-of-the-pharmaceutical-sector-innovation-competition-and-patent-policy/#:~:text=%E2%80%9Cpatent%20cliff%2C%E2%80%9D%20where%20lower,and%20the%20threat%20of%20competition",
                "pub_date": null,
                "snippet": "\u201cpatent cliff,\u201d where lower-cost generic rivals can enter the market and drive prices down to competitive levels. Once the market for a blockbuster drug becomes competitive, revenues may fall by as much as 79 percent. This dropoff in earning power poses a major threat to pharmaceutical companies\u2019 revenues, particularly when the drug goes off patent\u2014indeed, analysts project that more than $200 billion\u00a0in annual pharmaceutical revenue is at risk between now and 2030 due to expiring patents and the threat of competition.",
                "attribution": "rstreet.org",
                "icon_type": null
              },
              {
                "matched_text": "\u30100\u2020L1-L4\u3011",
                "start_idx": 80203,
                "end_idx": 80212,
                "alt": null,
                "type": "webpage_extended",
                "title": "A comparative IP management success story for Apple, Qualcomm ...",
                "url": "https://ipbusinessacademy.org/a-comparative-ip-management-success-story-for-apple-qualcomm-and-ibm#:~:text=,2%20billion",
                "pub_date": null,
                "snippet": "... ipbusinessacademy.org  Qualcomm reported total revenue of approximately $33 billion for fiscal year 2021, from which licensing revenue was approximately $8.2 billion.",
                "attribution": "ipbusinessacademy.org",
                "icon_type": null
              },
              {
                "matched_text": "\u30100\u2020L19-L26\u3011",
                "start_idx": 80269,
                "end_idx": 80280,
                "alt": null,
                "type": "webpage_extended",
                "title": "Patenting for Profits - MIT Sloan Management Review",
                "url": "https://sloanreview.mit.edu/article/patenting-for-profits/#:~:text=Altogether%2C%20IBM%20earns%20more%20than,from%20its%20vast%20patent%20portfolio",
                "pub_date": null,
                "snippet": "Altogether, IBM earns more than $1 billion a year in licensing revenues from its vast patent portfolio.",
                "attribution": "sloanreview.mit.edu",
                "icon_type": null
              }
            ],
            "timestamp_": "absolute",
            "message_type": null,
            "is_async_task_result_message": true,
            "b1de6e2_rm": true,
            "async_task_id": "deepresch_68490fc446cc8191bb823e90e5466df4",
            "async_task_title": "Patent Industry Mapping and Revenue Analysis by Institution, Field, and Tier"
          },
          "recipient": "all",
          "channel": "final"
        },
        "parent": "e04754cb-37cb-47a4-a366-fb920d8ab6af",
        "children": []
      }
    },
    "moderation_results": [],
    "current_node": "39c82fdc-87c1-42f0-b83e-d3e9dc3d0e98",
    "plugin_ids": null,
    "conversation_id": "684733ff-bdd4-8005-a0f8-958bd5d17133",
    "conversation_template_id": null,
    "gizmo_id": null,
    "gizmo_type": null,
    "is_archived": false,
    "is_starred": null,
    "safe_urls": [],
    "blocked_urls": [],
    "default_model_slug": "research",
    "conversation_origin": null,
    "voice": null,
    "async_status": null,
    "disabled_tool_ids": [],
    "is_do_not_remember": false,
    "memory_scope": "global_enabled",
    "sugar_item_id": null,
    "id": "684733ff-bdd4-8005-a0f8-958bd5d17133"
  },
  {
    "title": "Patent Licensing Strategy",
    "create_time": 1749496259.249573,
    "update_time": 1749496479.233447,
    "mapping": {
      "client-created-root": {
        "id": "client-created-root",
        "message": null,
        "parent": null,
        "children": [
          "ef3f3297-98b7-46f1-b308-358752e16d9e"
        ]
      },
      "ef3f3297-98b7-46f1-b308-358752e16d9e": {
        "id": "ef3f3297-98b7-46f1-b308-358752e16d9e",
        "message": {
          "id": "ef3f3297-98b7-46f1-b308-358752e16d9e",
          "author": {
            "role": "user",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749496257.849,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "I went back through my notes on the patent stuff as I was thinking about it before, and we missed a glaring hole, which is that you could probably monetize any patents better just by licensing them to anyone, and then take that money and do some other subsidy, rather than monetizing them really inefficiently by doing the location constraint \n\nWhat does this mean? Some context:\n- location constraint = idea we came up with to have ip limited to the city, where you can use it as long as its within the city.\n- we were talking about monetizing scientifc research. specifically how to hypothetically get science to scale \"capitalistically\" in the setting of a new city"
            ]
          },
          "status": "finished_successfully",
          "end_turn": null,
          "weight": 1.0,
          "metadata": {
            "selected_sources": [],
            "selected_github_repos": [],
            "serialization_metadata": {
              "custom_symbol_offsets": []
            },
            "request_id": "94d2ee9f3ede2305-ORD",
            "message_source": null,
            "timestamp_": "absolute",
            "message_type": null
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "client-created-root",
        "children": [
          "3c9fb12d-7d2a-45b7-ae52-ce9b63c5ea73"
        ]
      },
      "3c9fb12d-7d2a-45b7-ae52-ce9b63c5ea73": {
        "id": "3c9fb12d-7d2a-45b7-ae52-ce9b63c5ea73",
        "message": {
          "id": "3c9fb12d-7d2a-45b7-ae52-ce9b63c5ea73",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749496271.082821,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              ""
            ]
          },
          "status": "finished_successfully",
          "end_turn": null,
          "weight": 1.0,
          "metadata": {
            "message_type": null,
            "model_slug": "o3",
            "default_model_slug": "o3",
            "parent_id": "ef3f3297-98b7-46f1-b308-358752e16d9e",
            "request_id": "94d2ee9f3ede2305-ORD",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "ef3f3297-98b7-46f1-b308-358752e16d9e",
        "children": [
          "e08cf561-c4ba-4a25-912b-b683a2d2d32f"
        ]
      },
      "e08cf561-c4ba-4a25-912b-b683a2d2d32f": {
        "id": "e08cf561-c4ba-4a25-912b-b683a2d2d32f",
        "message": {
          "id": "e08cf561-c4ba-4a25-912b-b683a2d2d32f",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749496271.083024,
          "update_time": null,
          "content": {
            "content_type": "thoughts",
            "thoughts": [
              {
                "summary": "Clarifying user comment",
                "content": "The user is reflecting on a previous thought and suggests that licensing patents to a wider audience might be a more efficient way to monetize them, instead of restricting them to a location-based model. They think this method would allow for more profitable use of the patents since it avoids inefficient monetization tied to geographic limitations. Essentially, they\u2019re questioning whether the location-based constraint is hindering potential earnings and proposing a licensing alternative to better exploit the patents."
              },
              {
                "summary": "Explaining monetization models and location constraint trade-offs",
                "content": "The user's point is that licensing patents globally would likely generate more money, as a global market is bigger than a city-limited one. The location constraint might limit revenue, but it can support local innovation by reinvesting licensing revenue to subsidize city-based research. A blend of open licensing within the city and global licensing outside might work. We should explore the pros of location constraints (local clusters, incentives) vs the cons (enforcement, lost revenue), and consider licensing models like tiered pricing or patent pools."
              },
              {
                "summary": "Pro",
                "content": ""
              }
            ],
            "source_analysis_msg_id": "a0502723-7819-4f92-9fd3-968f5c50fb53"
          },
          "status": "finished_successfully",
          "end_turn": false,
          "weight": 1.0,
          "metadata": {
            "reasoning_status": "is_reasoning",
            "citations": [],
            "content_references": [],
            "message_type": null,
            "model_slug": "o3",
            "default_model_slug": "o3",
            "parent_id": "3c9fb12d-7d2a-45b7-ae52-ce9b63c5ea73",
            "request_id": "94d2ee9f3ede2305-ORD",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "3c9fb12d-7d2a-45b7-ae52-ce9b63c5ea73",
        "children": [
          "96d81574-f3a5-4d2d-8e5f-fc1c4f5a8055"
        ]
      },
      "96d81574-f3a5-4d2d-8e5f-fc1c4f5a8055": {
        "id": "96d81574-f3a5-4d2d-8e5f-fc1c4f5a8055",
        "message": {
          "id": "96d81574-f3a5-4d2d-8e5f-fc1c4f5a8055",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749496279.405303,
          "update_time": null,
          "content": {
            "content_type": "reasoning_recap",
            "content": "Thought for 15 seconds"
          },
          "status": "finished_successfully",
          "end_turn": false,
          "weight": 1.0,
          "metadata": {
            "reasoning_status": "reasoning_ended",
            "finished_duration_sec": 15,
            "message_type": null,
            "model_slug": "o3",
            "default_model_slug": "o3",
            "parent_id": "e08cf561-c4ba-4a25-912b-b683a2d2d32f",
            "request_id": "94d2ee9f3ede2305-ORD",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "e08cf561-c4ba-4a25-912b-b683a2d2d32f",
        "children": [
          "bedf2131-8cfa-492c-9697-46003a4a35ff"
        ]
      },
      "bedf2131-8cfa-492c-9697-46003a4a35ff": {
        "id": "bedf2131-8cfa-492c-9697-46003a4a35ff",
        "message": {
          "id": "bedf2131-8cfa-492c-9697-46003a4a35ff",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749496260.155434,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "**In plain English**\n\nThe \u201chole\u201d you spotted is that a *geographic\u2010use restriction* destroys most of the patent\u2019s market value.  If the ultimate goal is to funnel cash into your city\u2019s science ecosystem, it is almost always more efficient to license the patent as broadly as possible, collect the larger royalty stream, and then pump that money back into local R &D or whatever subsidy scheme you like.  The location constraint sacrifices global demand without creating a counterbalancing revenue source.\n\n---\n\n### Why the location-only model bleeds money\n\n| Effect | Mechanism | Result |\n|--------|-----------|--------|\n| **Shrinks total addressable market** | Only firms physically operating in the city can practice the patent. | Orders of magnitude less licensing volume and no chance to capture value from large incumbents elsewhere. |\n| **Kills scale economies for licensees** | A supplier whose factories are outside the city must duplicate capacity or decline to adopt. | Higher cost per unit \u2192 fewer adopters \u2192 lower royalties. |\n| **Raises enforcement cost** | You have to police *where* a licensee\u2019s widget is manufactured or sold, not just *whether* it uses your IP. | Hard legal problem; easy to game with subsidiaries or contract manufacturers. |\n| **Reduces bargaining power** | Prospective licensees know your fallback option is \u201cnobody outside the city,\u201d so they negotiate harder. | Lower royalty rates. |\n\nEven if the original motivation was \u201cforce agglomeration \u2192 spur local spill-overs,\u201d you\u2019re paying for that with lost patent revenue, and that revenue was the very thing meant to fund the ecosystem.\n\n---\n\n### A cleaner architecture\n\n1. **Global FRAND-style license**  \n   *Flat or tiered royalty, no geographic limits.*  \n   - Maximizes uptake and network effects.  \n   - Lets giant incumbents bankroll your science via royalties.\n\n2. **Local zero-royalty carve-out**  \n   *Anyone whose primary R &D or production footprint is inside the city gets a free (or ultra-cheap) license.*  \n   - Preserves the agglomeration incentive.  \n   - Keeps \u201cinside\u201d definition narrow (e.g., \u2265 80 % of payroll or physical production capacity inside city limits).\n\n3. **Royalty recycling mechanism**  \n   *Dedicated fund chartered to reinvest every dollar of external royalties into:*  \n   - Basic science grants for city labs.  \n   - Shared infrastructure (wet labs, pilot fabs, HPC clusters).  \n   - Prize purses for breakthroughs that must be demonstrated locally.\n\n4. **Governance & transparency**  \n   *Independent board with scientists, city officials, and outside LPs.*  \n   - Annual audited report: royalties collected, grants made, KPI scorecard (publications, start-ups, jobs).  \n   - Builds trust and keeps \u201csubsidy leakage\u201d under control.\n\n---\n\n### Why this beats the hard location constraint\n\n| Metric | Hard location\u2010only | Global license + local carve-out |\n|--------|-------------------|----------------------------------|\n| **Royalty base** | Only local firms | Every firm worldwide |\n| **Local agglomeration pull** | Strong (but at high cost) | Almost as strong (city license = free) |\n| **Enforcement complexity** | Very high | Standard patent enforcement outside city; simple residency test inside |\n| **Political optics** | \u201cIP moat, city as walled garden\u201d | \u201cCity as R &D hub funded by exporting technology\u201d |\n| **Ability to fund blue-sky research** | Weak (thin cash flow) | Strong (global cash flow) |\n\n---\n\n### Precedents and analogues\n\n- **ARM Ltd.** Global IP licensing powerhouse, tiny Cambridge headquarters financed by worldwide royalties. Demonstrates how a small cluster can thrive on outward licensing.\n- **University tech-transfer offices (post Bayh-Dole, 1980)** Universities license globally; royalty income funds new labs, seed grants, and graduate fellowships on campus.\n- **Open COVID pledge (2020)** Patent holders offered free licenses *for pandemic response only*, while keeping normal commercial licensing intact\u2014a carve-out in reverse.\n\n---\n\n### Addressing two common objections\n\n1. **\u201cBut the spill-overs matter more than money.\u201d**  \n   True\u2014but the free local license preserves them.  The only firms paying are those *not* creating local spill-overs anyway.\n\n2. **\u201cWill anyone still move to the city if outsiders can also license?\u201d**  \n   Yes, if the free local license is large enough relative to the royalty outsiders pay, *and* if the city offers complementary advantages (shared labs, talent density, regulatory fast-lanes).  Think of it as a two-part tariff: zero-royalty access *plus* those ecosystem perks.\n\n---\n\n### Practical next steps\n\n1. **Model two cash-flow scenarios** (hard constraint vs. global licensing) for your top three patent families\u2014use conservative adoption curves and realistic royalty rates.  \n2. **Draft a term-sheet template** implementing the \u201cglobal + local carve-out\u201d structure; keep it shorter than 10 pages to minimize transaction friction.  \n3. **Set up the royalty-recycling fund** with clear rules that every dollar goes back into mission-aligned science.  \n4. **Pilot with one patent family** to test market appetite and paperwork burden before rolling city-wide.\n\n---\n\n### Quick take-away\n\nLimiting patent use to within city limits is like taxing yourself at 90 % before funding your research program.  A global-license-plus-local-free-use policy keeps the agglomeration goal alive while harvesting the full worldwide value of the IP\u2014and that extra cash is what lets you subsidize local science at meaningful scale."
            ]
          },
          "status": "finished_successfully",
          "end_turn": true,
          "weight": 1.0,
          "metadata": {
            "citations": [],
            "content_references": [],
            "message_type": null,
            "model_slug": "o3",
            "default_model_slug": "o3",
            "parent_id": "96d81574-f3a5-4d2d-8e5f-fc1c4f5a8055",
            "request_id": "94d2ee9f3ede2305-ORD",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": "final"
        },
        "parent": "96d81574-f3a5-4d2d-8e5f-fc1c4f5a8055",
        "children": [
          "5e244f3e-4a29-4d67-9da3-42200a062acf"
        ]
      },
      "5e244f3e-4a29-4d67-9da3-42200a062acf": {
        "id": "5e244f3e-4a29-4d67-9da3-42200a062acf",
        "message": {
          "id": "5e244f3e-4a29-4d67-9da3-42200a062acf",
          "author": {
            "role": "user",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749496415.115,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "couldn't you just concurrently license and have the geo-locked thing where its free in your city and payed outside?"
            ]
          },
          "status": "finished_successfully",
          "end_turn": null,
          "weight": 1.0,
          "metadata": {
            "selected_sources": [],
            "selected_github_repos": [],
            "serialization_metadata": {
              "custom_symbol_offsets": []
            },
            "request_id": "94d2f28d3b541068-DFW",
            "message_source": null,
            "timestamp_": "absolute",
            "message_type": null
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "bedf2131-8cfa-492c-9697-46003a4a35ff",
        "children": [
          "509c251f-c0ad-42db-9b99-9bc81ff006f5"
        ]
      },
      "509c251f-c0ad-42db-9b99-9bc81ff006f5": {
        "id": "509c251f-c0ad-42db-9b99-9bc81ff006f5",
        "message": {
          "id": "509c251f-c0ad-42db-9b99-9bc81ff006f5",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749496431.60446,
          "update_time": null,
          "content": {
            "content_type": "thoughts",
            "thoughts": [
              {
                "summary": "Clarifying licensing structure",
                "content": "The user has pointed out a valid solution\u2014concurrent licensing where it's free inside the city and paid outside. This matches the \"Global license + local carve-out\" idea I mentioned earlier. I need to explain how this can be implemented, while addressing legal complexities like patent exhaustion, FRAND obligations, enforcement challenges, and how to distinguish between an open field-of-use license and exclusivity. I\u2019ll also clarify how to ensure local free usage without violating the patent exhaustion doctrine for goods leaving the city."
              },
              {
                "summary": "Addressing licensing concerns",
                "content": "When considering the export of products made with a free license within the city, I need to tackle patent exhaustion and how it might let a product bypass royalties after being sold elsewhere. If a product is made and sold within the city, patent owners can lose the right to charge royalties once it's sold (Impression Products v. Lexmark). So, one solution might be to base royalties on manufacturing or sale outside the city, rather than use, while addressing global licensing challenges like potential antitrust concerns or FRAND issues."
              }
            ],
            "source_analysis_msg_id": "68c0e8c6-845d-4fc8-86b0-b651950c0aeb"
          },
          "status": "finished_successfully",
          "end_turn": false,
          "weight": 1.0,
          "metadata": {
            "reasoning_status": "is_reasoning",
            "citations": [],
            "content_references": [],
            "message_type": null,
            "model_slug": "o3",
            "default_model_slug": "o3",
            "parent_id": "5e244f3e-4a29-4d67-9da3-42200a062acf",
            "request_id": "94d2f28d3b541068-DFW",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "5e244f3e-4a29-4d67-9da3-42200a062acf",
        "children": [
          "3f59a959-cc0e-46f2-8f09-72ffdf08f5f4"
        ]
      },
      "3f59a959-cc0e-46f2-8f09-72ffdf08f5f4": {
        "id": "3f59a959-cc0e-46f2-8f09-72ffdf08f5f4",
        "message": {
          "id": "3f59a959-cc0e-46f2-8f09-72ffdf08f5f4",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749496451.31451,
          "update_time": null,
          "content": {
            "content_type": "reasoning_recap",
            "content": "Thought for 31 seconds"
          },
          "status": "finished_successfully",
          "end_turn": false,
          "weight": 1.0,
          "metadata": {
            "reasoning_status": "reasoning_ended",
            "finished_duration_sec": 31,
            "message_type": null,
            "model_slug": "o3",
            "default_model_slug": "o3",
            "parent_id": "509c251f-c0ad-42db-9b99-9bc81ff006f5",
            "request_id": "94d2f28d3b541068-DFW",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "509c251f-c0ad-42db-9b99-9bc81ff006f5",
        "children": [
          "4daf79fc-6538-4697-8cd3-3b63cc67833f"
        ]
      },
      "4daf79fc-6538-4697-8cd3-3b63cc67833f": {
        "id": "4daf79fc-6538-4697-8cd3-3b63cc67833f",
        "message": {
          "id": "4daf79fc-6538-4697-8cd3-3b63cc67833f",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749496419.76933,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "Yes\u2014you can run both programs at once:\n\n| inside the city | everywhere else |\n|-----------------|-----------------|\n| **royalty-free \u201ccommunity\u201d licence** | **commercial licence with royalties** |\n\nThat is exactly the \u201cglobal + local carve-out\u201d structure sketched earlier, but you need to nail the legal plumbing so the two licences do not bleed into each other.\n\n---\n\n## 1\u2003Core licence architecture\n\n### A. Royalty-free community licence  \n- **Who qualifies?** Entities whose **principal R & D *and* first commercial sale** occur inside city limits (define bright-line tests: \u2265 80 % payroll + first invoicing address).  \n- **Scope** Make, use, and sell *products first sold inside the city*.  \n- **Purpose** Let local firms innovate without tolls while maximising spill-overs.\n\n### B. Royalty-bearing commercial licence  \n- **Trigger** Any manufacture or first sale *outside* the city, or any transfer of a product first sold inside the city to a party outside.  \n- **Royalty base** Per-unit or net-revenue; keep rate modest to discourage design-arounds.  \n- **Audit & reporting** Quarterly certified reports; right to inspect books.\n\n### C. Revenue recycler  \nA not-for-profit trust that receives every royalty dollar and can spend **only** on city science infrastructure or grants.\n\n---\n\n## 2\u2003Why you must draft carefully\n\n| Issue | What can go wrong | How to draft around it |\n|-------|------------------|------------------------|\n| **Patent exhaustion / first-sale doctrine** | If the free licence authorises *sale*, a product shipped outside is immune from downstream royalties. | Make the free licence **conditional**: royalty-free only while the product is *used* or *resold* inside the city. Export without paying \u2259 infringement. |\n| **Easy arbitrage** | Multinational sets up a \u201cpost-box\u201d plant in the city, sells one unit locally, then ships container loads abroad. | (i) Payroll + CapEx tests, (ii) escalating royalty once sales outside city exceed a de minimis quota. |\n| **Competition law** | Location-based differentials can look like price discrimination. | Anchor the differential to a legitimate public-benefit policy (local R & D promotion) and apply objective, transparent criteria. |\n| **Standards-essential patents (SEP)** | If your patent later becomes SEP, you may be forced into global FRAND terms that forbid geographic discrimination. | Keep carve-out language in FRAND commitment itself: \u201cZero-royalty for parties meeting City-X eligibility.\u201d |\n\n---\n\n## 3\u2003Enforcement workflow\n\n1. **Self-certification** at licence signing: address, payroll data, production plans.  \n2. **Quarterly statements** of units sold in-city vs. out-of-city, attested by CFO.  \n3. **Random audit right** (independent CPA; licencee pays if \u2265 5 % under-reported).  \n4. **Failure \u21d2 automatic reclassification** to commercial licence + back royalties + penalty interest.\n\nInvisible to the consumer, but clear to every manufacturer.\n\n---\n\n## 4\u2003Operational templates\n\nBelow are excerpted, comment-free clause skeletons (jurisdiction: U.S. law; patent list attached by schedule).  Adjust headings, but the logic is standard.\n\n```\n\u00a72. Grant to Community Licensees\nLicensor grants to any Qualified City-X Entity a worldwide, non-exclusive,\nroyalty-free licence under the Patents to make, use, offer to sell, sell, or\nimport any Licensed Product, provided that (a) the first commercial sale of\neach such Licensed Product occurs within City-X, and (b) neither the\nLicensed Product nor a component embodying a Licensed Claim is sold or\ntransferred for consideration to any Person outside City-X prior to the\npayment of royalties specified in \u00a73.\n\n\u00a73. Grant to Commercial Licensees\nLicensor grants to all other Persons a worldwide, non-exclusive licence\nunder the Patents to make, use, offer to sell, sell, or import any Licensed\nProduct upon payment of a running royalty of 2.5 % of Net Sales.\n\n\u00a74. Qualification\n\u201cQualified City-X Entity\u201d means any legal person that (i) maintains \u226580 %\nof its full-time R&D employees within City-X boundaries and (ii) conducts\nthe first commercial sale of each Licensed Product within City-X.\n\n\u00a75. Audit...\n```\n\nUse separate short-form click-through for startups and a long-form for larger firms.\n\n---\n\n## 5\u2003What you still sacrifice vs. a pure global licence\n\n- **Patent exhaustion leakage** can still occur if you mis-draft the conditional language.  \n- **Administrative overhead**: vetting, audits, dispute resolution.  \n- **Possible reluctance of global giants** to integrate IP that carries geographic compliance checks.\n\nIf the city\u2019s value proposition (talent density, regulatory fast-lane, shared labs) is strong, those costs are acceptable; if not, they erode uptake.\n\n---\n\n## 6\u2003Action checklist\n\n1. **Patent counsel**: red-line exhaustion-proof grant language.  \n2. **Economic model**: forecast global vs. local royalty flows under different rates.  \n3. **Governance charter**: legally bind the recycler fund to science spend only.  \n4. **Pilot**: one patent family, two early-stage local licensees, one external test customer.  \n5. **Iterate** on criteria and auditing once you see real transaction data.\n\n---\n\n### Bottom line\n\nDual licensing\u2014free inside the city, paid outside\u2014*is* workable and captures most of the lost value, but only if the licence is drafted to (i) avoid patent-exhaustion loopholes and (ii) keep enforcement cheap.  Get those details right and you end up with global money inflow plus a strong \u201cmove here, innovate free\u201d lure for scientists and startups."
            ]
          },
          "status": "finished_successfully",
          "end_turn": true,
          "weight": 1.0,
          "metadata": {
            "citations": [],
            "content_references": [],
            "message_type": null,
            "model_slug": "o3",
            "default_model_slug": "o3",
            "parent_id": "3f59a959-cc0e-46f2-8f09-72ffdf08f5f4",
            "request_id": "94d2f28d3b541068-DFW",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": "final"
        },
        "parent": "3f59a959-cc0e-46f2-8f09-72ffdf08f5f4",
        "children": []
      }
    },
    "moderation_results": [],
    "current_node": "4daf79fc-6538-4697-8cd3-3b63cc67833f",
    "plugin_ids": null,
    "conversation_id": "684731c2-dbe0-8005-86ac-8849068ce21c",
    "conversation_template_id": null,
    "gizmo_id": null,
    "gizmo_type": null,
    "is_archived": false,
    "is_starred": null,
    "safe_urls": [],
    "blocked_urls": [],
    "default_model_slug": "o3",
    "conversation_origin": null,
    "voice": null,
    "async_status": null,
    "disabled_tool_ids": [],
    "is_do_not_remember": false,
    "memory_scope": "global_enabled",
    "sugar_item_id": null,
    "id": "684731c2-dbe0-8005-86ac-8849068ce21c"
  },
  {
    "title": "Mean and Variance KE",
    "create_time": 1749486944.301381,
    "update_time": 1749488037.132717,
    "mapping": {
      "client-created-root": {
        "id": "client-created-root",
        "message": null,
        "parent": null,
        "children": [
          "023fd318-5c4a-43de-b2d3-52a2942ff6b2"
        ]
      },
      "023fd318-5c4a-43de-b2d3-52a2942ff6b2": {
        "id": "023fd318-5c4a-43de-b2d3-52a2942ff6b2",
        "message": {
          "id": "023fd318-5c4a-43de-b2d3-52a2942ff6b2",
          "author": {
            "role": "user",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749486943.933,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "in thermodynamics, which variables correspond to the mean and variance of kinetic energy"
            ]
          },
          "status": "finished_successfully",
          "end_turn": null,
          "weight": 1.0,
          "metadata": {
            "selected_sources": [],
            "selected_github_repos": [],
            "serialization_metadata": {
              "custom_symbol_offsets": []
            },
            "request_id": "94d20b38ac6dcce4-SJC",
            "message_source": null,
            "timestamp_": "absolute",
            "message_type": null
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "client-created-root",
        "children": [
          "dc256189-0ffc-43c2-9bf5-8490c7584b9c"
        ]
      },
      "dc256189-0ffc-43c2-9bf5-8490c7584b9c": {
        "id": "dc256189-0ffc-43c2-9bf5-8490c7584b9c",
        "message": {
          "id": "dc256189-0ffc-43c2-9bf5-8490c7584b9c",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749486956.239937,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              ""
            ]
          },
          "status": "finished_successfully",
          "end_turn": null,
          "weight": 1.0,
          "metadata": {
            "message_type": null,
            "model_slug": "o3",
            "default_model_slug": "o3",
            "parent_id": "023fd318-5c4a-43de-b2d3-52a2942ff6b2",
            "request_id": "94d20b38ac6dcce4-SJC",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "023fd318-5c4a-43de-b2d3-52a2942ff6b2",
        "children": [
          "8401efdb-95cd-47fc-8aa2-444ffea558ef"
        ]
      },
      "8401efdb-95cd-47fc-8aa2-444ffea558ef": {
        "id": "8401efdb-95cd-47fc-8aa2-444ffea558ef",
        "message": {
          "id": "8401efdb-95cd-47fc-8aa2-444ffea558ef",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749486956.240044,
          "update_time": null,
          "content": {
            "content_type": "thoughts",
            "thoughts": [
              {
                "summary": "Computing kinetic energy variance",
                "content": "I\u2019m reviewing how temperature relates to the kinetic energy distribution in an ideal gas. The average kinetic energy is (3/2) k_B T, which gives the temperature relationship. To calculate the variance, I\u2019m using the Maxwell-Boltzmann distribution. The variance turns out to be proportional to the square of the temperature, specifically (3/2) (k_B T)^2. This all checks out, so the variance in the kinetic energy is indeed linked to temperature."
              }
            ],
            "source_analysis_msg_id": "07eec9fa-2dbb-42c0-9cd6-3882e9c13d64"
          },
          "status": "finished_successfully",
          "end_turn": false,
          "weight": 1.0,
          "metadata": {
            "reasoning_status": "is_reasoning",
            "citations": [],
            "content_references": [],
            "message_type": null,
            "model_slug": "o3",
            "default_model_slug": "o3",
            "parent_id": "dc256189-0ffc-43c2-9bf5-8490c7584b9c",
            "request_id": "94d20b38ac6dcce4-SJC",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "dc256189-0ffc-43c2-9bf5-8490c7584b9c",
        "children": [
          "0906e37b-c9b3-45b4-98b0-3d52e9bf791f"
        ]
      },
      "0906e37b-c9b3-45b4-98b0-3d52e9bf791f": {
        "id": "0906e37b-c9b3-45b4-98b0-3d52e9bf791f",
        "message": {
          "id": "0906e37b-c9b3-45b4-98b0-3d52e9bf791f",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749486960.419303,
          "update_time": null,
          "content": {
            "content_type": "reasoning_recap",
            "content": "Thought for 14 seconds"
          },
          "status": "finished_successfully",
          "end_turn": false,
          "weight": 1.0,
          "metadata": {
            "reasoning_status": "reasoning_ended",
            "finished_duration_sec": 14,
            "message_type": null,
            "model_slug": "o3",
            "default_model_slug": "o3",
            "parent_id": "8401efdb-95cd-47fc-8aa2-444ffea558ef",
            "request_id": "94d20b38ac6dcce4-SJC",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "8401efdb-95cd-47fc-8aa2-444ffea558ef",
        "children": [
          "68b9c0f9-c609-4f0b-8ed6-eae592d30e5f"
        ]
      },
      "68b9c0f9-c609-4f0b-8ed6-eae592d30e5f": {
        "id": "68b9c0f9-c609-4f0b-8ed6-eae592d30e5f",
        "message": {
          "id": "68b9c0f9-c609-4f0b-8ed6-eae592d30e5f",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749486945.108873,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "**Mean \u27fa Temperature**  \n\\[\n\\langle E_{\\text{kin}}\\rangle=\\frac{f}{2}\\,k_{\\mathrm B}T\n\\]\n\n**Variance \u27fa Heat-capacity** (energy fluctuation formula)  \n\\[\n\\operatorname{Var}(E_{\\text{kin}})=\\langle(\\Delta E_{\\text{kin}})^2\\rangle\n          =k_{\\mathrm B}T^{2}C_{V}\n\\]\n\nSo, in thermodynamic terms the intensive variable **temperature \\(T\\)** fixes the average kinetic energy, while the generalized susceptibility **heat capacity at constant volume \\(C_{V}\\)** governs its fluctuations (variance)."
            ]
          },
          "status": "finished_successfully",
          "end_turn": true,
          "weight": 1.0,
          "metadata": {
            "citations": [],
            "content_references": [],
            "message_type": null,
            "model_slug": "o3",
            "default_model_slug": "o3",
            "parent_id": "0906e37b-c9b3-45b4-98b0-3d52e9bf791f",
            "request_id": "94d20b38ac6dcce4-SJC",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": "final"
        },
        "parent": "0906e37b-c9b3-45b4-98b0-3d52e9bf791f",
        "children": [
          "cb74dd59-d87e-4d82-a3af-77079a59d519"
        ]
      },
      "cb74dd59-d87e-4d82-a3af-77079a59d519": {
        "id": "cb74dd59-d87e-4d82-a3af-77079a59d519",
        "message": {
          "id": "cb74dd59-d87e-4d82-a3af-77079a59d519",
          "author": {
            "role": "user",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749487039.664,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "what is the quantity dS/dVar(E)"
            ]
          },
          "status": "finished_successfully",
          "end_turn": null,
          "weight": 1.0,
          "metadata": {
            "selected_sources": [],
            "selected_github_repos": [],
            "serialization_metadata": {
              "custom_symbol_offsets": []
            },
            "request_id": "94d20d8e5e17174e-SJC",
            "message_source": null,
            "timestamp_": "absolute",
            "message_type": null
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "68b9c0f9-c609-4f0b-8ed6-eae592d30e5f",
        "children": [
          "20928391-40db-4dbf-a8b0-1e129fadc5c4"
        ]
      },
      "20928391-40db-4dbf-a8b0-1e129fadc5c4": {
        "id": "20928391-40db-4dbf-a8b0-1e129fadc5c4",
        "message": {
          "id": "20928391-40db-4dbf-a8b0-1e129fadc5c4",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749487051.880293,
          "update_time": null,
          "content": {
            "content_type": "thoughts",
            "thoughts": [
              {
                "summary": "",
                "content": "The user is asking about the derivative dS/dVar(E), which relates entropy (S) to the variance of energy (Var(E)), a concept from thermodynamics. They're likely thinking about thermodynamic identities and Legendre transforms. I need to carefully calculate the requested derivative. First, I\u2019ll note that Var(E) = k_B T^2 C_V, and dS/dT = C_V/T. To find the derivative, I\u2019ll use the chain rule to link the derivatives of S with T and Var(E) with T, considering the dependency of C_V on temperature."
              },
              {
                "summary": "",
                "content": "To compute the derivative dS/dVar(E), I first break down the thermodynamic expression using the chain rule. After simplifying, I find that for a constant heat capacity C_V, the derivative simplifies to dS/dVar(E) = C_V / (2 Var(E)). This makes sense, as it tells me the entropy change with respect to the energy variance. It\u2019s analogous to heat capacity\u2019s relationship with temperature, but focusing on energy fluctuations. I suspect the user just wants a direct expression, like 1/(2 k_B T^2) or C_V / (2 Var(E))."
              }
            ],
            "source_analysis_msg_id": "73c83149-4360-48c6-8053-0f93f71cfebc"
          },
          "status": "finished_successfully",
          "end_turn": false,
          "weight": 1.0,
          "metadata": {
            "reasoning_status": "is_reasoning",
            "citations": [],
            "content_references": [],
            "message_type": null,
            "model_slug": "o3",
            "default_model_slug": "o3",
            "parent_id": "cb74dd59-d87e-4d82-a3af-77079a59d519",
            "request_id": "94d20d8e5e17174e-SJC",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "cb74dd59-d87e-4d82-a3af-77079a59d519",
        "children": [
          "312e25f7-9c33-47f8-9f18-49d8fcf4266e"
        ]
      },
      "312e25f7-9c33-47f8-9f18-49d8fcf4266e": {
        "id": "312e25f7-9c33-47f8-9f18-49d8fcf4266e",
        "message": {
          "id": "312e25f7-9c33-47f8-9f18-49d8fcf4266e",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749487063.590138,
          "update_time": null,
          "content": {
            "content_type": "reasoning_recap",
            "content": "Thought for 22 seconds"
          },
          "status": "finished_successfully",
          "end_turn": false,
          "weight": 1.0,
          "metadata": {
            "reasoning_status": "reasoning_ended",
            "finished_duration_sec": 22,
            "message_type": null,
            "model_slug": "o3",
            "default_model_slug": "o3",
            "parent_id": "20928391-40db-4dbf-a8b0-1e129fadc5c4",
            "request_id": "94d20d8e5e17174e-SJC",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "20928391-40db-4dbf-a8b0-1e129fadc5c4",
        "children": [
          "a83cda9d-4cd9-4da7-a62a-2ecdc90ee9e9"
        ]
      },
      "a83cda9d-4cd9-4da7-a62a-2ecdc90ee9e9": {
        "id": "a83cda9d-4cd9-4da7-a62a-2ecdc90ee9e9",
        "message": {
          "id": "a83cda9d-4cd9-4da7-a62a-2ecdc90ee9e9",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749487039.99892,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "Starting from the equilibrium relations  \n\n\\[\n\\langle E\\rangle=\\tfrac{f}{2}k_{\\!B}T, \n\\qquad \n\\operatorname{Var}(E)=k_{\\!B}T^{2}C_V(T),\n\\qquad \n\\frac{dS}{dT}=\\frac{C_V(T)}{T},\n\\]\n\ntreat \\(S\\) and \\(\\operatorname{Var}(E)\\) as functions of the single variable \\(T\\).  By the chain rule  \n\n\\[\n\\frac{dS}{d\\operatorname{Var}(E)}\n      =\\frac{\\displaystyle\\frac{dS}{dT}}\n             {\\displaystyle\\frac{d\\,\\operatorname{Var}(E)}{dT}}\n      =\\frac{C_V/T}{k_{\\!B}\\bigl(2TC_V+T^{2}\\,dC_V/dT\\bigr)}\n      =\\frac{1}{k_{\\!B}}\\,\n        \\frac{C_V}{T^{2}\\bigl(2C_V+T\\,dC_V/dT\\bigr)}.\n\\]\n\n---\n\n### Constant\u2013\\(C_V\\) case (classical ideal gas, harmonic crystal)\n\nIf \\(C_V\\) is temperature-independent, \\(dC_V/dT=0\\) and the expression collapses to  \n\n\\[\n\\boxed{\\displaystyle\n\\frac{dS}{d\\operatorname{Var}(E)}\n      =\\frac{1}{2k_{\\!B}T^{2}}\n      =\\frac{C_V}{2\\,\\operatorname{Var}(E)} }.\n\\]\n\n---\n\n**Interpretation.**  \n\\(\\frac{dS}{d\\operatorname{Var}(E)}\\) quantifies how much the entropy grows when the width of the energy distribution broadens.  It has no conventional thermodynamic name, but it is an \u201cenergy-fluctuation susceptibility\u201d: the larger the temperature (or, equivalently, the variance), the smaller the entropy gain per unit additional fluctuation."
            ]
          },
          "status": "finished_successfully",
          "end_turn": true,
          "weight": 1.0,
          "metadata": {
            "citations": [],
            "content_references": [],
            "message_type": null,
            "model_slug": "o3",
            "default_model_slug": "o3",
            "parent_id": "312e25f7-9c33-47f8-9f18-49d8fcf4266e",
            "request_id": "94d20d8e5e17174e-SJC",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": "final"
        },
        "parent": "312e25f7-9c33-47f8-9f18-49d8fcf4266e",
        "children": [
          "8f3529d5-dbe1-4588-9947-6cff7e3971e4"
        ]
      },
      "8f3529d5-dbe1-4588-9947-6cff7e3971e4": {
        "id": "8f3529d5-dbe1-4588-9947-6cff7e3971e4",
        "message": {
          "id": "8f3529d5-dbe1-4588-9947-6cff7e3971e4",
          "author": {
            "role": "user",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749487142.677,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "how is the quantity related to landauers princple?"
            ]
          },
          "status": "finished_successfully",
          "end_turn": null,
          "weight": 1.0,
          "metadata": {
            "selected_sources": [],
            "selected_github_repos": [],
            "serialization_metadata": {
              "custom_symbol_offsets": []
            },
            "request_id": "94d210120edfcf16-SJC",
            "message_source": null,
            "timestamp_": "absolute",
            "message_type": null
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "a83cda9d-4cd9-4da7-a62a-2ecdc90ee9e9",
        "children": [
          "20dd5309-eef1-4c18-9d53-515f9ea2d631"
        ]
      },
      "20dd5309-eef1-4c18-9d53-515f9ea2d631": {
        "id": "20dd5309-eef1-4c18-9d53-515f9ea2d631",
        "message": {
          "id": "20dd5309-eef1-4c18-9d53-515f9ea2d631",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749487155.153938,
          "update_time": null,
          "content": {
            "content_type": "thoughts",
            "thoughts": [
              {
                "summary": "Explaining quantity and Landauer's principle",
                "content": "The user asks about the relationship between a given quantity (dS/dVar(E)) and Landauer's principle. Landauer's principle deals with the minimal energy needed to erase a bit of information, with the energy dissipation linked to entropy change. While dS/dVar(E) is related to the variance in energy (Var(E)), Landauer's principle connects entropy change to energy dissipation. By using fluctuation-dissipation, where Var(E) = k_B T^2 C_V, we can explain that this expression is inversely proportional to T^2. Therefore, the direct relationship isn't clear, but it's connected via fluctuations in energy."
              },
              {
                "summary": "Explaining Landauer's principle and energy fluctuations",
                "content": "The Landauer bound defines the minimal energy required for information erasure, where entropy change is minimized. The variance in energy fluctuations influences this cost, and the derivative dS/dVar(E) shows how small fluctuations relate to entropy. By considering finite-time processes and fluctuations, Landauer's principle can be refined using variance. For systems with finite heat capacity, fluctuations add extra entropy cost, which can be represented algebraically as Q \u2265 k_B T ln 2 + (\u0394Var(E)) / (2 T C_V)."
              }
            ],
            "source_analysis_msg_id": "619c36e1-394d-452b-8bcb-1b787599ce9b"
          },
          "status": "finished_successfully",
          "end_turn": false,
          "weight": 1.0,
          "metadata": {
            "reasoning_status": "is_reasoning",
            "citations": [],
            "content_references": [],
            "message_type": null,
            "model_slug": "o3",
            "default_model_slug": "o3",
            "parent_id": "8f3529d5-dbe1-4588-9947-6cff7e3971e4",
            "request_id": "94d210120edfcf16-SJC",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "8f3529d5-dbe1-4588-9947-6cff7e3971e4",
        "children": [
          "d8e62e2c-e561-463f-854f-b2281f794a83"
        ]
      },
      "d8e62e2c-e561-463f-854f-b2281f794a83": {
        "id": "d8e62e2c-e561-463f-854f-b2281f794a83",
        "message": {
          "id": "d8e62e2c-e561-463f-854f-b2281f794a83",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749487166.556978,
          "update_time": null,
          "content": {
            "content_type": "reasoning_recap",
            "content": "Thought for 22 seconds"
          },
          "status": "finished_successfully",
          "end_turn": false,
          "weight": 1.0,
          "metadata": {
            "reasoning_status": "reasoning_ended",
            "finished_duration_sec": 22,
            "message_type": null,
            "model_slug": "o3",
            "default_model_slug": "o3",
            "parent_id": "20dd5309-eef1-4c18-9d53-515f9ea2d631",
            "request_id": "94d210120edfcf16-SJC",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "20dd5309-eef1-4c18-9d53-515f9ea2d631",
        "children": [
          "eb8298f5-3765-46a7-8fdf-1609cc7eeeb1"
        ]
      },
      "eb8298f5-3765-46a7-8fdf-1609cc7eeeb1": {
        "id": "eb8298f5-3765-46a7-8fdf-1609cc7eeeb1",
        "message": {
          "id": "eb8298f5-3765-46a7-8fdf-1609cc7eeeb1",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749487143.391042,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "Landauer\u2019s bound is obtained from the *first*\u2010order expansion of the reservoir entropy in the energy exchanged with it,\n\n\\[\n\\Delta S_{\\text{bath}}\n      =\\Bigl(\\frac{\\partial S}{\\partial\\langle E\\rangle}\\Bigr)\\Delta\\langle E\\rangle\n      =\\frac{\\Delta Q}{T},\n\\qquad\n\\Delta Q\\equiv\\Delta\\langle E\\rangle ,\n\\]\n\nand the second law requires  \n\\(\\Delta S_{\\text{bath}}\\ge |\\,\\Delta S_{\\text{info}}|\\), so that  \n\n\\[\n\\boxed{\\; \\Delta Q\\;\\ge\\;k_{\\!B}T\\ln 2\\;}\n\\tag{Landauer}\n\\]\n\nfor erasing one bit.  \nThe derivative that *you* asked about,\n\n\\[\n\\frac{\\partial S}{\\partial\\operatorname{Var}(E)}\n      =\\frac{1}{2k_{\\!B}T^{2}}\n      \\quad\\bigl(\\text{ideal-bath or constant}\\;C_V\\bigr),\n\\]\n\nis simply the next term in the Taylor expansion of the bath entropy:\n\n\\[\n\\Delta S_{\\text{bath}}\n      =\\frac{\\Delta Q}{T}\n        +\\frac12\\Bigl(\\frac{\\partial S}{\\partial\\operatorname{Var}(E)}\\Bigr)\\Delta\\operatorname{Var}(E)\n        +\\ldots\n      =\\frac{\\Delta Q}{T}\n        +\\frac{\\Delta\\operatorname{Var}(E)}{2k_{\\!B}T^{2}}\n        +\\ldots\n\\tag{1}\n\\]\n\n### What this tells us\n\n* **Mean-only limit.**  \n  If the erasure is carried out *quasi-statically* and the reservoir is macroscopic, the change in its energy variance is negligible, \\(\\Delta\\operatorname{Var}(E)\\simeq0\\).  Equation (1) collapses to the standard Landauer term.\n\n* **Finite-size or finite-time corrections.**  \n  For a small reservoir or a fast erasure protocol the variance does change.  Equality of the total entropy changes now reads\n\n  \\[\n  \\frac{\\Delta Q}{T}\n  +\\frac{\\Delta\\operatorname{Var}(E)}{2k_{\\!B}T^{2}}\n  \\;\\ge\\;\n  k_{\\!B}\\ln 2 .\n  \\]\n\n  Hence the minimum energetic cost becomes  \n\n  \\[\n  \\boxed{\\;\n  \\Delta Q\n  \\;\\ge\\;\n  k_{\\!B}T\\!\\left(\\ln 2\n        -\\frac{\\Delta\\operatorname{Var}(E)}{2k_{\\!B}^{2}T^{2}}\\right)\n  \\;}\n  \\quad\\text{(to first order in }\\Delta\\operatorname{Var}(E)).\n  \\]\n\n  *If* you insist on keeping the mean heat as close as possible to the Landauer value, the extra work is paid through an unavoidable **broadening of the reservoir energy distribution**\n\n  \\[\n     \\Delta\\operatorname{Var}(E)\\;\\ge\\;2k_{\\!B}T^{2}\\ln 2 .\n  \\]\n\n* **Fluctuation\u2013Landauer trade-off.**  \n  The derivative \\(\\partial S/\\partial\\operatorname{Var}(E)\\) therefore quantifies a *fluctuation cost*: every additional \\(k_{\\!B}T^{2}\\) of energy variance buys \\(1/2\\,k_{\\!B}\\) of entropy.  Just as \\(\\partial S/\\partial\\langle E\\rangle = 1/T\\) gives the heat price of entropy,  \n  \\(\\partial S/\\partial\\operatorname{Var}(E)\\) sets the **variance price of entropy**.  It provides the second-order correction to Landauer\u2019s principle that becomes relevant whenever energy fluctuations cannot be neglected.\n\n---\n\n**Bottom line.**  \nLandauer\u2019s bound comes from the *mean*-energy term in the entropy expansion; the derivative you computed supplies the next correction, revealing how tight (or loose) the bound must be once the erasure protocol perturbs not only the reservoir\u2019s average energy but also its fluctuations."
            ]
          },
          "status": "finished_successfully",
          "end_turn": true,
          "weight": 1.0,
          "metadata": {
            "citations": [],
            "content_references": [],
            "message_type": null,
            "model_slug": "o3",
            "default_model_slug": "o3",
            "parent_id": "d8e62e2c-e561-463f-854f-b2281f794a83",
            "request_id": "94d210120edfcf16-SJC",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": "final"
        },
        "parent": "d8e62e2c-e561-463f-854f-b2281f794a83",
        "children": [
          "4a3762ba-ef97-4e0e-857d-7fe4a90f6587"
        ]
      },
      "4a3762ba-ef97-4e0e-857d-7fe4a90f6587": {
        "id": "4a3762ba-ef97-4e0e-857d-7fe4a90f6587",
        "message": {
          "id": "4a3762ba-ef97-4e0e-857d-7fe4a90f6587",
          "author": {
            "role": "user",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749487599.288,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "does this mean you can do better than landauers bound?"
            ]
          },
          "status": "finished_successfully",
          "end_turn": null,
          "weight": 1.0,
          "metadata": {
            "selected_sources": [],
            "selected_github_repos": [],
            "serialization_metadata": {
              "custom_symbol_offsets": []
            },
            "request_id": "94d21b37db315c1d-SJC",
            "message_source": null,
            "timestamp_": "absolute",
            "message_type": null
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "eb8298f5-3765-46a7-8fdf-1609cc7eeeb1",
        "children": [
          "6b6c9c38-6923-408c-b0c0-862c19304d02"
        ]
      },
      "6b6c9c38-6923-408c-b0c0-862c19304d02": {
        "id": "6b6c9c38-6923-408c-b0c0-862c19304d02",
        "message": {
          "id": "6b6c9c38-6923-408c-b0c0-862c19304d02",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749487611.666029,
          "update_time": null,
          "content": {
            "content_type": "thoughts",
            "thoughts": [
              {
                "summary": "Considering Landauer's Bound",
                "content": "The user asked if extra variance could let me beat Landauer\u2019s bound. My previous answer derived a formula for minimum heat with variance change, suggesting that if variance increases, we could subtract from Landauer's bound. But we need to ensure the second law holds. Landauer's bound states that the minimal heat is tied to a decrease in reservoir entropy, so while variance alteration might reduce heat, it must still comply with this fundamental principle. In theory, variance could allow for less heat, but not violating the second law."
              },
              {
                "summary": "Clarifying Landauer\u2019s Bound",
                "content": "The user asks if we can beat Landauer\u2019s bound. Ultimately, no, we can't achieve that. The Landauer principle sets a minimal heat dissipation when erasing information, but even with changes in variance or fluctuations, the total energy cost remains tied to entropy production. In non-ideal environments or small reservoirs, we may temporarily reduce mean heat, but over multiple operations, the minimum heat dissipation will still be at least k_B T ln2. So, we can't asymptotically improve beyond the Landauer bound."
              }
            ],
            "source_analysis_msg_id": "95e91c3a-0328-412c-8a9b-8068693a750d"
          },
          "status": "finished_successfully",
          "end_turn": false,
          "weight": 1.0,
          "metadata": {
            "reasoning_status": "is_reasoning",
            "citations": [],
            "content_references": [],
            "message_type": null,
            "model_slug": "o3",
            "default_model_slug": "o3",
            "parent_id": "4a3762ba-ef97-4e0e-857d-7fe4a90f6587",
            "request_id": "94d21b37db315c1d-SJC",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "4a3762ba-ef97-4e0e-857d-7fe4a90f6587",
        "children": [
          "0c9f7e72-b810-40b6-8a0e-ef5efbcd722c"
        ]
      },
      "0c9f7e72-b810-40b6-8a0e-ef5efbcd722c": {
        "id": "0c9f7e72-b810-40b6-8a0e-ef5efbcd722c",
        "message": {
          "id": "0c9f7e72-b810-40b6-8a0e-ef5efbcd722c",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749487636.026472,
          "update_time": null,
          "content": {
            "content_type": "reasoning_recap",
            "content": "Thought for 33 seconds"
          },
          "status": "finished_successfully",
          "end_turn": false,
          "weight": 1.0,
          "metadata": {
            "reasoning_status": "reasoning_ended",
            "finished_duration_sec": 33,
            "message_type": null,
            "model_slug": "o3",
            "default_model_slug": "o3",
            "parent_id": "6b6c9c38-6923-408c-b0c0-862c19304d02",
            "request_id": "94d21b37db315c1d-SJC",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "6b6c9c38-6923-408c-b0c0-862c19304d02",
        "children": [
          "5e3f8e51-84a1-46e9-9ce5-ff341c4eec32"
        ]
      },
      "5e3f8e51-84a1-46e9-9ce5-ff341c4eec32": {
        "id": "5e3f8e51-84a1-46e9-9ce5-ff341c4eec32",
        "message": {
          "id": "5e3f8e51-84a1-46e9-9ce5-ff341c4eec32",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749487599.892664,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "**Short answer: No. You can momentarily push the *mean* heat below \\(k_{\\!B}T\\ln 2\\) by letting the reservoir absorb extra *fluctuation* entropy, but a full, cyclic accounting of resources still costs at least \\(k_{\\!B}T\\ln 2\\) of free energy per erased bit.**\n\n---\n\n### 1\u2003What we \u201cbeat\u201d when we widen the energy distribution  \nFor a single erasure step we derived, to first order,\n\n\\[\n\\Delta S_{\\text{bath}}\n      =\\frac{\\Delta Q}{T}\n       +\\frac{\\Delta\\operatorname{Var}(E)}{2k_{\\!B}T^{2}},\n\\qquad\n\\Delta S_{\\text{info}}=-k_{\\!B}\\ln 2 .\n\\]\n\nThe second law \\(\\Delta S_{\\text{bath}}+\\Delta S_{\\text{info}}\\ge 0\\) then allows\n\n\\[\n\\Delta Q \\ge k_{\\!B}T\\!\\left(\\ln 2-\n     \\tfrac{\\Delta\\operatorname{Var}(E)}{2k_{\\!B}^{2}T^{2}}\\right).\n\\]\n\nHence if you enlarge the reservoir-energy variance by \\(2k_{\\!B}T^{2}\\ln 2\\), the bound on *mean* heat seemingly falls to zero.  On that level one \u201cbeats\u201d the textbook Landauer figure.\n\n---\n\n### 2\u2003Why this does **not** violate Landauer in practice  \n\nLandauer\u2019s principle is fundamentally a **free-energy** bound:\n\n\\[\nW_{\\min}=k_{\\!B}T\\ln 2\n\\quad\\Longleftrightarrow\\quad\n\\Delta F_{\\text{universe}}\\ge k_{\\!B}T\\ln 2 .\n\\]\n\nThe reservoir starts in a Gibbs state \\(p_{\\! \\beta}(E)\\propto e^{-\\beta E}\\) that minimises nonequilibrium free energy  \n\\(F[p]\\equiv\\langle E\\rangle-T S=-k_{\\!B}T\\ln Z+T\\,\\mathcal D\\bigl[p\\Vert p_{\\!\\beta}\\bigr]\\),\nwhere \\(\\mathcal D\\) is the Kullback\u2013Leibler divergence.  \nAfter erasure the reservoir distribution \\(\\tilde p\\) with the same mean energy but larger variance *is not Gibbsian*.  Linearising \\( \\mathcal D[\\tilde p\\Vert p_{\\!\\beta}] \\) gives exactly the factor we subtracted from the heat:\n\n\\[\nT\\,\\mathcal D[\\tilde p\\Vert p_{\\!\\beta}]\n   =\\frac{\\Delta\\operatorname{Var}(E)}{2k_{\\!B}T^{2}}+O(\\Delta\\operatorname{Var}^{2}).\n\\]\n\nSo the work you avoided as heat re-appears as **non-equilibrium free energy stored in the reservoir**.  \nTo reuse the reservoir (close the thermodynamic cycle) you must thermalise it, dissipating that very amount of work as heat elsewhere.  The integrated cost over a full cycle is still\n\n\\[\nW_{\\text{cycle}}\\;\\ge\\;k_{\\!B}T\\ln 2 .\n\\]\n\n---\n\n### 3\u2003Operational interpretation  \n* **One-shot perspective.**  \n  A clever protocol can indeed dump less than \\(k_{\\!B}T\\ln 2\\) of *mean* heat into a finite bath, at the price of leaving the bath in a \u201cshaken\u201d state with an energy spread.  \n* **Resource-theory perspective.**  \n  The shaken state is a resource: it carries free energy \\(T\\mathcal D[\\tilde p\\Vert p_{\\!\\beta}]\\).  Any future computation that tries to operate cyclically must pay that debt, restoring the canonical state.  \n* **Asymptotic regime.**  \n  If you average over many erasures, or deal with a macroscopic bath that equilibrates between operations, \\(\\Delta\\operatorname{Var}(E)\\!\\to\\!0\\) and the ordinary Landauer bound re-emerges.\n\n---\n\n### 4\u2003Bottom line  \nYou may lower the *apparent* heat cost of a single erasure by injecting extra fluctuations, but you do **not** escape the fundamental free-energy cost.  Landauer\u2019s bound survives intact once the entire thermodynamic bookkeeping\u2014the bath\u2019s relaxation or reuse\u2014is included.  Fluctuations merely let you reshuffle where the cost is paid, not eliminate it."
            ]
          },
          "status": "finished_successfully",
          "end_turn": true,
          "weight": 1.0,
          "metadata": {
            "citations": [],
            "content_references": [],
            "message_type": null,
            "model_slug": "o3",
            "default_model_slug": "o3",
            "parent_id": "0c9f7e72-b810-40b6-8a0e-ef5efbcd722c",
            "request_id": "94d21b37db315c1d-SJC",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": "final"
        },
        "parent": "0c9f7e72-b810-40b6-8a0e-ef5efbcd722c",
        "children": [
          "6f63c182-23b8-41a2-898a-56808bdc38f4"
        ]
      },
      "6f63c182-23b8-41a2-898a-56808bdc38f4": {
        "id": "6f63c182-23b8-41a2-898a-56808bdc38f4",
        "message": {
          "id": "6f63c182-23b8-41a2-898a-56808bdc38f4",
          "author": {
            "role": "user",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749487750.736,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "could you do this successfully in out of equilibrium systems though?"
            ]
          },
          "status": "finished_successfully",
          "end_turn": null,
          "weight": 1.0,
          "metadata": {
            "selected_sources": [],
            "selected_github_repos": [],
            "serialization_metadata": {
              "custom_symbol_offsets": []
            },
            "request_id": "94d21eea5aa0cf22-SJC",
            "message_source": null,
            "timestamp_": "absolute",
            "message_type": null
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "5e3f8e51-84a1-46e9-9ce5-ff341c4eec32",
        "children": [
          "fa9a883d-7a82-4b53-8f51-70c6f19e7e41"
        ]
      },
      "fa9a883d-7a82-4b53-8f51-70c6f19e7e41": {
        "id": "fa9a883d-7a82-4b53-8f51-70c6f19e7e41",
        "message": {
          "id": "fa9a883d-7a82-4b53-8f51-70c6f19e7e41",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749487762.917173,
          "update_time": null,
          "content": {
            "content_type": "thoughts",
            "thoughts": [
              {
                "summary": "Addressing out-of-equilibrium systems",
                "content": "The question asks about potentially overcoming Landauer's bound in out-of-equilibrium systems. We've already discussed how Landauer bound limits free energy in equilibrium. For out-of-equilibrium scenarios, things change a bit: if the reservoir is out of equilibrium, the bound may indeed shift because of additional free energy in the system. But, even then, any improvement is still constrained by the second law of thermodynamics. I\u2019ll explain in detail, referencing concepts like free energy, resource theory, and fluctuation theorems to clarify the limits and possibilities."
              },
              {
                "summary": "Clarifying the concept of minimal work",
                "content": "The Landauer bound, in equilibrium, defines the minimum work required for a bit erasure. When dealing with a non-equilibrium reservoir, the bound changes slightly. The free energy above equilibrium can be used to reduce the work needed, but the second law still applies \u2014 you can't violate it. In non-equilibrium systems, factors like maintaining a steady state and dissipation come into play. The minimal work remains bounded, but the total system and reservoir dynamics are impacted by these nonequilibrium resources. I'll include clear discussion and formulas for both equilibrium and nonequilibrium scenarios."
              }
            ],
            "source_analysis_msg_id": "b9441d5e-b093-476a-9421-282d0e04a68a"
          },
          "status": "finished_successfully",
          "end_turn": false,
          "weight": 1.0,
          "metadata": {
            "reasoning_status": "is_reasoning",
            "citations": [],
            "content_references": [],
            "message_type": null,
            "model_slug": "o3",
            "default_model_slug": "o3",
            "parent_id": "6f63c182-23b8-41a2-898a-56808bdc38f4",
            "request_id": "94d21eea5aa0cf22-SJC",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "6f63c182-23b8-41a2-898a-56808bdc38f4",
        "children": [
          "943423e1-a717-4747-90b8-42fa74d4a063"
        ]
      },
      "943423e1-a717-4747-90b8-42fa74d4a063": {
        "id": "943423e1-a717-4747-90b8-42fa74d4a063",
        "message": {
          "id": "943423e1-a717-4747-90b8-42fa74d4a063",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749487776.210704,
          "update_time": null,
          "content": {
            "content_type": "reasoning_recap",
            "content": "Thought for 23 seconds"
          },
          "status": "finished_successfully",
          "end_turn": false,
          "weight": 1.0,
          "metadata": {
            "reasoning_status": "reasoning_ended",
            "finished_duration_sec": 23,
            "message_type": null,
            "model_slug": "o3",
            "default_model_slug": "o3",
            "parent_id": "fa9a883d-7a82-4b53-8f51-70c6f19e7e41",
            "request_id": "94d21eea5aa0cf22-SJC",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "fa9a883d-7a82-4b53-8f51-70c6f19e7e41",
        "children": [
          "e9602e38-90e4-4ec9-a0b5-73750f215308"
        ]
      },
      "e9602e38-90e4-4ec9-a0b5-73750f215308": {
        "id": "e9602e38-90e4-4ec9-a0b5-73750f215308",
        "message": {
          "id": "e9602e38-90e4-4ec9-a0b5-73750f215308",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749487751.110815,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "### Set-up\n\n*System* \\(S\\): one classical bit, initial Shannon entropy  \n\\(H_{\\mathrm i}(S)=\\ln 2\\).\n\n*Reservoir* \\(R\\): Hamiltonian \\(H_R\\), inverse temperature \\(\\beta\\) that fixes its *equilibrium* Gibbs state  \n\\(\\tau_R = e^{-\\beta H_R}/Z_R\\).  \nBut the actual initial state is some **athermal** density \\(\\rho_R\\neq \\tau_R\\).\n\nGlobal evolution \\(U\\) is energy-conserving: \\([U,\\,H_S+H_R]=0\\).\n\nWork cost (average over many realisations):\n\n\\[\nW = \\operatorname{Tr}\\!\\bigl[(H_S+H_R)\\,(\\rho_{SR}'-\\rho_{SR})\\bigr].\n\\]\n\n---\n\n### Nonequilibrium free energy as the book-keeping variable  \n\nDefine the nonequilibrium free energy functional\n\n\\[\n\\mathcal F(\\rho)\\;=\\; \\operatorname{Tr}\\![\\rho H_R]\\;-\\;T\\,S(\\rho)\n                \\;=\\; F_{\\mathrm{eq}}(T)\\;+\\;k_{\\!B}T\\,D\\!\\bigl(\\rho\\|\\tau_R\\bigr),\n\\]\n\nwhere \\(D(\\rho\\|\\tau)=\\operatorname{Tr}[\\rho\\ln\\rho-\\rho\\ln\\tau]\\) is the Kullback\u2013Leibler divergence.  \nFor any state \\(\\rho\\), \\(\\mathcal F(\\rho)\\ge F_{\\mathrm{eq}}\\); the *excess* (athermality)\n\n\\[\n\\Delta\\!\\mathcal F(\\rho)\\;=\\;k_{\\!B}T\\,D(\\rho\\|\\tau_R)\\ge0\n\\]\n\nis a work resource already stored in \\(R\\).\n\n---\n\n### General second-law inequality (resource-theory form)\n\nBecause the unitary is energy-preserving,\n\n\\[\nW \\;\\;\\ge\\;\\; \\Delta\\mathcal F\\bigl(\\rho_S\\bigr)\\;-\\;\\Delta\\!\\mathcal F\\bigl(\\rho_R\\bigr),\n\\tag{1}\n\\]\n\nwhere \\(\\Delta\\mathcal F(\\rho_S)\\) is the free-energy change of the bit and  \n\\(\\Delta\\!\\mathcal F(\\rho_R)=\\mathcal F(\\rho_R')-\\mathcal F(\\rho_R)\\).\n\n*Erasure* demands \\(\\Delta\\mathcal F(\\rho_S)=k_{\\!B}T\\ln 2\\).\nInsert this in (1):\n\n\\[\nW \\;\\;\\ge\\;\\; k_{\\!B}T\\ln 2\n              \\;-\\;k_{\\!B}T\\,\\Bigl[D(\\rho_R\\|\\tau_R)-D(\\rho_R'\\|\\tau_R)\\Bigr].\n\\tag{2}\n\\]\n\n---\n\n### Beating the \\(k_{\\!B}T\\ln 2\\) mean-heat **locally**\n\n* If the initial reservoir possesses athermality \\(\\Delta\\!\\mathcal F(\\rho_R)>0\\) and you let it relax toward equilibrium so that \\(D(\\rho_R'\\|\\tau_R)<D(\\rho_R\\|\\tau_R)\\), the second term in (2) is positive.  \n* You can therefore make \\(W < k_{\\!B}T\\ln 2\\) **for that single operation**\u2014even reach \\(W\\to0\\) if you spend all the available \\(\\Delta\\!\\mathcal F(\\rho_R)\\).\n\nTypical physical routes:\n\n| Reservoir feature | Example realisations | \u201cPayment\u201d that replaces heat |\n|-------------------|----------------------|------------------------------|\n| **Population inversion** (negative effective temperature) | Masers, lasing media | Loss of inversion energy |\n| **Squeezed or coherently driven bath** | Quantum optics \u201csqueezed reservoir\u201d experiments | Degradation of squeezing (phase-space area) |\n| **Chemical non-equilibrium** | ATP-hydrolysis baths in biomolecular machines | Consumption of chemical potential |  \n| **Steady-state gradient** \\(T_1\\neq T_2\\) | Two-temperature electronic reservoirs | Net entropy production in the maintained gradient |\n\nIn every case the protocol *spends* an originally stored nonequilibrium free energy.\n\n---\n\n### Why this never invalidates Landauer globally\n\n1. **Ath ermality is finite.**  \n   Once \\(\\rho_R\\) has relaxed to \\(\\tau_R\\) (or to a lower-free-energy steady state) its resource is exhausted.  \n   Resetting the reservoir to its original athermal state costs at least the same work you \u201csaved.\u201d\n\n2. **Cyclic operation.**  \n   Over a full cycle that returns *all* auxiliaries (including driving fields) to their initial states,\n\n   \\[\n   \\sum_{\\text{cycle}} W \\;\\;\\ge\\;\\; k_{\\!B}T\\ln 2.\n   \\]\n\n   The apparent gain in one step is offset elsewhere in the entropy ledger; total entropy production remains non-negative.\n\n3. **Fluctuation theorems.**  \n   Jarzynski\u2013Crooks relations hold for nonequilibrium baths when written in terms of *non-equilibrium free energy*.  They likewise enforce (2) and prohibit net violations.\n\n---\n\n### Connection to the variance-susceptibility picture\n\nNear equilibrium one can expand the athermality term\n\n\\[\nk_{\\!B}T\\,D(\\rho_R\\|\\tau_R)\n   =\\frac{\\operatorname{Var}(E)}{2k_{\\!B}T^{2}}-\\frac{\\kappa_3}{6(k_{\\!B}T)^3}+\\dots,\n\\]\n\nwith \\(\\kappa_3\\) the energy third cumulant.  \nYour derivative\n\n\\[\n\\frac{\\partial S}{\\partial\\operatorname{Var}(E)}=\\frac{1}{2k_{\\!B}T^{2}}\n\\]\n\nis exactly the leading susceptibility connecting the *excess free energy* stored in fluctuations to the entropy budget.  Far from equilibrium the full relative-entropy term replaces this quadratic approximation.\n\n---\n\n## Answer to your question\n\nYes\u2014if the reservoir (or environment) starts out of equilibrium, you can **temporarily** perform bit erasure with less than \\(k_{\\!B}T\\ln 2\\) of mean heat by *spending* the reservoir\u2019s stored nonequilibrium free energy (population inversion, squeezing, chemical potentials, temperature gradients, \u2026).  \nBut Landauer\u2019s bound re-emerges for any closed, cyclic, or steady-state operation once the work required to create or maintain that nonequilibrium resource is included.  You can shuffle the cost; you cannot eliminate it."
            ]
          },
          "status": "finished_successfully",
          "end_turn": true,
          "weight": 1.0,
          "metadata": {
            "citations": [],
            "content_references": [],
            "message_type": null,
            "model_slug": "o3",
            "default_model_slug": "o3",
            "parent_id": "943423e1-a717-4747-90b8-42fa74d4a063",
            "request_id": "94d21eea5aa0cf22-SJC",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": "final"
        },
        "parent": "943423e1-a717-4747-90b8-42fa74d4a063",
        "children": [
          "79af1dac-6df2-447a-aad9-9a731a35c438",
          "5a3ad552-999d-4531-9e94-213bde469560"
        ]
      },
      "79af1dac-6df2-447a-aad9-9a731a35c438": {
        "id": "79af1dac-6df2-447a-aad9-9a731a35c438",
        "message": {
          "id": "79af1dac-6df2-447a-aad9-9a731a35c438",
          "author": {
            "role": "user",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749487853.869,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "is it possible to erase a bit for free in a nonequilibrium setting?"
            ]
          },
          "status": "finished_successfully",
          "end_turn": null,
          "weight": 1.0,
          "metadata": {
            "selected_sources": [],
            "selected_github_repos": [],
            "serialization_metadata": {
              "custom_symbol_offsets": []
            },
            "request_id": "94d2216f193c24cd-SJC",
            "message_source": null,
            "timestamp_": "absolute",
            "message_type": null
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "e9602e38-90e4-4ec9-a0b5-73750f215308",
        "children": [
          "b94ad1f0-7408-4fcc-8d51-93ba1975839f"
        ]
      },
      "b94ad1f0-7408-4fcc-8d51-93ba1975839f": {
        "id": "b94ad1f0-7408-4fcc-8d51-93ba1975839f",
        "message": {
          "id": "b94ad1f0-7408-4fcc-8d51-93ba1975839f",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749487866.463152,
          "update_time": null,
          "content": {
            "content_type": "thoughts",
            "thoughts": [
              {
                "summary": "Considering the question on erasing a bit in nonequilibrium settings",
                "content": "The user is asking about the possibility of erasing a bit free of cost in a nonequilibrium setting, with thermodynamic rigor. The key factors here are the Landauer principle, free energy, and the role of nonequilibrium resources. While it seems possible under very specific conditions (like energy fluctuations in small systems), on a larger scale, the second law of thermodynamics dictates that there\u2019s always some cost. It's important to account for these costs globally, even if some negligible processes seem to defy this in isolated systems."
              }
            ],
            "source_analysis_msg_id": "e0aacd43-64b1-49c1-b58a-91fe0c52ef79"
          },
          "status": "finished_successfully",
          "end_turn": false,
          "weight": 1.0,
          "metadata": {
            "reasoning_status": "is_reasoning",
            "citations": [],
            "content_references": [],
            "message_type": null,
            "model_slug": "o3",
            "default_model_slug": "o3",
            "parent_id": "79af1dac-6df2-447a-aad9-9a731a35c438",
            "request_id": "94d2216f193c24cd-SJC",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "79af1dac-6df2-447a-aad9-9a731a35c438",
        "children": [
          "dd4d4bcd-fbf2-454b-9327-a3aa1c5af7c6"
        ]
      },
      "dd4d4bcd-fbf2-454b-9327-a3aa1c5af7c6": {
        "id": "dd4d4bcd-fbf2-454b-9327-a3aa1c5af7c6",
        "message": {
          "id": "dd4d4bcd-fbf2-454b-9327-a3aa1c5af7c6",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749487866.463319,
          "update_time": null,
          "content": {
            "content_type": "reasoning_recap",
            "content": "Thought for 8 seconds"
          },
          "status": "finished_successfully",
          "end_turn": false,
          "weight": 1.0,
          "metadata": {
            "reasoning_status": "reasoning_ended",
            "finished_duration_sec": 8,
            "message_type": null,
            "model_slug": "o3",
            "default_model_slug": "o3",
            "parent_id": "b94ad1f0-7408-4fcc-8d51-93ba1975839f",
            "request_id": "94d2216f193c24cd-SJC",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "b94ad1f0-7408-4fcc-8d51-93ba1975839f",
        "children": [
          "78ad4682-2b1f-4759-8fe0-08faf7ffe4a0"
        ]
      },
      "78ad4682-2b1f-4759-8fe0-08faf7ffe4a0": {
        "id": "78ad4682-2b1f-4759-8fe0-08faf7ffe4a0",
        "message": {
          "id": "78ad4682-2b1f-4759-8fe0-08faf7ffe4a0",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749487854.759529,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "**No. \u201cFree\u201d erasure is impossible once *all* resources are tallied.**  \nWhat you *can* do in a nonequilibrium set-up is *shift* the cost away from the average heat dumped into a thermal bath and into some other stock of free energy (athermal population, chemical work, squeezed light, temperature gradient, etc.). When that auxiliary resource is accounted for, the total nonequilibrium free-energy balance still satisfies\n\n\\[\n\\boxed{\\;\\Delta F_{\\text{universe}}\\;\\ge\\;k_{\\!B}T\\ln 2\\;} ,\n\\]\n\nexactly Landauer\u2019s bound.\n\n---\n\n### Why an apparent \u201cfree\u201d protocol never stays free\n\n| Attempted shortcut | What really pays for the erasure |\n|--------------------|-----------------------------------|\n| **Spend an inverted or squeezed reservoir** | The inversion/squeezing is a finite free-energy resource that must be created (or re-created) at a \u2265 \\(k_{\\!B}T\\ln 2\\) work cost. |\n| **Exploit a permanent gradient (\\(T_1\\neq T_2\\), chemical potential, etc.)** | Running erasure against the gradient produces entropy elsewhere; maintaining the gradient demands continuous power \u2265 \\(k_{\\!B}T\\ln 2\\) per bit erased in the long run. |\n| **Rely on rare thermal fluctuations (single-shot \u201clucky\u201d events)** | Fluctuation theorems guarantee that the probability of zero-work erasure is \\(\\exp(-\\beta k_{\\!B}T\\ln 2)=2^{-1}\\) times smaller for each bit; over many bits the average work converges to \u2265 \\(k_{\\!B}T\\ln 2\\). |\n| **Delegate the cost to a demon\u2019s memory** | Resetting the demon costs exactly the work it saved; the cycle closes at \u2265 \\(k_{\\!B}T\\ln 2\\). |\n\n---\n\n### Formal statement (nonequilibrium resource theory)\n\nFor any energy-conserving protocol with initial states \\(\\rho_S\\) (one bit) and \\(\\rho_R\\) (athermal reservoir),\n\n\\[\nW \\;\\;\\ge\\;\\;k_{\\!B}T\\ln 2\n             \\;-\\;k_{\\!B}T\\Bigl[D(\\rho_R\\|\\tau_R)-D(\\rho_R'\\|\\tau_R)\\Bigr],\n\\]\n\nwhere \\(D(\\,\\cdot\\!\\|\\tau_R)\\) is the Kullback\u2013Leibler divergence to the Gibbs state \\(\\tau_R\\).  \nYou can make the *local* work \\(W\\) zero only by reducing the reservoir\u2019s athermality by **at least** \\(k_{\\!B}T\\ln 2\\); recreating that athermality later costs the same amount of work or more.\n\n---\n\n### Bottom line\n\nA nonequilibrium environment lets you *redistribute* Landauer\u2019s cost\u2014sometimes hiding it from the heat ledger of a particular step\u2014but the second law forbids erasing information without expending an equivalent amount of organized energy somewhere in the total cycle. \u201cFree\u201d erasure is therefore unattainable; it always comes at the price of depleting another ordered resource."
            ]
          },
          "status": "finished_successfully",
          "end_turn": true,
          "weight": 1.0,
          "metadata": {
            "citations": [],
            "content_references": [],
            "message_type": null,
            "model_slug": "o3",
            "default_model_slug": "o3",
            "parent_id": "dd4d4bcd-fbf2-454b-9327-a3aa1c5af7c6",
            "request_id": "94d2216f193c24cd-SJC",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": "final"
        },
        "parent": "dd4d4bcd-fbf2-454b-9327-a3aa1c5af7c6",
        "children": []
      },
      "5a3ad552-999d-4531-9e94-213bde469560": {
        "id": "5a3ad552-999d-4531-9e94-213bde469560",
        "message": {
          "id": "5a3ad552-999d-4531-9e94-213bde469560",
          "author": {
            "role": "user",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749488008.867,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "is it possible to erase a bit for free, locally at least, in a nonequilibrium setting"
            ]
          },
          "status": "finished_successfully",
          "end_turn": null,
          "weight": 1.0,
          "metadata": {
            "request_id": "94d225396e9ced3e-SJC",
            "message_source": null,
            "timestamp_": "absolute",
            "message_type": null
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "e9602e38-90e4-4ec9-a0b5-73750f215308",
        "children": [
          "e2c8e723-19ef-4647-8ab7-74cec267da42"
        ]
      },
      "e2c8e723-19ef-4647-8ab7-74cec267da42": {
        "id": "e2c8e723-19ef-4647-8ab7-74cec267da42",
        "message": {
          "id": "e2c8e723-19ef-4647-8ab7-74cec267da42",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749488021.736615,
          "update_time": null,
          "content": {
            "content_type": "thoughts",
            "thoughts": [],
            "source_analysis_msg_id": "a883777c-04e1-4b73-b793-1e14d040d10f"
          },
          "status": "finished_successfully",
          "end_turn": false,
          "weight": 1.0,
          "metadata": {
            "reasoning_status": "is_reasoning",
            "citations": [],
            "content_references": [],
            "message_type": null,
            "model_slug": "o3",
            "default_model_slug": "o3",
            "parent_id": "5a3ad552-999d-4531-9e94-213bde469560",
            "request_id": "94d225396e9ced3e-SJC",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "5a3ad552-999d-4531-9e94-213bde469560",
        "children": [
          "4bbfbca7-e713-49d8-9534-4d7aee43e392"
        ]
      },
      "4bbfbca7-e713-49d8-9534-4d7aee43e392": {
        "id": "4bbfbca7-e713-49d8-9534-4d7aee43e392",
        "message": {
          "id": "4bbfbca7-e713-49d8-9534-4d7aee43e392",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749488021.736845,
          "update_time": null,
          "content": {
            "content_type": "reasoning_recap",
            "content": "Thought for 4 seconds"
          },
          "status": "finished_successfully",
          "end_turn": false,
          "weight": 1.0,
          "metadata": {
            "reasoning_status": "reasoning_ended",
            "finished_duration_sec": 4,
            "message_type": null,
            "model_slug": "o3",
            "default_model_slug": "o3",
            "parent_id": "e2c8e723-19ef-4647-8ab7-74cec267da42",
            "request_id": "94d225396e9ced3e-SJC",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": null
        },
        "parent": "e2c8e723-19ef-4647-8ab7-74cec267da42",
        "children": [
          "18a6a509-7aba-491d-b9fe-160bb2ec045e"
        ]
      },
      "18a6a509-7aba-491d-b9fe-160bb2ec045e": {
        "id": "18a6a509-7aba-491d-b9fe-160bb2ec045e",
        "message": {
          "id": "18a6a509-7aba-491d-b9fe-160bb2ec045e",
          "author": {
            "role": "assistant",
            "name": null,
            "metadata": {}
          },
          "create_time": 1749488010.693623,
          "update_time": null,
          "content": {
            "content_type": "text",
            "parts": [
              "### Short statement  \nYes: you can make the *local* (mean) heat flow into the immediate thermal bath **exactly zero** while resetting one bit\u2014*provided* you consume an equal amount of nonequilibrium free energy that is already present elsewhere in the set-up.  The operation is \u201cfree\u2019\u2019 only because the cost has been shifted to that auxiliary resource.\n\n---\n\n## 1\u2003Minimal model\n\n* Bit \\(S\\) with logical states \\(\\{0,1\\}\\) and degenerate Hamiltonian \\(H_S=0\\).  \n* Thermal reservoir \\(B\\) at temperature \\(T\\), Gibbs state \\(\\tau_B\\).  \n* A second system \\(R\\) (\u201cworking medium\u2019\u2019) initially in an athermal state \\(\\rho_R\\) that carries\n\\[\n\\Delta\\!F_R^{\\text{ath}}=k_{\\!B}T\\,D(\\rho_R\\Vert\\tau_R)>k_{\\!B}T\\ln2 .\n\\]\n\nPerform a global, energy-conserving unitary \\(U\\) that\n\n* maps \\(S\\) to the definite logical state \\(0\\),  \n* leaves the average energy of \\(B\\) unchanged,  \n* lowers the non-equilibrium free energy of \\(R\\) by exactly \\(k_{\\!B}T\\ln 2\\).\n\nBecause\n\\[\n\\Delta F_{\\text{universe}}=\n  \\underbrace{(-k_{\\!B}T\\ln2)}_{\\text{bit}}+\n  \\underbrace{(+k_{\\!B}T\\ln2)}_{\\text{athermal resource}}=0,\n\\]\nno work need be supplied \\((W=0)\\) and\n\\[\n\\langle Q_B\\rangle=0 .\n\\]\nThe bit is reset \u201cfor free\u2019\u2019 from the point of view of the local bath \\(B\\).\n\n---\n\n## 2\u2003Physical realisations\n\n| Athermal resource \\(R\\) | Mechanism that pays the cost | Experimentally demonstrated? |\n|-------------------------|-----------------------------|------------------------------|\n| **Population-inverted two-level system** (\\(T_{\\text{eff}}<0\\)) | Loss of inversion, stimulated emission | Yes (Josephson qubits, NV centres) |\n| **Single optical mode in a squeezed state** | Degradation of squeezing parameter \\(r\\) | Yes (cavity QED, trapped ions) |\n| **Chemical fuel molecules (ATP \u2192 ADP+P\\(_i\\))** | Consumption of chemical potential \\(\\Delta\\mu\\) | Yes (molecular motors, DNA logic) |\n| **Temperature gradient \\(T_1>T_2\\)** | Entropy flow from hot to cold reservoir | Yes (mesoscopic electronic devices) |\n\nAll obey the inequality  \n\\[\n\\Delta F_R^{\\text{ath}}\\;\\ge\\;k_{\\!B}T\\ln2 .\n\\]\n\n---\n\n## 3\u2003Why Landauer is not violated globally\n\nThe \u201cspent\u2019\u2019 resource ends in a lower-free-energy state \\(\\rho_R'\\) with  \n\\(\\Delta\\!F_R^{\\text{ath}}(\\rho_R')= \\Delta\\!F_R^{\\text{ath}}(\\rho_R)-k_{\\!B}T\\ln2\\).\n\n*To close a thermodynamic cycle* you must restore \\(R\\) to its original athermal condition, which costs at least \\(k_{\\!B}T\\ln2\\) of work or heat supplied **somewhere**.  The free erasure is therefore a one-off draw-down of stored nonequilibrium free energy, not a perpetual loophole.\n\n---\n\n## 4\u2003Fluctuation viewpoint\n\nNear equilibrium the resource expenditure can be written in cumulants; to leading order\n\\[\n\\Delta\\!F_R^{\\text{ath}}\\simeq\n  \\frac{\\operatorname{Var}_R(E)}{2k_{\\!B}T^{2}}\n  +\\cdots .\n\\]\nSetting \\(\\operatorname{Var}_R(E)\\! = 2k_{\\!B}T^{2}\\ln2\\) provides exactly the free energy required for a zero-heat erasure.  This is the fluctuation-based route you derived earlier via  \n\\(\\partial S/\\partial\\operatorname{Var}(E)=1/(2k_{\\!B}T^{2})\\).\n\n---\n\n### Bottom line  \nA single bit can indeed be erased with no local dissipation if another part of the apparatus donates at least \\(k_{\\!B}T\\ln2\\) of **nonequilibrium free energy**\u2014whether stored as inversion, squeezing, chemical bias, or macroscopic gradients.  Landauer\u2019s bound remains intact for any full cycle, because regenerating that nonequilibrium resource inevitably costs the same amount."
            ]
          },
          "status": "finished_successfully",
          "end_turn": true,
          "weight": 1.0,
          "metadata": {
            "citations": [],
            "content_references": [],
            "message_type": null,
            "model_slug": "o3",
            "default_model_slug": "o3",
            "parent_id": "4bbfbca7-e713-49d8-9534-4d7aee43e392",
            "request_id": "94d225396e9ced3e-SJC",
            "timestamp_": "absolute"
          },
          "recipient": "all",
          "channel": "final"
        },
        "parent": "4bbfbca7-e713-49d8-9534-4d7aee43e392",
        "children": []
      }
    },
    "moderation_results": [],
    "current_node": "18a6a509-7aba-491d-b9fe-160bb2ec045e",
    "plugin_ids": null,
    "conversation_id": "68470d60-2bd8-8005-9cb8-55d214a702a3",
    "conversation_template_id": null,
    "gizmo_id": null,
    "gizmo_type": null,
    "is_archived": false,
    "is_starred": null,
    "safe_urls": [],
    "blocked_urls": [],
    "default_model_slug": "o3",
    "conversation_origin": null,
    "voice": null,
    "async_status": null,
    "disabled_tool_ids": [],
    "is_do_not_remember": false,
    "memory_scope": "global_enabled",
    "sugar_item_id": null,
    "id": "68470d60-2bd8-8005-9cb8-55d214a702a3"
  }
]